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Abstract 
 
The inability of central nervous system (CNS) neurons to regenerate results in lost neural 
connectivity and is common to many neurological disorders. This loss of connectivity 
results in functional deficit following trauma such as spinal cord injury (SCI) and has been 
implicated in many neurodegenerative diseases including Alzheimer’s disease (AD). 
Throughout this project a robust, reliable and physiologically relevant 3D model of human 
neuritogenesis was developed and applied to investigate the process of neurite inhibition, 
along with its underlying signalling mechanisms. 
 
SCI results in the formation of a glial scar; involving the activation of astrocytes and 
secretion of inhibitory molecules that act through receptors to inhibit neurite growth 
thereby reducing neural connectivity. This project describes several approaches used to 
investigate this process including growth substrate coating, biomimetic 2D/3D 
functionalised growth surfaces and the development of a co-culture model to study 
reactive astrocyte-neuron interactions. Each approach has successfully led to neurite 
inhibition, and we have also demonstrated the ability of small molecules to restore 
neurite outgrowth despite the presence of inhibitory stimuli. 
 
Inhibition of neurite growth is also associated with β-amyloid (Aβ) deposition, a hallmark 
of AD. Neurites that pass through deposits become dystrophic and their ability to form 
connections is reduced. This study has also focussed on elucidating the molecular 
mechanisms that underpin Aβ-mediated inhibition, through growth substrate coating, 
exogenous Aβ application and the development of a disease-specific neurite outgrowth 
model based on iPSC technology, all of which successfully led to inhibition of neurite 
outgrowth. Small molecules that target specific downstream signalling events were used 
to restore neurite growth in the presence of inhibitory Aβ. This has helped identify 
common signalling pathways involved in neurite inhibition in both SCI and AD.  
 
Activation of the Rho A and ROCK signalling pathway is common to neurite inhibition in 
the glial scar and AD. This thesis provides compelling evidence as to the common role of 
Rho A activation in neurite inhibition. A ROCK inhibitor, Y-27632 and ibuprofen, an 
inhibitor of Rho A, were used to restore neurite outgrowth in the inhibitory models 
described throughout this project. These data suggest a common role for Rho A and ROCK 
activation in neurite inhibition, inhibition of which may provide a useful therapeutic 
strategy to promote regeneration in the CNS and enhance neuronal connectivity in many 
neurological disorders.  
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Chapter I: Introduction 
 
1.1 Development of the Central Nervous System  
 
The central nervous system (CNS) is comprised of two main organs, the brain that 
processes received information, and the spinal cord, which transmits sensory information 
from the peripheral nervous system (PNS) to the brain.  The role of the CNS is to receive 
and process information resulting in an appropriate response to the signal received along 
with controlling essential processes such as motor function. 
 
Three connective tissue membranes, the meninges, protect the entire CNS; the outer 
membrane is the dura mater followed by the arachnoid mater with the inner most 
membrane being the pia mater1. Cerebrospinal fluid (CSF) fills the subarachnoid space 
(the space between the arachnoid and pia mater) while the epidural space (the space 
between the dura mater and periosteum) is filled with fibrous and adipose connective 
tissue, providing protection to the tissue of the CNS2.  
 
The spinal cord ranges from 43 – 45 cm in length and extends from the base of the brain 
to the first lumbar vertebrae (L1), as the vertebral column grows faster than the spinal 
cord2.  A cross-section of the spinal cord reveals a central core of grey composed of 
interneurons, cell bodies, dendrites and glial cells. The grey matter is surrounded by white 
matter composed of mostly myelinated axons. Ascending tracts relay information from 
the PNS to brain, while descending tracts transmit information from the brain to the 
periphery2.  
 
The brain is the most complex organ in the human body and contains a heterogenic 
population of cell types including neurons and supporting glial cells4.  The mature brain is 
composed of more than 100 billion neurons that form complex neuronal networks, with 
the adult brain being estimated to have more than 60 trillion connections5. The brain is 
also composed of a series of interconnected cavities that form the CSF filled ventricular 
system that provides protection to the brain and is also involved in the removal of waste 
and the transport of substances5.  
 
In embryonic development, the nervous system begins to form as the embryo reorganises 
into the three germ layers (ectoderm, mesoderm and endoderm)6. Signalling from the 
posterior margin of the embryo induces formation of the neural plate, which develops 
bilateral neural folds that fuse at the midline creating the neural tube7,8. Development and 
closure of the neural tube usually completes by 28 days post-conception and failure to 
close can result in neural tube defects (NTDs) such as spina bifida and anecephaly7. 
 2 
Dorsoventral patterning of the neural tube depends on the relative quantities of 
dorsalizing factors such as bone morphogenetic protein (BMP) from the non-neural 
ectoderm and ventralizing factors including sonic hedgehog (Shh) from the notochord and 
floor plate6.  Retinoic acid (RA) is a patterning factor that contributes to both dorsoventral 
and anteroposterior patterning of the neural plate and along with WNTs and fibroblast 
growth factors (FGFs) is involved in organisation of the spinal cord and posterior 
hindbrain9. The relative quantities of morphogens such as RA, Shh and BMP in the 
developing neural tube gives rise to the cell types that develop from resident stem cells. 
Therefore, fully understanding the signalling pathways activated by such morphogens can 
help elucidate the mechanisms behind neural differentiation of stem cells and can be used 
in vitro to generate populations of cells for use in disease modelling to further understand 
pathogenic mechanisms or to generate pools of cells for regenerative medicine purposes.  
 
1.1.1 Neuritogenesis 
 
Neuritogenesis is a process that occurs during the development of the individual neuron 
and results in the formation of complex neuronal circuitry that is essential for nervous 
system function. Neurites are cytoskeletal processes that extend from the cell body of the 
developing neuron and with a growth cone at the distal tip, later become the axon and 
dendrites of the mature neuron10. The ability of neurites to sprout and form at the right 
time and in the correct orientation forms the basis of neuronal connectivity, which in turn 
ensures correct brain functioning.  
 
Neurite formation occurs in three distinct phases; first budding occurs, where the initial 
bud begins to protrude from the cell breaking the original round, spherical cellular shape. 
The bud then develops into a neurite, which later matures into an axon or dendrite, a 
process that is summarised in Figure 1-110.  
 
Neuritogenesis is heavily influenced by external stimuli, particularly extracellular-matrix 
(ECM) proteins such as tenascins11, collagen, and laminin, which all have important roles 
in axonal development and navigation. Cell signalling events initiated by extra-cellular 
stimuli result in cytoskeletal modulation, which ultimately induces neurite guidance and 
elongation12. Laminin is thought to induce neurite development by forming a complex 
with integrin receptors that dimerise at the cell membrane transmitting signals to the 
actin cytoskeleton. This is thought to induce micro-domain and receptor induced calcium 
rises that stimulate membrane changes leading to neurite protrusion10.  
 
The initial sprouting of a neurite from the cell body of a developing neuron depends on 
force generated from within the cell. Microtubules and membrane addition are known to 
be important in the elongation, polarity and speed of neurite development, however 
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alone, these processes do not generate enough force required for initial neurite extension, 
this is thought to be driven by the actin cytoskeleton10.  
 
 
Fig 1-1: Stages of neurite development.  
Initial stages of neurite development as shown by phase contrast images of rat embryonic 
hippocampal neurons in culture along with a schematic depicting the stages of neurite 
outgrowth. The initial budding stage highlights the neurite sprout with a blue arrow. 
Neurites then extend as the cell differentiates and as the cell matures, morphological 
polarisation leads to the formation of the mature axon (highlighted by the red arrow) and 
dendrites.  Adapted from Da Silva & Dotti.  
 
 
1.1.1.1 The Role of the Actin Cytoskeleton in Neuritogenesis 
 
The growth cone, located at the distal tip of the developing neurite is rich in cytoskeletal 
components, predominantly actin fibrils. The growth cone contains a central core that is 
filled with organelles and growing microtubules (MTs) essential for the development of 
the neurite13. The peripheral area of the growth cone that surrounds the central region is 
made up of actin-based lamellipodia and filopodia, which drive neurite extension10. 
Lamellipodia consist of an actin meshwork that has adhesion functions, and induces the 
tension necessary for growth cone movement and neurite extension. Whereas fliopodia 
consist of actin bundles that promote rapid extension of developing neurites. Within the 
growth cone, actin is thought to polymerise at the leading edge, before disassembling and 
receding to the peripheral area where it can re-polymerise, driving the protrusion of the 
neurite10. 
 
The Rho pathway is a well-characterised signalling pathway involved in the control of 
actin dynamics and Rho GTPases are ubiquitously expressed proteins that are heavily 
involved in this signalling cascade. The Rho family of proteins includes: Rho A, Rac1 and 
Cdc42 all of which play a role in neurite outgrowth and guidance. Rho A negatively 
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regulates the process, as activation of Rho A inhibits neurite outgrowth10,14, whereas, 
activation of Rac and Cdc42 is required for neurite outgrowth. Rho GTPases impact 
neurite outgrowth through inducing actin remodeling and they achieve this through the 
formation of multi-molecular complexes that contain regulatory proteins and actin-
binding proteins. Actin-binding proteins include Ena/VASP that couple actin to the cell 
surface, Arp2/3 that nucleates actin, proteins that promote actin depolymerisation 
(ADF/cofilin) and proteins that promote polymerisation at the barbed end of the actin 
filament (profilin) along with many more proteins.10  
 
The exact molecular pathway that controls actin dynamics in neurite extension and 
growth remains relatively unknown; however, through studies focusing on cell migration 
and Rho GTPase binding partners, a potential signalling pathway has been outlined in 
Figure 1-210. The extracellular, neurite-initiating stimulus such as a component of the ECM 
is thought to bind to a cell surface receptor, inducing activation of downstream signaling 
molecules. Receptor activation is thought to transmit signals through guanine-nucleotide 
exchange factors (GEFs) or guanine-nucleotide-dissociation inhibitors (GDIs) and GTPase 
activating proteins (GAPs) to a series of effector proteins such as Rho A and its 
downstream effector Rho A Kinase (ROCK), WASP, and Arp2/3, inducing actin 
instability10. Relaxation of the actin meshwork allows microtubules to penetrate the area, 
altering membrane dynamics and promoting neurite sprouting.  
 
Although the general signalling pathway remains relatively unclear, the molecular 
signalling pathway that follows receptor activation by specific stimuli is beginning to be 
uncovered. For example, nerve growth factor (NGF) induces neurite formation in cells 
cultured in vitro15,16 and is associated with an increase in Rac 1 and Cdc42 activity. This is 
associated with Rho A inactivation, resulting in signalling events that are associated with 
neuritic growth.  This is thought to be induced by activation of the Ras-linked tyrosine 
kinase receptor (TrkA) by NGF which in turn activates Ras and PI 3-kinase followed by 
activation of Cdc42 and Rac 1 and deactivation of Rho A and ROCK17. This signalling 
cascade results in the induction of neurite outgrowth. However, although much of the 
signalling pathway, upstream of Cdc42, Rac 1 and Rho A has been elucidated for the NGF 
ligand, this is not the case for all ligands that influence neuritogenesis and the 
complexities of this cascade remain unclear. 
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Fig 1-2: The role of the Rho signalling pathway in neurite development and inhibition.  
Extracellular signals act through a receptor dependent mechanism leading to activation of Rho GTPases (Rac and Cdc42) and inhibition of Rho A. Activation of Rac, 
Cdc42 and their downstream signalling partners, WASP and Arp2/3 combined with inhibition of Rho A and downstream ROCK, induces neurite development. This 
results in instability allowing the intrusion of microtubules to the area and membrane breaching promoting neurite growth. Efforts have been made promote 
neurite regeneration by using small molecules to inhibit Rho A (C3 transferase, ibuprofen) or ROCK (fasudil, Y-27632). 
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The complexity of this signalling pathway can be highlighted by the protein Arp2/3 the 
role of which in neurite development is not fully understood, however it is known to 
promote branching of actin filaments by promoting actin nucleation18. Loss of function of 
Arp2/3 through siRNA in cultured neurons does not inhibit neurite outgrowth, but 
actually increases the number of shorter, more irregular neurites19. However, 
overexpression of N-WASP an activator of Arp2/3 increases the number of neurites20, 
which demonstrates the complex role of Arp2/3 signalling in neurite outgrowth18 and 
demonstrates how so many aspects of this pathway may remain not fully understood.  
 
Although the detailed molecular mechanism of this signalling pathway in neuritogenesis 
remains relatively unknown, manipulation of this pathway is still commonly used to 
enhance neurite outgrowth in in vitro cultures. Activation of Rho A and its downstream 
signalling molecule ROCK, inhibits neurite outgrowth, therefore inhibition of Rho A and 
ROCK signalling can be used as a strategy to enhance neurite outgrowth. ROCK inhibitors 
such as, Y-2763221–24 and fasudil21,25 are commonly used to enhance neurite outgrowth 
cultures in vitro, and have even been shown to overcome inhibitory stimuli in non-
permissive environments26,27.   
 
Inhibition of Rho A signalling is another commonly used strategy to enhance neurite 
outgrowth cultures, C3-transferase (an inhibitor of Rho A), can be used to increase neurite 
outgrowth28,29.  Interestingly, Roloff et al, demonstrate the ability of the non-steroidal 
anti-inflammatory drug (NSAID), ibuprofen, to enhance neurite outgrowth in cultures 
derived from human pluripotent stem cells differentiated toward a neural linage21. This 
study found that ibuprofen not only targets cyclooxygenase enzymes resulting in its anti-
inflammatory function, but also suppresses Rho A activity to induce neurite 
outgrowth21,30,31. Therefore, understanding the detailed molecular mechanism that 
underpins neurite development can be important to help enhance neuronal cultures in 
vitro and also to develop therapeutic interventions in the context of neurite inhibition that 
is common to many CNS disorders.  
 
1.1.1.2 Neurite Outgrowth in Disease 
 
Inability of neurites to regenerate and restore lost neuronal connections is common to 
many nervous system disorders ranging from trauma32–34 to neurodegenerative 
diseases35–38.  Neurite inhibition results in growth cones becoming dystrophic and left 
unable to form connections with other cells, which has a major impact in connectivity and 
the transmission of nervous signals39. 
 
Trauma to central nervous system results in the formation of a glial scar, which is a large 
obstacle in the treatment of spinal cord injury (SCI). The glial scar involves the secretion 
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of inhibitory molecules from reactive astrocytes and the release of inhibitory molecules 
from myelin debris, which act through receptors to activate Rho A signalling, in turn 
inducing neurite inhibition33,34,39. Similarly, the β-amyloid (Aβ) peptide implicated in 
Alzheimer’s disease (AD) pathogenesis, has also been found to induce neurite inhibition 
through a Rho A dependent signalling mechanism36,40.  The α-synuclein peptide associated 
with Parkinson’s disease (PD) has been linked with neurite inhibition in vitro37 and 
inhibition of neurite outgrowth has even been implicated in neurological conditions such 
as schizophrenia41,42 and Down’s syndrome43,44.  
 
Understanding the molecular mechanisms that underpin neurite outgrowth and inhibition 
is important, as neurite inhibition is so widespread throughout disorders of the CNS. 
Further insights into the molecular pathways that govern neurite inhibition can lead to 
the development of mechanisms that intervene within the process, resulting in rational 
therapeutic design. Consequently, there is a need for physiologically relevant in vitro 
models of neuritogenesis to help elucidate the downstream signalling events that induce 
neurite inhibition and to screen potential molecules that may be able to overcome 
inhibition in the presence of inhibitory stimuli.  
 
1.1.2 The Retinoic Acid Pathway in Neural Development 
 
Retinoic acid (RA) is a derivative of vitamin A that cannot be synthesised and must be 
obtained from the diet, from meat in the form of retinyl esters or β-carotene from plant 
sources45. RA belongs to a family of molecules known as retinoids, of which it is the most 
active naturally occurring substance46.  It is an important signalling molecule involved in 
embryonic development, and has a particularly important role in the patterning and 
differentiation of the developing nervous system. Deficiencies in vitamin A, historically, 
have resulted in defects in a wide range of biological systems including: keratinisation of 
epithelia, anaemia, blindness and loss of immune function. Vitamin A deficiency in animals 
has also been found to lead to nerve degeneration and symptoms similar to that of motor 
neuron disease46. This large range of symptoms highlights the importance of RA as a 
signalling molecule in development, especially in development of the nervous system.  
 
 1.1.2.1 Retinoic Acid Metabolism and Signalling 
 
Retinoids are obtained from the diet and stored in the liver, lungs, bone marrow and 
kidneys. Retinoids are transported from these storage sites to target cells as retinol, which 
is released into the bloodstream and transported bound to retinol-binding protein 4 
(RBP4) in the plasma46. Target cells, through an interaction between RBP4 and its 
membrane receptor, STRA6, take up retinol, allowing it to enter the cytoplasm9. Once in 
the cell, retinol is bound to retinol-binding protein 1 (RBP1) and metabolised in a two-
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step process by retinol dehydrogenase 10 (RDH10) and retinaldehdye dehydrogenases 
(RALDHs) to produce all-trans retinoic acid (ATRA)47.  
 
Usually two retinoic-acid-binding proteins (CRABP1 and CRABP2) bind to ATRA in the 
cytoplasm and assist translocation of RA to the nucleus. Once in the nucleus, RA binds to a 
transcription complex, that includes a pair of ligand-activated transcription factors: the 
RA receptor (RAR) and retinoic X receptor (RXR)9. This complex can be made up from 
three different RAR (RARα, RARβ and RARγ) and three different RXRs (RXRα, RXRβ and 
RXRγ) with each molecule having several different isoforms46. Together this receptor 
heterodimeric pair binds to a DNA sequence, the retinoic acid response element (RARE). 
This results in induction of gene expression with over 500 genes having been observed to 
be retinoic acid inducible9. Following induction of RARE, ATRA exits the nucleus and is 
broken down in the cytoplasm by CYP26 and P450 enzymes47.  A schematic overview of 
the RA signalling pathway is shown in Figure 1-3.  
 
Retinoic acid can act by both paracrine and autocrine mechanisms to induce expression of 
genes essential to neuronal development and differentiation9. For this reason it is an 
important signalling molecule involved in embryonic development and as also been 
harnessed for use in vitro to promote neuronal differentiation of human pluripotent stem 
cells45. 
 
 
 
Fig 1-3: Metabolism and molecular mechanism of retinoic acid signalling.  
Retinol binding protein 4 (RBP4) transports retinol to its target cells where it enters the 
cytoplasm with the help of the transmembrane receptor, STRA6. Retinol then binds to 
retinol binding protein 1 (RBP1) and is metabolised to Ral by retinol dehydrogenase 10 
(RDH10) and then to retinoic acid (RA) by retinaldehyde dehdryogenases (RALDHs). RA 
either acts in a paracrine fashion on other target cells or through an autocrine mechanism. 
RA is translocated to the nucleus by cellular retinoic-acid binding protein 2 (CRPB2) 
where it can bind to retinoic acid receptors (RARs) and retinoic X receptors (RXRs) that 
form heterodimers and bind to DNA at the retinoic acid response element (RARE) 
inducing transcription of target genes. Taken from Clarke et al.   
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 1.1.2.2 Retinoic Acid in Nervous System Development 
 
Retinoic acid is heavily involved in the patterning and differentiation of the nervous 
system in vivo. It contributes toward both dosoventral46 and anteroposterior48 patterning 
of the neural plate and tube during the early development events of the nervous system. 
The role of RA in anteroposterior patterning is to induce posterior hindbrain and anterior 
spinal cord organisation, along with other signalling molecules including WNTs and FGFs. 
In the absence of RA signalling, the posterior hindbrain is missing and spinal cord 
abnormal46. This process is tightly regulated due to the generation of RA in the posterior 
mesoderm, which is tightly controlled by the CYP26C1 enzyme that breaks down RA 
resulting in a concentration gradient. Newly formed somites in the developing neural tube 
release RA along with other signalling molecules that include Shh and BMPs dorsally, 
which act together to determine cellular fate of sensory, motor and interneurons46.  
 
The role of RA in the patterning of neuraxis was first studied by the treatment of 
developing embryos with an excess of RA in species including Xenopus48–50, zebrafish, 
mice and rats46. In the case of RA treatment, anterior structures were lost (including the 
forebrain and eyes) and the hindbrain and spinal cord expanded to compensate for this 
loss48. A repression in anterior genes such as Otx2, Emx1 and Dlx1 and an induction in 
posterior genes such as Krox20, Hox and Pax2, which explains the observed expansion of 
the hindbrain and spinal cord46. Alteration of RA signaling through selective ligands for 
the RAR and RXR receptors causes an upregulation in posterior gene expression, similar 
to that seen with RA excess49. Therefore, it is thought that a gradient of RA within the 
developing nervous system is responsible for patterning and that shifting the gradient 
anteriorly by increasing RA signalling can reduce forebrain and midbrain formation. 
Whereas, shifting the gradient posteriorly by decreasing RA signaling results in an 
enlargement of the forebrain and midbrain46. This dramatic effect on neural development 
highlights the important role that RA plays in the developmental process and the 
importance of a delicate signalling gradient that leads to successful neural development.   
 
RA induces differentiation of cells toward glia and neuronal lineages through the 
induction of transcription of many genes that encode: transcription factors, structural 
proteins, enzymes, cell surface receptors and other signalling molecules. RA inducible 
genes include transcription factors such as nuclear factor κB (NFκB), SOX1 and SOX6, 
along with proteins such as protein kinase Cε (PKCε) and microtubule-associated protein 
2 (MAP2) and elements of the canonical WNT pathway9. RA may also function to suppress 
particular signalling pathways in its role to induce neuronal differentiation, as shown by 
Verani et al, whose study identifies an increase in the WNT pathway inhibitor Dickkopf-1 
(Dkk-1) upon RA induction of neural differentiation in mouse stem cells51.   
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The number of primary neurons that develop in fish and amphibians is controlled by RA 
signalling and the addition of RA to the embryo results in an increase in primary neuron 
number and a change in their positioning52,53. An inhibition in RA signalling in these 
species results in a decrease in primary neuron number and embryos are left unable to 
respond to physical stimulation46.  Similarly, in retinoid-deficient mice, neurons of the 
hippocampal denate gyrus are reduced; suggesting RA signalling is an important step in 
the early differentiation pathway of hippocampal neurons45. Therefore, promotion of 
neuronal differentiation by RA makes it a useful tool to generate neurons in vitro.  
 
 1.1.2.3 Retinoic Acid in the Mature Nervous System  
 
Peripheral neurons are capable of regeneration following injury, however, neurons in the 
CNS are unable to regenerate, which poses an obstacle in the treatment of CNS injury. 
Following a peripheral nerve injury, RA signalling is induced, to promote neuronal 
regrowth and regeneration by activating the same signalling mechanisms involved in 
neuronal development9. The receptor, RARβ2, is upregulated following peripheral nerve 
injury, however is not expressed in the adult spinal cord, suggesting that an upregulation 
in this receptor is involved in the neurite outgrowth promoting response to peripheral 
nerve injury9,54.  
 
RA is thought to act upon neurons promoting the protrusion of neurites from the cell 
body, however expression of RARβ2 within Schwann cells and macrophages, may suggest 
that RA also acts upon surrounding cells to promote the formation of a more permissive 
environment for neurite outgrowth9. A proposed mechanism for this is the secretion of 
neurite promoting factors such as neurotrophin and NGF, however, the signalling events 
that follow peripheral nerve injury appear to be complicated and not well understood. A 
potential mechanism is outlined in Figure 1-4. RA is also thought to promote neuronal 
regeneration by inhibiting the pro-inflammatory effects of macrophages that upregulate 
RARs following injury9. Understanding the role of RA in peripheral nerve regeneration is 
important in the development of therapeutics aimed at targeting this pathway to promote 
neural regeneration in both the PNS and CNS.  
 
Injury to the CNS such as spinal cord injury (SCI) induces an increase in RA signalling 
activity that peaks 4 – 7 days post-injury9. However, unlike injury to the PNS, neurons are 
unable to regenerate following CNS injury, due to the formation of a glial scar, an 
environment that is inhibitory to neurite outgrowth39. Wong et al demonstrate the 
potential neurite-promoting role of RA following spinal injury, by inducing over 
expression of RARβ2 in rat dorsal root ganglion (DRG) cultures in vitro and in injured rats 
in vivo, which resulted in significant neurite outgrowth and functional recovery following 
SCI55. This highlights the potential role of RA for use in therapeutic interventions in both 
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CNS and PNS injury and the need for further understanding of the signalling pathways 
that govern tissue and cellular regeneration, as RA signalling has also been implicated in 
limb and lung regeneration56.   
 
 
 
Fig 1-4: The potential role of retinoic acid in regeneration following peripheral 
nerve injury.  
Retinoic acid (RA) inhibits the secretion of inflammatory cytokines from macrophages, 
which express retinoic acid receptors (RARs). Schwann cells also express RARs and RA 
induces secretion of neurotrophins including nerve growth factor (NGF) and signalling 
molecules such as sonic hedgehog (SHH). The secretion of neurotrophins supplements the 
beneficial effects of RA on neuronal regeneration, and also enhances production of RA 
from damaged neurons.  
 
 
One of the roles of RA in the mature nervous system is thought to be the maintenance of 
neuronal plasticity. Vitamin A deprived mice and rats have been found to show signs of 
cognitive impairment and memory deficits that can be reversed by the restoration of 
vitamin A to the diet. This suggests an important role for RA in the maintenance of 
memory functions57–59.  A similar memory loss phenotype is observed in ageing animals 
and can be restored by induced RA signalling60,61, which has even been found to effectively 
rescue memory deficits in a mouse model of Alzheimer’s disease62. This further 
emphasises the need to better understand RA signalling in the mature nervous system.  
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1.2 In Vitro Models of Neurite Outgrowth 
 
Neurite outgrowth is an important developmental process, impairment of which is 
common to many neurological disorders, which in turn has a detrimental effect on 
neuronal connectivity. Neurite inhibition poses an obstacle in the treatment of many 
diseases; therefore, the development of accurate in vitro models to study the mechanisms 
that underpin the process is an extremely active area of research. Applications of neurite 
outgrowth models range from the screening of potential drug candidates to investigations 
into molecular developmental and pathological mechanisms. Such models are often used 
for toxicology studies to determine the neurotoxicity of compounds and in drug discovery. 
Most in vitro neurite outgrowth assays rely on analysis and quantification of micrographs 
to determine neurite elongation and regression, which can be inaccurate and time 
consuming63. Therefore, there is a need for improved models of neuritogenesis that can be 
adapted for high throughput screening techniques to enable rapid identification and 
screening of compounds.    
 
1.2.1 Limitations of the Use of Retinoic Acid In Vitro 
 
Retinoic acid, due to its role in the development of the nervous system, is often used in 
vitro to promote neuronal differentiation and neurite outgrowth in cell cultures64,65. 
Neuronal models based on the differentiation of pluripotent stem cells, such as embryonic 
stem (ES) cells and embryonal carcinoma (EC) cells, often harness the neuronal 
differentiation properties of ATRA to generate functional neurons for studies21,66–72. 
Similarly, SH-SY5Y neuroblastoma cells, a cell line commonly used for neurite outgrowth 
assays, are usually treated with ATRA to induce a more neuronal phenotype along with 
the outgrowth of neurites73–77. However, ATRA induction of differentiation in SH-SY5Y 
cells has recently come into question as it is thought to effect cell susceptibility to 
neurotoxins, therefore may not be suitable for use in neurotoxicity screening assays78. 
 
Although ATRA is commonly used to induce neuronal differentiation in vitro, its use is 
limited as it readily breaks down when exposed to light and heat79. ATRA contains five 
unsaturated double bonds, which leaves it prone to isomerisation and results in the 
formation of breakdown products such as, 9-cis and 13-cis retinoic acids, which may have 
an unwanted biological activity80. Therefore, as ATRA can readily breakdown, its use in 
vitro is limited, as the exact concentration of ATRA in a particular solution is variable and 
high concentrations may be needed to induce the desired differentiation and to account 
for the breakdown of the compound over the culture period. For this reason, synthetic 
more stable retinoid compounds have been developed for use in induction of neuronal 
differentiation studies.      
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1.2.1.1 Synthetic Retinoid Analogues 
 
As light and heat exposure is unavoidable during cell culture, much effort has been placed 
in the development of synthetic retinoid analogues that are more stable and practical for 
use in vitro than the naturally occurring ATRA. Previously, it has been demonstrated that 
only 37 % of ATRA remains in solution following a 3-day exposure to laboratory 
fluorescent light, due to instability that is thought to arise from the conjugated linker 
region81.  However, synthetic retinoids have been developed such as EC23 that replace 
sections of the polyene chain with an acetylene moiety and phenyl rings providing 
complete stability, with 100 % EC23 remaining following a 3-day exposure period to 
light81.  Another synthetic retinoid analogue was developed to better resemble the 
structure of the ATRA molecule, AH61, which shows signs of isomerisation following 
exposure to light, but only one other isomer was detected and 86 % of the original 
compound remained81. The structure of retinoid analogues including ATRA, EC23, EC19 
and AH61, are shown in Figure 1-5. 
 
 
 
 
Fig 1-5: Chemical structures of synthetic retinoid analogues. 
Naturally occurring ATRA (A) readily isomerises when exposed to light and heat i.e 
laboratory conditions. Therefore synthetic retinoid compounds have been developed that 
are more stable and practical for use in vitro, AH61 (B) shares a similar structure with 
ATRA but is more stable and does not break down as readily as ATRA. EC23 (C) (CO2H in 
position 4) is completely stable with no evidence of degradation and is a potent inducer of 
neural differentiation, whereas EC19 (C) (CO2H in position 3) induces non-neural, 
epithelial-like differentiation in human pluripotent stem cells. 
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Christie et al, addressed the biological activity of the synthetic retinoid, EC23 by 
determining that neuronal differentiation in both human neuroprogenitor and human 
embryonic stem cells was enhanced by the molecule82.  EC23 was found to induce 
expression of neuronal markers such as β-III-tubulin (TUJ-1) and NF-200 to a greater 
extent at lower concentrations (10 nM) than ATRA and to a similar extent at high 
concentrations (100 nM) in ReN cell 197VM progenitor cells82. Similarly, the biological 
activity of AH61 was assessed by Clemens et al, and it was found that AH61 has similar 
neuronal differentiation inducing properties to the naturally occurring ATRA, in an 
embryonal carcinoma (EC) cell model of neuronal development81.  AH61 was found to 
induce loss of stem cell markers such as SSEA-3 and TRA-1-60 along with induction of the 
early neuronal marker A2B5 to a similar level as ATRA, as measured by flow cytometry81. 
Therefore both AH61 and EC23 have previously been found to induce neuronal 
differentiation in culture to a similar extent to ATRA with significantly enhanced stability 
when exposed to light. 
 
Subtle variations in retinoid structure can significantly impact the biological function of 
the molecule, as can be demonstrated by the synthetic molecule, EC19. Similarly to EC23, 
when exposed to light for a 3-day period, EC19 remains completely unaltered83. However, 
the biological function of EC19 differs from that of EC23 in that EC19 appears to induce 
epithelial-like differentiation of embryonal carcinoma cells, as opposed to neuronal 
differentiation. In another study, Christie et al, demonstrate that EC cells exposed to 10 
μM of each retinoid for a 21-day period exhibit completely distinct morphological 
appearances83. Cells treated with ATRA appear heterogeneous with areas of neural 
rosettes and areas containing flat epithelial-like cells, however, EC23 induced cells appear 
to contain more neural rosettes and less epithelial-like areas, whereas, EC19 treated cells 
contain large areas of flat epithelial-like cells with no evidence of neural rosettes83.  
Expression of cytokeratin-8 (an epithelial marker) was induced to a greater degree by 
EC19, whereas, expression of TUJ-1 (a neuronal marker) was induced to a greater degree 
by EC2383,84. Therefore, the differences in biological activity between EC19 and EC23 are 
induced by only subtle variations in their structure, highlighting the importance in 
structural design during the development of novel synthetic retinoid molecules. 
 
The development of novel, synthetic, retinoid molecules has provided advances in the 
field of stem cell biology and the development of differentiation protocols, particularly 
neuronal differentiation. Stable, synthetic retinoids do not isomerise as readily when 
exposed to light and heat compared with the naturally occurring ATRA, therefore, are 
more practical for use in vitro, as exposure to these factors cannot be avoided.  
 
Retinoid compounds are often used in vitro to promote neuronal differentiation and 
maturation. However, this is not a requirement of all commonly used cell types to ensure 
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neurite development in vitro, as primary cell types derived from animal tissue, such as 
DRG often contain mature neurons. However certain cancer cell lines, including the 
commonly used SH-SY5Y along with pluripotent cells, require RA-induced maturation to 
develop neurites and mature in culture. Each neurite-forming cell type often has its own 
distinct set of advantages and disadvantages, therefore, the appropriateness of a 
particular cell type should be considered when developing in vitro models. 
 
1.2.2 Dorsal Root Ganglia  
 
Dorsal root ganglia (DRG) refers to a collection of cell bodies from afferent sensory fibres 
located where the cervical, thoracic, lumbar and sacral spinal nerves enter the spinal 
cord85.  As the soma of such cells is located on a side branch of the main axon it is easily 
accessible for patch clamp recordings, therefore this cell type is often considered for 
neurological studies86. In vitro culture of DRG neurons within hours of seeding, result in 
the development of several long, thin and uniform axons tipped with growth cones that 
express axonal marker proteins87. However, long-term culture results in a more mature 
morphology that better reflects that of DRG neurons in vivo87. For this reason, DRG 
neurons are often explanted from many animals, including chick88,89, mouse90,91 and 
rat89,92–94 for use in in vitro models of neurite outgrowth.  
 
DRG neurons are primary cultures, explanted from experimental animals and are thought 
to overcome some of the disadvantages associated with immortalised cell lines. For 
example, immortalised cell lines that have been genetically manipulated may result in an 
altered phenotype and variations from their native functions95. The continual passaging of 
cell lines can also lead to further genetic variation, resulting in a phenotype that may be 
far removed from the native in vivo cell type95.  Szpara et al characterised the gene 
expression of neurites generated from DRG cultures and found that many transcripts 
expressed during in vivo development are also expressed during neurite extension in 
vitro96.  Therefore, in vitro neurite outgrowth assays based on explanted DRG neurons are 
thought to provide a reliable model to study the process of neurite outgrowth.  
 
Although neurite outgrowth from primary DRG cultures has been compared favorably 
with neurite outgrowth in vivo, there are some disadvantages to the use of such cells in 
neurite outgrowth assays. Isolation of primary cells may be difficult, resulting in a 
heterogeneous population of cells that may include glial subtypes and neurons that vary 
in response to stimuli, signal conduction and neurochemistry85. Similarly, the method of 
isolation along with the age of the animal, may contribute to phenotypic variations in the 
resultant cellular population97. Such variation is problematic in the development of robust 
neurite outgrowth assays for use in pharmaceutical development and drug discovery, 
where a standardised and reproducible assay is essential.   
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1.2.3 Cerebellar Granular Neurons 
 
Cerebellar granular neurons (CGN) constitute the largest homogenous population of 
neurons within the mammalian brain and provide the basis of many well-characterised 
primary in vitro culture models98. Primary CGN cultures are a popular in vitro model used 
to study many aspects of neurobiology including developmental, functional and 
pathological processes. Unlike DRG neurons, cellular isolation is particularly efficient 
resulting in more homogenous populations of cells with an estimated 90 % purity of 
cultures98.  CGN cells are usually explanted from post-natal rats99,100 for use in vitro; 
however, animal derived cells may not be suitable for studying certain aspects of human 
biology due to physiological differences between the species. This is a factor that should 
be considered when selecting an appropriate neurite outgrowth assay for a particular 
study.  
 
CGN form the basis of many in vitro models of neurite outgrowth and have been used to 
study many aspects of neuritogenesis. For example, Wantanabe et al, use primary mouse 
CGNs to study the role of the cell adhesion molecule L1 and its downstream signalling 
events in neurite outgrowth101. Many studies that focus on the role of specific hormones in 
neurite outgrowth do so by the use of CGN in vitro models. For example, Farwell et al 
focus on the role of thyroxine in brain development and neurite outgrowth, elucidating a 
novel actin-dependent mechanism by which the hormone drives neurite outgrowth102. 
Similarly, a study by Tankiwaki and Schwartz investigates the role of somatostatin in the 
induction of neurite outgrowth, concluding that the hormone is involved in neurite 
initiation103. Studies such as these highlight the valuable role of CGN-based in vitro 
models.    
 
1.2.4 SH-SY5Y Neuroblastoma Cells  
 
A major limitation in the use of primary mammalian neurons such as DRG and CGN is that 
once terminally differentiated, neurons lose their proliferative capability. For this reason, 
immortalised cell lines provide an appealing alternative. The SH-SY5Y neuroblastoma 
sub-line was derived from the parental line SK-N-SH which itself was derived from a 
human metastatic bone tumour biopsy104. SH-SY5Y cells differentiate in response to 
retinoic acid and are one of the most common cell types used routinely for neurite 
outgrowth studies105–108.  
 
Prior to differentiation, SH-SY5Y cell populations can be expanded on a large scale with 
ease and using low cost medium, which is an advantage compared with primary cell 
types109. Similarly, SH-SY5Y cells are of human origin therefore their physiology may be 
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more relevant when studying human disease as opposed to animal derived explanted cell 
types. However, SH-SY5Y cells themselves present limitations.  Original SH-SY5Y cultures 
were heterogeneous containing both adherent and floating cell types, many studies focus 
only upon adherent populations of SH-SY5Y with floating cells being discarded without 
mention in media changes109. Similarly, the original SK-N-SH population contained both 
neuron-like and epithelial-like sub-populations of cells that were later isolated in the 
development of the SH-SY5Y sub-line110.  
 
Although the relevance of SH-SY5Y for neurite outgrowth studies has been called into 
question109, they still form the basis of one of the most popular in vitro models of 
neuritogenesis and are commonly used to study the process. Nicolini et al used retinoic 
acid differentiated SH-SY5Y cells to assess the neurotoxic effect of chemotherapy drugs 
along with their effect on neurite outgrowth111. In this study it was found that results 
obtained in vitro within the SH-SY5Y model of neurite development, were similar to those 
found previously in vivo111. Therefore, it was concluded that SH-SY5Y cells could provide a 
reliable model for the screening of neurotoxicity induced by chemotherapy drugs111. 
However, although commonly used, there are many limitations associated with the use of 
SH-SY5Y cells in vitro including their neoplastic nature, mixed morphology and limited 
capacity for neuritogenesis and these factors must be considered when using SH-SY5Y 
cells109. 
 
1.2.5 PC12 Cells 
 
The PC12 cell line was derived from a transplantable rat adrenal pheochromocytoma and 
generates neurites reversibly upon induction by nerve growth factor (NGF)112. Induction 
of PC12 cell differentiation by NGF results in a peripheral sympathetic phenotype113 and 
the synthesis of catecholamines112, therefore the use of this model to study central 
nervous system disorders may be limited.  
 
Due to the ability of PC12 cells to readily differentiate and generate neurites upon 
induction by NGF, their main application in vitro has been to study the role of NGF in 
neurite development15,114,115.  Initially, Gunning et al116 and later Richter-Landsberg & 
Jastroff117 used the NGF – PC12 induction model to investigate the role of cyclic adenosine 
monophosphate (cAMP) in NGF-mediated signalling. Although PC12 cells are a suitable 
model for the study of NGF signalling, their neoplastic nature and short neurites may 
result in limitations for use in certain applications.  
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1.2.6 Pluripotent Stem Cells 
 
Pluripotent stem cells (PSCs) are unspecialised cells that can differentiate into cell types 
from each of the three germ layers118–120. There are three main types of pluripotent stem 
cell commonly used in neuronal differentiation studies (outlined in Figure 1-6) including, 
embryonic stem (ES) cells derived from the inner core of the developing blastocyst, along 
with their malignant counterpart, the embryonal carcinoma (EC) cell derived from 
teratoma tumours69. More recently induced pluripotent stem cell (iPSC) technology 
involving the reprogramming of adult somatic cells121–123 has gained popularity as this cell 
type avoids the ethical considerations associated with ES cells and malignant 
characteristics associated with EC cells.  
 
The ability of PSCs to self-renew and differentiate into specialised subtypes including 
mature neurons has resulted in PSCs forming the basis of many in vitro models124. PSCs 
also have the potential to generate a population of neuronal subtypes for the purpose of 
cell replacement therapies125 used to treat neurodegenerative diseases and clinical trials 
are underway for the application of this technology in the treatment of Parkinson’s 
disease125–128. Many groups have focused on the development of robust and reproducible 
neuronal differentiation protocols to generate functional, mature neurons for use both in 
vitro and in vivo. 
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Fig 1-6: Types of pluripotent stem cell commonly used in neural differentiation 
studies. 
Embryonic stem (ES) cells are derived from the inner cell mass of the developing 
blastocyst, whereas embryonal carcinoma (EC) cells are derived teratocarcinomas. EC 
cells are the malignant counterparts of ES cells and both cell types are commonly used to 
generate neuronal cell populations. Induced pluripotent stem cells (iPSCs) are generated 
through reprogramming of adult somatic cells resulting in an undifferentiated phenotype. 
iPSCs overcome some of the ethical implications associated with ES cells and the 
malignant phenotype associated with EC cells, along with having potential applications for 
personalised medicine 
 
 
1.2.6.1 Embryonic Stem Cells 
 
Embryonic stem (ES) cells are pluripotent stem cells derived from the inner cell mass of 
the blastocyst from surplus embryos generated by in vitro fertilisation (IVF)129. They are 
characterised by their expression of pluripotency markers including extracellular markers 
such as SSEA-3, SSEA-4 and TRA-1-60 and transcription factors including Oct 4 and 
Nanog129. When injected into immunocompromised mice, ES cells form teratomas 
containing tissue from each germ lineage, an assay used to determine the differentiation 
potential of newly isolated cell lines130,131. 
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Neuronal differentiation of ES cells is not only an important process to generate functional 
neurons for in vitro models and in vivo cell replacement, but can be used as a tool to 
understand the signalling mechanisms involved in neuronal development. Application of 
morphogens such as retinoic acid (RA) can be used to direct ES cells toward a neural 
lineage. The combination and concentration of morphogens used in a differentiation 
protocol determines the phenotype of the resultant neuronal population132, as shown in 
Figure 1-7.  
 
The generation of specific neuronal subtypes is important in the production of cell 
populations for transplantation and also to study disease mechanisms in vitro. For 
example, RA exposure followed by sonic hedgehog (Shh) treatment results in the 
differentiation of motoneurons in vitro as described by Li et al132,133. Harper et al 
demonstrate a potential application of the resultant motoneurons to study the process of 
neurite outgrowth in vitro in a comparison with motoneuron injured rats134.  Other 
neuronal differentiation procedures include the culture of ES cells as embryoid bodies 
(EBs)135, dual-SMAD inhibition136 and FGF induction137, combinations of which can be 
used to obtain specific neuronal subtypes. 
 
Although there are many differentiation protocols available that generate functional 
neurons from ES cells, few are used to study neurite outgrowth. ES cell-derived neurons 
are usually used for drug screening, cell replacement therapy or to study developmental 
processes. However, ES cell popularity for use in neurite outgrowth assays may now 
increase due to the publication of a methodology by Harril et al that details the use of an 
ES cell-derived neuronal cell line, hN2™, in an automated, high-throughput neurite 
outgrowth assay138.  This study compares the effects of known inhibitors of neurite 
outgrowth in standard assays such as DRG cultures with hN2™ cells analysed using 
automated image analysis techniques138. It was found that neurites from both models 
behaved in a similar manner when exposed to inhibitory compounds, therefore it was 
concluded that hN2™ cells could provide a reliable model of neurite outgrowth suitable 
for high-throughput screening138.  
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Fig 1-7: Morphogen induction of specific neuronal phenotypes. 
The fate of embryonic stem (ES) cells can be directed toward a neural phenotype by the 
application of morphogens that induce signalling pathways involved in embryonic 
development. The order and combination in which morphogens are applied, determines 
the specific subset of neurons generated. This schematic depicts some of the major stages 
in the generation of common neuronal subtypes.  
 
 
1.2.6.2 Embryonal Carcinoma Cells  
 
Embryonal carcinoma (EC) cells are the malignant counterpart of the ES cells derived 
from teratocarcinomas, malignant germ cell tumours69. They offer a robust and simple 
model to study developmental pathways due to their pluripotent nature and ability to 
form teratomas in immunocompromised mice69. Unlike ES cells, their maintenance is 
relatively simple and growth medium inexpensive. They also overcome the ethical 
implications involved in the derivation of ES cells from viable embryos.  
 
There are two main EC-cell lines commonly used in neural differentiation and outgrowth 
studies, P19 mouse derived cells139–142 and N-TERA2 human derived EC cells21,66,143,144. 
 22 
Both lines differentiate into functional neurons when exposed to RA and are commonly 
used to study the process of neurite outgrowth, however, the N-TERA2 line has the 
advantage of being human derived, therefore is more applicable to medical applications 
such as drug screening and investigations into pathological mechanisms.   
  
The original N-TERA2 EC cell line was derived from a lung metastasis of a male germ cell 
tumour and many clonal lines have now been derived from the original parental line.  For 
example, in 1984 Andrews derived the NTERA2.cl.D1 subline that when exposed to RA 
loses expression of pluripotency markers such as SSEA-3 and results in a heterogeneous 
cell population containing neuronal subtypes145. Similarly, in 2000 Przyborski derived 
another subline, TERA2.cl.SP12 from the original N-TERA2 parent line through 
immunomagnetic sorting based on expression of SSEA-3146. The TERA2.cl.SP12 subline 
was found to respond to RA and differentiate readily, displaying enhanced differentiation 
compared with other clonal lines and resulting in the production of both neurons and 
glia146.  
 
Since its derivation, the TERA2.cl.SP12 clonal subline has formed the basis of many well-
characterised neurite outgrowth models82,147–150, as RA exposure leads to the generation 
of mature70,71, electrophysiolocially active neurons72 that are suitable for many 
applications.  Stewart et al demonstrate the culture of TERA2.cl.SP12 cells as spheroid 
structures that when exposed to RA generate neurites that radiate from the central 
cellular aggregate148. This overcomes some of the difficulties posed by traditional 
monolayer neurite outgrowth cultures, where neurites form a network of overlapping, 
branching processes that are difficult to trace and quantify, as shown in Figure 1-8. This 
cellular aggregate approach to neurite generation allows for efficient neurite 
quantification as each neurite originates from a single perikaryon.    
 
 
 
Fig 1-8: Neurite outgrowth from monolayer and spheroid cultures of EC cells.  
Embryonal carcinoma (EC) cells can be cultured as monolayers or spheroids and neurites 
can be generated in either culture system. Neurite outgrowth (green) from monolayers 
(A) of cells results in the formation of complex neuronal circuitry, however, when tracing 
neurites for quantification it is difficult to determine the perikaryon (blue) associated 
with each neurite. Spheroid (B) culture offers a solution to this, as neurites radiate from 
one central point, allowing for more accurate quantification.  
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1.2.6.3 Induced Pluripotent Stem Cells 
 
Induced pluripotent stem cells (iPSCs), unlike ES and EC cells, are derived from adult 
somatic cells. The generation of iPSCs involves the reprogramming of cells151,152 such as 
skin fibroblasts, typically this is achieved through retroviral transfection of a cocktail of 
transcription factors usually including: Oct3/4, c-Myc, Klf4 and Sox2122,153. This results in 
a pluripotent cellular population with similar properties and expression of pluripotency 
markers as ES cells153 whilst avoiding the ethical implications associated with the use of 
embryonic tissue. Pioneering studies by Takahashi et al, first describe the reprogramming 
of mouse fibroblasts154 and then apply the same principles to successfully reprogram 
human fibroblasts, forming one of the first human iPSC lines121.  
 
Due to their ability to indefinitely self-renew and when stimulated, differentiate into 
functional cell types including neurons, there has been a focus on the development of 
robust iPSC neural differentiation protocols124,125,155. Neural differentiation procedures 
used to direct the fate of iPSCs, generally adhere to the same principles as those used in ES 
culture. Morphogens are used to stimulate developmental pathways and to induce 
neuronal phenotypes. For example, Hu et al, demonstrate the ability of iPSCs to 
differentiate in a comparison with ES cell differentiation156. This study found that when 
differentiated using common techniques such as RA and Shh induction, iPSCs generated 
functional neural and glial subtypes to the same extent as ES cells156.   
 
Although iPSC-derived neurons are rarely used in specific neurite outgrowth studies, the 
development of iPSC technology has resulted in many opportunities to study complex 
disease states in vitro. Neurodegenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease are multifaceted, complex disorders; therefore the ability to produce 
disease specific in vitro models based on patient derived cells has led to many 
advancements in this field.   
 
Yagi et al describe the isolation of fibroblasts from two Alzheimer’s disease patients with 
mutations in presenilin 1 and 2 components of γ-secretase, which is involved in the 
generation of β-amyloid species157. This study then describes the subsequent 
reprogramming of the fibroblasts into iPSCs and induction of neuronal differentiation to 
produce neurons with disease specific characteristics such as an elevated Aβ42:Aβ40157. 
Similarly, patient obtained iPSC-derived neurons have been used to study the molecular 
pathogenesis associated with Parkinson’s disease and have been shown to accumulate α-
synuclein, a hallmark of the disease158,159.  
 
The development of iPSC based complex disease models in vitro not only has implications 
in the development of more reliable drug screening models160 but also has applications in 
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the field of personalised medicine124. Patient specific cells can be generated using iPSC 
technology to produce a pool of differentiated cells for transplantation purposes or 
personalised drug screening that are genetically identical to the individual (summarised 
in Figure 1-9)124,125. This can lead to personalised in vitro models with an enhanced 
predictive value that can be used to determine the effect of a drug on a specific individual.  
 
 
 
 
 
Fig 1-9: Application of induced pluripotent stem cell technology in drug 
development. 
A schematic representing the development of induced pluripotent stem cell (iPSC) 
populations and their application in drug development. Patient derived somatic cells such 
as fibroblasts can be reprogrammed to form iPSCs that can subsequently be differentiated 
into mature neurons. iPSC-derived neurons then have applications in personalised 
medicine, as patient specific models can be generated for drug screening. iPSCs also have 
applications in the in vitro modelling of complex diseases that can be used for high 
throughput screening and identification of specific drug candidates.  
 
 
1.3 3D Cell Culture Technologies 
 
Cells are the building blocks of complex, three-dimensional (3D) tissues within the body; 
however, in vitro, cells are often cultured in a two-dimensional (2D) environment. Cells 
cultured on flat, 2D growth substrates can often differ significantly from their in vivo 
counterpart as their morphology, cell-to-cell contacts, cell-to-matrix contacts and 
differentiation may all be altered161. Cells cultured in 2D adapt to their microenvironment, 
resulting in cell flattening and cytoskeletal remodelling162. This leads to changes in the 
internal structure of the cell along with nuclear shape, ultimately resulting in altered gene 
and protein expression, impacting cellular behaviour due to the close relationship 
between cell structure and function162. Many aspects of the cellular microenvironment 
impact the function of the cell, including three-dimensionality and nutritional status 
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(summarised in Figure 1-10), all of which should be considered when developing an in 
vitro cell-based model161.  
 
This is of particular importance, as 3D culture technology can help to restore a 
cytoskeletal architecture more reminiscent of native cells, which in turn effects cellular 
function, as the two are so closely connected162. Similarly, nutritional status, is also an 
important consideration when developing an in vitro model or engineering a tissue-like 
construct. This depends on the tissue of interest, as development of a “healthy” tissue 
construct may require adequate oxygenation and nutritional excess. However, there are 
other occasions such as tumour development, when in vivo tissues are exposed to hypoxia 
and nutrient insufficiency that can lead to necrosis161. This is of particular relevance in the 
screening of chemotherapeutic drugs, specifically as some are hypoxia-targetting, and the 
level or absence of necrosis in a tumour model may convey resistance to such drugs, 
which would not be the case in vivo162. Therefore, when developing an in vitro cell-based 
model, the culture parameters that are the most consistent with the native cellular 
microenvironment should be considered, which will differ depending on the tissue of 
interest. 
 
 
 
 
Fig 1-10: Microenvironmental factors that affect cellular behaviour. 
A schematic representing aspects of the cellular microenvironment that effect cellular 
function and behavior. Most aspects of the microenvironment affect the way in which a 
cell behaves and in turn should be considered when developing in vitro cell-based models. 
For example, 3D cell culture technology is becoming more widely adopted as traditional 
2D growth substrates induce changes in cellular structure that effect the function and 
protein expression of a cell. Equally, the oxygen availability of each culture model should 
be considered as many physiological tissues exist in hypoxic conditions. To produce the 
most accurate in vitro model possible that best reflects the in vivo environment, each 
aspect of the physiological microenvironment should be considered. 
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One of the hurdles faced by the pharmaceutical industry is that many of the drugs that 
show promising effects in vitro, fail to demonstrate the required clinical safety and 
efficacy for approval for human use163,164.  Most in vitro, cell-based models commonly used 
in drug development and safety testing, routinely adopt 2D cell culture conditions, such as 
the Caco-2 monolayer model of intestinal permeability165,166 and HepG2 model of 
hepatotoxicity167,168. However, due to cellular inconsistencies in vitro and in vivo, when 
candidate drugs are tested in animal models, drugs that were initially thought to be 
suitable may exhibit unwanted effects162. This is thought to be due to the altered cellular 
structure and function associated with 2D culture and there is now much focus on the 
development 3D cell-based, in vitro models with better predictive value161,169,170.  
 
There are many 3D cell culture technologies commonly used in the development of in 
vitro models, each has its own advantages and disadvantages that should be assessed 
prior to use. Spheroid culture systems are perhaps the most basic method of recreating a 
3D environment and are most commonly used in stem cell culture, whilst scaffold based 
technologies can provide support and 3D growth cues to cultures and range from ECM-
based hydrogels to solid polymer scaffolds161,162. However, all 3D technologies aim to 
provide a more physiologically relevant microenvironment maintaining native cellular 
structure and function, to provide more reliable insights into biological processes161,162. 
 
1.3.1 Spheroid Cultures 
 
The most simple 3D cell culture system is that of the spheroid culture, which is a scaffold 
free methodology that promotes the culture of cells as multi-cellular aggregate structures. 
Within spheroids, cells form cell-to-cell contacts and secrete their own ECM components 
providing a more favourable microenvironment than the traditional 2D culture setting162. 
The most traditional methodology of aggregate induction is that of the hanging drop 
technique, whereby cells are cultured within a suspended droplet on the lid of a tissue 
culture plate and aggregates form at the apex of the drop171. However, other aggregate 
induction methodologies (outlined in Figure 1-11) also include the culture of cells on low 
adherent substrates allowing them to form cellular aggregates in suspension172. 
Alternatively, specialised tissue culture plates are available that contain microwells that 
force the cells into close proximity resulting in spheroids of a controlled size, such as the 
AggreWell™ plate173. 
 
Spheroid culture techniques are most commonly employed in the culture of pluripotent 
stem cells. Cellular aggregates composed of ES cells, known as embryoid bodies (EBs), can 
provide insight into the mechanisms of early differentiation events that occur during 
embryonic development174. The culture of EBs mimics many of the events involved in 
early embryonic development and therefore can be a very valuable tool in the study of 
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developmental mechanisms, however, there are a number of problems associated with 
spheroid cultures174. For example, a lack of diffusion both of gasses and nutrients into the 
centre of large EBs can result in a hypoxic environment that may lead to necrosis162.   
 
 
 
Fig 1-11: Spheroid culture methodologies. 
Schematics representing each method of cellular aggregate induction used routinely in 
spheroid culture systems. The hanging drop methodology (A) involves the culture of cells 
in drops of growth medium, suspended from the lid of a tissue culture plate and cellular 
aggregates (blue) form at the apex of each drop. Low adherent substrates can be used to 
culture cells in suspension (B) and cells begin to form clumps that develop into cellular 
aggregates over the culture period. A micrograph (C) demonstrates the microwells visible 
at the bottom of each culture well within an AggreWell™ plate. Cells that are cultured 
within the microwells are forced into close proximity and ultimately spheroids can be 
harvested from the plate. Scale bar: 500 µm.  
 
 
The formation of EBs mimics the initial stages in embryogenesis, and therefore this 
technique is often used in differentiation protocols to provide a more physiologically 
relevant setting174. Particularly, neural differentiation of ES cells is commonly achieved 
through EB culture combined with the application of morphogens to direct stem cell fate 
toward a neural lineage. EB neural differentiation methodologies result in the generation 
of neurons, through the dissociation of differentiated spheroid structures135 that can 
subsequently be used for transplantation137 or in vitro purposes175–177 such as neurite 
outgrowth assays. An example application of spheroid differentiation cultures is 
highlighted by a study from Doers et al that describes the isolation of iPSCs from patients 
with fragile X syndrome and their subsequent neural differentiation as spheroids to 
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provide a disease specific in vitro model178. Differentiated neurospheres were dissociated 
and re-plated as neuronal cultures and the ability of patient-derived neurons to form 
neurites was found to be impaired178.  
 
1.3.2 Hydrogel Technology 
 
Scaffold structures are often used to provide a 3D environment for cell growth and 
development in vitro. Hydrogels are an example of scaffold-based technology and are 
comprised of a loose framework of cross-linked molecules usually of natural origin such 
as agarose, fibrin, collagen or hyaluronic acid in a high water content gel162. These 
materials contain cell adhesion sites and provide a biochemically favourable environment 
by re-capitulating some aspects of the native ECM, along with providing a 3D environment 
for cell growth, both of which are important factors in providing a physiologically relevant 
microenvironment (summarised in Figure 1-10)162,179.   
 
As with all 3D cell culture technology, there are some limitations to the use of hydrogels 
that must be considered prior to use. Cells are usually encapsulated into the gels through 
a process that may require exposure to UV light to cure the gel and promote 
polymerisation, which may have adverse effects upon the cells180. Difficulty of nutrient 
diffusion throughout the gel may limit the length of time cultures are able to be 
maintained for, resulting in cells being cultured for relatively short periods of time162. 
However, there are also many advantages in the use of hydrogels, particularly in the field 
of tissue engineering. Once cells are encapsulated within the hydrogel, they are able to 
grow and develop cell-cell interactions with the potential to result in tissue formation180. 
Once a tissue has developed within the gel, the gel can be degraded through enzymatic 
digestion resulting in a scaffold-free tissue-like structure, as described in Figure 1-12180.  
 
Common applications of hydrogel technology include the study of cellular migration and 
branching162 such as neuritogenesis, therefore hydrogels are commonly used in neurite 
outgrowth studies179,181,182. Tibbet et al, demonstrate the differences between neural cells 
cultured as a monolayer and within a hydrolytically degradable polyethylene glycol based 
hydrogel179. Within the hydrogel, cells form a spheroid-like structure and neurites radiate 
from the central sphere within the 3D space179. This has advantages over the traditional 
monolayer culture, as neurite quantification is more simple and precise, as neurites do not 
form complex networks, along with providing a more physiologically relevant 3D 
geometry to study the development of neurites. 
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Fig 1-12: Development of tissue-like structures within hydrogels. 
A schematic representing the development of tissue-like structures within hydrogel 
scaffolds. Single cells are initially encapsulated within the gel through the polymerisation 
of gel precursors (blue). Within the gel, cells begin to secrete their own ECM components 
(orange) and form cell-to-cell contacts resulting in tissue-like structures. The gel can then 
be enzymatically degraded, leaving a scaffold-free, tissue-like structure remaining. 
 
 
Hydrogel based approaches are currently being considered for use in the repair of nerve 
injuries, particularly as they can be biodegradable, proving a suitable candidate for 
cellular delivery in vivo. Assuncao-Silva et al, propose a strategy that combines a co-
culture approach of neurons with adipose derived stem cells and glial derived 
neurotrophic factor within a hydrogel based culture system to enhance neurite outgrowth 
in the context of peripheral nerve injury (PNI)181. Similarly, Shepard et al describe the 
combination of gene delivery with biodegradable hydrogels to promote neurite 
outgrowth and to potentially overcome the obstacles that limit regeneration in the 
nervous system182.  
 
1.3.3 Fibrous Scaffolds 
 
Similarly to hydrogels, fibrous scaffolds provide a 3D support for developing cells and 
electro-spinning is used to generate the most commonly used fibrous scaffolds162. 
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Electrospinning allows for the generation of nanofibrous scaffolds that can be made from 
either synthetic or natural polymers that can have a bioactive function183.  Passing a 
polymer jet through an electric field and collecting the resultant material on a grounded 
surface162 results in the formation of 3D mesh of non-woven nano and microfibres183. 
Nanofibrous scaffolds are highly porous and have a high surface area to volume ratio 
along with providing a large range of topological features that encourage cellular 
adhesion and proliferation183.  
 
One of the major advantages of the electrospinning technique is that the orientation of 
fibres can be determined. Fibres within the scaffold can be aligned producing directional 
scaffolds on which cells can adhere and elongate, providing alignment and directionality 
to cultures162. This particularly has applications in the generation of neuronal grafts for 
implantation in the case of PNI184–186. The alignment of nanofibre scaffolds is also thought 
mimic the structure of certain aspects of the ECM, including the arrangement of collagen 
fibrils162. Nanofibres can also be functionalised by the incorporation of ECM motifs such as 
laminin into the scaffold that promotes the outgrowth of neurites and enhances neuronal 
cultures, providing a more physiologically relevant environment187. 
 
However, the 3D support which nanofibres provide has been called into question as cells 
adhere to the surface of the scaffold with minimum penetration183. Therefore, some may 
believe that there is little difference between 2D cell culture and cells cultured within a 
nanofibre scaffold. However, although cells do not migrate into the scaffold, they receive 
nutrients and growth cues from the 3D topography of the scaffold, providing a uniquely 
3D culture environment183.  
 
Electrospun nanofibres are commonly used in the field of neural tissue engineering and 
due to their aligned nature, are often used to direct neurite outgrowth. A study by Xie et al 
describes a combined approach to enhance the neural differentiation of ES cells188. This 
study combines two different forms of 3D technology through differentiation of ES cells as 
spheroids (EBs) before seeding neural progenitor cells onto an electrospun biodegradable 
polymer for the repair of nerve injuries. In this case the electrospun scaffold was found to 
not only enhance neural differentiation but also to provide growth cues and guidance for 
the developing neurites themselves188.  
 
Nanofibrous scaffolds are routinely used in neurite outgrowth studies, with the 
composition of the scaffold such as its diameter and surface properties determining the 
extent to which neurites develop189,190. Therefore, variability in the production of such 
scaffolds impacts the reproducibility of a particular neurite outgrowth assay, preventing 
its widespread adoption within the pharmaceutical industry. However, this offers 
flexibility that may be required in an academic setting, as modifications may be made to 
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the production to enable investigations into the effect of certain aspects of the material 
(surface coupling with ECM components, structure/order, directionality, diameter, 
conduction, etc.) upon neuritogenesis.  
 
1.3.4 Porous Scaffolds 
 
Porous scaffolds provide a 3D microenvironment in which cells can infiltrate and retain a 
morphology reminiscent of the in vivo tissue. Within porous scaffolds, cells form contacts 
with neighbouring cells resulting in structures that resemble the native tissue162. Various 
materials have been used to generate porous scaffolds for cell culture applications, 
however, inert, non-degradable materials perhaps seem to be the most widely adopted for 
in vitro purposes162. These consist of internal pore structures connected by voids in which 
cells can grow and growth medium can diffuse throughout191. There are many 
mechanisms employed in the generation of such scaffolds including: emulsion templating, 
leachable particles and gas foam technology191.  
 
Most non-degradable scaffolds are polystyrene based and as polystyrene is inert and 
stable. These products have a long shelf life particularly in comparison to hydrogels or 
biodegradable scaffolds made from natural sources191. Conventional 2D tissue culture 
plastic-ware is usually polystyrene based, therefore 3D polystyrene scaffolds offer an 
opportunity for direct comparison between 2D and 3D culture, allowing investigation 
specifically into the effect of a 3D geometry on cellular function191. However, polystyrene 
is not a particularly physiologically relevant material, as cells are never exposed to this 
material in vivo and polystyrene scaffolds fail to recapitulate the in vivo biochemical 
environment. This can be overcome by adsorption of ECM proteins192 to the scaffold, or by 
the functionalisation of such scaffolds193 to provide a more biochemically favourable 
environment.  
 
Emulsion templating is a production technique used in the manufacture of porous, 
polystyrene scaffolds such as Alvetex® Scaffold. Alvetex® Scaffold is a commercially 
available, inert, polystyrene scaffold manufactured using a biphasic emulsion191. The 
scaffold is created through a polymerisation reaction consisting of an aqueous and non-
aqueous monomer/surfactant phase191,194–196. The resultant scaffold is termed a poly-
HIPE (high internal phase emulsion) and consists of a network of voids and 
interconnecting windows (internal structure of Alvetex® is shown in Figure 1-13)191. 
Alvetex® is manufactured into a 200 μm thick disc and is available in insert formats that 
are compatible with standard tissue culture plastic-ware, as shown in Figure 1-13. 
Scaffolds such as this provide a highly porous 3D cell culture microenvironment that 
promotes the exchange of nutrients, waste products and gasses191. 
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Fig 1-13: Alvetex® Scaffold: A porous polystyrene scaffold for 3D cell culture. 
Alvetex® Scaffold inserts (A) are compatible with standard tissue culture plastic-ware. 
Within the culture well (B), growth medium connects the outer and inner chambers 
providing an abundance of nutritional material. An electron micrograph (C) reveals the 
internal porous, structure of scaffold with internal voids of 40 µm on average and 
interconnecting windows of approximately 13 µm.  
 
 
Similarly to the other 3D cell culture technologies discussed thus far, polystyrene scaffolds 
such as Alvetex® have applications in the field of neuroscience. Specifically, Alvetex® 
Scaffold is commonly used in the development of in vitro models including differentiation 
methodologies and neurite outgrowth models based upon stem cell derived neurons. In a 
study by Hayman et al the ability of Alvetex® to provide a 3D environment for the growth 
and differentiation of human stem cell derived neurons was established150. In a later study 
by Hayman et al it was found that neuritogenesis was actually enhanced by the culture of 
neurons within a 3D environment compared with traditional 2D culture, as evidenced by 
elevated expression of known markers of neurite outgrowth including, nestin, MAP2 and 
NeuroD147. The ability of glial and neuronal populations to form functional circuitry 
within a 3D environment was assessed by Smith et al, who found that cells cultured 
within Alvetex® Scaffold exhibited a more physiologically relevant phenotype in terms of 
morphology, pharmacology and electrophysiology197.   
 
1.4 Conclusions 
 
In conclusion, neurite outgrowth is an important developmental process, essential to the 
maintenance of proper neural connectivity. Inhibition of neurite outgrowth is common to 
many disorders of the nervous system including trauma such as spinal cord injury and 
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neurodegeneration including Alzheimer’s disease. For this reason, the development of 
reliable, robust and reproducible in vitro neurite outgrowth models is essential, not only 
to study the underlying mechanisms of neurite inhibition, but also to screen potential 
compounds that may be able to recover neurite growth. 
 
As described in this chapter, 3D cell culture technology can provide a more physiologically 
relevant environment to study cellular processes, and polystyrene scaffolds have even 
been previously demonstrated to enhance neuritogenesis. Although neurite outgrowth 
models currently exist, there are many limitations in their application to routinely test the 
ability of compounds to induce neurite degeneration or regeneration. Perhaps most 
importantly quantification of neurite outgrowth currently relies on neurite tracing using 
image analysis software. This can be laborious and error prone, which is why there is 
need for a novel model of neurite outgrowth that can be more easily and accurately 
quantified, amenable to high throughput applications. Synthetic retinoid compounds can 
induce robust neuronal differentiation from human pluripotent stem cells, and have been 
shown to reproducibly induce neuritogenesis. 3D cell culture technology in combination 
with the robust neuronal differentiation of human pluripotent stem cells induced by 
synthetic retinoid analogues, may provide a novel in vitro model of neuritogenesis that 
better recapitulates in vivo neurite development, with greater efficiency and accuracy. 
This model may then be applied to specific disease pathways to uncover the molecular 
signalling events common to the process of neurite inhibition.   
 
1.4.1 Project Aims  
 
This project aims to build upon current knowledge of neurite induction, to develop a 
novel 3D in vitro model of human neuritogenesis, combining human pluripotent stem 
cells, synthetic retinoid analogues and 3D cell culture technology in the form of Alvetex® 
Scaffold. This physiologically relevant model of human neurite outgrowth can be applied 
to study the role of neurite inhibition in the context of spinal cord injury and Alzheimer’s 
disease, identifying signalling pathways common to both pathologies. We hypothesise that 
combining the aforementioned technology will allow us to develop an improved, novel 
model of human neurite development that better mimics the in vivo developmental 
process. Once developed, we then plan to apply this model to several neurological 
pathologies to begin to dissect the molecular signalling events that govern neurite 
inhibition and regeneration in the CNS. 
 
Furthermore, the identification of such signalling mechanisms can allow for the 
identification of critical points where intervention by small molecules may result in the 
restoration neurite growth. This demonstrates the application of such a model in the 
screening of potential compounds and the assessment of neurotoxicity of potential drug 
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candidates. We hypothesise that inhibition in the Rho A/ROCK signalling cascade may 
lead to neurite regeneration, despite the presence of inhibitory stimuli, aiding our 
understanding of the inhibitory pathways involved in loss of neuronal connectivity within 
the CNS.   
 
To further enhance the model, protein surface technology will be employed to 
functionalise 2D and 3D growth substrates to improve the physiological relevance and 
standardise the model. This technology can then be used to further identify neurite 
inhibitory/enhancing motifs and to enhance our understanding of the molecular 
processes involved in neurite growth and inhibition. 
 
1.4.2 Project Objectives 
 
 Develop and characterise a robust and reproducible, novel in vitro model of 
human neurite outgrowth by combining human pluripotent stem cell, synthetic 
retinoid and 3D cell culture technologies. 
 
 Apply the novel 3D model of neuritogenesis to study the molecular mechanisms 
underpinning neurite inhibition in the context of the glial scar that forms 
following spinal cord injury.  
 
 Investigate the ability of the β-amyloid peptide involved in Alzheimer’s disease to 
induce neurite inhibition and potential mechanisms of recovery. 
 
 Identify potential neurite enhancing and inhibitory motifs through the use of 
protein surface technology to produce functionalised growth substrates that can 
be used to further enhance and standardise the novel 3D model of neurite 
outgrowth. 
 
 
 
 
 
 
 
 
 
 
 35 
Chapter II: Materials & Methods 
 
2.1 Introduction 
 
A number of scientific techniques were used throughout this thesis, in order to investigate 
and probe neurite development and inhibition. These range from advanced cell culture 
techniques, to immunofluorescence and histological processing analyses, which have 
allowed for the development of the novel human neurite outgrowth model described and 
applied throughout the chapters of this work. This chapter outlines the main scientific 
techniques that have been utilised throughout this study.  
 
2.2 Cell Culture 
 
 2.2.1 Maintenance of Human Pluripotent Stem Cells 
 
The human embryonal carcinoma (EC) stem cell line, TERA2.cl.SP12 is a sub-line of the 
original TERA-2 line isolated by Prof. Stefan Przyborski (Durham University). The original 
TERA-2 line was isolated from a lung metastasis of a primary malignant embryonal 
carcinoma in the testis. The TERA2.cl.SP12 sub-line was isolated from the original TERA-2 
line based on expression of the pluripotency marker SSEA-3 and exhibits enhanced neural 
differentiation when exposed to retinoic acid146.  
 
TERA2.cl.SP12 pluripotent stem cells were maintained in Dulbecco’s modified Eagle’s 
medium with high glucose (DMEM-HG, Gibco, Cramlington, UK) supplemented with 10 % 
heat-treated foetal bovine serum (FBS, Gibco), 2 mM L-glutamine (Gibco) and 20 active 
units of Penicillin and Streptomycin (Gibco). Cells were incubated at 37 °C and 5 % CO2 in 
a humidified environment. Cells were maintained at high confluence in 75 cm2 culture 
flasks (BD Falcon, Erembodegem, Belgium) to ensure their pluripotent phenotype and 
passaged every 3 – 4 days. Cells were dissociated using acid washed glass beads 
(ThermoFisher, Cramlington, UK) to mechanically dislodge cells, which were then split in 
a 1:3 ratio and seeded into further 75 cm2 culture flasks.  
 
TERA2.cl.SP12 cells were stored at -140 °C in FBS supplemented with 10 % dimethyl 
sulfoxide (DMSO, Sigma-Aldrich, Dorset, UK). Cells were frozen at a 1:3 ratio from a 
confluent 75 cm2 culture flask and resuspended in freezing medium before being slowly 
frozen at a rate of -1 °C per minute. Revival of cells was preformed rapidly and cells were 
transferred immediately from -140 °C storage into a 37 °C water bath to thaw.  Cells were 
then transferred into 9 mL of warm maintenance medium before being centrifuged at 
1000 rpm for 3 mins. DMSO containing supernatant was then aspirated and the remaining 
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cell pellet was resuspended in 10 mL maintenance medium before being seeded into a 25 
cm2 (BD Falcon) culture flask. Revived cells were incubated at 37 °C and 5 % CO2 in a 
humidified environment for 2 – 3 days and passaged at a 1:1 ratio into a 75 cm2 culture 
flask.  
  
 
Fig 2-1: TERA2.cl.SP12 human pluripotent stem cells at low and high confluence. 
Phase contrast micrographs of the embryonal carcinoma cell line, TERA2.cl.SP12 at low 
(A) and high confluence (B). Cells are maintained at high confluence to ensure their 
pluripotent phenotype. Scale bars: 100 μm. 
 
 
 2.2.2 Maintenance of U-251MG Human Glioblastoma/Astocytoma Cells 
 
U-251MG (formerly known as U-373MG) cells (European Collection of Authenticated Cell 
Cultures, Salisbury, UK) are adherent human glioblastoma astrocytoma cells, derived from 
a malignant glioblastoma tumour by explant technique. Cell morphology is pleomorphic, 
astrocytoid198. 
 
U-251MG cells were maintained in Minimum Essential Eagle’s Medium with Earle’s Salts 
Solution (EMEM, Gibco) and supplemented with 10 % heat-treated FBS, 2 mM L-
glutamine, 1 % Non-Essential Amino Acids (NEAA, Gibco), 1 mM Sodium Pyruvate (Gibco) 
and 20 active units of Penicillin and Streptomycin. Cells were maintained in 75 cm2 
culture flasks (Greiner Bio One, Gloucester, UK) and sub-confluent cultures (70 – 80 %) 
were split every 3 – 4 days at a ratio of 1:3 – 1:6. Passaging of cells involved the 
detachment of cells via trypsinisation with 3 mL of 0.25 % trypsin/2 mM EDTA solution 
(Gibco). Loosely adhered cells were then washed off the surface of the flask with 7 mL 
maintenance medium, which also acts to neutralise trypsin solution. The whole 10 mL cell 
suspension was then collected and centrifuged at 1000 rpm for 3 mins and cells were 
resuspended in 3 mL maintenance medium before being split and seeded in further 75 
cm2 culture flasks containing 15 mL of maintenance medium.  
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U-251MG cells were stored at -140 °C in FBS containing 10 % DMSO. A single cell 
suspension was obtained via trypsinisation as previously described from a confluent 75 
cm2 culture flask and split 1:3 for freezing and storage at -140 °C.  Cells were revived as 
previously described in section 2.1.1 for TERA2.cl.SP12 cells.  
 
 
Fig 2-2: U-251MG human astroglioma cells at low and high confluence. 
Phase contrast micrographs of the glioma cell line, U-251MG at low (A) and high 
confluence (B). Scale bars: 100 μm. 
 
 
 2.2.3 Maintenance of U-118MG Glioblastoma/Astrocytoma Cells 
 
U-118MG (ATCC, Manassas, USA) cells are adherent human glioblastoma cells of mixed 
morphology. The cell line was derived from a grade IV human brain glioblastoma, 
astrocytoma and cells are tumorigenic in nude mice199.  
 
U-118MG cells were maintained in DMEM-HG supplemented with 10 % heat-treated FBS, 
2 mM L-glutamine and 20 active units of Penicillin and Streptomycin. Cells were 
incubated at 37 °C and 5 % CO2 in a humidified environment. Cells were maintained in 75 
cm2 tissue culture flasks and passaged every 3 – 4 days at 70 – 80 % confluence. Passaging 
of cells was by trypsinisation with 3 mL 0.25 % trypsin/2 mM EDTA solution and loosely 
adhered cells were washed from the surface of the culture flask with 7 mL maintenance 
medium. The whole 10 mL cell suspension was then collected and centrifuged at 1000 
rpm for 3 mins and cells were resuspended in 3 mL maintenance medium before being 
split and seeded in further 75 cm2 flasks containing 15 mL of maintenance medium. 
 
Storage of U-118MG cells was at -140 °C in FBS containing 10 % DMSO. A single cell 
suspension was obtained via trypsinisation as previously described from a confluent 75 
cm2 culture flask and split 1:3 for freezing and -140 °C storage.  Cells were revived as 
previously described in part 2.1.1 for TERA2.cl.SP12 cells.  
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Fig 2-3: U-118MG human astroglioma cells at low and high confluence. 
Phase contrast micrographs of the glioma cell line, U-118MG at low (A) and high 
confluence (B). Scale bars: 100 μm. 
 
 
2.2.4 Induction of Differentiation of Human Pluripotent Stem Cells in 2D Monolayer 
Cultures 
 
For 2D monolayer differentiation studies, human pluripotent stem cells (TERA2.cl.SP12) 
were seeded at a density of 200,000 cells per 25 cm2 culture flask and incubated for 24 
hours to allow cells to adhere to the culture surface. Following 24 hours incubation, the 
culture medium was replaced with medium containing retinoid compounds: ATRA 
(Sigma-Aldrich), EC23 (ReproCELL Europe, Sedgefield, UK) or AH61 (Chemistry 
Department, Durham University, Durham) at concentrations of 0.001 μM, 0.01 μM, 1 μM 
and 10 μM. Cells were cultured for a further 7 days with a media change on the 4th day of 
culture. Cell surface marker expression was then analysed by flow cytometry following 7-
day retinoid treatment.  
 
 2.2.5 Formation of Neurospheres from Human Pluripotent Stem Cells 
 
Confluent cultures of TERA2.cl.SP12 human pluripotent stem cells were trypsinised using 
0.25 % trypsin/2 mM EDTA solution to create a single cell suspension before viable cells 
were counted using a trypan blue (Sigma-Aldrich) exclusion assay and a haemocytometer. 
Cells were then seeded in suspension culture at a density of 1.5 x 106 cells per sterile, 
untreated, biological, 90 mm Petri dish (ThermoFisher).  Cells were incubated in 20 mL 
maintenance medium for 24 hours at 37 °C and 5 % CO2 in a humidified environment to 
promote cell aggregation. 
 
Following 24 hours in culture, cells began to aggregate and retinoid compounds were 
added directly to the 24 hour-old culture medium from the time of cell seeding, to avoid 
disaggregation of newly formed cellular aggregates. To achieve a final concentration of 
0.01 μM EC23, 20 μL of 0.01mM EC23 stock solution was added to 20 mL maintenance 
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medium forming the basis of the differentiation medium. Cell aggregates were further 
maintained in suspension for 21 days at 37 °C and 5 % CO2 in a humidified environment. 
Differentiation medium was changed every 3 – 4 days by transferring the suspension 
culture to a 50 mL conical tube (Greiner Bio One) allowing the cell aggregates to collect at 
the bottom of the tube. The old differentiation medium was then carefully aspirated away, 
leaving a sediment of cell aggregates at the bottom of the tube. Fresh differentiation 
medium was then added to the tube and the cell aggregates were resuspended and seeded 
into a fresh 90 mm untreated Petri dish. Following 21 days culture, human pluripotent 
stem cell aggregates become fully matured neurospheres capable of forming neurites. 
 
 2.2.6 Induction of Neurite Outgrowth from Stem Cell Derived Neurospheres 
 
Following 21 days differentiation, stem cell derived neurospheres were cultured on 2D 
and 3D (Alvetex® Scaffold) growth substrates coated with laminin and poly-D-lysine to 
promote neurite outgrowth, as described by Clarke et al149.  
  
  2.2.6.1 Coating of Growth Substrates for Neurite Outgrowth Studies 
 
Alvetex® Scaffold 12-well format inserts (ReproCELL Europe) were prepared by plasma 
treatment using the K1050X Plasma Asher at a power level of 40 W, for 5 mins. Treated 
scaffolds and conventional 48-well tissue culture treated plates were coated overnight at 
room temperature with 10 μgmL-1 poly-D-lysine (Sigma-Aldrich) and laminin (Sigma-
Aldrich) solution. Coating solution was prepared by adding 500 μL of 1 mgmL-1 Laminin 
from Engelberth-Holm-Swarm murine sarcoma membrane and 500 μL of 1 mgmL-1 poly-
D-lysine solution (poly-D-lysine powder (Sigma-Aldrich) reconstituted in 1 mL phosphate 
buffered saline (PBS)) to 49 mL PBS without Ca++, Mg++ (Lonza, Basel, Switzerland). To 
each well of a 48 well tissue culture plate, 150 μL coating solution was added and 300 μL 
coating solution was added to each Alvetex® Scaffold. Following overnight incubation at 
room temperature, coating solution was removed and growth substrates were washed 
three times with PBS and stored in PBS prior to neurosphere seeding.  
  
  2.2.6.2 Seeding of Neurospheres for Neurite Outgrowth Assays 
 
Following 21 days differentiation, neurospheres were collected using a 20 mL serological 
pipette (Greiner) and passed through a 100 μm cell strainer (BD Falcon) to remove any 
single cells or cellular debris. Neurospheres were then washed with fresh maintenance 
media (without retinoid compounds) and backwashed into a new 90 mm Petri dish. 
Maintenance media containing mitotic inhibitors: 1 μM cytosine arabinose (Sigma-
Aldrich), 10 μM 5’fluoro 2’deoxyuridine (Sigma-Aldrich) and 10 μM uridine (Sigma-
Aldrich) was added to each well of a poly-D-lysine and laminin coated 48-well plate (500 
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μL per well) or to a 12-well culture plate containing poly-D-lysine and laminin coated 12-
well format Alvetex® Scaffold inserts (4 mL per scaffold). A 200 μL pipette tip was used to 
transfer 20 μL of media containing 1 – 2 neurospheres into each 2D well or 50 μL 
containing 5 – 10 neurospheres onto each Alvetex® Scaffold. Neurospheres were then 
incubated for 10 days at 37 °C and 5% CO2 in a humidified environment. Throughout this 
time, the culture medium was not changed to avoid disruption to the developing neurites. 
Following 10 days incubation, the cell aggregates were fixed with 4% paraformaldehyde 
(PFA, Sigma-Aldrich) and stored in PBS prior to immunofluorescence analysis.  
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Fig 2-4: Flow chart summarising the stages of the neurite outgrowth process in both 2D and 3D culture. Human pluripotent stem cells are maintained in 2D 
culture (A, scale bar: 100 μm), seeded in suspension culture at a density of 1.5 x 106 cells per Petri dish and allowed to aggregate for 24 hours. Retinoid compounds 
are then added directly to the culture medium to induce neural differentiation for 21 days (B, scale bar 100 μm), following which, neurospheres are seeded either 
into either 2D culture plates (C, scale bar: 200 μm) or onto Alvetex® Scaffolds for 3D culture (D, scale bar: 200 μm). Neurospheres are maintained for a further 10 
days with mitotic inhibitors before being fixed for immunofluorescence analysis.   
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 2.2.7 Image Analysis 
  
  2.2.7.1 Neurite Quantification 
 
To quantify neurite outgrowth, neurospheres were stained for the pan-neuronal marker, 
β-III-tubulin (TUJ-1) that highlights neurites radiating from the aggregate. Digital images 
(TIFF format) of the staining were recorded and opened in the image analysis software, 
Image J (imagej.nih.gov). The scale was set in the software by tracing the scale bar on the 
image and selecting Analyze > Set Scale and entering the length of the scale bar in μm. 
Neurites were then traced using the “Freehand Line” tool and recorded by selecting 
Analzye > Measure, followed by Analyze > Draw.  This produced a table containing the 
number assigned to each neurite and the length of each neurite in μm. This raw data was 
then analysed to give the total number of neurites per neurosphere, the average neurite 
length, and the neurite density, which is the number of neurites normalised to aggregate 
perimeter.   
 
A sampling method of quantification was developed to ensure efficient and accurate 
neurite quantification. This involved overlaying a grid onto each image and using a 
random number generator (random.org) to select three squares per image to quantify. 
This method was found to produce data that was not significantly different to counting 
every neurite per neurosphere and deemed adequate to be used throughout this project.  
 
TUJ-1
 
Fig 2-5: Quantification of neurite outgrowth using Image J software.  
A grid overlay was placed over the original image to be quantified in Image J and three 
squares per image were randomly chosen using a random number generator to be 
quantified. The neurites radiating from the central aggregate in the selected squares were 
traced using the “freehand line” tool and measured. Scale bar: 500 μm. 
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  2.2.7.2 Migration Analysis 
 
Image J software was also used to analyse the area of migration around an aggregate. The 
scale was calibrated in the software as described in section 2.2.7.1. Images of the nuclear 
stain Hoechst were opened in image J to highlight the aggregate body along with the 
nuclei of cells that had migrated away from the main bulk of the aggregate. The “Freehand 
Selection” tool was then used to trace the perimeter of the aggregate and also the zone of 
nuclei that had clearly migrated from the aggregate (Figure 2-6). Each selection was then 
measured by selecting Analyze > Measure which produced a table containing the area of 
each measurement. The zone of migration was then calculated as a percentage of 
aggregate area.  
 
Hoechst
AB
 
Fig 2-6: Analysis of area of migration using Image J software. 
The area of central body of the aggregate was measure using Image J (A, red) followed by 
the area of the zone of migration (B, green). This allowed calculation of the percentage 
zone of migration. Scale bar: 500 μm. 
 
 
 
 2.2.8 Media Supplementation  
 
Throughout this thesis, a number of small molecules were used to direct the 
differentiation of pluripotent potent stem cells or to influence neurite outgrowth.  
Retinoid compounds used to promote neural differentiation were added to suspension 
cultures of pluripotent stem cell aggregates during the differentiation period of culture or 
to 2D monolayer cultures and replaced every 3 – 4 days. Molecules that were used to 
manipulate neurite outgrowth, were added to the culture medium containing mitotic 
inhibitors during the neurite outgrowth period of culture and not replaced for the entirety 
of the 10-day culture (unless otherwise stated).  
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1. Differentiation Phase
Stem cell aggregates maintained in suspension for 21 days with retinoids. 
2. Neurite Outgrowth Phase
Differentiated neurospheres incubated on coated surfaces for 10 
days. Small molecules may be added at this point to investigate 
their effects on neurite outgrowth.
ATRA
EC23
AH61
Table 2-1
Y-27632
Ibuprofen
β-amyloid
Etc.
Table 2-2
 
Fig 2-7: Generation of neurite outgrowth from human pluripotent stem cells is a two-step process. 
Initially, stem cell aggregates were maintained in suspension with retinoid molecules for 21 days to promote their differentiation (1. Differentiation Phase). Fully 
differentiated neurospheres were then placed on ECM coated 2D and 3D surfaces and maintained for a further 10 days with mitotic inhibitors, at which point 
neurites begin to protrude from the body of the neurosphere (2. Neurite Outgrowth Phase).  During the neurite outgrowth phase a variety of molecules were added 
to cultures to determine their effect on neurite outgrowth. 
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Stock solutions of each compound were aliquoted and stored at -20 °C. An example of a 
calculation used to determine the volume of vehicle in which to dissolve a compound 
producing a desired stock solution is given below. A similar calculation was used to 
determine the stock solution parameters of each molecule used throughout this study by 
altering the molecular weight, known mass and required concentration.  
 
Stock Solution Example – EC23 
 
MW = 332 g 
Known Mass = 10 mg 
Desired Concentration = 10 mM 
 
1M = 332 g in 1,000 mL 
(÷ 100) 10mM = 3.32 g in 1,000 mL 
x = (0.01 g (known mass) / 3.32 g) x 1,000 
x = 3.01 mL DMSO to dissolve 10 mg to give 10 mM stock solution 
 
Compound Structure Molecular 
Weight /g 
Vehicle Supplier 
ATRA 
 
300.44 DMSO Sigma-Aldrich 
EC23 
 
332.44 DMSO ReproCELL 
Europe 
AH61 
 
322.19 DMSO Chemistry 
Department  
(Durham 
University) 
   
Table 2-1: Small molecules used to direct pluripotent stem cell differentiation.  
The details of retinoid molecules added either at the suspension culture stage to promote 
neuronal differentiation of human pluripotent stem cell aggregates or to 2D monolayer 
cultures for differentiation studies.  
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Compound Molecular Weight /g Vehicle Supplier Description 
Chondroitinase ABC 120,000 0.01 % BSA Sigma-Aldrich Enzyme that cleaves GAG chains from chondroitin 
sulphate proteoglycans rendering them inactive 
Y-27632 dihydrochloride 320.26 H2O Tocris Selective p160 ROCK inhibitor 
Ibuprofen 206.28 DMSO Sigma-Aldrich Non-steroidal anti-inflammatory drug 
β-amyloid 1-40 4329.8 1 % acetic acid Sigma-Aldrich β-amyloid fragment most abundant in healthy 
brain 
β-amyloid 1-42 4514.08 50 mM Tris Buffer Tocris β-amyloid fragment closely linked to Alzheimer’s 
disease pathogenesis 
NEP 1-40 4626.14 H20 Sigma-Aldrich Antagonist peptide to the Nogo-66 receptor 
  
Table 2-2: Agents used to manipulate neurite outgrowth. 
The details of supplements added to culture media containing mitotic inhibitors during neurite outgrowth phase of culture. 
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2.2.9 Culture of ReproNeuro Glu Cells 
 
ReproNeuro Glu cells (ReproCELL, Kanagawa, Japan) are iPSC derived neuroprogenitor 
cells that have a propensity to form mature glutamatergic neurons. Somatic cells obtained 
from a healthy individual are reprogrammed to form iPSCs that in turn are differentiated 
to form neuroprogenitor cells. These cells are revived from frozen as neuroprogenitors 
and cannot be passaged or propagated, so must be used directly in an experimental 
procedure upon revival. 
 
 
 
Fig 2-8: Schematic depicting the derivation of ReproNeuro Glu cells.  
Somatic cells are obtained from a healthy individual and reprogrammed to form iPSCs. 
iPSCs are then differentiated to form a pool of glutamatergic precursor cells (ReproNeuro 
Glu) that upon revival and culture in Glu Maturation Medium, ultimately form mature 
neurons with glutamatergic properties. 
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   2.2.9.1 Revival of ReproNeuro Glu Cells from Cryopreservation 
 
Cells were stored in vapour phase liquid nitrogen and were transferred to a Dewar 
containing liquid nitrogen for revival. To revive cells the lid of the frozen cell vial was 
partially opened to release the pressure and frozen cells were thawed at 37 °C for 90 
seconds while gently swirling. If cells are thawed for longer than 90 seconds, there is a 
significant loss of viability. The contents of the vial were decanted into 10 mL of pre-
warmed Glu Thawing Medium (ReproCELL) and the vial was rinsed with 1 mL of Glu 
Thawing Medium to ensure all cells were collected. The cells were then centrifuged at 350 
g for 5 minutes at room temperature and gently re-suspended in 2 mL of Glu Maturation 
Medium (ReproCELL) supplemented with 120 μL of Glu Additive (ReproCELL) and 100 
active units of penicillin/streptomycin. The cell suspension was then topped up with 1 mL 
Glu Maturation Medium to give a final concentration of 1.0 x 106 cells per mL for cell 
seeding.  
 
  2.2.9.2 2D Monolayer Culture of ReproNeuro Glu Cells 
 
For 2D monolayer cultures, cells were seeded onto 16 mm diameter glass coverslips in a 
12-well tissue culture plate.  Coverslips were coated in 0.002 % poly-L-lysine solution 
(Sigma-Aldrich) (0.01 % poly-L-lysine solution diluted in PBS), for 3 hours at 37 °C.  Poly-
L-lysine solution was then removed and the coverslips were washed twice in PBS prior to 
coating in 200 μL Glu Coat (ReproCELL) solution (150 μL of Glu Coat diluted in 5 mL PBS) 
overnight at 37 °C. 
 
Prior to cell seeding, Glu Coat solution was removed and 280 μL of cell suspension 
following revival from cryopreservation was added to each well of the 12-well culture 
plate containing a glass coverslip. This achieved a final seeding density of 2.8 x 105 cells 
per well and wells were topped up with Glu Maturation Medium to give a final volume of 
1.4 mL. Cells were incubated at 37 °C and 5 % CO2 in a humidified atmosphere for 14 days 
to allow the development of mature neurons with a 50 % media change on the 3rd and 7th 
day of culture. Following the 14 day culture period, cells were washed in PBS and fixed in 
4 % PFA for immunofluorescent analysis. 
 
 
 
 
 
 
 
 
 49 
A B
 
 
Fig 2-9: ReproNeuro Glu cells mature over a 14-day culture period. 
Phase contrast micrographs depicting ReproNeuro Glu cells cultured in 2D immediately 
following seeding (A) and following 14 days in culture (B), cells have adopted a more 
neural morphology. Scale bars: 100 μm 
 
 
  2.2.9.3 3D Culture of ReproNeuro Glu Cells 
 
Alvetex® Scaffold 12-well format inserts were prepared by plasma treatment using the 
K1050X Plasma Asher at a power level of 40 W, for 5 mins. Treated scaffolds were washed 
in PBS and incubated in 300 μL of 0.002 % poly-L-lysine solution at 37 °C for 3 hours. 
Scaffolds were then washed in PBS twice before being coated in 300 μL Glu Coat solution 
overnight at 37 °C. 
 
Coated scaffolds were placed in a 12-well tissue culture plate and a cloning cylinder with 
an internal diameter of 3.4 mm was placed on the scaffold. Into the cylinder 40 μL of cell 
suspension was placed, resulting in a seeding density of 4 x 105 cells per scaffold. The 
cloning cylinder containing the cell suspension was incubated upright on the scaffold for 
10 mins at 37 °C and 5 % CO2 in a humidified environment. Following 10 minutes the 
cloning cylinder was then removed and the scaffold was incubated for a further 30 mins at 
37 °C and 5 % CO2 in a humidified environment before being topped up with 4 mL Glu 
Maturation Media. Scaffolds were then incubated for 14 days to allow the maturation of 
the neurons with a 50 % media change on day 3 and 7 of culture. Following 14 days 
incubation, scaffolds were fixed in 4 % PFA for analysis. 
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Fig 2-10: Concentrated seeding of ReproNeuro Glu on Alvetex® Scaffold using a 
cloning cylinder. 
To achieve concentrated seeding on Alvetex® Scaffold, a 3.4 mm diameter cloning cylinder 
was used. The cell suspension was added directly to the cloning cylinder, which was 
incubated vertically on the scaffold for 10 minutes before removal. The scaffold was then 
incubated for a further 30 minutes without the cloning cylinder before being topped up 
with 4 mL Glu Maturation Medium.  
 
 
  2.2.9.4 Neurosphere Formation from ReproNeuro Glu Cells  
 
AggreWell 800 plates (STEMCELL Technologies, Cambridge, UK) were used to induce 
spheroid formation from ReproNeuro Glu cells. The plates contain microwells that force 
the cells into close proximity promoting the formation of spheroid structures. The plates 
were prepared by rinsing each well in 2 mL Glu Maturation Medium. This was then 
removed and 0.5 mL Glu Maturation Medium was added to each well and the plate was 
centrifuged at high speed (2000 g for 5 mins) to displace any bubbles from the 
microwells. Cells were then seeded into each well with 1 mL of cell suspension (1 x 106 
cells) added to each well.  Cells were then pipetted up and down gently, to ensure even 
distribution of cells throughout the well, and each well was topped up with 0.5 mL Glu 
Maturation Medium.  The plate was then centrifuged at 100 g for 3 minutes to capture the 
cells in the microwells and incubated at 37 °C and 5 % CO2 in a humidified environment 
for 24 hours to allow spheroid formation. Following 24 hours incubation, spheroids were 
harvested from microwells using a p1000 pipette to gently pipette the medium within the 
wells up and down, forcing the spheroids from their microwells. Cell aggregates were 
collected and passed through a 100 μm cell strainer; aggregates collected in the strainer 
(aggregates > 100 μm) were then backwashed into a sterile 90 mm Petri dish prior to 
seeding for neurite outgrowth assays.   
 
 
 
 
 51 
2.2.9.5 Neurite Outgrowth Assay from ReproNeuro Glu derived 
Neurospheres 
 
Following the formation of neurospheres, cell aggregates were plated onto either 48-well 
tissue culture plates or 12-well format Alvetex® Scaffold. 48-well plates were coated with 
150 μL per well of 0.002 % poly-L-lysine solution for 2 hours at 37  °C and washed twice 
in PBS before being coated in 150 μL Glu Coat solution overnight at 37  °C. Scaffolds were 
prepared as per section 2.2.9.3 3D Culture.  
 
Coating solution was removed from 48-well tissue culture plates and 12-well format 
Alvetex® Scaffolds, wells were then topped up with 500 μL Glu Maturation Medium and 
scaffolds were placed in 12-well culture plates with 4 mL Glu Maturation Medium.  
Neurospheres were seeded using a 200 μL pipette tip to transfer 20 μL containing 2-3 
neurospheres into each 2D well, and 40 μL containing 5-10 neurospheres onto each 
scaffold. Neurospheres were then cultured for 10 days in Glu Maturation Medium during 
which time neurites begin to protrude from the neurospheres. The medium was not 
changed throughout the neurite outgrowth period to avoid disruption of the developing 
neurites. Following 10 days culture, the neurospheres were fixed in 4 % PFA for analysis. 
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2.2.10 Culture of ReproNeuro Cells 
 
ReproNeuro cells (ReproCELL) differ from ReproNeuro Glu cells in that they are a mixed 
population of iPSC derived neuroprogenitor cells. Somatic cells obtained from a healthy 
individual are reprogrammed to form iPSCs and in turn differentiated to generate 
neuroprogenitor cells. The cells are revived from frozen as neuroprogenitors and cannot 
be passaged or propagated, so must be used directly in an experiment upon revival. 
 
 
 
Fig 2-11: Schematic depicting the derivation of ReproNeuro cells.  
Somatic cells obtained from a healthy individual were reprogrammed to form iPSCs. The 
iPSCs were differentiated to form a pool of mixed precursor cells (ReproNeuro) that upon 
revival and culture in Maturation Medium, ultimately form a mixed population of mature 
neurons. 
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  2.2.10.1 Revival of ReproNeuro Cells from Cryopreservation 
 
Cells were stored and revived as per section 2.2.9.1 Revival of ReproNeuro Glu Cells from 
Cryopreservation, however the composition of Maturation Medium (ReproCELL) differed. 
Maturation Medium was prepared by adding 520 µL of Additive A (ReproCELL) and 100 
active units of penicillin/streptomycin to each 40 mL bottle of Maturation Medium.  
 
  2.2.10.2 2D Monolayer Culture of ReproNeuro Cells 
 
For 2D monolayer cultures, cells were seeded onto 16 mm diameter glass coverslips in a 
12-well tissue culture plate.  Coverslips were coated with 0.002 % poly-L-lysine (diluted 
0.01 % poly-L-lysine solution (Sigma-Aldrich) in PBS) for 2 hours at 37 °C.  Poly-L-lysine 
solution was then removed and the coverslips were washed twice in PBS prior to coating 
with 200 μL ReproCoat (ReproCELL) solution (150 μL of ReproCoat diluted in 5 mL PBS), 
overnight at 37 °C. 
 
Prior to cell seeding, coating solution was removed and 280 μL of cell suspension 
following revival from cryopreservation was added to each well, achieving a final seeding 
density of 2.8 x 105 cells per well. Wells were topped up with Maturation Medium to give a 
final volume of 1.4 mL and cells were incubated at 37 °C and 5 % CO2 in a humidified 
atmosphere for 14 days. This promotes the development of mature neurons and cells 
received a 50 % media change on the 3rd and 7th day of culture. Following the 14 day 
culture period, cells were washed in PBS and fixed in 4 % PFA for immunofluorescent 
analysis. 
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Fig 2-12: ReproNeuro cells mature over a 14-day culture period. 
Phase contrast micrographs showing ReproNeuro Glu cultured in 2D 24 hours following 
seeding (A) and following 14 days in culture (B), cells have adopted a more neural 
morphology. Scale bars: 100 μm 
 
 
  2.2.10.3 Neurosphere Formation from ReproNeuro Cells  
 
Neurospheres were formed using AggreWell plates using the same methodology 
described for ReproNeuro Glu cells. The protocol is described in section 2.2.9.4.4 
Neurosphere Formation from ReproNeuro Glu Cells. 
 
  2.2.10.4 Neurite Outgrowth Assay from ReproNeuro derived Neurospheres 
 
Following the formation of neurospheres, cell aggregates were seeded onto either 48-well 
tissue culture plates or 12-well format Alvetex® Scaffold. Alvetex® Scaffolds were 
prepared by plasma treatment using the K1050X Plasma Asher at a power level of 40 W, 
for 5 mins. Treated scaffolds and 48-well plates were coated with 0.002 % poly-L-lysine 
solution for 2 hours at 37 °C and washed twice in PBS before being coated in ReproCoat 
solution overnight at 37 °C.  
 
Coating solution was removed from 2D and 3D growth substrates. 2D wells were then 
topped up with 500 μL Maturation Medium and scaffolds were placed in 12-well culture 
plates with 4 mL Maturation Medium.  Neurospheres were seeded using a 200 μL pipette 
tip to transfer 20 μL containing 2-3 neurospheres into each 2D well, and 40 μL containing 
5-10 neurospheres onto each scaffold. 2D cultures were maintained for 24 hours post-
seeding, whilst 3D cultures were maintained for 10 days prior to fixation in 4 % PFA for 
analysis. 
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Fig 2-13: Schematic summarising neurosphere formation and neurite outgrowth from ReproNeuro cell lines. 
ReproNeuro and ReproNeuro Glu cells are revived from frozen directly into an AggreWell™ 800 plate. The plate is then centrifuged to capture the cells in the 
microwells and incubated for 24-48 hours to form spheroid structures. Neurospheres are then harvested and seeded on coated coated 2D (48-well tissue culture 
plate) and 3D (12-well format Alvetex® Scaffold) surfaces. 2D cultures are then maintained for a further 24 hours (ReprNeuro) or 10 days (ReproNeuro Glu), 
whereas 3D cultures are maintained for a 10 day period to promote neurite outgrowth. Following the neurite outgrowth phase of culture samples are then fixed 
with 4 % PFA and immunofluorescence analysis. 
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2.3 Flow Cytometry 
 
Flow cytometry was used to determine the expression of cell surface antigens using 
fluorescent antibodies. Cells tagged with fluorescent antibodies were quantified using a 
flow cytometer to determine average percentage expression of an antigen in a population 
of cells. This technique was used to analyse the expression of stem cell and differentiation 
markers in populations of pluripotent stem cells exposed to various differentiation 
conditions.  
 
 2.3.1 Sample Preparation 
 
Pluripotent stem cells were differentiated as described in section 2.2.4 Induction of 
Differentiation of Human Pluripotent Stem Cells in 2D Monolayer Cultures and a single cell 
suspension obtained via trypsinisation as previously described. Cells were then washed in 
PBS and re-suspended in 1 mL blocking buffer (0.1 % bovine serum albumin (BSA, Sigma-
Aldrich) in PBS). Cells were then centrifuged at 800 rpm for 3 minutes, counted using a 
haemocytometer and seeded in a 96-well round-bottomed, untreated flow cytometry 
plate at a density of 150,000 cells per well. The plate was then centrifuged at 800 rpm at 4 
°C for 3 minutes to pellet cells.  
  
2.3.2 Immunostaining of Cell Suspension 
 
Following centrifugation, cells were then re-suspended in 50 μL of the appropriate 
primary antibody diluted in blocking buffer and incubated for 1 hour on ice. Primary 
antibodies and their dilutions are shown in Table 2-3. 
 
Antibody Dilution Supplier 
SSEA-3 1:5 DSHB 
A2B5 1:20 Abcam 
P3X 1:10 P. Andrews (University of Sheffield) 
 
Table 2-3: Primary antibodies used to stain extracellular markers for flow 
cytometric analysis. 
 
 
Following incubation with the primary antibody, cells were washed three times in 100 μL 
blocking buffer and centrifuged at 800 rpm at 4 °C for 3 minutes.  The cells were then 
incubated for 1 hour in the dark with an anti-mouse IgM secondary antibody (Sigma-
Aldrich) diluted 1:50 in blocking buffer. Cells were then washed three times in blocking 
buffer and re-suspended in 200 μL blocking buffer for flow cytometric analysis. 
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 2.3.3 Flow Cytometric Analysis 
 
The Millipore GuavaCyte Plus Flow Cytometer (Millipore, Consett, UK) was calibrated 
using the Guava Check Kit (Millipore). This involved passing quality control beads of 
known size, fluorescence and shape, through the machine to determine a percentage 
coefficient of variance (CV). A percentage CV of less than 5 % should be obtained before 
sample analysis.  
 
Cell clumps and debris were eliminated from analysis using forward and side-scatter 
gates to ensure fluorescence detected was from single cells. Settings were adjusted to the 
negative control (P3X) which is an antigen expressed only on mouse cells and should not 
react with the human cells, as shown in Figure 2-15. 
 
 
 
Fig 2-14: Settings used to analyse expression of extracellular markers of human 
pluripotent stem cells using flow cytometry.  
Side scatter and forward scatter plots (A) were used to gate for intact cells, and eliminate 
signal caused by cellular debris. The circle (M1) represents the cells that have been 
selected for analysis. P3X is an antigen expressed by mouse cells and acts as a negative 
control when analysing samples of human cells (B). Settings were adjusted to P3X 
fluorescence using a histogram marker (M1) to select the population of cells that did not 
fluoresce when stained for this marker, as any fluorescence is likely to be background, 
non-specific signal. These settings were then applied to all other samples. The stem cell 
marker SSEA-3 (C) is highly expressed in undifferentiated human pluripotent stem cells, 
and the positive population of cells is highlighted by the histrogram marker. The early 
neuronal differentiation marker, A2B5 (D) is expressed at extremely low levels in 
undifferentiated cells, with its histogram closely resembelling that of the negative control, 
P3X.   
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 2.4 Histology and Immunofluorescence Staining 
 
 2.4.1 Fixation of 2D Cultures 
 
To fix 2D cultures, media was aspirated and cultures were washed in PBS before being 
incubated in 4 % PFA at room temperature. 2D neurite outgrowth cultures were 
incubated in PFA for 1 hour to allow penetration of the fixative into the mass of cells, 
while 2D monolayer cultures were incubated in PFA for 30 minutes. Following fixation 
cells were washed 3 times in PBS and stored in PBS prior to processing.  
 
 2.4.2 Fixation of 3D Alvetex® Scaffolds 
 
Avetex® Scaffolds were unclipped from their plastic settings and washed in PBS prior to 
fixation in 4 % PFA overnight at 4 °C. Scaffolds were then washed three times in PBS prior 
to either wax embedding or whole mount immunofluorescence analysis. 
 
 2.4.3 Paraffin Wax Embedding and Sectioning of 3D Alvetex® Scaffolds 
 
Fixed scaffolds were dehydrated through a series of ethanol baths: 30, 50 70, 80, 90, 95 
and 100 % ethanol for 15 minutes each. In the case of 3D neurite outgrowth cultures the 
70 % ethanol step was substituted with 0.1 % crystal violet (Sigma-Aldrich) dissolved in 
70 % ethanol to stain aggregates and aid visualisation during the sectioning process.  
 
Following dehydration, samples were transferred to histoclear (National Diagnostics, East 
Riding, UK) for 15 minutes. Samples were then incubated at 60 °C in a 1:1 mixture of 
melted paraffin wax (ThermoFisher) and histoclear, for 30 minutes followed by an 
incubation at 60 °C for an hour with melted paraffin wax only. Scaffolds were then cut in 
half and embedded in paraffin wax using plastic moulds (CellPath, Newton, UK) and 
embedding cassettes (ThermoFisher) to allow for transverse sectioning. Wax blocks were 
allowed to solidify overnight. 
 
Alvetex® Scaffolds embedded in paraffin wax were sectioned at 6 μm using a Leica 
Microtome RM2125RT and mounted onto charged superfrost microscope slides 
(ThermoFisher). 3D neurite outgrowth cultures were stained with crystal violet to allow 
visualisation and to ensure aggregate sample is within wax section. 
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Fig 2-15: Crystal violet visualisation of cell aggregates cultured in 3D, embedded in 
paraffin wax. 
Cell aggregates cultured on Alvetex® Scaffold were embedded in paraffin wax for 
sectioning. To visualise cell aggregates during the sectioning process, they were stained 
with crystal violet solution. Each section was mounted onto a microscope slide and 
examined for the presence of a cellular aggregate prior to processing. Scale bar: 200 μm. 
 
 
 2.4.4 Haematoxylin and Eosin (H&E) Staining 
 
Paraffin wax sections containing Alvetex® Scaffold were deparaffinised in histoclear 
before being rehydrated through a series of ethanols: 100 % ethanol for 2 minutes and 95 
% followed by 70 % ethanol for 1 minute each. Samples were then washed in deionised 
water for 1 minute followed by staining in Mayer’s Haematoxylin (Sigma-Aldrich) for 5 
minutes.  Slides were then washed in deionised water for 30 seconds, followed by alkaline 
ethanol for 30 seconds to blue the nuclei. Samples were then dehydrated through 70 % 
and 95 % ethanol for 30 seconds each and stained in eosin solution (Sigma-Aldrich) for 1 
minute. Slides were then dehydrated in 95 % ethanol twice for 10 seconds each, 100 % 
ethanol for 15 seconds then 30 seconds and cleared twice in histoclear for 3 minutes each. 
Slides were then mounted in DPX (ThermoFisher) ready for microscopy using a Leica 
ICC50 high definition camera mounted on a Leica microscope.  
 
 2.4.5 Immunofluorescent Analysis of 3D Cultures 
 
  2.4.5.1 Scaffold Whole Mounts 
 
Fixed, whole Alvetex® Scaffolds were permeablised in 0.1 % Triton X-100 (Sigma-Aldrich) 
for 20 minutes at room temperature. Scaffolds were then blocked for 30 minutes in a 
blocking solution consisting of: 1 % normal goat serum (NGS, Sigma-Aldrich) and 0.01 % 
Tween (Sigma-Aldrich) in PBS.  Scaffolds were then placed on a microscope slide and a 
hydrophobic barrier pen (Vector Laboratories, Peterbrough, UK) was used to draw a 
circle around the scaffold membrane to contain the antibody solution. Scaffolds were 
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incubated on microscope slides with the relevant primary antibody solution diluted in 
blocking buffer for 2 hours at room temperature and then washed three times for 10 
minutes in blocking buffer. Scaffolds were once again placed on microscope slides and 
incubated with the relevant secondary antibody diluted in blocking buffer with the 
addition of the nuclear dye Hoechst 33342 (ThermoFisher) for 1 hour at room 
temperature. Scaffolds were then washed 3 times for 10 minutes in blocking buffer prior 
to mounting on microscope slides with Vectashield anti-fade mounting medium (Vector 
Laboratories).   
 
  2.4.5.2 Scaffold Cross-Sections 
 
Paraffin wax sections were deparaffinised in histoclear for 15 minutes and rehydrated in 
100 % ethanol, 70 % ethanol and PBS for 5 minutes each. To retrieve antigens, samples 
were then incubated in a 95 °C water bath for 20 minutes with citrate buffer. The slides 
were allowed to cool and then blocked in a solution of 20 % NGS and 0.4 % Triton X-100 
in PBS for an hour at room temperature.  Slides were then incubated with the primary 
antibody diluted in blocking buffer overnight at 4 °C. Samples were then washed 3 times 
in PBS for 10 minutes each and incubated with the secondary antibody, diluted in 
blocking buffer with the nuclear dye Hoechst at room temperature for an hour. Slides 
were washed 3 times in PBS for 10 minutes each prior to mounting with Vectashield anti-
fade mounting medium.  
 
 2.4.6 Immunofluorescence Staining of 2D Cultures 
 
Fixed samples of cells cultured in 2D were permeabilised with 0.1 % Triton-X100 in PBS 
for 10 minutes followed by blocking on ice for 1 hour in 1 % NGS, 0.01 % Tween in PBS. 
Primary antibody was then added to samples and incubated for 1 hour whilst gently 
rocking.  Samples were then washed three times in blocking buffer for 10 minutes each 
followed by incubation with the fluorescent secondary antibody and nuclear dye Hoechst 
33342 for 1 hour, which was specific for the primary antibody used.  Cells were then 
washed for a further 3 times for 10 minutes each in blocking buffer prior to microscopy. 
Antibodies were diluted in blocking buffer and are listed in section 2.4.7 Summary of 
Antibodies used in Immunofluorescence. 
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 2.4.7 Summary of Antibodies used in Immunofluorescence 
 
Target Dilution Host Species Supplier Product 
Code 
β-III-tubulin 1:600 Rabbit Cambridge Bioscience 3525-100 
Nestin 1:100 Mouse Abcam ab22035 
Neurofilament-L 1:100 Mouse Life Technologies 130400 
Neurofilament-M 1:100 Mouse Sigma-Aldrich N2787 
Neurofilament-H 1:500 Rabbit Abcam ab8135 
GFAP 1:100 Mouse Sigma-Aldrich G3893 
Chondroitin 
Sulphate 
1:100 Mouse Abcam ab11570 
 
Table 2-4: Primary antibodies used in immunofluorescence. 
Primary antibodies used for immunofluorescence, with their working dilution and the 
host species. All antibodies were diluted in blocking buffer. 
 
Antibody Dilution Emission (max) 
Wavelength /nm 
Supplier Product 
Code 
Alexafluor 
anti-rabbit 488 
1:600 525 ThermoFisher A-11034 
Alexafluor 
anti-mouse 488 
1:600 525 ThermoFisher A-11001 
Alexafluor 
anti-mouse 594 
1:600 617 ThermoFisher A-21203 
Hoechst 33342 1:1000 461 ThermoFisher H3570 
 
Table 2-5: Secondary antibodies and dyes used in immunofluorescence. 
Secondary fluorescent conjugated antibodies and their respective emission wavelengths 
and the fluorescent nuclear dye hoechst 33342. All antibodies were diluted in blocking 
buffer. 
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2.5 Western Blotting 
 
 2.5.1 Generation of Cellular Lysates 
 
  2.5.1.1 Formation of Lysates from 2D Cultures 
 
Cellular lysates were generated using a lysis buffer that consisted of Mammalian Protein 
Extraction Reagent (MPER™, ThermoFisher) with 1 % protease inhibitor cocktail (Sigma-
Aldrich). Flasks of cells cultured in 2D were washed in ice-cold PBS and incubated with 
lysis buffer on ice, on a rocking platform for 15 minutes. Following incubation, cells were 
then detached using a cell scraper (ThermoFisher) and collected in a microcentrifuge tube 
(StarLab, Milton Keynes, UK) for centrifugation at 4 °C, 12,000 g for 15 minutes. The 
supernatant was then collected and stored at - 80 °C until use. 
 
  2.5.1.2 Formation of Lysates from 3D Alvetex® Scaffold Cultures 
 
Alvetex® Scaffolds were unclipped from their plastic casing and washed in ice-cold PBS 
prior to incubation with lysis buffer (composition described in 2.5.1.1 Formation of Lysates 
from 2D Cultures). Scaffolds were incubated on ice for 30 minutes in lysis buffer and 
vortexed for 10 seconds, every 5 minutes during this time. Samples were then centrifuged 
at 4 °C, 12,000 g for 15 minutes and the supernatant was collected and stored at - 80°C 
until use. 
 
 2.5.2 Bradford Protein Assay 
 
A Bradford Assay was used to determine the concentration of protein present in each 
cellular lysate, to ensure that equal protein levels of each sample were compared.  To a 
96-well flat-bottomed plate, 250 μL of Quick Start™ Bradford 1 x Dye Reagent (Bio-Rad, 
Hertfordshire, UK) and 5 μL of each BSA Protein Standard (Bio-Rad) were added. Protein 
standards range in concentration from 0.125 to 2.0 mgmL-1 to produce a standard curve 
that unknown samples can then be compared to.  Lysates were thawed on ice and 5 μL of 
each sample was added to a well containing 250 μL of Bradford reagent and 
samples/standards were incubated with the reagent for 5 minutes before absorbance was 
determined at 590 nm using a BioTek, ELx800 microplate reader. 
 
Quantification of lysate protein content was obtained through plotting a linear regression 
through the standard curve data using GraphPad Prism software. The equation of the 
straight line could then be obtained and rearranged to find the x value (protein 
concentration) by substituting the y value (absorbance) for each sample. An example is 
shown below: 
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Fig 2-16: Typical standard curve for protein quantification by Bradford Assay. 
A typical standard curve plotted from absorbance at 590 nm for a series of protein 
standards. A linear regression was plotted through the data set and an R2 value obtained 
(0.8731 for this data set) which demonstrates the relationship between the two variables, 
the closer to 1, the more the variables correlate. Plotting a linear regression determines 
the equation of the line, which can then be rearranged and the absorbance of protein 
lysates of unknown concentration can be substituted into the equation to determine their 
concentration.   
 
 
Equation of Linear Regression: y = 0.0005301x + 0.5062 
 
Rearranged to make x the subject: x = y – 0.5062 
          
 
Sample of unknown protein concentration with an average absorbance of 1.429 at 590 nm 
 
y = 1.429; x = 1.429 – 0.5062 
 
 
x = 1740 μgmL-1 
 
 
2.5.3 SDS Polyacrylamide Gel Electrophoresis 
 
Protein lysates were prepared for electrophoresis by incubation with 4 x Laemmli sample 
buffer (Bio-Rad) and 10 % 2-mercaptoethanol (Sigma-Aldrich) at 95 °C for 5 minutes. 
Samples were then loaded into an any-kD pre-cast polyacrylamide gel (Bio-Rad) and run 
at 120 V for 1-2 hours in 1 x TGS buffer (Biorad).  
 
 
 
0.0005301 
0.0005301 
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 2.5.4 Protein Transfer 
 
Electrophoresed samples were then transferred onto a nitrocellulose membrane (GE 
Healthcare, Buckinghamsire, UK) by constructing the following onto the black side of a 
transfer cassette: sponge, blotting paper, gel, nitrocellulose membrane, blotting paper, 
sponge.  The transfer sandwich was then rolled using a roller to remove any bubbles and 
placed into the transfer tank with an ice block in transfer buffer (3.03 g tris, 14.41 g 
glycine, 200 mL methanol in 1 L H20). The transfer was for overnight at 4 °C at 15 V 
followed by 2 hours the following day at 30 V.   
 
 
Fig 2-17: Schematic representing the transfer sandwich used in western blotting. 
The transfer sandwich is assembled in transfer buffer and involves the stacking of 
sponges and blotting paper with the SDS-Page gel containing the electrophoresed samples 
and a nitrocellulose membrane sandwiched between the layers.   
 
 
 2.5.5 Immunostaining and Exposure of Membrane 
 
Following protein transfer, membranes were blocked at room temperature for an hour in 
5 % milk powder dissolved in 0.1 % Tween in PBS. Primary antibodies were then diluted 
in 5 % milk solution and incubated with the membrane overnight at 4 °C. Membranes 
were washed 3 times for 5 minutes in 0.1 % Tween and incubated with the secondary 
antibody diluted in 5 % milk solution for an hour at room temperature. This was followed 
by 3 washes for 5 minutes in 0.3 % Tween solution and 3 washes for 5 minutes in 0.1 % 
Tween solution.  The Clarity™ ECL detection kit (Biorad) was used for detection as per the 
manufacturer’s instruction, the two solutions were mixed in a 1:1 ratio and incubated for 
5 minutes with the membrane followed by exposure with photographic film 
(ThermoFisher).   
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 2.5.6 Summary of Antibodies 
 
Target Dilution Host Species Supplier Product 
Code 
Versican 1:2,500 Rabbit Abcam ab177480 
GFAP 1:4,000 Mouse Sigma G3893 
β-actin 1:10,000 Mouse Abcam ab8224 
Anti-rabbit-HRP 1:4,000 Goat Santa Cruz 
Biotechnology 
SC-2030 
Anti-mouse-HRP 1:4,000 Goat Sigma-Aldrich A4416 
 
Table 2-6: Antibodies used in western blotting. 
Primary and secondary antibodies used in western blotting. Secondary antibodies are 
HRP conjugated and all antibodies were diluted in 5 % milk solution. 
  
2.6 Microscopy 
 
 2.6.1 Phase Contrast Imaging of Live Cultures 
 
Phase contrast images of live cell cultures were obtained using the Leica DFC 310FX with 
digital camera DMI 3000B with objectives: x5, x10, x20. 
 
 2.6.2 Brightfield Imaging 
 
Histology samples were imaged using a Leica ICC50 High Definition camera mounted onto 
a Leica microscope and objectives: x5, x10, x20 and x40. Images were captured using 
Leica EZ software. 
 
 2.6.3 Fluorescence Imaging 
 
  2.6.3.1 Conventional Fluorescence Imaging 
 
Fluorescent images used for quantification of neurite outgrowth were obtained using the 
Leica DFC 310FX with digital camera DMI 3000B and objectives: x5, 10 and x20. Filters: 
DAPI, 488 nm. Images were captured using Leica V4 software. 
 
  2.6.3.2 Confocal Imaging 
 
Leica SP5 confocal laser scanning microscope was used to obtain high-resolution 
representative images with objectives: x10 HCX PL APO CS, x20 HCX PL APO oil UV, x40 
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HCX PL APO Oil UV and x63 HCX PL APO Oil UV.  Images were captured using Leica AF 
software. 
 
The Zeiss 880 confocal laser scanning microscope with airy scan was also used to obtain 
high-resolution images with objectives: x10 EC Plan Neo DC I, x20 Plan Apochromat DIC II, 
x40 EC Plan Neo DIC II and x63 Plan Aprochromat DIC II. The tile scan feature was used to 
obtain high-resolution images of whole neurospheres and their surrounding neurite 
outgrowth by capturing a 3x3 tiled area from the centre of the cell aggregate.  Images 
were captured using Zeiss Zen software. 
 
Please note that, dark areas in the centre of neurospheres are an artifact of using confocal 
microscopy to obtain high quality images, as the light has difficulty penetrating the large 
mass of the neurosphere. When images are captured using conventional fluorescence 
microscopy this phenomenon is not observed. 
 
 
Fig 2-18: Hoechst staining of cell aggregates imaged using conventional and 
confocal microscopy. 
Hoechst staining highlights the nuclei of the cells that reside within the cellular aggregate; 
therefore staining is mainly confined to aggregate body, with a small number of nuclei 
that have migrated from the cell aggregate. When imaged using conventional fluorescence 
microscopy (A) the hoechst staining appears solid. However, when imaged using confocal 
microscopy (B), there appears to be a dark region in the centre of the aggregate. This is an 
artifact of confocal microscopy, due to the inability of the light to penetrate the aggregate 
mass and is enhanced by the scattering of out of focus light from the confocal microscope. 
Scale bars: A = 500 μm, B = 200 μm 
 
2.7 Statistical Analysis   
 
GraphPad Prism v7 was used to assess statistical significance of results and the relevant 
statistical test was used depending on the data set including: Student’s T-test, One-way 
ANOVA and Two-way ANOVA and unless otherwise stated a Gaussian distribution is 
assumed. Significance is depicted graphically for each data set with * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001.  
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Chapter III: Development of Robust and Reproducible 
Human Pluripotent Stem Cell Derived Models of Neurite 
Outgrowth 
 
3.1 Introduction 
 
Neuritogenesis is an important developmental process, essential to the formation of 
complex neuronal networks and connections10. Inhibition of neurite outgrowth is 
common to many disorders of the central nervous system (CNS)40–44 ranging from trauma 
in the form of spinal cord injury33,39 to neurodegenerative diseases including Alzheimer’s 
disease35,36 and Parkinson’s disease37. For this reason, the development of in vitro models 
that recapitulate the process of neuritogenesis has been a highly active area of research. 
However, there is still need for a physiologically relevant, robust and reproducible model 
of neurite outgrowth that can be applied to study the molecular processes that underpin 
neurite inhibition in the context of a variety of disorders of the nervous system. In 
addition to this, robust in vitro neurite outgrowth models, also offer the ability to 
routinely screen compounds, to test their neurotoxic or regeneration promoting 
properties. For this reason, the development of a robust, reproducible, and physiologically 
relevant model of neuritogenesis is essential, to provide a tool for routine use in the 
screening of such compounds.  
 
3.1.1 Embryonal Carcinoma (EC) Cells as a Model of Neuritogenesis 
 
Embryonal carcinoma (EC) cells are pluripotent stem cells that form the basis of many 
neural differentiation studies and are well characterised69.  Stefan Przyborski first 
isolated the TERA2 sub-line, TERA2.cl.SP12 in 2001, which has since formed the basis of 
many neurological studies146. The TERA2.cl.SP12 subline was identified as expressing 
high levels of pluripotency markers such as SSEA-3/4 and TRA-1-60 in the 
undifferentiated state and high levels of differentiation markers such as A2B5 and VIN-IS-
56 upon retinoic acid induction146.  Therefore, due to their high expression of early 
neuronal markers such as A2B5 upon retinoic acid exposure, TERA2.cl.SP12 cells are 
thought to undergo neuronal differentiation more readily than other clonal lines such as 
NTERA2.cl.D1 or the heterogeneous parental line itself, TERA2146. 
 
Due to their pluripotent nature EC cell-based models offer insight into the developmental 
processes involved in human embryonic development69. As cells derived from the TERA2 
lineage readily undergo robust neuronal differentiation, they have been used to study the 
molecular processes involved in neuronal differentiation and development. Przyborski et 
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al describe a transcriptional profiling analysis that compared TERA2-derived, retinoic 
acid induced neurons with in vivo and in vitro developing neural cells71. It was found that 
neurons differentiated from TERA2 cultures express similar genes and proteins to 
developing neurons in vivo. Various individual neuron-specific genes, including: nestin, 
Pax6 and NKx6.1 along growth-related proteins known to be involved in vertebrate 
neurogenesis (SCG10, GAP43) were expressed in differentiated TERA2 cultures and 
aligned closely with gene expression of developing neural cells both in vitro and in vivo71. 
Therefore, it was demonstrated that neurogenesis upon retinoic acid induction of human 
pluripotent stem cells is conserved and the resultant neurons share similarities with their 
in vivo counterpart. Similarly, TERA2 derived neurons have also been characterised in 
terms of functionality and have been found to be electrophysiologically active72. Therefore 
EC cells can provide a source of functional, well-characterised neurons for use in in vitro 
neuronal models such as those used to study neurite outgrowth. 
 
One of the main limitations of standard models of neurite outgrowth lies within the 
quantification methodology, as most models rely on the tracing of individual neurites 
using image analysis software63,200. When neurons are cultured as traditional monolayers, 
they form a network of overlapping, branching neurites that prove difficult to trace and 
subsequently quantify63.  Stewart et al describe two distinct methodologies for the 
induction of neuronal differentiation by retinoic acid in TERA2.cl.SP12 cells, first as 
monolayer cultures and secondly as spheroids cultured in suspension148. Both 
methodologies induced successful neuronal differentiation, measured by downregulation 
of stem cell markers and upregulation of neuronal markers. However, when differentiated 
spheroids were cultured on ECM coated surfaces, neurites were found to radiate from the 
central spheroid structure148. This may provide a more easily quantifiable alternative, as 
each neurite radiates from a central point with no evidence of branching, therefore 
promoting easier, less time consuming and more accurate neurite tracing.   
 
Therefore, EC cells can offer insights into the developmental processes that are involved 
in human embryonic development. They form the basis of many robust neuronal 
differentiation studies and the mature neurons that they generate have been 
characterised and found to express similar proteins as their in vivo counterpart71, as well 
as displaying functional electrophysiological characteristics72. For this reason, EC cell-
derived neurons have been extensively studied and characterised and are commonly used 
to generate in vitro neuronal cell-based models21,66,69,70,72,84,145,146,148. 
 
3.1.2 Enhancement of Neurite Outgrowth by 3D Culture Technology 
 
When developing in vitro cell-based models, many aspects of the microenvironment 
should be considered in order to generate the most physiologically relevant model 
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possible161,162. Particularly, many studies now focus on the use of 3D cell culture 
technology to provide a more physiological geometry and growth cues for cultured 
cells161,162,191. One way in which this may be achieved is through the use of specifically 
designed 3D scaffolds, such as the commercially available Alvetex® scaffold. Alvetex® 
scaffold is a porous, polystyrene polyHIPE with an internal structure comprised of pores 
and interconnecting windows that promote the influx of culture medium into the 
scaffold191. The use of Alvetex® has been demonstrated in a wide variety of in vitro models 
ranging from the generation of skin equivalents201 to the enhancement of hepatocyte 
function202. 
 
Polystyrene, 3D scaffolds such as Alvetex® have previously been demonstrated to enhance 
neuronal differentiation and neurite outgrowth as described by Hayman et al147. This 
study focused on the culture of retinoic acid treated TERA2.cl.SP12 cells either in 2D 
conditions or within the 3D scaffold and found that 3D cultures had developed a more 
extensive network of individual neuritic processes compared with their 2D 
counterpart147. A molecular analysis revealed that expression of markers associated with 
developing neurons were up-regulated in 3D cultures indicating an ongoing expansion of 
the neuronal network with continuing neurite development147. Similarly, the protein 
MAP2ab, associated with maturation of the neuronal cytoskeleton was enhanced by 3D 
culture, indicating maturation of the 3D neural network and the development of more 
extensive neurite networks compared with 2D cultured cells147.  
 
Therefore, 3D cell culture technology has applications in the development of more 
physiologically relevant culture models, to maintain a more in vivo-like geometry in which 
to culture cells. Furthermore, this technology has been demonstrated to further enhance 
current models of neurite outgrowth and to provide a favourable environment for the 
development of complex neuronal networks.   
 
3.1.3 Enhancement of Neurite Outgrowth by Manipulation of Rho Signalling 
 
The process of neuritogenesis in vivo, involves extensive remodelling of the actin 
cytoskeleton, and relies heavily upon the Rho signalling cascade10,13, as described in 
Chapter I. As actin dynamics provide the driving force that induces neurite extension, 
manipulation of this process is a common strategy employed in the enhancement of 
current neurite outgrowth in vitro models. For example, Roloff et al describe inhibition of 
Rho and its downstream target, ROCK, to enhance their current N-TERA2 derived model 
of neuritogenesis21. This study found that inhibition of Rho by the analgesic, ibuprofen, 
enhanced neurite outgrowth significantly21. Similarly, fasudil and Y-27632, both inhibitors 
of Rho’s downstream effector, ROCK, significantly enhanced neurite outgrowth in NTERA-
2 derived neurons21.     
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Inhibition of ROCK is a strategy to enhance neurite outgrowth that has also been applied 
to other model systems including those base on PC-12 cells. Both Y-27632 and H-1152 are 
inhibitors of ROCK that have been demonstrated to enhance neurite outgrowth from PC-
12 cells in a time and dose-dependent manner203. However, this effect is not conserved 
within all neuronal subtypes, as Y-27632 alone has limited neurite-enhancing effect in 
retinal ganglion cells and only when in combination with ciliary neurotrophic factor is this 
enhancement observed204.  
 
Although inhibition of Rho and ROCK signalling can enhance in vitro neurite outgrowth in 
some models of neuritogenesis, its suitability in neurite inhibition studies should be 
considered. Inhibition of Rho and ROCK is commonly used to overcome neurite inhibition 
in a non-permissive environment such as the presence of inhibitory molecules associated 
with spinal cord injury25–27,30,32. Therefore, if for example, Y-27632 is already incorporated 
in the basic model, the addition of inhibitory stimuli may not result an inhibitory 
response, as the intrinsic presence of Y-27632 may recover and mask any such effect. 
Therefore, the suitability of incorporation of any Rho/ROCK pathway inhibitor should be 
assessed prior to incorporation into any model with particularly consideration of the 
particular application of such model. 
 
3.1.4 Applications of a Physiologically Relevant Neurite Outgrowth Model 
 
Neuritogenesis is an important developmental process, essential in the formation of 
neuronal circuitry and connections205. Impairment of neurite outgrowth is common to 
many pathologies of the nervous system, including spinal cord injury33,39,206, Alzheimer’s 
disease35,36, Parkinson’s disease37, schizophrenia41 and Down’s syndrome43. For this 
reason there is need for a physiologically representative model of neuritogenesis that can 
be used to probe the underlying molecular mechanisms that underpin neurite inhibition 
and generation. Furthermore, in vitro models of neurite outgrowth can be used to screen 
the potential for agents to overcome neurite inhibition and aid in the discovery of new 
drugs to intervene and recover the process124. Also, as new drugs are developed, part of 
their safety assessment requires any neurotoxic effects to be identified and measured, 
therefore neurite outgrowth models may provide useful tools for this63. Therefore, there 
is great demand and need for an in vitro, cell-based model of neuritogenesis that better 
reflects the in vivo process of neurite development. 
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Fig 3-1: The mechanisms by which Y-
27632 and ibuprofen promote neurite 
generation.  
A schematic representation of how 
activation of Rac and Cdc42, along with 
inhibition of Rho A leads to neurite 
elongation (A). Activation of Rac and Cdc42 
enhances de novo elongation through the 
promoting of polymerisation at the barbed 
end of the actin filament through anti-
capping proteins ENA/VASP enhanced by 
fascin. Convergent elongation is also 
promoted, whereby Arp2/3 drives actin 
branching and the bundling of filaments. 
ADF/cofilin depolymerises actin at the 
pointed end, freeing G-actin monomers for 
polymerisation at the barbed end, whilst 
also driving propulsion of the growth cone. 
This depolymerisation also allows for actin 
re-organisation, which promotes 
microtubule penetration into the growth 
cone of the developing neurite. Inhibition of 
Rho A results in activation of Myson II 
which leads to myosin driven contractility 
and neurite elongation. Rho A and ROCK 
activation is inhibited when neurite 
outgrowth is active, however in the 
presence of an inhibitory stimulus, ROCK 
leads to the phosphorylation of a number of 
downstream targets, which has an 
inhibitory effect upon neurite outgrowth. A 
schematic representation depicts the 
mechanism by which Y-27632 inhibits 
ROCKI/II (B), through competitive 
inhibition of ATP binding. Ibuprofen 
however, induces activation of the 
transcription factor PPARγ, which inhibits 
Rho A and promotes the transcription of 
anti-inflammatory associated genes (C). 
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3.1.5 Conclusions 
 
Due to the importance of neuritogenesis in neuronal development and its implications in 
neurological pathologies, there is a need for the development of a robust and reproducible 
model of neuritogenesis. In this chapter we describe the combination of 3D cell culture 
technology in the form of Alvetex® Scaffold with human pluripotent stem cells and 
synthetic retinoid analogues to produce a robust and reproducible model of human 
neuritogenesis that can be applied to study the process of neurite inhibition in the context 
of different nervous system disorders.  
 
 3.1.5.1 Chapter Aims 
 
This chapter aims to investigate and optimise the role of synthetic retinoid analogues 
(EC23 and AH61) in differentiation and neurite development from the human embryonal 
carcinoma cell line, TERA2.cl.SP12. Synthetic retinoids have previously been reported to 
readily induce neural differentiation of TERA2.cl.SP12 cells81–84,149 and this chapter aims 
to optimise this process with a specific focus on the induction of neuritogenesis from 
spheroid cultures in a similar manner as described by Stewart et al148, along with a 
thorough characterisation of the resultant neurites. Furthermore, this chapter aims to 
adapt the spheroid neurite outgrowth culture system outlined by Steward et al148, into a 
3D culture environment using Alvetex® Scaffold, to produce a more physiologically 
relevant model to apply to the study of neurite inhibitory mechanisms. In addition to this 
EC cell-derived model of neuritogenesis, this chapter also aims to apply the principles of 
spheroid induction of neuritogenesis to an iPSC-derived neurite outgrowth model. 
Throughout this chapter the ability of inhibitors of Rho/ROCK signalling to enhance 
neurite outgrowth within these models will be assessed and their appropriateness for use 
in applications to study neurite inhibition will be discussed. 
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3.1.5.2 Chapter Objectives 
 
 Evaluate the effect of natural and synthetic retinoid compounds on neural 
differentiation of TERA2.cl.SP12 cells. 
 
 Optimise the concentration and retinoid compound most appropriate for use in 
TERA2.cl.SP12 derived spheroid model of neurite outgrowth.  
 
 Develop and evaluate a novel quantification methodology to reduce time-
consuming neurite tracing.  
 
 Fully characterise the resultant neurites obtained from retinoid-induced 
differentiation of TERA2.cl.SP12 cells, to determine if the expression of 
cytoskeletal markers is conserved within the system.  
 
  Adapt the 2D spheroid based model of neuritogenesis into a 3D culture system 
using Alvetex® Scaffold to produce a more physiologically relevant model of 
neurite outgrowth.  
 
 Use iPSC technology to develop another novel model of neurite outgrowth in 2D 
and 3D culture systems. 
 
 Examine the ability of Rho and ROCK inhibition to enhance neurite outgrowth in 
both EC and iPSC-derived neurite outgrowth models. 
 
3.2 Materials & Methods 
 
The methodologies used throughout this chapter are detailed in the main Materials & 
Methods section of this thesis (Chapter II). The main aim of this chapter was to develop 
robust and reproducible models of human neurite outgrowth, one of which was based on 
a human embryonal carcinoma cell line. This model was well developed and characterised 
throughout this chapter. In addition to this, a novel method of neurite quantification was 
also developed to further enhance the reliability of this model as an assay. A Standard 
Operating Procedure (SOP) for this methodology was established and can be found in 
Appendix I.  
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3.3 Results 
 
3.3.1 Neural Differentiation of Human Pluripotent Stem Cells Induced by Synthetic 
Retinoid Compounds 
 
To determine the ability of synthetic retinoids EC23 and AH61, along with the naturally 
occurring ATRA to induce neural differentiation of human pluripotent stem cells, 
TERA2.cl.SP12 EC cell monolayers were incubated with the compounds for 7 days. As can 
be seen in Figure 3-2 (A), phase contrast micrographs reveal typical stem cell morphology 
of undifferentiated TERA2.cl.SP12 cells and cells are packed tightly into colonies at high 
confluence. Monolayers differentiated with 0.01 μM ATRA (Figure 3-2B) however, appear 
to contain areas where cells appear larger and lose their typical stem cell morphology 
with monolayers appearing heterogenous. Similarly, monolayers treated with synthetic 
compounds (EC23 and AH61) appear to lose their characteristic stem cell-like 
morphology and adopt a more differentiated phenotype with monolayers appearing more 
homogenous than those differentiated with ATRA.  
 
To compare the ability of each compound to induce neural differentiation of 
TERA2.cl.SP12 monolayers, cell surface marker expression by flow cytometry was 
measured. This analysis revealed changes in expression of the stem cell marker SSEA-3 
(Figure 3-2E) and the early neuronal marker A2B5 (Figure 3-2F) with retinoid treatment.  
The pluripotency marker SSEA-3 is highly expressed in undifferentiated cells and declines 
with increasing concentration of each compound tested (0.001 – 10 μM). At all 
concentrations, treatment with the synthetic retinoids EC23 and AH61 results in 
significantly less expression of SSEA-3 than ATRA treatment, and AH61 also induced 
SSEA-3 loss to a significantly greater extent than EC23 at each concentration. 
 
A2B5, an early neuronal antigen is found at extremely low levels in the undifferentiated 
TERA2.cl.SP12 population and expression is induced by retinoid treatment.  Lower 
concentrations of synthetic retinoids (0.001 – 0.01 μM) induce expression of A2B5 to a 
significantly higher degree than ATRA, indicating greater neural induction. However, 
increasing retinoid concentration results in a smaller difference between the compounds 
and at 1 μM there is no significant difference in A2B5 expression amongst the compounds 
tested.  
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Fig 3-2: Induction of differentiation of human pluripotent stem cells with retinoid compounds. 
Representative phase contrast images of TERA2.cl.SP12 cells cultured as 2D monolayers (A) and treated with ATRA (B), EC23 (C) and AH61 (D) for 7 days. Flow 
cytometry (E) analysis of cellular expression of the stem cell marker, SSEA-3 (E) and the early neuronal marker, A2B5 (F) from 2D monolayers treated with retinoid 
compounds for 7 days  (data represent mean ± SEM, n=9; 3 samples of cells were stained from 3 independent differentiation studies). Synthetic retinoids induce 
loss of SSEA-3 expression and induction of A2B5 expression to a greater extent than ATRA at low concentrations. Two way ANOVA with Tukey’s multiple 
comparisons test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  Scale bars: 200 μm. 
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3.3.2 Development and Characterisation of a Robust and Reproducible Model of Human 
Neurite Outgrowth in 2D Culture  
 
To develop a spheroid-based human pluripotent stem cell-derived model of neurite 
outgrowth, a two-step culture methodology was developed. The methodology of which is 
outlined in Chapter II (2.2.5 Formation of neurospheres from human pluripotent stem cells, 
2.2.6 Induction of neurite outgrowth from stem cell derived neurospheres). In brief, 
monolayers of TERA2.cl.SP12 cells were dissociated and seeded in suspension to promote 
aggregation and then differentiated with retinoid compounds for 21 days to form mature 
neurospheres. Neurospheres were cultured on poly-D-lysine and laminin coated surfaces 
for a further 10 days, during which time neurospheres adhered to the growth substrates 
and neurites began to protrude from the neurospheres in a radial fashion. During the 10-
day neurite outgrowth period, retinoids were not included in the growth medium, 
however mitotic inhibitors were added to prevent excess cell proliferation.   
 
Quantification of neurite outgrowth was achieved by examination of TUJ-1 positive 
staining, a pan-neuronal marker that highlights neurite outgrowth. Neurites were then 
traced using image analysis software (Image J), however tracing each individual neurite is 
an extremely time consuming process that can be prone to error. For this reason, a 
sampling procedure was developed to establish an accurate and efficient quantification 
methodology. TERA2.cl.SP12 derived neurospheres were differentiated with increasing 
concentrations of ATRA and quantified by tracing every neurite (Figure 3-3A). The same 
data set was then analysed using a sampling method that involved the overlay of a grid 
onto the image and the random selection of three squares per image to quantify (Figure 3-
3B). Data sets from both quantification methods were compared and a statistical analysis 
demonstrated that there was no significant difference (ns) in the number of neurites per 
neurosphere (Figure 3-3C) or the neurite density (Figure 3-3D) of each neurosphere 
when using either quantification method. Therefore the sampling method of 
quantification was deemed a satisfactory method of neurite quantification for use 
throughout this study.  
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Fig 3-3: Development of an efficient method for the quantification of neurite 
outgrowth.  
Representative images showing TUJ-1 positive neurites (green) radiating from 
neurospheres and neurites were traced using Image J software (white). All neurites 
protruding from each neurosphere were counted (A) and compared with a sampling 
method (B) whereby a grid was overlaid onto each image and three squares were selected 
randomly to quantify. Scale bars: 500 μm. Quantification of the number of neurites per 
neurosphere (C) and neurite density (D) for cell aggregates differentiated with a range of 
concentrations of ATRA (0.001 μM – 10 μM), and quantified by both fully counting neurite 
outgrowth and by employing the sampling method described. No significant (ns) 
difference was found between counting all neurites (fully counted) and the efficient 
sampling method developed through two-way ANOVA analysis and Tukey’s multiple 
comparison test (data represent mean ± SEM, n=6-9; 2-3 neurospheres were quantified 
from 3 independently differentiated pools of neurospheres). 
 
 
In order to optimise the differentiation process, the ability of synthetic retinoids to induce 
neurite generation from human pluripotent stem cell aggregates was analysed over a 
range of concentrations (0.001 – 10 μM). Neurite outgrowth was identified by 
immunofluorescence (Figure 3-3A) whereby nuclei (blue) remained within the central 
cellular aggregate whilst neurites (green, TUJ-1+) extended radially from the central 
aggregate body. Neurospheres differentiated with ATRA (Figure 3-4Aa,d) appear to have 
generated less neurites and neurite growth appears to be less uniform than those 
neurospheres differentiated with the same concentration EC23 (Figure 3-4Ab,e) or AH61 
(Figure 3-4Ac,f).  
 
Quantification of neurite outgrowth from neurospheres differentiated with each retinoid 
compound revealed that at lower concentrations (0.001 – 0.01 μM) those neurospheres 
differentiated with EC23 and AH61 produced significantly more neurites (Figure 3-4B) 
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than those differentiated with ATRA. Similarly, when normalised to aggregate size, the 
neurite density (Figure 3-4C) of neurospheres differentiated with synthetic compounds 
was significantly higher than those differentiated with ATRA. However, the difference in 
neurite outgrowth between the compounds tested becomes less pronounced at higher 
retinoid concentrations (1 – 10 μM) with no significant difference in the neurite density 
between compounds at these concentrations. This is thought to be due to the maximal 
capacity of neurite outgrowth from the neurospheres being reached, particularly as 
increasing the concentration of retinoid molecules further did not increase neurite 
outgrowth. Therefore, it was determined that 0.01 μM EC23 was the optimum condition 
for inducing neuritogenesis from stem cell derived neurospheres. This is because 0.01 μM 
EC23 induced the generation of significantly more neurites per neurosphere and 
neurospheres were of a greater neurite density than those aggregates differentiated by 
ATRA and AH61. The optimal set of conditions was used to induce neuronal 
differentiation and neurite generation for the remainder of this study.  
 
To further characterise the neurites generated from stem cell-derived neurospheres 
induced by 0.01 μM EC23, expression of known cytoskeletal markers were analysed over 
time. It was found that nestin, an intermediate filament protein found in neural stem cells 
and progenitors, was expressed early in culture (Figure 3-5A-D). Maximal expression of 
nestin was observed at day 2, whereas more intermediate neurite outgrowth markers 
such as neurofilament-L (Figure3-5E-H) and neurofilament-M (Figure 3-5I-L) are 
expressed later in culture, during the intermediate time points analysed (days 4 – 10). The 
marker of neurite maturation, neurofilament-H (Figure 3-5Q-T), was expressed maximally 
at day 20 in extended cultures. The pan-neuronal marker TUJ-1 highlights the extension of 
neurites from the neurospheres over time (Figure 3-5Q-T) with neurites beginning to 
protrude from the neurosphere at day 2 and increasing in length over the 20-day culture 
period.     
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Fig 3-4: Induction of neurite outgrowth using natural and synthetic retinoid 
compounds. 
Representative confocal images of neurospheres (A) differentiated with a range of 
concentrations (0.001 μM – 10 μM) of ATRA (a-d), EC23 (e-h) and AH61 (i-l) and 
subsequently cultured in 2D. TUJ-1 positive neurites are highlighted in green and radiate 
from the central body of the neurosphere with nuclei being stained blue. Scale bars: 200 
μm. Quantification examining the number of neurites per neurosphere (B) (data represent 
mean ± SEM, n=15-24; between 5-8 neurospheres were quantified from 3 independently 
differentiated pools of neurospheres), the number of neurites per µm of aggregate 
circumference, neurite density (C) (data represent mean ± SEM, n=15-24 between 5-8 
neurospheres were quantified from 3 independently differentiated pools of 
neurospheres) and neurite length (D) (data represent mean ± SEM, n=100; 33 neurites 
from 3 independently differentiated neurospheres were measured). Synthetic molecules 
induce greater neuritogenesis at lower concentrations than the naturally occurring ATRA 
and 0.01 μM EC23 was found to be the optimum differentiation condition in terms of 
neurite number and density. This condition was therefore selected for use throughout the 
project. Data was analysed using a two-way ANOVA with Tukey’s multiple comparison 
test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 3-5: Characterisation of neuronal 
differentiation through the stages of 
neurite outgrowth from neurospheres 
over 20 days in 2D culture. 
Neurospheres were cultured on poly-D-
lysine and laminin coated 2D surfaces for 
up to 20 days. Representative confocal 
images of expression over time of nestin (A-
D), neurofilament-L (E-H), neurofilament-M 
(I-L), neurofilament-H (M-P), and TUJ-1 (Q-
T). Scale bars: (A-P): 50 µm , (Q-T): 100 µm. 
Nestin, a marker of neuronal stem cells is 
expressed early in culture, whereas more 
intermediate markers of neurite outgrowth 
such as NF-L and NF-M are expressed 
midway through culture and NF-H, a mature 
marker of neurite outgrowth is expressed at 
later stages of culture. This suggests that 
neurite outgrowth within this model, shares 
similarities with neurite outgrowth during 
development of the nervous system. 
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3.3.3 Development of a Novel Stem Cell Derived Neurite Outgrowth Model within a 3D 
Culture System 
 
This 2D fully optimised and characterised model of neuritogenesis was then combined 
with well-established 3D cell culture technology to provide a more physiologically 
representative model of neurite development. Building on previous work that has 
demonstrated enhanced neuritogenesis on 3D Alvetex® Scaffold membranes147,150. This 
study has utilised the same technology to produce a more characterised and advanced 
model of neuritogenesis with many applications to study neurite growth and inhibition.  
 
Alvetex® scaffold is a highly porous cell culture scaffold specifically developed for 3D cell 
culture applications and is compatible with traditional tissue culture plastic-ware (Figure 
3-6A). The internal structure of Alvetex® scaffold is visible under scanning electron 
microscopy (SEM, Figure 3-6B) and comprises of voids with an average size of 40 μm and 
interconnecting windows of 13 μm. Alvetex® membranes are suspended in well inserts 
providing an appropriate substrate on which to perform 3D cell culture.  
 
Neurospheres differentiated with the optimal 0.01 μM EC23, were cultured on Alvetex® 
scaffold coated with poly-D-lysine and laminin for 10 days with the addition of mitotic 
inhibitors. A cross-section of Alvetex® scaffold (Figure 3-6C) reveals that the neurosphere 
predominantly remains on top of the scaffold with only a few nuclei (hoechst stained 
blue) penetrating the material. In contrast, extensive neurite outgrowth (TUJ-1 positive 
staining – green) can be observed within the 3D material. The scaffold provides a more 
physiologically relevant environment and physical 3D space for neurites to grow and 
develop.  
 
A view from above the scaffold indicates that the neurosphere itself remains on top of the 
scaffold (Figure 3-6D) whereas, neurites can be visualised from the bottom surface of the 
scaffold (Figure 3-6E), having penetrated the entire 200 μm depth of the material.  A 
schematic demonstrates the difference in neurite development from neurospheres 
cultured in 2D (Figure 3-6F) and 3D (Figure 3-6G). When cultured in 2D neurites (green) 
radiate from the central cellular aggregate (blue), whereas in 3D culture, the body of the 
aggregate remains on top of the scaffold whilst the neurites penetrate the depth of the 
material and are visible from the underside, providing a novel means of quantification.  
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Fig 3-6: Development of a novel 3D model of neurite outgrowth. 
Image of Alvetex® Scaffold 12-well inserts (A) and a scanning electron micrograph 
demonstrating the internal structure of the scaffold (B) with voids of 40 µm and 
interconnecting windows of 13 µm. Extensive neurite outgrowth can be observed within 
the 3D scaffold (C) with TUJ-1 positive neurites staining green and nuclei blue, imaged 
using confocal microscopy. The majority of the neurosphere remains on top of the scaffold 
(D) with neurites growing into the 3D material. Neurites can be visualised on the bottom 
of the scaffold (E), having extended through 200 µm of Alvetex® Scaffold. A schematic 
depicts the difference in neurite development between 2D (F) and 3D (G) culture. 
Neurospheres are depicted blue and neurites green. In 2D culture neurospheres radiate 
from the central neurosphere, whereas in 3D the neurites penetrate the depth of Alvetex® 
scaffold. Scale bars: 100 µm. 
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3.3.4 Investigation into the Role of Rho A/ROCK Signaling in Neurite Outgrowth 
 
Neurite growth is controlled by a balance between signalling pathways involving the 
neurite promoting effects of Rac/Cdc42 and Rho A-mediated inhibitory signalling, which 
have opposing effects upon the actin cytoskeleton resulting in neurite growth or 
inhibition10,13,207, as shown in Figure 3-6.  For this reason many in vitro models of neurite 
outgrowth involve the addition of inhibitors of Rho A and ROCK to enhance neurite 
growth by reducing inhibitory signalling21–24,29,30,203,204,208,209. Such molecules include 
ibuprofen, an inhibitor of Rho A and the selective ROCK inhibitor, Y27632. To investigate 
the effect of Rho A/ROCK signaling within the human pluripotent stem cell derived model 
of neurite outgrowth described herein, Y-27632 and ibuprofen were added to 2D and 3D 
neurite outgrowth cultures. 
 
 
Fig 3-7: A balance between Rac and Rho signalling controls neurite growth. 
Activation of Rac and Cdc42 drives neurite protrusion, whereas activation of Rho A 
promotes growth cone collapse. Neurite growth is dependent upon the balance between 
these two opposing signaling mechanisms due to their actions upon the actin 
cytoskeleton. Rac and Cdc42 activation promotes actin polymerisation and destabalises 
actin filaments resulting in membrane breaching, whereas Rho A activation results in 
stabalisation of actin filaments and inhibition of membrane breaching.  
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  3.3.4.1 Inhibition of ROCK by Y-27632 
 
To investigate the role of ROCK inhibition and to potentially enhance neuritogenesis 
within this stem cell derived model, the selective ROCK inhibitor Y-27632, was added to 
the culture medium of neurospheres at a range of concentrations (0.5 – 50 μM), during 
the 10-day neurite outgrowth phase of culture. Neurite outgrowth (TUJ-1+, green) from 
neurospheres cultured in 2D (Figure 3-8A) with 0.5 μM Y-27632 (Figure 3-7Ac,d) appears 
to differ only slightly from neurite outgrowth from untreated neurospheres (Figure 3-
8Aa,b). However, higher concentrations such as 10 μM – 50 μM of Y-27632 have a drastic 
effect on neurite outgrowth, with a significantly greater number of TUJ-1 positive neurites 
visibly radiating from the central neurosphere. It also appears that at 10 μM – 50 μM Y-
27632, fewer nuclei and cell bodies are visible outside of the cellular aggregate than in 
untreated and 0.5 μM treated neurospheres. 
 
Quantification of the number of neurites per neurosphere (Figure 3-8B) and neurite 
density (Figure 3-8C) of the neurospheres (neurite number normalised to neurosphere 
size) reveals that both parameters increase in a dose dependent manner with increasing 
Y-27632 concentration. Treatment with 0.5 μM Y-27632 increases neurite number and 
density slightly, however this increase is not statistically significant. Whereas, treatment 
with 10 – 50 μM Y-27632 results in a significant increase in neurite number and density 
compared with the control. Neurite length (Figure 3-8D) however, decreases in a dose 
dependent manner with increasing Y-27632 treatment. There is little difference in the 
length of neurites produced by neurospheres treated with 0.5 μM Y-27632, however 
higher concentrations such as 10 – 50 μM Y-27632 resulted in a dose dependent 
inhibition of neurite length. Similarly, as observed in the fluorescence micrographs, the 
migration of nuclei from the central neurosphere (Figure 3-8E) was inhibited by Y-27632 
treatment. Migration was significantly inhibited compared with the control at 10 – 15 μM 
Y-27632. 
 
Neurospheres cultured in 3D were also treated with Y-27632 to potentially enhance 
neurite outgrowth within the 3D culture system (Figure 3-9). Neurospheres are visible 
from the top view of the scaffold (Figure 3-8Aa,c,e,g,i) whilst TUJ-1 (green) positive 
neurites have visibly penetrated the depth of the scaffold as viewed from below (Figure 3-
9Aa,b,d,f,h,j). In the absence of Y-27632 significant neurite outgrowth can be viewed from 
the bottom of the scaffold (Figure 3-9Ab) and with increasing Y-27632 concentration, 
particularly at 15 – 50 μM Y-27632 treatment (Figure 3-8g-j) it appears that neurite 
outgrowth penetrating the scaffold is significantly enhanced. This is reflected in 
quantification of the number of neurites penetrating the scaffold (Figure 3-9B), which 
demonstrates little difference in neurite outgrowth between untreated neurospheres and 
those treated with 0.5 μM Y-27632. However, treatment with 10 – 50 μM Y-27632 
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resulted in an increase in the number of neurites penetrating the 3D material and 50 μM 
treatment resulted in a statistically significant increase in neurite outgrowth compared 
with the control. 
 
 
 
 86 
 
 
Fig 3-8: Enhancement of 2D neurite 
outgrowth by the selective ROCK 
inhibitor, Y-27632. 
Representative confocal images (A) of TUJ-
1 positive (green) neurite outgrowth from 
neurospheres cultured in 2D with a range 
of concentrations (0 – 50 µM) of Y-27632, 
a selective inhibitor of the ROCK enzyme. 
Nuclei are highlighted in blue. Scale bars: 
(Aa,c,e,g,i): 200 µm, (Ab,d,f,h,j): 50 µm. 
Number of neurites per neurosphere (B) 
(data represent mean ± SEM, n=15-18; 3 
repeats from independent pools of cells 
were conducted, from which 15-18 
neurospheres were quantified) and neurite 
density (C) (data represent mean ± SEM, 
n=15-18; 3 repeats from independent 
pools of cells were conducted, from which 
15-18 neurospheres were quantified) are 
both greatly increased in a dose dependent 
manner by the addition of Y-27632 to the 
culture medium during the neurite 
outgrowth phase of culture. However, 
neurite length (D) (data represent mean ± 
SEM, n=457-984; between 457-984 
neurites were measured from 15-18 
neurospheres differentiated on 3 separate 
occasions) and percentage area of 
migration from the central body of the 
aggregate (E) (data represent mean ± SEM, 
n=9; 3 neurospheres were samples from 3 
independent differentiation studies) are 
both inhibited by increasing 
concentrations of Y-27632. Data analysed 
by an ordinary one-way ANOVA with 
Tukey’s multiple comparisons test: * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, **** = p 
< 0.0001. 
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Fig 3-9: Enhancement of 3D neurite outgrowth by the selective ROCK inhibitor, Y-27632. 
Representative confocal images (A) of neurospheres sitting on top of Alvetex® Scaffold (Aa,c,e,g,i) and TUJ-1 (green) positive neurites are visible from the underside 
of the scaffold (Ab,d,f,h,j). Nuclei are highlighted in blue. Scale bars: 200 µm. Neurospheres were cultured with a range of concentrations (0 – 50 µM) of Y-27632 
throughout the 10 day neurite outgrowth phase of culture, and quantification of neurites that have penetrated the scaffold (B) (data represent mean ± SEM, n=6-9; 
neurite outgrowth was analysed from 2-3 neurospheres from 3 independently differentiated pools of neurospheres) demonstrates the ability of the molecule to 
enhance neurite outgrowth in a dose dependent manner. Data analysed by an ordinary one-way ANOVA with Tukey’s multiple comparisons test: * = p < 0.05, ** = p 
< 0.01, *** = p < 0.001, **** = p < 0.0001. 
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  3.3.4.2 Inhibition of Rho A by Ibuprofen 
 
To investigate the ability of inhibition of Rho A to potentially enhance neurite outgrowth 
within this stem cell-derived model of neuritogenesis, ibuprofen the non-steroidal anti-
inflammatory drug and inhibitor of Rho A30, was added to the neurosphere culture 
medium for the duration of the 10-day neurite outgrowth period. A range of ibuprofen 
concentrations were tested (0 – 750 μM) and neurospheres cultured in 2D (Figure 3-10A) 
appear to generate more TUJ-1 positive (green) neuritic extensions at higher 
concentrations of ibuprofen such as 750 μM (Figure 3-10Ak,l). Similarly to Y-27632 
treatment, 750 μM ibuprofen treatment seems to result in fewer nuclei migrating from the 
central cellular body. However, the effect upon neurite generation does not seem as 
profound as that of Y-27632, neurospheres treated with higher concentrations of 
ibuprofen (500 – 750 μM) do appear to generate more neurites than untreated 
aggregates.    
 
Quantification of neurite outgrowth from ibuprofen treated neurospheres reveals that 
both neurite number (Figure 3-10B) and density (Figure 3-10C) increase in a dose 
dependent manner with ibuprofen treatment. Treatment with higher concentrations of 
ibuprofen, ranging from 100 – 750 μM result in a statistically significant increase in both 
neurite number and density compared with untreated neurospheres. Similarly to Y-27632 
treatment, neurite length (Figure 3-10D) decreases with increasing ibuprofen 
concentration resulting in a significant inhibition in neurite length with 500 – 750 μM 
ibuprofen. An inhibition in migration of cells from the central neurosphere (Figure 3-10E) 
was also documented and appeared to respond to ibuprofen treatment in a dose-
dependent fashion, although a slight (not statistically significant) increase in migration 
was observed with 10 μM ibuprofen.  
 
In 3D culture neurospheres are visible on top of the scaffold (Figure 3-11Aa,c,e,g,i,k) and 
significant neurite penetration is observed from the bottom view of the scaffold (Figure 3-
11Ab,d,f,h,j,l). In the absence of ibuprofen treatment (Figure 3-11 Aa,b) significant 
neuritogenesis can be observed from the underside of the scaffold. As ibuprofen 
treatment increases in concentration (10 – 100 μM) it appears that the number of TUJ-1 
positive (green) neurites penetrating the 3D material increases. However at the highest 
concentrations of ibuprofen tested (500 – 750 μM) fewer neurites appear to be visible on 
the underside of the scaffold, as opposed to 100 μM ibuprofen.  
 
Similarly, quantification (Figure 3-11B) reveals an increase in the number of neurites 
penetrating the scaffold with increasing ibuprofen concentration, in a dose-dependent 
manner up to 500 μM. However, as ibuprofen concentration increases to 750 μM, the 
number of neurites penetrating the 3D material dramatically declines. This could be due 
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to the fact that ibuprofen inhibits neurite length in 2D culture (Figure 3-10), therefore at 
the highest concentrations of ibuprofen tested, fewer neurites are able to penetrate the 
200 μm depth of the scaffold, thus are visible from the underside. Concentrations of 100 
μM and 500 μM ibuprofen were found to significantly enhance neurite outgrowth in 3D 
culture compared with untreated controls. 
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Fig 3-10: Enhancement of 2D neurite 
outgrowth by ibuprofen, an inhibitor 
of Rho A. 
Representative confocal images (A) of 
neurospheres cultured in 2D with 
increasing concentrations of ibuprofen (0 
– 750 µM). The pan-neuronal marker 
TUJ-1 is stained in green and nuclei are 
highlighted in blue and form the body of 
the aggregate.  Scale bars: (Aa,c,e,g,i,k): 
200 µm (Ab,d,f,h,j,l): 50 µm. 
Quantification of neurite outgrowth 
revealed that with increasing 
concentrations of ibuprofen, the number 
of neurites per neurosphere (B) (data 
represent mean ± SEM, n=15-24; 
between 5-8 neurospheres were 
quantified from 3 independently 
differentiated cell populations) and the 
density of the neurites (C) (data 
represent mean ± SEM, n=15-24; 
between 5-8 neurospheres were 
quantified from 3 independently 
differentiated cell populations) increased 
in a dose dependent manner with 
ibuprofen concentration. However, 
neurite length (D) (data represent mean 
± SEM, n=521-1273; between 521-1273 
neurites were measured from 5-8 
neurospheres sampled from 3 
independently differentiated 
neurosphere populations) and migration 
of cells from the aggregate (E) (data 
represent mean ± SEM, n=7-9) decrease 
with increasing ibuprofen concentration, 
particularly at higher concentrations. 
One-way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001. 
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Fig 3-11: Enhancement of 3D neurite outgrowth by ibuprofen, an inhibitor of Rho A.  
Representative confocal images (A) of neurospheres cultured in 3D with increasing concentrations of ibuprofen (0 – 750 µM). The body of the neurosphere is 
visible from the top view of the scaffold (Aa,c,e,g,i,k) and neurites that have penetrated the 3D material are visible from below the scaffold (Ab,d,f,h,j,l). TUJ-1 
highlights neurite outgrowth in green and hoechst stains nuclei in blue. Scale bars: 200 µm. Quantification of the neurites that have penetrated the scaffold (B) (data 
represent mean ± SEM, n=6-9; neurite outgrowth was quantified from 2-3 neurospheres from each of 3 independently differentiated populations of neurospheres) 
demonstrates that ibuprofen enhances neurite outgrowth up to high concentrations, however, this effect is lost at 750 µM. Data analysed using an ordinary one-way 
ANOVA with Tukey’s multiple comparisons test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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3.3.5 Development of a Novel iPSC Derived Model of Neurite Outgrowth 
 
In addition to the development and characterisation of a robust and reproducible EC-cell 
derived model of neurite outgrowth, an iPSC-derived neurite outgrowth model was also 
developed. This required the use of ReproNeuro, iPSC-derived neuroprogenitor cells210,211 
which were cultured as neurospheres and subsequently neurite outgrowth was observed. 
Two different populations of ReproNeuro cells were used for the development of this 
model, ReproNeuro Glu cells which are glutamatergic neuroprogenitor cells and 
ReproNeuro cells which form a mixed population of neuroprogenitors (Figure 3-12)212. 
ReproNeuro cells do not require differentiation by EC23, as the cells are received as 
differentiated neuroprogenitor cells that mature through the course of the culture period 
through the use of ReproNeuro Maturation medium.  
 
 
 
Fig 3-12: Derivation of ReproNeuro cell lines.  
ReproNeuro Glu and ReproNeuro cells are both derived from fibroblasts isolated from 
human donors. The fibroblasts are then reprogrammed to form populations of iPSCs that 
subsequently undergo differentiation to promote the formation of neuroprogenitor cells. 
However different differentiation procedures are used to generate the two cell lines. This 
results in the formation of ReproNeuro Glu, a population of predominantly glutamatergic 
neuroprogenitors, and ReproNeuro, a mixed population of neuroprogenitor cells. 
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 3.3.5.1 Development of a ReproNeuro Glu Derived Model of Neurite Outgrowth 
 
In order to form spheroid structures from ReproNeuro Glu cells, AggreWell™ plates were 
used to force cells into close proximity with one another (Figure 3-13). AggreWell™ plates 
contain microwells, initially filled with bubbles (Figure 3-13A), which can be removed by 
centrifugation (Figure 3-13B). ReproNeuro Glu cells were then seeded within the plates 
and incubated for 24 hours, during which time cells form 3D spherical structures due to 
the nature of the microwells forcing cells into close contact with one another (Figure 3-
13C,D). ReproNeuro Glu-derived neurospheres were then harvested (Figure 3-13E) and 
seeded onto ECM-coated growth substrates for a 10-day neurite outgrowth period (Figure 
3-13F,G) during which, neurites began to radiate from the central neurosphere, similar to 
the TERA2.cl.SP12 derived model of neuritogenesis described previously.  
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Fig 3-13: Formation of neurospheres from ReproNeuro Glu, iPSC derived neuroprogenitor cells and induction of 2D neurite outgrowth. 
AggreWell™ 800 plates prior to centrifugation (A) have small bubbles at the bottom of each microwell, following the addition of culture medium and centrifugation 
at high speed; bubbles are removed from the microwells (B). ReproNeuro Glu cells were revived and immediately seeded into AggreWell™ plates. Following 24 
hours incubation, cells formed spheroid structures in each microwell (C,D), which were then harvested from the plate (E). Neurospheres were then seeded on 2D 
surfaces coated in ReproNeuro Glu coating solution and cultured for 10 days (F,G). Scale bars: A-D: 500 µm, E-G: 200 µm. 
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In order to characterise the cell line, ReproNeuro Glu cells were also cultured as a 
monolayer (Figure 3-14A) and were found to express the pan-neuronal marker TUJ-1 
(Figure 3-14B) whilst forming an extensive neuronal network as visible by both phase 
contrast and fluorescence microscopy. ReproNeuro Glu-derived neurospheres formed via 
AggreWell™ plates were cultured for a 10-day neurite outgrowth period, during which 
time neurites can be seen to visibly radiate from the central sphere by phase contrast 
microscopy (Figure 3-14C). Similarly, staining for the pan-neuronal marker TUJ-1 (Figure 
3-14D) highlights the vast expanse of neurites generated by the neurosphere during this 
culture period. Significant neurite outgrowth can be observed radiating from the central 
cellular aggregate and neurites appear extremely long. Most nuclei appear to have 
remained within the central spheroid with few nuclei appearing to have migrated from 
the cellular mass. ReproNeuro Glu cells cultured within Alvetex® scaffold form complex 
networks of TUJ-1 positive neurons (Figure 3-14E,F) within the 3D microenvironment. 
From the top view of the scaffold (Figure 3-14E) a large volume of intertwining neurons 
are visible and the bottom view of the scaffold (Figure 3-14F) reveals those neurites that 
have penetrated the entire 200 μm depth of the 3D material. 
 
To compare both 2D models of neurite outgrowth described thus far in this chapter, 
neurite outgrowth from ReproNeuro Glu-derived neurospheres (Figure 3-15Aa) and 
TERA2.cl.SP12 derived neurospheres differentiated with 0.01 μM EC23 (Figure 3-15Ab) 
was compared. Neurites that stain positive for TUJ-1 (green) can be seen to protrude from 
both neurospheres in a radial manner. However, ReproNeuro Glu-derived neurospheres 
are extremely small in size compared with TERA2.cl.SP12-derived neurospheres. In both 
cases nuclei appear restricted to the central cellular mass with little migration from the 
neurosphere. ReproNeuro Glu-derived neurospheres appear to produce many more and 
longer neurites than TERA2.cl.SP12 cell derived neurospheres, as visible via fluorescence 
microscopy.  
 
Quantification reveals a similar number of neurites per neurosphere from both 2D 
cultured models (Figure 3-15B), however the difference in aggregate size between the 
two models results in this being a poor reflection of the neurite generation properties of 
each type of neurosphere. The neurite density (Figure 3-15C), gives a more reliable 
comparison of the ability of each type of neurosphere to produce neurites, and reveals 
that ReproNeuro Glu-derived neurospheres produce significantly more neurites per μm of 
neurosphere circumference compared with TERA2.cl.SP12-derived neurospheres. 
Similarly quantification of neurite length (Figure 3-15D) reveals that neurites generated 
by ReproNeuro Glu-derived neurospheres are significantly longer than their 
TERA2.cl.SP12 derived counterparts.  
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Although neurite outgrowth appears to be enhanced in ReproNeuro Glu-derived 
neurospheres, the TERA2.cl.SP12-derived model of neuritogenesis will still be used 
throughout this study for a number of reasons. Primarily, the ability of TERA2.cl.SP12 
cells to produce functional neurons and differentiate in response to retinoid compounds 
has been clearly documented previously along with their ability to form neurites in 3D, 
and this model is a well-known robust model of neurogenesis. Furthermore, EC cells are 
widely available and their consumables more economically favourable than the 
specialised media and supplements required for ReproNeuro Glu culture. Therefore the 
TERA2.cl.SP12 model was continually used throughout the remainder of the project. 
 
 
Fig 3-14: Development of a neurite outgrowth model from ReproNeuro Glu, iPSC 
derived neuroprogenitor cells. 
A representative phase contrast image of ReproNeuro Glu cells cultured as a 2D 
monolayer (A) and stained for the pan-neuronal marker, TUJ-1 (green) with nuclei being 
highlighted in blue (B). Extensive neurite outgrowth can be observed from neurospheres 
cultured in 2D under phase contrast microscopy (C) and TUJ-1 (green) staining (D) 
highlights the full extent of neurite outgrowth from the neurosphere. ReproNeuro Glu 
cells were also cultured in 3D in Alvetex® scaffold and stained for TUJ-1 expression 
(green). Cells can be seen forming neuronal networks on the top of the scaffold (E) and 
neurites have even penetrated the 3D material, as visible from the underside view of the 
scaffold (F). Scale bars: A-D: 200 µm, E-F: 100 µm. 
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Fig 3-15: Comparison of two novel human pluripotent stem cell derived models of 
neurite outgrowth in 2D culture. 
Representative confocal images (A) of neurite outgrowth from a neurosphere formed 
from iPSC derived neuroprogenitor cells (Aa) and from the optimised neurite outgrowth 
methodology for TERA2.cl.SP12 differentiation (Ab). The pan-neuronal marker TUJ-1 
(green) highlights neurite outgrowth and nuclei (blue) are restricted to the cell aggregate. 
Scale bars: 200 µm. TERA2.cl.SP12 derived neurospheres produce more neurites per 
neurosphere (B) (data represent mean ± SEM, n=3-27; 1-9 neurospheres were quantified 
from 3 independently cultured cell populations) than ReproNeuro Glu cell aggregates 
when cultured in 2D on ECM coated surfaces. However, when this is normalised to 
aggregate size by measuring neurite density (C) (data represent mean ± SEM, n=3-27; 1-9 
neurospheres were quantified from 3 independently cultured cell populations), 
ReproNeuro Glu cell aggregates produce significantly more neurites per µm of aggregate 
circumference. The average neurite length (D) (data represent mean ± SEM, n=114-1343; 
between 114-1343 neurites were measured from a total of 3-27 neurospheres obtained 
from 3 independent cell cultures), is significantly greater in ReproNeuro Glu cultures than 
TERA2.cl.SP12 cultures. Data analysed using an unpaired T-test assuming a Gaussian 
distribution: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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3.3.5.2 Development of a ReproNeuro Derived Model of Neurite Outgrowth 
 
Spheroids were generated from ReproNeuro neuroprogenitor cells through a similar 
methodology as ReproNeuro Glu cells, however a number of differences feature in the two 
methodologies. AggreWell™ plates are prepared in the same manner as previously 
described, the air bubbles present in the microwells (Figure 3-16A) were removed via 
centrifugation (Figure 3-16B). ReproNeuro cells are then seeded within the plates, 
however unlike with ReproNeuro Glu cells, ReproNeuro cells are cultured for 48 hours 
rather than 24 hours. The length of this incubation period was doubled, as cells had not 
appeared to form tight spheroids within the microwells of the plate at 24 hours, and 
following 48 hours incubation, clear 3D structures were visible within the plate (Figure 3-
16C). 
 
Following the 48-hour incubation period, neurospheres were harvested from the plate 
(Figure 3-16D) and seeded onto ECM-coated 2D and 3D surfaces to promote the induction 
of neurite outgrowth. Neurospheres were observed daily following seeding and at 24 
hours in culture significant neurite outgrowth could be observed to radiate from the 
central cellular mass, under phase contrast (Figure 3-16E). However following the 
additional 9 days in culture, (a total of 10 days neurite outgrowth the same length of time 
as ReproNeuro Glu) the cellular aggregate completely lost its structure as the majority of 
cells had migrated from the neurosphere (Figure 3-65F). For this reason it was decided 
that cultures should be fixed at day 1 post-neurosphere seeding in 2D as both neurites 
and structural integrity were observed at this time point. However, a neurite outgrowth 
period of 24 hours is unsuitable for 3D neurite outgrowth cultures as this time interval 
does not allow for neurites to traverse the entire 200 μm depth of the 3D scaffold. 
Therefore 3D cultures were maintained for 10 days, as there is no evidence of cellular 
migration in 3D culture. The optimised methodology developed for neurite outgrowth 
from ReproNeuro cells differs then from ReproNeuro Glu cells in the AggreWell™ plate 
incubation time (48 hours rather than 24 hours) and in the neurite outgrowth period for 
2D cultures (24 hours rather than 10 days).  
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Fig 3-16: Formation of neurospheres from ReproNeuro, iPSC derived neuroprogenitor cells and 2D neurite outgrowth. 
Phase contrast images showing the stages of neurosphere formation from ReproNeuro neuroprogenitor cells. AggreWell™ 880 plates were centrifuged at high 
speed to remove air bubbles from the microwells (A,B). ReproNeuro cells were seeded into the AggreWell™ plate and centrifuged to collect the cells in each 
microwell, they were then incubated for 48 hours to form spheroid structures (C) and harvested from the plate (D). Neurospheres were then cultured on 2D 
surfaces coated with ReproNeuro coating solution and incubated for 24 hours (E).  Following 24 hours incubation, significant neurite outgrowth was visible under 
phase contrast; therefore cultures were fixed at this point. However, if further incubated for the full 10 day duration, neurospheres lost their structure as significant 
migration of cells from the spheroid structure was evident (F). Scale bars: A-B: 500 µm, C-F: 200 µm. 
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To characterise the growth and development of ReproNeuro neuroprogenitor cells, the 
cells were cultured as a monolayer in addition to neurospheres. Monolayer cultures of 
ReproNeuro cells examined via phase contrast microscopy (Figure 3-17A) reveal a large 
number of cells that have not adhered to the growth substrate, despite the adhesion 
promoting ECM-coating. This could be due to a loss of cell viability, as the manufacturer’s 
cellular revival protocol states that a loss of viability may be likely during the revival of 
cells from cryopreservation. However, a number of cells have adhered to the 2D growth 
substrate and have extended long neuritic-like processes. Immunofluorescence staining 
for the pan-neuronal marker TUJ-1 (Figure 3-17B) highlights the extent of the cellular 
processes and confirms that they are in fact neurites. A large number of nuclei (blue) 
within the cellular monolayer appear to reside within colonies with TUJ-1 positive (green) 
extensions protruding from each colony. 
 
Neurospheres formed from ReproNeuro cells and subsequently cultured in 2D conditions 
for 24 hours demonstrate extensive neurite outgrowth visible by phase contrast 
microscopy (Figure 3-17C).  A large number of cellular processes can be observed to 
radiate from the central cellular mass and a few non-adherent cells are visible outside of 
the neurosphere. Immunofluorescence analysis of neurospheres cultured for 24 hours in 
2D (Figure 3-17D) reveals TUJ-1 positive neurites (green) extending from the central 
neurosphere in a radial manner, whilst nuclei (blue) remain within the aggregate mass 
with no evidence of cellular migration.  
 
ReproNeuro-derived neurospheres cultured in 3D (Figure 3-17E,F) upon ECM-coated 
Alvetex® scaffold, generate neurites that rather than radiating from the central cellular 
mass in 2D culture, penetrate the depth of the 3D material following 10 days in culture. 
The mass of the neurosphere containing a multitude of nuclei (blue) remains on top of the 
3D material with no evidence of nuclear infiltration into the scaffold (Figure 3-17E). 
Neurites do not visibly radiate from the central scaffold as with 2D culture, but the bottom 
view of the scaffold (Figure 3-17F) confirms that neurites have penetrated the entire 200 
μm depth of the material having exited the bottom of the scaffold. 
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Fig 3-17: Development of a neurite outgrowth model from ReproNeuro, iPSC 
derived neuroprogenitor cells. 
A representative phase contrast image of ReproNeuro cells cultured as a 2D monolayer 
(A) and an immunofluorescence image highlighting the pan-neuronal marker TUJ-1 
(green) and nuclei (blue) (B). Extensive neurite outgrowth can be observed from 
neurospheres cultured in 2D conditions under phase contrast (C) and TUJ-1 (green) 
positive neurites can be seen extending from the central cellular aggregate, with nuclei 
(blue) mainly being confined to the spheroid structure (D). In 3D culture the 
neurospheres can be seen from the top view (E) of scaffold with nuclei being highlighted 
blue and TUJ-1 expression in green. From the bottom view of the scaffold (F) neurites can 
be seen to have penetrated the depth of the 3D material having exited from the bottom of 
the scaffold. Scale bars: 100 µm. 
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3.3.5.3 Potential Mechanisms to Enhance Neurite Outgrowth from iPSC-derived 
Neurospheres 
 
This chapter also aims to identify the potential of Rho A and ROCK inhibition to enhance 
neurite outgrowth in iPSC-derived neurons. This involved the addition of Y-27632 and 
ibuprofen to inhibit ROCK and Rho A respectively, to 2D and 3D cultures of ReproNeuro-
derived neurospheres. As described previously, 2D cultures were maintained with each 
compound only for 24 hours due to issues with cellular migration, whereas 3D cultures 
were maintained with compounds for the 10-day duration of the neurite outgrowth 
period. In addition to this, the neurotrophic effects of astrocytes within the CNS and the 
effect of this upon neurite outgrowth were also investigated due to the use of ReproNeuro 
MQ astrocyte conditioned medium.    
 
  3.3.5.3.1 Inhibition of ROCK by Y-27632 
 
To investigate the ability of Y-27632 to enhance neuritogenesis, the small molecule 
inhibitor of ROCK was added to the culture medium of 2D ReproNeuro cultures at varying 
concentrations (0 – 15 μM) for the 24-hour neurite outgrowth phase of culture. 
Immunofluorescence staining (Figure 3-18A) highlighting expression for the pan-
neuronal marker TUJ-1 (green) reveals little obvious difference in neurite extension 
between the concentrations tested. This could be due to the reduced culture period of 24-
hours which may not be long enough to elicit the dramatic effects of Y-27632 as observed 
in the EC-cell derived model of neuritogenesis. However neurites that have extended from 
neurospheres cultured with 15 μM Y-27632 (Figure 3-17Ag,h) appear longer than those 
that were generated from neurospheres in the absence of the molecule (Figure 3-17Aa,b). 
 
Quantification of the number of neurites per neurosphere (Figure 3-18B) reveals little 
difference between 0 μM and 0.5 μM treatment, however, 10 μM Y-27632 induced a 
significant increase in the average number of neurites per neurosphere. This enhancing 
effect of Y-27632 was lost at the highest concentration tested (15 μM). Similarly, the 
density of neurites surrounding each neurosphere (Figure 3-18C) appears to increase 
with Y-27632 concentration up to 10 μM Y-27632. The observation of 15 μM resulting in a 
reduction in the number of neurites per neurosphere was not observed when normalised 
to neurosphere size and expressed as neurite density.  
 
The observation of neurite length increasing with Y-27632 treatment made during the 
analysis of the immunofluorescence images (Figure 3-18A) was confirmed by 
quantification detailing the average length of neurites (Figure 3-18D). All concentration of 
Y-27632 tested were found to induce a significant increase in neurite length compared 
with the untreated control, with 15 μM treatment resulting in the greatest enhancement 
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of neurite length. Although there is little evidence of cellular migration from ReproNeuro-
derived neurospheres in 2D culture, Y-27632 was found to inhibit the little migration that 
does occur (Figure 3-18E). All concentrations of Y-27632 tested resulted in a distinct 
inhibition of cellular migration with 15 μM Y-27632 treatment resulting in a statistically 
significant inhibition.  
 
ReproNeuro-derived neurospheres were also cultured in 3D (Figure 3-19A) for 10 days 
with the same range of concentrations of Y-27632 (0 – 15 μM). Neurospheres remain on 
top of the scaffold (Figure 3-19Aa,c,e,g) whilst TUJ-1 positive (green) neurites penetrate 
the depth of the 3D material and are visible from the underside of the scaffold (Figure 3-
19Ab,d,f,h). Without Y-27632 treatment (Figure 3-19Aa,b), few neurites can be seen to 
have penetrated the depth of the 3D material and with 0.5 μM treatment (Figure 3-
19Ac,d) almost no neurites are visible from the bottom view of the scaffold. However 
increasing Y-27632 concentration to 10 μM (Figure 3-18Ae,f) and 15 μM (Figure 3-
19Ag,h) results in a larger number of visible neurites from the underside of the scaffold. 
 
This is further evidenced by quantification of the number of neurites penetrating Alvetex® 
scaffold for each treatment condition (Figure 3-19B). Neurospheres cultured in 3D 
without Y-27632 treatment are seen to produce a small number of neurites that are able 
to fully penetrate the 3D material. Treatment with 0.5 μM Y-27632 resulted in an 
inhibition of neurite penetration, which was evident from the representative 
immunofluorescence images (Figure 3-19A) and treatment with 10 – 15 μM Y-27632 
resulted in an enhancement of neurite outgrowth within the 3D culture environment. The 
highest concentration of Y-27632 tested, 15 μM resulted in a statistically significant 
increase in neurite penetration throughout the 200 μm depth of the scaffold in 
comparison to 0 – 0.5 μM Y-27632.  
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Fig 3-18: Enhancement of neurite outgrowth from ReproNeuro derived neurospheres by the selective ROCK inhibitor, Y-27632 in 2D culture. 
Representative confocal images of ReproNeuro derived neurospheres cultured in 2D conditions with supplementation of the culture medium with increasing concentrations (0 – 
15 µM) of Y-27632 (A).  TUJ-1 positive neurites (green) can be seen to radiate from the central cellular aggregate with nuclei (blue) mainly being restricted to the aggregate body. 
Scale bars: 100 µm. The number of neurites per neurosphere (B) (data represent mean ± SEM, n=9; 3 neurospheres from 3 individual vials of frozen cells from the supplier) is 
significantly enhanced with the addition of 10 µM Y-27632 to the culture medium and when this is normalised to aggregate size, neurite density (C) (data represent mean ± SEM, 
n=9; 3 neurospheres from 3 individual vials of frozen cells from the supplier) increases in a dose dependent manner with increasing Y-27632 concentration. Similarly, neurite 
length (D) (data represent mean ± SEM, n=171-225; between 171-225 neurites were measured from 3 neurospheres obtained from 3 individual vials of frozen cells from the 
supplier) is enhanced with the supplementation of the culture medium with Y-27632, whereas migration of cells from the neurosphere (E) (data represent mean ± SEM, n=3; 
migration was measured from 1 neurosphere per vial of frozen cells from the supplier) significantly decreases with Y-27632 supplementation. Ordinary one-way ANOVA with 
Tukey’s multiple comparison test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
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Fig 3-19: Enhancement of neurite outgrowth from ReproNeuro Glu derived neurospheres by the selective ROCK inhibitor, Y-27632 in 3D culture. 
Representative confocal images of ReproNeuro derived neurospheres cultured in 3D with supplementation of the culture medium with increasing concentrations 
(0 – 15 µM) of Y-27632 (A). Neurosphere bodies can be seen from the top view of the scaffold (Aa,c,e,g) with nuclei (blue) being restricted to the cellular aggregate 
and TUJ-1 positive neurites (green) can be seen to have penetrated the depth of the 3D material from the bottom view of the scaffold (Ab,d,f,h). Scale bars: 100 µm. 
Quantification of the number of neurites that have penetrated the scaffold (B) (data represent mean ± SEM, n=3; neurite outgrowth from 3 neurospheres per 
scaffold was quantified and due to limited cell availability this was not repeated with multiple cell populations) with each Y-27632 concentration reveals that at 
higher concentrations (10 – 15 µM) neurite outgrowth is significantly enhanced within this 3D model of neuritogenesis. One-way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
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  3.3.5.3.2 Inhibition of Rho A by Ibuprofen 
 
To investigate the ability of ibuprofen, an inhibitor of Rho A, to promote neurite growth 
from ReproNeuro-derived neurospheres in 2D culture, varying concentrations (0 – 500 
μM) of the compound were added to the culture system for the 24-hour duration of the 
neurite outgrowth period. Immunofluorescence data (Figure 3-20A) highlighting 
expression of the pan-neuronal marker TUJ-1 (green) reveals the extent of neurite 
outgrowth from neurospheres cultured in each condition. Significant neurite outgrowth 
can be seen to radiate from neurospheres cultured in the absence of ibuprofen (Figure 3-
19Aa,b) and ibuprofen treatment (10 – 500 μM) appears to result in the development of 
shorter neurites. Treatment with 500 μM (Figure 3-20Ag,h), particularly, appears to result 
in fewer, extremely short neurites. 
 
Ibuprofen treatment results in an increase in the number of neurites per neurosphere 
(Figure 3-20B) with increasing concentration of ibuprofen, until the highest concentration 
of 500 μM is reached and neurite number reverts to a similar level as the untreated 
control. Treatment with 100 μM ibuprofen resulted in significantly more neurites per 
neurosphere than the untreated control, however this effect was lost at 500 μM, as 
significantly fewer neurites were generated than with 500 μM treatment.  A similar effect 
was noted when this was normalised to neurosphere size and expressed as neurite 
density (Figure 3-20C), possibly as the size of neurospheres is well controlled due to the 
use of AggreWell™ plates during their formation. In terms of neurite density 100 μM 
induced a significant increase compared with the untreated control, which was lost at 500 
μM, as neurite density returned to a level that was similar to the control.  
 
Quantification of the average neurite length (Figure 3-20D) reveals a similar trend to that 
observed from the immunofluorescence data (Figure 3-19A). Ibuprofen treatment at all 
concentrations tested (10 – 500 μM) was found to significantly inhibit neurite length. 
Similarly, the migration (Figure 3-20E) of cells from the central cellular mass was also 
inhibited with all concentrations of ibuprofen treated. 
 
Ibuprofen treatment was also found to have a similar effect in ReproNeuro-derived 
neurospheres cultured in 3D conditions. Neurospheres remained on top of the scaffold 
(Figure 3-21Aa,c,e,g) whilst TUJ-1 positive (green) neurites visible from the underside of 
the scaffold (Figure 3-20 Ab,d,f,h). Neurospheres cultured without ibuprofen treatment 
(Figure 3-21Aa,b) generate few neurites were visible from the bottom of the scaffold. Low 
concentrations of ibuprofen 10 μM (Figure 3-20Ac,d) appear to reduce the number of 
neurites visible from the underside of the scaffold, whereas 100 μM (Figure 3-21Ae,f) 
treatment appears to enhance the number of neurites that have visibly penetrated the 
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scaffold. Interesting 500 μM (Figure 3-21Ag,h) treatment, again appears to result in a 
reduction of the number of neurites that are visible from the underside of the scaffold.     
 
Quantification of the number of neurites that have penetrated the scaffold (Figure 3-21B) 
demonstrates that low concentrations of ibuprofen such as 10 μM, result in a slight 
increase in neurite penetration into the scaffold. However, increasing the concentration of 
ibuprofen 10-fold to 100 μM results in a significant increase in neurite penetration of the 
scaffold. The highest concentration of ibuprofen tested, 500 μM, resulted in a decline in 
neurite penetration, with neurite outgrowth returning to a similar level as the control. 
This could be due to the reduction of neurite length observed in 2D culture, as if neurite 
length is inhibited then the number of neurites long enough to span the 200 μm depth of 
the scaffold will be reduced.   
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Enhancement of neurite outgrowth from ReproNeuro derived neurospheres in 2D culture by ibuprofen, an inhibitor of Rho A. 
Representative confocal images of ReproNeuro derived neurospheres cultured in 2D with a range of concentrations (0 - 500 µM) of ibuprofen (A). Nuclei are stained in blue and the 
pan-neuronal marker, TUJ-1 in green, highlights neurites. Scale bars: 100 µm. Quantification of the number of neurites per neurosphere (B) (data represent mean ± SEM, n=9; 3 
neurospheres from 3 independent vials of cryopreserved cells from the supplier) and the neurite density of the neurospheres (C) (data represent mean ± SEM, n=9; 3 neurospheres 
from 3 independent vials of cryopreserved cells from the supplier) reveals that neurite outgrowth is enhanced with ibuprofen up to the highest concentration tested, 500 µM, at 
which point the level of neuritogenesis returns to that of the control. However, neurite length (D) (data represent mean ± SEM, n=141-256; between 141-256 neurites in total were 
measured from 3 neurospheres each from 3 independent vials of cells) and cellular migration from the neurospheres (E) (data represent mean ± SEM, n=3; due to limited cell 
availability 3 neurospheres from 1 population of cells were quantified) are both inhibited by the supplementation of the culture medium with ibuprofen.  One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 3-21: Enhancement of neurite outgrowth from ReproNeuro derived neurospheres in 3D culture by ibuprofen, an inhibitor of Rho A. 
Representative confocal images of ReproNeuro derived neurospheres cultured in 3D with a range of concentrations (0 - 500 µM) of ibuprofen (A). Neurospheres 
can be seen to remain on top of the scaffold (Aa,c,e,g) with nuclei being stained blue, and TUJ-1 positive neurite (green) can be observed to have penetrated the 
depth of the 3D material and are visible from the bottom view of the scaffold (Ab,d,f,h). Scale bars: 100 µm. Quantification of the number of neurites to have 
penetrated the scaffold (B) (data represent mean ± SEM, n=3; neurite outgrowth from 3 neurospheres per scaffold was quantified and due to limited cell availability 
this was not repeated with multiple cell populations) reveals that at lower concentrations of ibuprofen (10 – 100 µM) neurite outgrowth is enhanced from the 
control, however at the highest concentration of ibuprofen (500 µM) neurite outgrowth returns to a similar level as the control. One-way ANOVA with Tukey’s 
multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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  3.3.5.3.3 Neurotrophic Effects of Astrocyte Conditioned Medium 
 
Astrocytes within the CNS are known for the metabolic support that they provide to 
neurons, particularly glutamate metabolism213–216. It is also well known that astrocytes 
secrete trophic factors such as soluble growth factors including nerve growth factor (NGF) 
that promote and support the growth of neurons217–219. For this reason astrocyte 
conditioned medium such as ReproNeuro MQ medium is thought to contain neurotrophic 
factors and has been designed for use with ReproNeuro cells. Previously ReproNeuro MQ 
medium has been demonstrated to enhance electrophysiological recordings from 
ReproNeuro cells212. This sub-section aims to address the role of MQ astrocyte 
conditioned medium within the ReproNeuro model of neurite outgrowth, and its ability to 
potentially enhance neurite outgrowth.   
 
Therefore, the hypothesis that ReproNeuro MQ medium, conditioned by astrocytes, 
contains soluble factors that may promote neurogenesis and enhanced functionality of the 
cultured neurons, led to the theory that this medium may also be able to enhance neurite 
outgrowth within this ReproNeuro-based model of neuritogenesis. This was first assessed 
within the 2D culture environment and immunofluorescence staining for TUJ-1 (green) 
(Figure 3-22A) revealed that those neurospheres cultured in MQ medium (Figure 3-
22Ac,d) appear to produce more neurites which are longer compared to the their control 
medium counterparts (Figure 3-22Aa,b). Supplementation of MQ medium with 10 μM Y-
27632 (Figure 3-22Ae,f) or 100 μM ibuprofen (Figure 3-22g,h) did not appear to make 
any noticeable difference in the neurite outgrowth except perhaps Y-27632 treated 
neurites may be a little longer than those cultured in MQ medium alone.  
 
Quantification of the number of neurites per neurosphere (Figure 3-22B) supports the 
observations made on the basis of the immunofluorescence data. Neurospheres cultured 
in MQ medium produce significantly more neurites than those cultured in control 
ReproNeuro medium and Y-27632 supplementation of MQ medium further enhances 
neurite outgrowth. Supplementation of MQ medium with ibuprofen however, appears to 
induce inhibition of neurite outgrowth compared with MQ medium alone. Similarly 
neurite density (Figure 3-22C) is enhanced significantly by MQ medium alone and with 
and Y-27632 supplementation. However the neurite density of the neurospheres is 
significantly reduced to a level that is similar to ReproNeuro control medium, in the 
presence of 100 μM ibuprofen.  
 
Similarly, neurite length (Figure 3-22D) is significantly enhanced by MQ medium and 
further enhanced by the addition of 10 μM Y-27632. Although the average neurite length 
is inhibited with the addition of ibuprofen to MQ medium, neurites are still significantly 
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longer than those generated in control ReproNeuro medium, however the neurite 
enhancing effects of MQ medium are reduced.       
 
A similar observation was made in 3D culture, as those neurospheres cultured in control 
ReproNeuro medium appear to produce few neurites capable of penetrating the entire 
depth of the scaffold, as visible from the bottom view (Figure 3-23Aa,b). However 
neurospheres cultured in MQ medium appear to generate a large amount of neurites that 
are visible from the underside of the scaffold (Figure 3-23Ac,d). MQ medium 
supplementation with both 10 μM Y-27632 (Figure 3-23Ae,f) and 100 μM ibuprofen 
(Figure 3-23Ag,h) seem to have an inhibitory effect upon neurite outgrowth in 3D culture, 
as fewer neurites are visible from the underside of the scaffold.  
 
The number of neurites penetrating the scaffold (Figure 3-23B) for each condition 
resulted in both ReproNeuro and MQ media producing a similar amount of neurites 
capable of complete penetration of the scaffold. However, both supplementation with Y-
27632 and ibuprofen was found to significantly inhibit neurite penetration compared 
with MQ medium alone. This could perhaps be due to Y-27632 or ibuprofen induced 
inhibition of neurite length as demonstrated in the 2D TERA2.cl.SP12-based model of 
neuritogenesis however, this effect has not been observed in ReproNeuro derived 
neurites cultured in 2D. 
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Fig 3-22: Enhancement of neurite 
outgrowth from ReproNeuro derived 
neurospheres through a combination 
of conditioned medium and inhibition 
of Rho/ROCK signalling in 2D culture. 
Representative confocal images (A) of 
ReproNeuro derived neurospheres 
cultured in 2D with standard ReproNeuro 
medium (Aa,b) or astrocyte conditioned, 
MQ medium (Ac,d) in combination with 
the selective ROCK inhibitor, Y-27632 
(Ae,f) or ibuprofen (Ag,h). Neurite 
outgrowth is highlighted by staining for 
the pan-neuronal marker, TUJ-1 and 
nuclei are stained in blue. Scale bars: 100 
µm. Quantification of the number of 
neurites per neurosphere (B) (data 
represent mean ± SEM, n=3-9; neurite 
outgrowth from 1-3 neurospheres was 
quantified per vial of cells from the 
supplier, of which there were 3), neurite 
density of the neurospheres (C) (data 
represent mean ± SEM, n=3-9; neurite 
outgrowth from 1-3 neurospheres was 
quantified per vial of cells from the 
supplier, of which there were 3) and 
neurite length (D) (data represent mean ± 
SEM, n=64-463; the length of 64-463 
neurites was measured from 1-3 
neurospheres per vial of cells from the 
supplier, of which there were 3) 
demonstrate that all three aspects of 
neurite outgrowth are enhanced with the 
MQ medium and can be further enhanced 
by Y-27632 supplementation. One-way 
ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, **** = p < 0.0001. 
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Fig 3-23: The effect of astrocyte-conditioned medium on 3D neurite outgrowth from ReproNeuro derived neurospheres. 
Representative confocal images (A) of ReproNeuro derived neurospheres cultured in 3D with standard ReproNeuro medium (Aa,b) or astrocyte conditioned, MQ 
medium (Ac,d) supplemented with Y-27632 (Ae,f) or ibuprofen (Ag,h). Neurospheres remain on the top of the scaffold (Aa,c,e,g) with nuclei being stained blue, 
whilst TUJ-1 positive (green) neurites can be seen to have penetrated the depth of the 3D material (Ab,d,f,h). Scale bars: 100 µm. Quantification of neurite 
penetration (B) (data represent mean ± SEM, n=3; neurite outgrowth from 3 neurospheres per scaffold was quantified and due to limited cell availability this was 
not repeated with multiple cell populations) reveals that a similar number of neurites penetrate the scaffold with both ReproNeuro and MQ media but 
supplementation with Y-27632 and ibuprofen inhibits the number of neurites that penetrate the scaffold. One-way ANOVA with Tukey’s multiple comparisons: * = 
p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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3.4 Discussion 
 
Neuritogenesis is an important developmental process that promotes the formation of 
complex neuronal signalling pathways, essential to the proper functioning of the nervous 
system. Inability of neurons to undergo neuritogenesis and the resultant inhibition in 
neuronal connectivity is common to many nervous system disorders. Impaired neurite 
outgrowth has been implicated in a wide range of nervous system pathologies including 
spinal cord injury26,33,34,39,220, Down’s syndrome43,221 and schizophrenia42 along with 
Alzheimer’s35,36 and Parkinson’s disease37. As neurite inhibition is common to such a large 
variety of nervous system disorders, there is need for a well-characterised and 
physiologically representative model of neuritogenesis that has the ability to screen 
potential drug candidates and recover inhibitory responses to provide possible 
therapeutic strategies.  
 
Current in vitro neurite outgrowth models are usually based on the culture of stem 
cells21,66–68, cancer cells104–106 or primary animal derived cells64,222,223 in monolayers. 
However, monolayer cultures can prove difficult to quantify, as it may not be possible to 
trace each individual neurite back to its parental cell body within an intricate neurite 
network using image analysis software224. The neurite outgrowth methodologies 
described within this chapter involve the application of spheroid culture techniques to 
generate neurite outgrowth radially from a single cellular aggregate. This produces a 
neurite outgrowth assay where neurites can be easily traced, combined with an efficient 
sampling method to enhance quantification, which is more amenable to scaling up and 
high throughput screening.  
 
3.4.1 Development of a Novel Human Pluripotent Stem Cell Derived Model of 
Neuritogenesis 
 
 3.4.1.1 Embryonal Carcinoma Cell Based Model of Neurite Outgrowth 
 
The first neurite outgrowth model described within this chapter is based upon neural 
differentiation of a human embryonal carcinoma cell line TERA2.cl.SP12. The initial 
optimisation process in the development of this model of neuritogenesis involved the 
selection of appropriate differentiation conditions.  
 
Retinoic acid (ATRA), the naturally occurring metabolite of vitamin A has traditionally 
been used to promote neural differentiation in vitro45,64,67,75,78,111,145. However, there are 
many problems associated with ATRA use including chemical instability, which results in 
the breakdown of the compound when exposed to light and heat i.e laboratory 
conditions79. This can give rise to many inconsistencies and variations within culture 
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models. For this reason the ability of synthetic retinoid analogues to induce neural 
differentiation and neurite outgrowth from TERA2.cl.SP12 cells was addressed. Both EC23 
and AH61 have previously been demonstrated to significantly enhance neural 
differentiation compared with ATRA83,84 and the findings within this Chapter support this. 
The synthetic retinoid EC23 was found to be a potent inducer of neurite outgrowth to a 
much greater extent than AH61 and EC23. This was particularly noted at lower 
concentrations, as EC23 had a greater effect upon reduction of stem cell markers and 
induction of neuronal markers. The increased neuronal differentiation effects of EC23 
evidenced within this Chapter are most likely due to increased stability of the molecule 
and potency in comparison with ATRA, as EC23 contains a non-isomerisable conjugated 
linker unit that does not readily isomerise83,84.  The optimum differentiation conditions of 
0.01 μM EC23 were selected for use throughout the remainder of the project. 
 
This TERA2.cl.SP12 based model of neuritogenesis also has the advantage of being 
derived from human cells, therefore is more relevant for the study of human diseases that 
those models based on primary animal cells. Characterisation of this model and 
assessment of markers associated with neurite development in vivo is consistent with 
previously published evidence69–72,146,148. Expression of known cytoskeletal markers over 
time indicate that neurite outgrowth observed in the model shares similarities with the 
early stages of nervous system development. Neurofilament (NF) proteins are expressed 
heterogeneously throughout the developing nervous system225–229 and expression of NFs 
throughout the culture period is as expected. Similarly, nestin a known marker of neural 
stem cells230–233 is expressed very early in the neurite outgrowth period of culture, prior 
to neurite extension, as would be expected. Therefore, this suggests that neurite 
outgrowth within the model is conserved and undergoes a similar process as developing 
neurons in vivo. 
 
Many widely adopted in vitro models of neurite outgrowth generally utilise conventional 
2D cell culture methods, however this is not physiologically representative as neurites 
develop within 3D space in vivo. Traditional 2D culture techniques have their limitations 
as the growth of cells upon 2D substrates is far removed from the complex environment 
that cells experience in vivo161,162. When cultured in a 2D environment, cells flatten and 
their cytoskeleton becomes remodeled resulting in changes that do not resemble the 
function of their in vivo counterparts161,162.  
 
Previously, 3D cell culture technology has been used to enhance neuritogenesis from a 
stem cell-derived model147,150. Therefore, the development of a physiologically relevant 
model of neurite outgrowth within this Chapter has involved the combination of stable 
synthetic retinoids with a robust neurosphere generation technique and quantifiable 
neurite outgrowth in 2D and 3D culture. The culture of neurospheres within a 3D 
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environment results a more physiologically relevant geometry for the development of 
neurites, limiting some of the problems associated with 2D culture. This is particularly 
important to enable confidence that findings obtained in vitro are representative of in vivo 
processes such as predictions as to the suitability of molecules as potential 
therapeutics162. 
 
There is need for a robust and reproducible, physiologically relevant model of human 
neurite development, as this process is impaired in such a vast range of neurological 
pathologies. A reliable model of neuritogenesis such as the EC-derived model described in 
this chapter, has many applications ranging from screening of potential drug candidates 
for neurotoxicity or the ability of drugs to overcome inhibitory stimuli, investigations into 
the molecular signalling events that underpin neurite inhibition in disease and also 
studies into the developmental process of neuritogenesis itself.  
 
 3.4.1.2 Induced Pluripotent Stem Cell Based Model of Neurite Outgrowth 
 
In addition to the TERA2.cl.SP12 model of neurite development, this chapter also 
describes the optimisation and development of an iPSC-derived model of neurite 
outgrowth. iPSC-based in vitro models have many advantages over other systems 
including that they are human derived124. In addition to this as, iPSC cells can be obtained 
directly from patients in a minimally invasive manner, there is an opportunity to provide 
patient specific in vitro models for drug screening124,234 and disease specific in vitro 
models of complex neurological diseases157,235–238, that otherwise would be modeled by 
more basic systems that are unable to recapitulate multiple aspects of the disease. 
 
The cells described in this chapter are iPSC-derived neuroprogenitor cells that include 
ReproNeuro Glu cells, and ReproNeuro cells. ReproNeuro Glu cells produce a population 
of predominantly glutamatergic neurons, whereas ReproNeuro cells produce a population 
of neurons containing mixed subtypes212,234. ReproNeuro are the first commercially 
available human iPSC-derived neuroprogenitor cells and since their isolation have been 
used in electrophysiology212, dopamine metabolism210, oxidative stress239 and brain 
development studies211. However, they have yet to be reported to form the basis of a 
study with the primary objective of assaying neurite outgrowth.  
 
As described previously, spheroid-based neurite outgrowth models where neurites 
radiate from the central aggregate structure have advantages over traditional monolayer 
assays in terms of quantification. For this reason AggreWell™ technology was employed to 
generate ReproNeuro-derived spheroid structures. AggreWell™ plates are often used to 
generate embryoid bodies in the culture of ES cells240–244, however here; the plates have 
been used to generate neurospheres from differentiated neuroprogenitor cells. At this 
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point potential differences between the two ReproNeuro cell lines became evident. 
ReproNeuro Glu cells readily formed spheroids within 24 hours whereas, ReproNeuro 
cells required at least a 48-hour incubation before 3D structures were visible. This 
perhaps suggests an inherent difference in cell-cell adherence between the two cell lines.  
 
Furthermore, once spheroids were seeded for the neurite outgrowth phase of culture, 
differences in cellular migration became apparent. Cultures of both cell lines were 
observed daily by phase contrast microscopy to track the progress of 2D cultures. 
Following 24 hours in culture, both cell lines had produced a large number of neurites, 
visibly radiating from the neurosphere. However as the neurite outgrowth period 
progressed, ReproNeuro Glu neurospheres cultured in 2D retained their structure and 
cultures were analysed at 10 days. Whereas, ReproNeuro neurospheres cultured in 2D 
had completely lost their structural integrity as a large mass of cells had migrated from 
the cellular aggregate. ReproNeuro cultures were therefore analysed at 24 hours post 
neurosphere seeding rather than the standard 10-day neurite outgrowth period. This may 
be a limitation of the ReproNeuro model, as depending upon the application, cultures may 
need to be maintained for a duration greater than 24 hours and the effects of certain 
molecules may require a longer culture period to become evident. 
 
Therefore, ReproNeuro cells appear to exhibit variations in cellular adhesion and 
migration compared with ReproNeuro Glu cells. This could be due to the inherent 
differences between the cell lines, in that the ReproNeuro lineage gives rise to a 
heterogenous population of neuronal subtypes that may express variances in adhesion 
and migration behaviour212,234. It could also be due to differential expression of 
components in key biological pathways that underpin these important cellular processes. 
For example Rac/cdc245–248, integrins249–253, focal adhesions254–257 and cellular junctions258 
are all involved in cellular adhesion and migration. Interestingly, cellular adhesion, 
migration and neurite outgrowth are all interconnecting processes259–261, and an impaired 
ability of cells to form adhesions and migrate, may impact their ability to form neurites.     
 
In addition to this 2D model of neuritogenesis, similarly to the TERA2.cl.SP12 outgrowth 
model, ReproNeuro derived neurospheres were also cultured in a 3D environment to 
produce a more physiologically relevant model162. The aim of this was to produce a more 
physiologically accurate depiction of the process of neuritogenesis that occurs in vivo and 
provide a more reliable model with which to study the developmental process and to 
screen potential drug candidates.      
 
iPSC-derived in vitro models are useful in the study of complex diseases, as iPSCs can be 
obtained from patients with specific mutations or phenotypes and subsequently 
differentiated into the cell type of interest124,125,234. This is particularly relevant in terms of 
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neurobiology, as neurodegenerative diseases including Alzheimer’s and Parkinson’s 
disease are multi-faceted, complex diseases262–266 and in vitro modelling generally only 
recapitulates limited aspects of the disease. Similarly, interest in personalised medicine is 
increasing, as iPSC technology allows for the isolation of a somatic cell from a patient, 
reprogramming and differentiation, to produce patient specific in vitro models that can be 
used to assess the suitability of a drug on a patient-to-patient basis124. However iPSC-
based models also have limitations such as expensive consumables associated with their 
culture and production difficulties in terms of their manufacture. For these reasons the 
use of iPSC-derived neurospheres throughout this project is limited to the areas where it 
was thought to be most beneficial (Alzheimer’s disease modelling – Chapter V) and the 
most widely used neurite outgrowth assay throughout this project is the better-
characterised TERA2.cl.SP12-based model.  
 
3.4.2 Mechanisms to Enhance Neurite Outgrowth from Existing Neurite Outgrowth 
Models 
 
Many studies that focus on the development of robust models of neurite outgrowth also 
assess potential mechanisms by which to enhance their models. This can be achieved 
through a number of approaches including reducing inhibitory signalling (inhibition of 
Rho A-mediated signalling)21, electrical stimulation267–270, providing a permissive growth 
substrate (ECM coatings)271–275, co-culture with supporting cells276–278 or addition of 
exogenous growth factors to cultures15,279–282.  Another focus of this chapter is to assess 
the effect of inhibition of Rho A and its downstream signalling pathway along with the use 
of astrocyte conditioned medium as methodologies to enhance neurite outgrowth in both 
EC and iPSC-based models of neuritogenesis. 
 
 3.4.2.1 Inhibition of Rho A and ROCK Signalling 
 
The actin cytoskeleton along with the signalling events that control its function, are 
integral in the formation and extension of neurites within the nervous system. Rac 1 and 
Cdc42 are responsible for the promotion of membrane breaching by stimulating actin 
destabilisation and polymeration14,17,283,284. Whereas, activation of Rho A and downstream 
ROCK is responsible for stabalisation of actin filaments, inhibition of membrane breaching 
and growth cone stalling14,17,283,284. Neurite growth is dependant upon a balance between 
these two signalling pathways. As a strategy to enhance neurite outgrowth within their 
models many in vitro assays opt for the inclusion of inhibitors of Rho A (C3 transferase, 
ibuprofen) or ROCK (fasudil, Y-27632) in their basic methodology21,23,203. Data within this 
chapter addresses the use of ibuprofen and Y-27632 to enhance neurite outgrowth within 
both TERA2.cl.SP12 and ReproNeuro 2D and 3D models of neuritogenesis. 
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In 2D neurite outgrowth cultures of TERA2.cl.SP12 treated with both Y-27632 and 
ibuprofen, a similar effect is observed. This is as expected as both Y-27632 and Rho A 
inhibit different components of the same signalling pathways. Both molecules are noted to 
enhance neurite number and density significantly but significantly inhibit neurite length, 
particularly at high concentrations. This may suggest reciprocal control of neurite number 
and length, perhaps due to the role of Rho A and ROCK in the stabilisation of actin 
filaments. Inhibition of these signalling events may enhance membrane breaching and 
neurite formation, however as actin filament stabilisation is reduced, filament extension, 
thus neurite length may also be reduced. However, a more in depth analysis of the actin 
dynamics in Y-27632 and ibuprofen treated neurites would be required to confirm this.  
 
A similar effect is noted in the ReproNeuro 2D model of neuritogenesis as both Y-27632 
and ibuprofen were generally found to enhance neurite number and density but only 
ibuprofen was found to inhibit neurite length. This variation in response to Y-27632 in 
ReproNeuro cells could be due to altered Rho A and ROCK signalling within the cell line, as 
hypothesised previously. However, other in vitro models based upon foetal-derived 
neurons or DRG cultures provide evidence that Rho A and ROCK inhibition can enhance 
neurite length28,285–287. This could be due to the fact that most studies incubate their 
cultures with such supplements for short time frames with the incubation period 
described by Fuentes et al only consisting of 8 hours286. The data described within this 
chapter was obtained following a 10-day incubation with each molecule. It could 
therefore be hypothesised that inhibition of Rho A and ROCK may enhance neurite length 
in short-term cultures, but neurite extension may slow over time resulting in a reduction 
in length in longer-term cultures.  
 
An inhibition in migration of cells from the central body of the neurosphere is consistently 
observed in 2D cultures of TERA2.cl.SP12 and ReproNeuro cultures treated with Y-27632 
and ibuprofen. This may be expected as GTPase signalling and actin dynamics are both 
heavily implicated in the process of cellular migration. During cell migration activation of 
Rac is required at the front edge of the cell to promote actin polymerisation and 
membrane protrusion, similar to its role in neurite extension288–290. However, Rho A is 
thought to regulate the contraction and retraction forces required for cellular propulsion 
at the rear of the cell and its cellular distribution is inverse to that of Rac288–290. The role of 
Rho A in cellular migration supports the observations made in this chapter as inhibition of 
Rho A may lead to inhibition of cellular propulsion forces required for migration. There is 
little focus in the literature on the role of Rho A/ROCK inhibition in cellular migration. 
However evidence to support this finding is described in a study by Wang et al who use Y-
27632 to inhibit migration in tongue squamous cell carcinoma cells291. Similarly, Imamura 
et al describe the ability of Y-27632 to suppress tumour cell invasion292. 
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More physiologically relevant 3D models of neuritogenesis based upon TERA2.cl.SP12 and 
ReproNeuro cells are also described in this chapter. 3D cell culture in the form of Alvetex® 
scaffold provides a more physiological geometry and microenvironment for the 
development of neurites, therefore this is thought to overcome some of the problems 
associated with 2D culture and provide experimental outcomes more representative of 
the in vivo situation162. Treatment of 3D cultures with Y-27632 and ibuprofen produced 
consistent results amongst the two cell lines. Y-27632 was found to enhance neurite 
outgrowth in 3D in a dose dependent manner, whilst ibuprofen was found to enhance 
neurite outgrowth in a similar manner, however at the highest concentrations tested was 
found to reduce neurite outgrowth. A reason for this apparent reduction in neurite 
outgrowth by ibuprofen in 3D culture could be that the 3D system involves the 
quantification of neurites that have penetrated the 200 μm depth of the scaffold. In 2D 
culture ibuprofen was found to inhibit neurite length, therefore in 3D cultures fewer 
neurites may be able to traverse the 200 μm depth of the 3D material for quantification.  
 
Therefore, data within this chapter demonstrates the ability of a range of inhibitors of Rho 
A and ROCK to enhance neurite outgrowth in two human pluripotent stem cell derived 
models of neurite outgrowth in 2D and 3D culture. The addition of Y-27632 and ibuprofen 
to the culture medium could be incorporated into the model methodology to provide an 
enhanced neurite outgrowth model for applications such as neurotoxicity testing and 
study of neurite inhibition. However, the main aim of this project and application of such 
models is to study the role of neurite inhibition in neurological disorders and both Y-
27632 and ibuprofen have been well documented in the literature to promote neurite 
regeneration in the presence of inhibitory stimuli26,27,36. Therefore the decision was made 
not to include small molecule supplementation (Y-27632 and ibuprofen) in the basic 
model protocol, as this could reduce the sensitivity of the model to inhibitory molecules 
and also have adverse effects upon neurite length.  
 
 3.4.2.2 Neurotrophic Effects of Astrocytes 
 
Astrocytes are glial cells that are distributed throughout the nervous system and provide 
metabolic support to neurons through a number of functions including, regulation of 
blood flow, ion homeostasis, synapse function and metabolism293,294. The effects of soluble 
factors secreted by astrocytes and astrocyte-conditioned medium, upon a range of 
biological functions have been investigated including, the blood brain barrier and brain 
vasculature295–298, oligodendrocye development299 and ion transport300. However little is 
known about the effect of astrocyte-conditioned medium upon neurite outgrowth and 
elongation.  
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The constituents of astrocyte-conditioned medium depend upon the phenotype of the 
astrocytes cultured within the medium.  For example, astrocytes that have adopted a 
reactive phenotype secrete chondroitin sulphate proteoglycans (CSPGs) that are 
inhibitory to neurite development33,39,220,301. However, astrocyte conditioned-medium has 
also been found to contain growth factors such as an insulin-like factor thought to 
promote neuronal survival and nerve growth factor302–305.  Therefore if the state of the 
astrocytes used to generate the conditioned medium is not known, then it becomes 
difficult to hypothesise the effects of the medium upon neurite outgrowth.  
 
Data within this chapter describe the ability of ReproNeuro MQ astrocyte-conditioned 
medium to enhance neurite outgrowth from iPSC-derived neurospheres in 2D culture. 
Neurospheres cultured within the astrocyte-conditioned medium produced significantly 
more and significantly longer neurites than their control counterparts, this could further 
be slightly enhanced by the supplementation of Y-27632 to the culture medium, although 
this effect was not found to be statistically significant. Furthermore, the addition of 
ibuprofen to astrocyte-conditioned medium was found to reverse the neurite promoting 
effects of the medium, restoring neurite outgrowth to a similar level as the control. This 
could be due to an adverse effect of the NSAID upon some unknown signalling pathway or 
an interaction with the soluble factors within the medium rendering them less potent. 
However, in 3D culture the effect of the astrocyte-conditioned medium was less apparent 
and both Y-27632 and ibuprofen were found to inhibit neurite penetration.  
 
However, as ReproNeuro MQ medium is commercially available and little information is 
given by the manufacturer as to its constituents, understanding the signalling processes at 
play in this system is difficult. Due to the neurite enhancing effects observed in 2D culture, 
it is thought that the astrocytes used to condition this medium are not reactive in nature, 
although due to its undefined composition, ReproNeuro MQ medium was not used 
elsewhere in the project. 
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3.5 Conclusion 
 
This chapter has described the development of two novel pluripotent stem cell-based 
models of neurite outgrowth and their applications to study neurite growth in 2D or 3D 
culture. The optimisation of synthetic retinoid compounds and their use in the induction 
of differentiation and neurite outgrowth from human EC cells was identified and a robust 
and reproducible model of neuritogenesis developed. This model was then characterised 
to ensure that protein expression was similar in vitro and in vivo. Furthermore, this calso 
describes the translation of this model into a 3D culture environment to potentially 
provide a more physiological representation of neurite development.  
 
Although this neurite outgrowth assay improves on those currently used throughout the 
literature, there are some limitations associated with this assay. Particularly in the 3D 
culture assay, as to be quantified neurites must traverse the 200 μm depth of the 3D 
material, therefore, assay sensitivity is limited to those neurites long enough to penetrate 
the scaffold. Similarly, it is assumed that little sprouting occurs in 3D as there is no 
evidence of this in 2D culture. However, if sprouting were to occur within the scaffold, this 
would significantly impact neurite quantification, as neurites would not have originated 
from a single perikaryon. The 3D environment, in which neurites develop within this 
model, provides scaffolding that allows neurites to adopt a more physiological geometry; 
however, it does not recapitulate other aspects of the developing nervous system such as 
stiffness and biochemical environment. Despite these limitations, in this chapter, we 
present a well-characterised and versatile model that has been applied to study neurite 
inhibition in a variety of neurological disorders. 
 
In addition to the EC-derived model of neuritogenesis, an iPSC-derived model was also 
developed based upon the same spheroid culture principles. Both models have 
advantages for use in specific applications. For example, the EC-derived model is more 
robust and well characterised therefore versatile and suitable for a wide range of 
applications. However the iPSC-based model of neurite outgrowth provides opportunities 
to study complex diseases and personalised drug screening. The development of both 
models represents significant advances in the field and each model provides a useful in 
vitro tool to enhance our understanding of the process of neuritogenesis.  
 
Furthermore the ability of small molecules and potential growth factor infused medium to 
enhance outgrowth in these models was analysed. It was found that inhibition of Rho A 
and ROCK can enhance some aspects of neurite growth, whilst inhibiting others, 
suggesting a complex role for this signalling pathway in neurite development. The 
suitability of incorporation of such supplements in the basic model protocol was 
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considered and it was decided that this could impact the opportunity to study neurite 
inhibition so Y-27632 and ibuprofen will not be included in the basic protocol. 
 
Therefore, two robust and reproducible models of neurite growth have been developed in 
2D and 3D culture systems. Future work outlined within the remaining chapters of this 
thesis will focus on applications of such models to study the role of neurite growth and 
inhibition within the context of neurological diseases. 
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Chapter IV: Investigation into the Molecular Mechanisms 
that Underpin Neurite Inhibition in the Glial Scar 
 
4.1 Introduction 
 
4.1.1 Spinal Cord Injury 
 
Traumatic spinal cord injury (SCI) is a debilitating condition that can result in paralysis 
and have a significant impact on the quality of life of an individual206. There are thought to 
currently be between 183,000 – 230,000 people living in the USA with SCI with around 
10,000 new cases reported each year306. The main causes of SCI include motor vehicle 
accidents (36-48 %) followed by violence (5-19 %), falls (17-21 %) and recreational 
activities (7-16 %)306. The average cost of treating an individual with SCI over a lifetime is 
thought to be between $0.5 – $2 million306. Therefore SCI places not only a significant 
amount of strain upon patients and their families in terms of emotional and financial 
burdens but also on healthcare systems.  
 
Other neurological impairments often accompany SCI and traumatic brain injury is 
associated with nearly half of all SCI. Therefore, a thorough neurological assessment is 
essential in the diagnosis of SCI and should include an evaluation of mental status, cranial 
nerves, motor, sensory and autonomic systems along with coordination and gait306. The 
American Spinal Injury Association (ASIA) impairment scale is used clinically to 
determine the severity of injury and consists of five grades depending upon the level of 
functional deficit (Table 4-1)306. The level of paralysis is determined by the position of the 
injury within the spinal cord (Figure 4-1) with injury to the cervical level segments often 
resulting in full or partial quadriplegia307.  
 
Current SCI treatment remains largely palliative and includes preventing the progression 
of injury, handling pain syndromes, implementing bowel and bladder training regimes, 
managing sensory loss and teaching patients how to cope with their disabilities2. The 
main obstacle in the treatment of SCI is the inability of neurons to regenerate and 
reinnervate damaged nerves. This occurs due to the formation of an inhibitory 
environment known as the glial scar that forms a non-permissive barrier, preventing the 
development of neurites and restoration of lost neuronal connections34,39.  
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Grade Description 
A Complete paralysis: no sensory or motor function preserved in the sacral segments 
S4 – S5  
B Incomplete paralysis: sensory but not motor function preserved below the 
neurological level and extending through the sacral segments S4 – S5 
C Incomplete paralysis: motor function preserved below the neurological levels and 
most key muscles have a grade < 3 
D Incomplete paralysis: motor function preserved below the neurological level and 
most key muscles have a grade > 3 
E Normal motor and sensory function 
 
Table 4-1: ASIA impairment scale for SCI. 
A table detailing the main characteristics of each grade of SCI as determined by the ASIA 
impairment scale, used in clinical practices to determine the extent of injuy306. 
 
 
 
Fig 4-1: Degrees of spinal cord injury.  
The human spinal cord comprises of 31 spinal nerve segments divided into four groups 
dependent upon the area of the body that they control, and damage to nerves in each area 
of the spinal cord effects specific areas of the body. The cervical nerves control the 
function of muscles and glands, whilst also receiving sensory input from the neck, 
shoulder arms and hands. The thoracic nerves are associated with chest and abdominal 
walls whereas the lumbar nerves are associated with the lower body, specifically hips and 
legs. The sacral nerves control the genitals and functioning of the lower digestive tract 
and the coccygeal nerve supplies the skin over the coccyx. Image modified from Silva et al.   
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4.1.2 Development of the Glial Scar 
 
Damage to the spinal cord results in a series of cellular and molecular events that evolve 
over several days resulting in a chronic glial scar. The glial scar is a dynamic structure 
with different cell types participating in different events resulting in an inhibitory 
environment that prevents the reinnervation of neurons. Macrophages from the blood 
and microglia from the surrounding tissues represent the first cell types to respond in the 
hours following CNS injury33.  In the days following injury large numbers of 
oligodendrocyte precursor cells are then recruited from the surrounding tissue33. The 
area of insult finally forms a glial scar containing a large number of reactive astrocytes 
that proliferate and slowly migrate to the injury site, eventually filling the vacant space 
left by the injury33. Within the glial scar, intact and damaged neurons develop dystrophic 
growth cones and scarring is often associated with the development of a fluid-filled cyst, 
as shown in Figure 4-239.  
 
 
 
 
Fig 4-2: Formation of the glial scar following CNS injury.  
Damage to nerve fibres and their surrounding tissues in the adult CNS results in the 
formation of an inhibitory environment known as the glial scar. The severed ends of axons 
form characteristic dystrophic growth cones and are exposed to the inhibitory 
mechanisms that are involved in glial scar formation. Inflammatory cells and reactive 
astrocytes are recruited to the site of injury and over time this leads to the formation of a 
glial scar, often accompanied by the formation of a fluid-filled cyst. This results in the 
formation of a hostile glial environment for axonal repair. Image taken from Yiu and He2. 
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Glial scar development results in the formation of an inhibitory environment that 
suppresses neurite outgrowth. There are many mechanisms that contribute toward 
inhibition of neurite outgrowth in the glial scar including mechanical inhibition in the 
form of a meshwork of reactive astrocytes, and biochemical inhibition in the form of 
inhibitory molecules present on damaged myelin or secreted from reactive 
astrocytes33,34,39.  
 
 4.1.2.1 Physical Inhibition of Neurite Outgrowth 
 
One of the major inhibitory components of the glial scar is the accumulation of reactive 
astrocytes that mechanically block the outgrowth of neurites from developing neurons 
within the injured area. Following injury, astrocytes become hypertrophic and undergo 
cell division. They acquire a reactive phenotype associated with upregulation of the 
intermediate filament protein, glial fibrillary acidic protein (GFAP) and their morphology 
becomes hyperfilamentous33. Reactive astrocytes form a meshwork of tightly interwoven 
processes, bound together by tight and gap junctions, which provides a barrier, 
mechanically blocking the outgrowth of neurites in the area of the scar33.  
 
Understanding the role of reactive astrocytes in glial scar development is important in the 
development of novel therapeutic targets to intervene in the process. This is highlighted 
by Tian et al who demonstrate that the cell cycle inhibitor, olomoucine, can reduce the 
number of GFAP positive cells in a rat model of SCI associated with a recovery in 
functional deficit and reduction in the release of pro-inflammatory cytokines308.     
 
4.1.2.2 Chemical Inhibition of Neurite Outgrowth 
 
Biochemical inhibition of neurite outgrowth is also a main contributing factor toward the 
inhibitory environment that arises post-injury. There are two main groups of inhibitory 
molecules implicated in the glial scar: chondroitin sulphate proteoglycancs (CSPGs) 
secreted from reactive astrocytes and inhibitory molecules found on damaged myelin 
(MAG, Nogo, OMGP)33,34,39. Although CSPGs and the myelin inhibitors act through different 
receptors, they are thought to converge on a similar signalling pathway involving Rho and 
ROCK activation that ultimately disrupt the actin cytoskeleton, resulting in growth cone 
collapse and neurite retraction25,26,309,310.  
  
  4.1.2.2.1 Chondroitin Sulphate Proteoglycans 
 
Reactive astrocytes inhibit neurite outgrowth in the glial scar through multiple 
mechanisms including mechanical blockage and the secretion of inhibitory chondroitin 
sulphate proteoglycans (CSPGs). CSPGs (aggrecan, brevican, neurocan, versican and 
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phosphacan)39 are a family of inhibitory ECM molecules and are composed of a protein 
core with large, highly sulphated glycosaminoglycan (GAG) chains attached311, as shown 
in Figure 4-3. The inhibitory effects of CSPGs are thought to depend upon the GAG side 
chains, as treatment with chondroitinase ABC, an enzyme that cleaves GAG chains from 
the protein core, has resulted in functional recovery in animal models of SCI312–314.  
 
 
 
Fig 4-3: Chondroitin sulphate proteoglycan structure.  
Chondroitin sulphate proteoglycans (CSPGs) are a family of single core proteins. Their 
structure includes the addition of glycosaminoglycan (GAG) (red) sidechains, attached to a 
single protein core (green) at serine residues by a tetrapeptide linker. The N-terminal 
domain (orange) binds through linker proteins to hyaluronan and the C-terminal domain 
(blue) that can associate with ECM components.  
 
 
One of the proposed mechanisms by which CSPGs are thought to induce inhibition of 
neurite outgrowth is through the masking of neurite-promoting motifs within the ECM. 
CSPGs are thought to mask adhesion sites found throughout the ECM, impacting neurite 
outgrowth and inhibiting the neurite enhancing effects of certain ECM components such 
as laminin261,315,316. In a study by Mckeon et al, antibodies targeted against components of 
the laminin molecule were found to inhibit chondroitinase ABC-mediated rescue of 
neurite outgrowth in an in vivo model of the glial scar317. This suggests a potential 
interaction between CSPG and laminin-mediated effects on neurite outgrowth, and it is 
thought that one action of CSPGs may be to block the neurite promoting effects of laminin.  
 
Although CSPGs are thought to interact with the ECM, they are also known to induce an 
intracellular signaling cascade resulting in growth cone collapse through the activation of 
cell surface receptors. Several CSPG receptors have been reported, including PTPσ, LAR 
phosphatase, NgR1 and NgR3318. A transgenic study by Xu et al demonstrated the role of 
the LAR receptor following injury, and found that deletion of LAR resulted in improved 
 129 
functional recovery following SCI in mice319. Similarly, Shen et al evidenced binding of 
CSPGs to the PTPσ receptor along with recovery of neurite outgrowth in a receptor 
knockout, cell-based model320. The Nogo receptors (NgR) plays a crucial role in the 
induction of neurite inhibition as mediated by the myelin inhibitors; however, NgR1 and 
NgR3 are also thought to be activated by CSPGs. Dickendesher et al demonstrate the 
binding of the GAG domain of CSPG molecules to NgR1 and NgR3 in a cell-based neuronal 
model, and further evidence the functional role of these receptors through a knockout 
study321. 
 
Although CSPGs activate a number of receptors, the intracellular signalling cascade that 
they initiate is thought to be common to all receptors. The Rho A signalling pathway 
controls actin dynamics and CSPG-mediated receptor activation is thought to activate Rho 
A and ultimately its downstream effector, Rho A-associated kinase (ROCK)39. Activation of 
this signalling cascade results in growth cone collapse and repulsion of axon guidance. 
Many mechanisms of neural regeneration focus on inhibition of the downstream targets 
(Rho A and ROCK)23,25–27,30,204,322 as opposed to targeting receptor activation, as multiple 
receptors are involved in the induction of CSPG-mediated neurite inhibition, whereas Rho 
A activation is a common inhibitory mechanism.  
 
  4.1.2.2.2 Myelin Inhibitors 
 
Inhibitory molecules can also be found on the myelin debris from damaged neurons 
within the glial scar. The myelin inhibitors include Nogo, which is a member of the 
reticulon family of membrane proteins of which there are three isoforms (Nogo-A, -B and 
–C) generated by alternative splicing39. Nogo-A is the best characterised of the Nogo 
isoforms and contains an amino-terminal domain (amino-Nogo) specific to the Nogo-A 
isoform, along with a 66 amino acid loop domain (Nogo-66) that is common to all three 
isoforms39. Although Nogo-66 is thought to be the extracellular domain whilst amino-
Nogo remains intracellular, some amino-Nogo has been detected on cell surfaces and both 
domains are known to inhibit neurite outgrowth39.  
 
Myelin inhibitors also include myelin-associated glycoprotein (MAG), a transmembrane 
protein with five immunoglobulin-like domains in its extracellular region that is both 
expressed as a cell surface protein and is thought to be released as soluble factor upon 
injury39,323. Oligodendrocyte myelin glycoprotein (OMGP) is also an inhibitor of neurite 
outgrowth found on myelin debris and is a GPI-anchored protein containing a leucine-rich 
repeat (LRR) domain39,323.  
 
Many studies have focused on elucidating the receptor and downstream signalling events 
that result in myelin-mediated neurite inhibition, with the view to intervene in the 
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pathway and induce neurite recovery. The Nogo receptor (NgR) is a GPI-linked protein 
expressed on many types of neuron that is known to interact with the Nogo-66 domain of 
Nogo-A324 along with both MAG325 and OMGP326, which are structurally different from 
Nogo. NgR lacks an intracellular domain, therefore, acts through co-receptors including 
p75327,328, TROY329 and LINGO1330.  
 
Binding of the myelin ligands to NgR results in the formation of a receptor complex 
consisting of NgR and its co-receptor. This induces a rapid rise in intracellular Ca2+, which 
in turn results in Rho A and ROCK activation, similarly to CSPG-mediated signalling, 
inducing growth cone collapse331. Furthermore, it also thought that the receptor complex 
is then internalised and transported to the cell body in signalling endosomes, where a 
decrease in the levels of phosphorylated cyclic AMP response element-binding (CREB) is 
observed332. This is associated with a downregulation in the transcription of growth 
promoting genes and transcription factors332. Understanding the complexities of NgR 
signalling has resulted in the design of blocking antibodies333–335, receptor 
antagonists336,337 and soluble receptors338 that have induced functional recovery in animal 
models of SCI, highlighting the importance of elucidating the underlying signalling 
mechanisms.  
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Fig 4-4: Molecular signalling events that 
lead to neurite inhibition in the glial 
scar.  
Upon injury astrocytes become reactive, up 
regulate the intermediate filament protein 
GFAP and form long processes that 
interweave, resulting in a tightly woven 
meshwork that mechanically blocks the 
outgrowth of resident neurites. Reactive 
astrocytes also secrete CSPG molecules 
that act through receptors including: LAR, 
PTPσ, NgR1 and NgR3 to activate Rho A 
and ROCK signalling events. Similarly, 
myelin associated inhibitors of neurite 
outgrowth found on myelin debris from 
damaged nerves, include: MAG, Nogo-66, 
OMGP and Amino-Nogo. With the 
exception of Amino-Nogo, which binds to 
an unknown receptor, all of the myelin 
inhibitors bind to and activate NgR1, which 
along with its co-receptors LINGO, P75 and 
TROY, activates the Rho A signalling 
pathway. The NgR1 receptor complex is 
also internalised and through activating 
CREB is associated with the down 
regulation of growth promoting gene 
transcription. Activation of Rho A and 
downstream ROCK, results in the 
stabalisation of actin filaments which leads 
to growth cone collapse and neurite 
retraction.  
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4.1.3 Disease Modelling of the Glial Scar 
 
Disease models of the glial scar provide a tool to enable the investigation into the 
pathological mechanisms by which neurite inhibition is achieved. This can be useful to 
uncover both the cellular and molecular processes that contribute toward neurite 
inhibition, increasing our understanding of the process. Furthermore, both in vivo and in 
vitro based models of the glial scar can be useful in the screening of potential compounds 
and substances to overcome inhibition in this context. 
 
There are advantages and disadvantages to both in vitro and in vivo based disease models, 
such as in vitro models are generally far removed from the complex setting of the in vivo 
injury and may only include a limited number of cell types. However, this may be an 
advantage depending upon the hypothesis being tested, as it offers a reductionist 
approach whereby individual mechanisms can be tested without the impact of complex 
interacting pathways. Although in vivo glial scar models recreate the large number of 
events that occur following injury, generally they are based on either rat or mouse 
models, therefore the relevance when comparing to human SCI may be questionable. It is 
therefore important to fully evaluate the available options in terms of disease modelling 
when deciding upon the most appropriate model to apply to a particular research 
question.  
 
 4.1.3.1 Current in Vivo Models of the Glial Scar 
 
Most in vivo models of the glial scar involve the induction of SCI in mouse or rat-based 
systems. Under anaesthesia, the spinal cord of mice and rats is cut or damaged and the 
resultant symptoms studied for functional abnormalities such as motor function 
deficits339,340.  This provides a complex physiological setting to study the interaction 
between different cell types and biological systems, such as the invasion of immune cells 
and the inflammatory response evoked upon injury341,342, which would not usually be able 
to be studied in basic cell-based in vitro systems.  
 
Animal based models of SCI are essential in the testing and identification of potential 
therapeutic compounds, as in vitro models are able to identify compounds that have a 
positive effect on neurite outgrowth but this may not necessarily translate into a 
functional recovery in vivo. Bradbury et al first describe the beneficial effects of 
chondroitinase ABC (Ch’ase) treatment following lesions to the dorsal column of adult 
rats312. This study observes a functional recovery of locomotor and proprioceptive 
behaviour in injured rats, suggesting that Ch’ase treatment may provide a useful 
treatment strategy in human SCI312,343. This initial study has since been built upon by 
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further groups who have identified the optimal time post-injury for Ch’ase delivery344 and 
also combination therapies345 that can enhance the recovery effects.   
 
A distinct advantage to mouse-based in vivo models is the ability to create transgenic 
animals to study the up or downregulation of particular genes and proteins. This allows 
for the identification of key elements involved in signalling pathways and responses. For 
example, Menet et al describe functional recovery in double knockout, vimentin and GFAP 
deficient mice, two cytoskeletal components of reactive astrocytes346. Functional recovery 
in this study was found to correlate with reduced glial reactivity, thus, highlighting the 
important role of the reactive astrocyte in the formation of the inhibitory environment 
that arises post-SCI346,347. Furthermore, the role of the receptor, LAR, in CSPG-mediated 
neurite inhibition was first identified in transgenic, knockout mice348. Injured LAR 
knockout mice were observed to undergo significant locomotor functional recovery, along 
with axonal regrowth, therefore, highlighting the important role of the receptor in neurite 
inhibition348.  
 
Although animal models provide complex, physiological systems to study the events that 
surround SCI, they are animal based models as oppose to human, and there may be subtle 
differences in the way in which mice or rat neurons react to stimuli compared with human 
neurons. This can pose problems in the translation of potential therapeutic approaches, as 
compounds that have had favourable effects in animal models may not have the desired 
effects in humans due to their inherent physiological differences. Similarly, the ethical use 
of animals in scientific research is continually under question349, particularly in terms of 
wastage of animals, therefore in vitro cell-based models provide an attractive alternative.  
 
 4.1.3.2 Current in Vitro Models of the Glial Scar 
 
Cell-based in vitro models of neurite outgrowth, as discussed in Chapter I, can often be 
adapted to study the process of neurite inhibition through several methods including the 
treatment of growth substrates with inhibitory molecules such as CSPGs. Cell-based 
models offer advantages over in vivo models in that human-derived cell lines can be used, 
avoiding the physiological discrepancies associated with animal models. Similarly, cell-
based models are amenable to high-throughput screening and have applications in drug 
screening and discovery to identify possible compounds that are able to overcome neurite 
inhibition within particular systems. With emerging 3D cell culture technology, in vitro 
cell-based models are becoming more physiologically relevant and reliable for drug 
screening purposes.  
 
Vahidi et al describe the development of a microfluidic strip system to test the ability of 
molecules to inhibit neurite outgrowth350.  This comprised of alternating strips of 
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permissive and non-permissive substrates with a solution of CSPGs being applied to a 
series of strips to produce the non-permissive sites350. Neurons were then cultured on the 
surfaces and were only able to develop along the permissive stripes due to CSPG-
mediated inhibition350. This allows the alignment of neurons in culture and can provide a 
screening tool to test the ability of compounds to overcome CSPG-mediated inhibition. For 
example, compounds such as Ch’ase can be applied in the culture medium, resulting in 
neurons no longer developing in aligned columns within the permissive strips, as 
inhibition has been overcome and neurons can now migrate onto the previously non-
permissive strips350. A similar strip-based neurite outgrowth assay was employed by 
Monnier et al to determine the ability of an inhibitor of Rho A (C3 transferase) and an 
inhibitor of ROCK (Y-27632) to overcome CSPG-mediated neurite inhibition chick retina 
ganglion cells26. 
 
Other methods of modelling aspects of the glial scar in vitro involve the co-culture of 
neurons and astrocytes to study their interactions. However, the in vitro culture of 
astrocytes generally results in their activation351, resulting in a reactive phenotype. 
Depending upon the application of the in vitro model, this may or may not be desired. 
Studies have revealed that the culture of astrocytes in a 3D environment using hydrogel351 
or scaffold-based systems192 allows them to retain their native, non-reactive phenotype. 
East et al demonstrate an application of this technology by using non-reactive astrocytes 
cultured within a hydrogel as an assay of reactivity352. This system was used to investigate 
the effect of potential stem cell therapies such as, neural stem cells, adipose-derived stem 
cells and mesenchymal stem cells on the induction of astrogliosis352. This is important, as 
repairing spinal cord damage via stem cell therapy should not contribute toward glial 
scarring, as this would have adverse effects upon recovery.  This system was also used in 
another study by East et al to investigate the role of astrocyte-mediated neurite inhibition 
in rat DRG neurons353. 
 
Therefore, in vitro models can be used to model specific aspects as the glial scar such as 
CSPG-mediated inhibition or neuronal-glial interactions, this provides a more simplified 
system to study the underlying molecular mechanisms without interference from other 
cell types or systems. However, when developing therapeutic strategies to intervene in 
the events that follow SCI, one must consider all the complexities of the in vivo situation in 
which case the use of in vivo models may be more appropriate.  
 
4.1.4 Neurite Regeneration Beyond the Glial Scar 
 
The major obstacle in the treatment of SCI is the inability of neurons to regenerate and 
restore lost neuronal conenctions220. The main barrier in the regeneration of neurons is 
the glial scar, which is an inhibitory environment composed of several components 
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including reactive astrocytes, CSPGs and myelin inhibitors. For this reason, there has been 
a great effort in the development of mechanisms to overcome the inhibitory factors that 
contribute to glial scarring, with the aim of restoring functional recovery following injury.  
 
 4.1.4.1 Chondroitinase ABC 
 
Chondroitinase ABC (Ch’ase) is an enzyme purified from Proteus vulgaris that cleaves GAG 
side chains from CSPG molecules354, rendering them inactive and leaving a protein core 
with a carbohydrate stub220. Cleavage of the GAG chains from the CSPG molecule prevents 
receptor activation along with activation of the downstream signalling pathway including 
Rho and ROCK activation that leads to growth cone collapse. Therefore, this enzyme has 
potential therapeutic applications in overcoming CSPG-mediated inhibition of neurite 
outgrowth in the glial scar and restoring lost neuronal connections. 
 
The therapeutic benefits of Ch’ase treatment have been demonstrated by many studies. 
Most notably a study by Bradbury et al established the ability of intrathecal Ch’ase 
treatment to upregulate regeneration-associated proteins and promote functional 
locomotor recovery in adult rats with lesioned dorsal columns312. This was further 
observed by Huang et al who demonstrate the ability of Ch’ase to induce the outgrowth of 
new fibres in a rat-based model of SCI355.  
 
However, the use of Ch’ase in this regenerative context is thought to be limited, as 
aggrecan digested by Ch;ase has been found to still induce neurite inhibition220. This is 
thought to be due to the remaining protein and sugar stub post-digestion, as although its 
inhibitory potency is lost, it has still has been demonstrated to inhibit neurite outgrowth 
in DRG cultures220. 
 
 4.1.4.2 Blocking Nogo Receptor Signalling 
 
The Nogo-66 receptor (NgR1) is activated by many inhibitory molecules found within the 
glial scar, including, Nogo, MAG, OMGP and CSPGs. For this reason, it is an attractive target 
in the pursuit of neurite recovery and there are many strategies that have been explored 
to reduce NgR-mediated neurite inhibition including blocking antibodies333,334,356, 
receptor antagonists336,337,357 and soluble receptors338,358.   
 
IN-1 is a monoclonal antibody specific to the Nogo-A molecule, that has been shown to 
have positive effects when administered post-SCI to rats334 and primates333. Both Merkler 
et al356 and Leibscher et al334 demonstrate the ability of IN-1 to restore locomotion 
function in rat models of SCI, however through differing antibody delivery techniques. 
Liebsher et al334 delivered the antibody through an intrathecal catheter whereas Merkler 
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et al356 implanted IN-1 secreting hybridoma cells into the injury site. In both cases animals 
that received the antibody treatment recovered to a greater degree than control animals, 
both in terms of function and histology.    
 
Another approach at hindering NgR mediated signalling is through the use of a receptor 
antagonist peptide such as Nogo-A extracellular peptide residues 1-40 (NEP 1-40)332. NEP 
1-40 is a soluble peptide that contains the first 40 amino acids of Nogo-66 and 
competitively binds NgR, preventing receptor activation332. This has been shown to have 
positive effects on neurite outgrowth both in vitro and in vivo, providing a potential 
therapeutic target. NEP 1-40 has been reported to have beneficial effects in rat-based 
models of SCI when administered both at the time of injury337,357 and on a delayed 
timescale336 and in both cases resulted in functional recovery and axon sprouting.   
 
Similarly, a soluble Nogo-66 receptor has been shown to bind Nogo, MAG and OMGP, 
mopping them up and preventing them from activating NgR and its downstream 
signalling cascade. This has been demonstrated in vivo following delivery of the purified, 
soluble receptor intrathecally after midthoracic dorsal over-hemisection in rats358. 
Delivery of the receptor resulted in axonal sprouting and improved electrical conductivity 
along with improved locomotion358. A soluble, truncated, Nogo-66 receptor has also been 
used in vitro to recover neurite outgrowth on myelin and Nogo, non-permissive 
substrates338.  
 
 4.1.4.3 Enhancement of Intrinsic Growth Cues 
 
Most of the commonly used approaches to promote neurite regeneration in the injured 
spinal cord, focus on the reduction of inhibitory cues, however, enhancing the intrinsic 
growth stimuli within the CNS can also have positive regenerative effects. For example, 
there have been several reports that the neurite promoting effects of nerve growth factor 
(NGF)274 may restore functionality and improve connectivity following SCI359–363. A study 
by Oudega et al demonstrates the ability of NGF infusion post-spinal cord injury in rats to 
promote regeneration of fibres that bridge the glial scar363. In a later study by Oudega et 
al, other neurotrophins such as brain-derived neurotrophic factor (BDNF) were found to 
have little impact on NGF-induced enhancement of neural connectivity362. Other 
neurotrophins such as glial-derived neurotrophic factor (GDNF), neurotrophin-3 and 
BDNF, have also been shown to have neurite enhancing capabilities361.  
 
Other approaches have focused on enhancing neurite promoting effects of the ECM and 
promoting cellular-ECM interactions. Only as neurons mature, do they lose their ability to 
regenerate and embryonic neurons are known to have a higher capacity for regeneration 
than adult neurons. This was demonstrated by Maureen Condic, who determined that 
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postnatal neurons could be cultured on non-permissive, CSPG-coated surfaces with no 
adverse effect to neurite outgrowth364. However, this was not the case with adult-derived 
neurons whose neurite outgrowth was significantly inhibited on CSPG surfaces364. This 
finding led to a comparison of cell-adhesion markers on both postnatal and adult neurons, 
which found that integrin expression was significantly lower in adult neurons364. This 
study then focused on the role of integrin-mediated neurite outgrowth in terms of 
inhibition and found that when integrin-binding was blocked using an antibody, neurons 
could not adhere to the growth substrate and develop neurites364. This was 
complemented by an overexpression study that found when mature, adult neurons 
overexpress integrins, their neurite outgrowth can be enhanced and rescued within an 
inhibitory environment364.     
 
Reducing the inhibitory cues that mediate neurite inhibition within the glial scar by Nogo 
receptor blocking or Ch’ase treatment can promote functional recovery, as discussed 
previously. However, this is not the only mechanism by which inhibition can be overcome, 
and enhancing the intrinsic capacity for neurite growth can recover the inhibitory 
phenotype in much the same way.  Therefore, the outcome of neurite growth is dependent 
upon a balance between both inhibitory and growth cues, both of which should be taken 
into account when designing a potential therapeutic intervention.   
 
4.1.4.4 Manipulation of Rho A/ROCK Signalling 
 
Many efforts have been made to intervene in the downstream signalling events that occur 
following receptor activation within the glial scar. Particularly the focus has been on the 
Rho A signaling cascade, which is a mechanism common to many receptors implicated in 
glial scar signalling including those which respond to CSPGs and those which respond to 
myelin inhibitors. Inhibition of Rho A and downstream ROCK, are common strategies 
employed to recover neurite inhibition in the context of the glial scar220.  
 
Multiple mechanisms of Rho A inhibition have been shown to enhance neurite outgrowth 
in the presence of inhibitory stimuli, such as the bacterial enzyme C3 transferase220. C3 
transferase is an enzyme produced by the bacterium Clostridium botulinum that 
covalently attaches an ADP-ribose moiety to Rho A, inactivating the molcule365. The ability 
of C3 transferase to overcome neurite inhibition in vitro was demonstrated by Dergham et 
al366. This study involved the culturing of primary cortical neurons on inhibitory 
substrates including those composed of myelin, CSPGs and a mixture of myelin and CSPGs 
alone366. Treatment with C3 transferase resulted in recovery of neurite outgrowth on the 
inhibitory surfaces366 and this effect has further been evidenced by a number of 
studies28,287,367. 
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Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen relieve pain and 
inflammation through the inhibition of cylcooxygenases, however, ibuprofen has also 
been found to be an intracellular inhibitor of Rho A30,368. Ibuprofen is thought to inhibit 
Rho A signalling through a peroxisome proliferator-activated receptor γ (PPARγ) 
dependent mechanism31 and has previously been shown to enhance neurite outgrowth in 
human model neurons21. Wang et al demonstrate the ability of ibuprofen to overcome 
neurite inhibition both in vitro and in vivo369. This study found that subcutaneous 
administration of ibuprofen following spinal cord contusion resulted in functional 
recovery in rats with twice as many rats achieving a hind limb weight-bearing status369. 
This functional recovery was also accompanied by an increase axonal sprouting following 
SCI369.  
 
Inhibition of ROCK, an enzyme downstream of Rho A, is another commonly employed 
strategy to reduce neurite inhibition in the glial scar. There is a large body of evidence in 
the literature that documents the ability of the selective ROCK inhibitor, Y-27632, to 
overcome neurite inhibition, and its effects have been demonstrated both in vitro an in 
vivo26,27,204,209,366,370,371. Gopalakrishnan et al demonstrate the ability of Y-27632 to 
overcome neurite inhibition on non-permissive CSPG-coated substrates in a PC12 model 
of neurite outgrowth27. Chan et al found a similar result in a rat-based in vivo model of SCI, 
in that high-dose Y-27632 treatment resulted in a functional recovery and increased 
axonal sprouting209.  
 
Fasudil is another inhibitor of ROCK commonly used to restore neurite following SCI372,373. 
An in vivo study by Nishio et al revealed that immediate local delivery of fasudil to the 
injured spinal cord of rats, resulted in recovery of hind limb function and enhanced axonal 
sprouting374. However, when fasudil treatment was delayed and began only four weeks 
post-operatively, no functional or histological effects were observed374. This suggests that 
the method and timeframe for treatment may result in a difficult translation of these 
molecules into clinical practice. However, BA-210, a drug which blocks the activation of 
Rho A, has shown promising results in initial clinical trials through improvement of motor 
function in patients with pre-existing SCI375.   
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Fig 4-5: Targets for intervention in 
the glial scar signalling pathway 
that can restore neurite outgrowth 
within the inhibitory environment.  
There are several approaches that 
have been used throughout the 
literature to promote the growth of 
neurites in the non-permissive 
environment that forms post-SCI. One 
of which is the digestion of CSPGs by 
Chondroitinase ABC, which cleaves 
GAG chains from the molecules leaving 
the CSPGs unable to interact with their 
receptors. IN-1 is a monoclonal 
antibody targeted to Nogo-66 that 
binds to the inhibitory molecule, 
blocking ligand-receptor binding. 
Similarly, a soluble Nogo receptor has 
been developed that sequesters MAG, 
Nogo-66 and OMGP, again preventing 
ligand-receptor binding. The NgR1 
receptor antagonist peptide NEP 1-40 
mimics the extracellular loop domain 
of the Nogo molecule and 
competitively binds to the receptor, 
preventing signal transduction. 
Methods to inhibit the intracellular 
signalling events focus on the 
inhibition of Rho A by molecules such 
as C3 transferase and ibuprofen or 
inhibition of ROCK by fasudil or Y-
27632. Inhibition of these signalling 
events leads to actin de-stabalisation 
and promotion of neurite outgrowth.  
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4.1.5 Conclusions 
 
SCI is a debilitating condition that is difficult to treat due to the inhibitory glial scar that 
forms following injury that prevents the regeneration of resident neurons. There are 
many inhibitory pathways that contribute to the glial scar including the activation of 
receptors by inhibitory molecules, leading to a Rho A and ROCK dependent signalling and 
growth cone collapse. Many attempts have been made to elucidate the molecular 
mechanisms that underpin neurite inhibition in the glial scar and this has given rise to the 
development of potential treatments such as Ch’ase, Nogo receptor blockage and 
inhibition of Rho A/ROCK signalling, that have all shown promising effects in vitro and in 
vivo. This chapter describes the application of a novel, 3D, human-derived, in vitro model 
of neurite outgrowth, to investigate the process of neurite inhibition in terms of the glial 
scar. We also describe mechanisms, by which neurite outgrowth can be restored in the 
presence of inhibitory stimuli, demonstrating the potential use for this in vitro system in 
drug screening and discovery. 
 
 4.1.5.1 Chapter Aims 
 
This chapter aims to investigate the role of CSPG-mediated signalling in the process of 
neurite inhibition that occurs within the glial scar. This Chapter discusses several 
different methodologies in the pursuit of CSPG-mediated inhibition including, the coating 
of growth substrates with inhibitory molecules and various investigations into the release 
of CSPGs from glioma cells that resemble the reactive astrocytes from the glial scar, with 
the aim of developing a novel co-culture model with which to study neurite inhibition.   
 
Furthermore, this chapter aims to further elucidate the molecular mechanisms that 
underpin CSPG-mediated neurite inhibition along with the identification of small 
molecules that may be able to overcome such inhibition. This chapter aims to 
demonstrate the potential application of this novel model of human neuritogenesis as a 
screening tool, able to identify novel molecules that may be of therapeutic value. This 
chapter also evaluates the role of inhibitors of Rho A/ROCK signalling in overcoming 
CSPG-mediated neurite inhibition, enhancing our understanding of the signalling 
mechanisms involved in this process.  
 
We hypothesise that incorporating CSPG molecules into our novel neurite outgrowth 
model, either in the form of coatings or secreted from glioma cells, will result in inhibition 
of neurite growth from stem cell-derived human neurites. We also hypothesise that 
application of small molecules, will be able to overcome this inhibitory response, through 
intervention in the downstream signalling response to CSPG-receptor activation. This 
provides an application of the novel human-derived 3D model of human neuritogenesis 
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described in Chapter III, and evidences the use of this model as an assay for neurite 
outgrowth that can be used to measure inhibition and regeneration.  
 
 4.1.5.2 Chapter Objectives 
 
 Investigate the ability of aggrecan coating of 2D and 3D growth substrates to 
induce neurite inhibition in human-derived neurites.  
 
 Investigate the ability of Rho A (ibuprofen) and ROCK (Y-27632) inhibition to 
overcome aggrecan mediated neurite inhibition, on non-permissive 2D and 3D 
growth substrates. 
 
 Evaluate the suitability of glioma cell lines for use in a co-culture model of neurite 
inhibition to recapitulate reactive astrocytes found within the glial scar.  
 
 Assess the effect of confluency and growth rate on expression of reactive 
astrocyte markers in glioma cells.  
 
 Develop a 2D co-culture methodology to study the process of astrocyte-induced 
neurite inhibition and methods of recovery.  
 
 Investigate the effect of Rho A (ibuprofen) and ROCK (Y-27632) inhibition on 
glioma cell proliferation and phenotype.  
 
 Investigate the impact of medium conditioned by glioma cells cultured in 2D or 
3D on neurite outgrowth and the effect of Rho A and ROCK inhibition in this 
system.  
 
 Develop a novel 2D/3D co-culture system whereby neurites and glioma cells are 
not in contact with one another to study the effects of glioma cell conditioned 
medium on neurite outgrowth. 
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4.2 Materials & Methods 
 
 4.2.1 Aggrecan Coating of Growth Substrates for Neurite Inhibition Studies 
 
For neurite inhibition studies, substrates were coated with aggrecan in addition to 
standard poly-D-lysine and laminin coating solution, to provide an inhibitory substrate for 
neurite outgrowth.  Neurospheres were formed as described in section 2.2.5 Formation of 
Neurospheres from Human Pluripotent Stem Cells and seeded as in section 2.2.6.2 Seeding 
of Neurospheres for Neurite Outgrowth Assays, however the coating of 2D and 3D growth 
substrates differs from that of the standard neurite outgrowth assay. Aggrecan from 
bovine articular cartilage (Sigma-Aldrich) was reconstituted in PBS without Ca++ and 
Mg++ at 1 mgmL-1. The desired volume of aggrecan solution was then added to the 
standard coating solution of 10 μgmL-1 poly-D-lysine and laminin. For example, to achieve 
a final concentration of 50 μgmL-1 aggrecan, 1 mL of 1 mgmL-1 aggrecan solution was 
added to 19 mL of 10 μgmL-1 poly-D-lysine and laminin coating solution. Throughout this 
study a range of 0.5 – 50 μgmL-1 aggrecan coating was used. Both 2D and 3D growth 
substrates were then coated overnight at room temperature and washed twice in PBS 
prior to neurosphere seeding. 
 
4.2.2 3D Culture of Glioma Cells 
 
Both U-118MG and U-251MG glioma cell lines were cultured in 3D using Alvetex® Scaffold 
using the following methodology. Alvetex® Scaffold 12-well format inserts were prepared 
by plasma treatment using the K1050X Plasma Asher at a power level of 40 W, for 5 mins 
to render the scaffolds hydrophilic. The scaffolds were then washed in PBS twice before 
being washed in culture medium. Scaffolds were then placed in a standard 12-well tissue 
culture plate and unless otherwise stated, 0.5 million glioma cells were seeded per 12-
well Alvetex® insert. Cells were seeded using a concentrated method of seeding, whereby 
cells were seeded in a volume of 50 μL growth medium, which was added directly to the 
centre of the scaffold. Scaffolds were then incubated at 37 °C and 5 % CO2 in a humidified 
environment for one hour before the wells were topped up with 4 mL culture medium. 
Cells were incubated for 24 hours to allow them to adhere before the culture medium and 
tissue culture plate were replaced. This removes any cells that may have passed through 
the 3D material and adhered to the bottom of each well i.e be growing in 2D within the 
well, as these cells may release paracrine factors that may interfere with the growth of the 
cells within the 3D material. Cells were then cultured in 3D for up to 10 days (unless 
otherwise stated) with a 50 % media change on day 5 of culture.   
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4.2.3 MTT Cell Viability Assay 
 
The MTT tetrazolium reduction assay was used to measure viable cells with active 
metabolism. The assay involves the application of the MTT reagent to cells that metabolise 
the substrate forming a purple coloured formazan product that accumulates as an 
insoluble precipitate in and around cells. The product can be solubilised using organic 
solvents and measured using a spectrophotometer to produce data that represent the 
number of viable cells and metabolic activity.  
 
Monolayer cultures were washed in sterile PBS prior to the addition of 1 mgmL-1 thiazolyl 
blue tetrazolium bromide (Sigma-Aldrich) dissolved in phenol red free DMEM-HG (Gibco) 
and incubated for 1 hour at 37 °C, 5 % CO2 in a humidified environment. MTT solution 
was then aspirated from cultures and cells were incubated with acidified isopropanol for 
10 minutes at room temperature on a shaking platform. To each well of a flat-bottomed 
96-well plate, 200 μL isopropanol and 20 μL of sample were added to each well. 
Absorbance was then measured at 570 nm using a BioTek, ELx800 microplate reader. 
 
4.2.4 TUNEL Assay 
 
The DeadEnd™ Fluorometric TUNEL System (Promega, Southampton, UK) was used to 
detect apoptotic cells in cultures of U-251MG cells treated with modulators of Rho/ROCK 
signaling.  Cells were seeded onto 16 mm diameter sterile glass coverslips in a 12-well 
tissue culture plate at a density of 50,000 cells per well. Cells were then incubated at 37 
°C, 5 % CO2 in a humidified environment for 24 hours in 4 mL maintenance medium 
before medium was replaced with 4 mL DMEM with 2mM L-glutamine, 10 % heat treated 
FBS, 20 active units of Penicillin and Streptomycin supplemented with the small molecule 
of interest. Cultures were then maintained for 10 days with a 50 % media change on day 5 
of culture. Following 10 days the coverslips were fixed in 4 % PFA at room temperature 
for 20 minutes prior to analysis. 
 
Samples were permeabilised in 0.2 % Triton X-100 in PBS for 5 minutes before being 
washed twice in PBS for 5 minutes. A positive control coverslip was prepared by 
incubating the sample with 100 μL of DNase I buffer containing 5 UmL-1 of DNase I for 10 
minutes at room temperature. All samples were then incubated with 100 μL equilibration 
buffer and were allowed to equilibrate at room temperature for 10 minutes. Samples were 
then protected from light and incubated for 60 minutes at 37 °C in a humidified 
environment with 50 μL of reaction mixture containing: 45 μL of equilibration buffer, 5 μL 
nucleotide mix and 1 μL rTdT enzyme. A negative control was also prepared, however the 
reaction mixture for this coverslip contained 1 μL of dionized H2O replacing the 1 μL rTdT 
enzyme. Cells were then incubated with 2X SSC for 15 minutes at room temperature to 
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stop the reaction. Finally, coverslips were washed twice in PBS for 5 minutes and were 
mounted using Hardset Vectasheild containing DAPI (Vecta Laboratories). 
 
 4.2.5 Chondroitin Sulphate ELISA 
 
To determine the CSPG content of glioma cell conditioned medium, an enzyme-linked 
immunosorbent assay (ELISA) was used to detect the chondroitin sulphate (CS) motif 
present on the CSPG molecule. The human chondroitin sulphate ELISA kit (Abbexa, 
Cambridge, UK) was used and manufacturer’s instructions were followed.  
 
Conditioned medium collected from glioma cell cultures was prepared for analysis by 
centrifugation at 2000 x g for 20 minutes to remove any precipitate. A standard curve of 
known CS concentration was prepared as described in manufacturer’s instructions 
initially, 5 tubes were labelled 1500, 1000, 500, 250 and 125 pgmL-1. Standard diluent 
buffer was added to each tube in the following volumes: 200 μL in 1500 and 1000 pgmL-1 
tubes and 300 μL in each remaining tube. To the 1500 pgmL-1 tube 400 μL of 2250 pgmL-1 
standard solution was added and then 400 μL was taken from the 1500 pgmL-1 tube and 
added to the 1000 pgmL-1 tube and 300 μL was then taken from each tube and added to 
the following tube in a serial dilution to achieve the final concentrations.  
 
Each diluted standard and sample was then added in triplicate to wells within the pre-
coated ELISA plate, provided with the kit (50 μL per well), along with standard diluent 
buffer to provide a zero well. The plate was then sealed and incubated at 37 °C for 30 
minutes before being washed 5 times in wash buffer. HRP conjugant reagent was then 
added to each well (50 μL) excluding the zero well and incubated for a further 30 minutes 
at 37 °C. The plate was then washed 5 times in wash buffer prior to the addition of 50 μL 
TMB substrate A and 50 μL TMB substrate B was then added to each well and the plate 
was incubated for 15 minutes at 37 °C. Following this final incubation 50 μL of stop 
solution was added to each well and he colour changed to yellow. Absorbance was then 
measured at 450 nm using a BioTek, ELx800 microplate reader. 
 
A standard curve of corrected absorbance against chondroitin sulphate concentration was 
plotted using GraphPad Prism 6 and linear regression was fitted through the points, as 
shown in Figure 4-6.  The equation of the regression was obtained and rearranged to 
make x the subject, y (absorbance of the test value) was then substituted into the 
equation. This results in the calculation of the chondroitin sulphate concentration of each 
known absorbance. An example is shown below: 
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Fig 4-6: Typical standard curve of chondroitin sulphate quantification obtained 
from an ELISA. 
A typical standard curve plotted from absorbance at 450 nm for a series of standard 
solutions of known chondroitin sulphate concentration. A linear regression was plotted 
through the data set and an R2 value obtained (0.971 for this data set) which 
demonstrates the relationship between the two variables, the closer to 1, the more 
correlated the variables are. Plotting a linear regression determines the equation of the 
line, which can then be rearranged and the absorbance of conditioned medium of 
unknown chondroitin sulphate content can be substituted into the equation to determine 
their concentration.     
 
 
 
 
Calculation: 
 
y = 0.004046x – 0.1120 
 
x = y + 0.1120 
  
 
e.g For an absorbance at 450 nm of 0.119, substitute y: 
 
x = 0.119 + 0.1120 
 
 
x = 57 pgmL-1 
 
 
 
 
 
 
 
0.004046 
0.004046 
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4.2.6 Co-culture of U-251MG cells and Neurospheres in 2D 
 
For 2D co-culture of U-251MG cells and human pluripotent stem cell derived 
neurospheres, 48-well tissue culture plates were coated overnight with 10 μgmL-1 poly-D-
lysine and laminin solution, as described in section 2.1.6.1 Coating of Growth Substrates for 
Neurite Outgrowth Studies. However, whereas for mono-culture experiments, substrates 
were coated 24 hours prior to the end of differentiation of stem cell aggregates, for co-
culture experiments tissue culture plates were coated 48 hours prior to the end of 
differentiation. Following overnight coating of tissue culture plates, U-251MG cells were 
seeded in each well at a density of 40,000 cells per well of a 48-well tissue culture plate 
(unless otherwise stated). Cells were incubated overnight at 37 °C and 5 % CO2 in a 
humidified environment to allow cells to adhere to the substrate. For neurosphere 
seeding, maintenance medium was removed from each well containing glioma cells and 
0.5 mL TERA2.cl.SP12 maintenance medium containing mitotic inhibitors (1 μM cytosine 
arabinose, 10 μM 5’fluoro 2’deoxyuridine and 10 μM uridine) was added to each well and 
1 – 2 neurospheres were then placed into each well. Neurosphere and glioma cell co-
cultures were then incubated for the standard 10 day neurite outgrowth period and 
received a 50 % media change on day 5 of culture, before being fixed in 4 % PFA for 
fluorescent analysis. 
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Fig 4-7: A flow chart summarising the stages of a co-culture model combining neurospheres and glioblastoma cells in 2D culture. 
Human pluripotent stem cells were seeded in suspension culture at a density of 1.5 x 106 cells per sterile 90 mm Petri dish and allowed to aggregate for 24 hours. 
EC23 was then added to the culture following 24 hours, at a concentration of 0.01 μM and cell aggregates were further maintained for 21 days. 48 hours prior to the 
end of the differentiation period, 48-well culture plates were coated with poly-D-lysine and laminin solution overnight before U-251MG glioma cells were seeded 
into them. The cells were allowed 24 hours to adhere to the coated surface before neurospheres were seeded onto the monolayer of glioma cells and incubated with 
mitotic inhibitors for 10 days. Co-cultures were then fixed in 4 % PFA for immunofluorescent processing.  
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4.2.7 Conditioning of Growth Medium 
 
4.2.7.1 Conditioning of Growth Medium by 2D and 3D Cultured U-251MG 
Cells 
 
To study the paracrine effects of inhibitory molecules secreted from U-251MG cells, 
medium was taken from 2D and 3D cultures of U-251MG cells and was used during the 
neurite outgrowth phase of culture of human stem cell derived neurospheres. For 2D 
media conditioning, U-251MG cells were seeded in 175 cm2 culture flasks at density of 1 
million cells per flask in 30 mL of maintenance medium. Cells were then incubated 
overnight at 37 °C and 5 % CO2 in a humidified environment to allow cell attachment, 
before media was replaced with 30 mL of TERA2.cl.SP12 maintenance medium. Cells were 
then incubated for a further 10 days with a 50 % media change on the 5th day of culture.  
 
Similarly for 3D conditioning of media, cells were seeded at a density of 0.5 million cells 
per scaffold using the concentrated seeding method on 12-well format Alvetex® scaffolds 
that were prepared by plasma treatment (as described in section 4.2.2 3D Culture of 
Glioma Cells). Scaffolds were incubated overnight at 37 °C and 5 % CO2 in a humidified 
environment to allow cell attachment before being transferred into a new 12-well tissue 
culture plate with 4 mL of TERA2.cl.SP12 maintenance medium. Scaffolds were incubated 
for a further 10 days with a 50 % media change on the 5th day of culture. 
 
Following 10 days of culture, media was taken from 2D and 3D cultures of U-251MG for 
use in the neurite outgrowth assay described in section 2.1.6 Induction of Neurite 
Outgrowth from Stem Cell Derived Neurospheres. 
 
 4.2.7.2 Conditioning of Growth Medium in a 2D/3D Co-culture System 
 
To study the direct effect of U-251MG conditioned medium on neurite outgrowth from 
human pluripotent stem cell derived neurospheres, glioma cells and neurospheres were 
cultured within the same well of a tissue culture plate, however not within direct contact 
of one another. U-251MG cells were seeded at a density of 0.05 million cells per well of a 
12-well tissue culture plate in 4 mL of U-251MG maintenance medium, 24 hours prior to 
the end of differentiation of stem cell aggregates. Cells were incubated overnight at 37 °C 
and 5 % CO2 in a humidified environment to allow cell attachment. Medium was then 
removed and 4 mL of TERA2.cl.SP12 maintenance medium containing mitotic inhibitors 
(1 μM cytosine arabinose, 10 μM 5’fluoro 2’deoxyuridine and 10 μM uridine) was added to 
each well. Poly-D-lysine and laminin coated Alvetex® scaffolds (see section 2.1.6.1 Coating 
of Growth Substrates for Neurite Outgrowth Studies for coating of scaffolds) were then 
placed in each U-251MG containing well and 5 – 10 neurospheres were seeded onto each 
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scaffold. Cultures were then further maintained for 10 days with a 50 % media change on 
the 5th day of culture before being fixed in 4 % PFA for immunofluorescent analysis. 
 
 
 
Fig 4-8: A schematic depicting different methods of co-culture of glioma cells and 
neurospheres. 
Glioma cells (U-251MG, red) were cultured in 2D in the bottom of a 48-well tissue culture 
plate and allowed to adhere for 24 hours prior to the addition of a neurosphere (blue), 
which was then subsequently cultured on top of the glioma cell monolayer (A) during 
which time neurites (green) radiate from the aggregate, this is described as 2D co-culture. 
To investigate the paracrine effect of secreted factors from U-251MG cells on neurite 
outgrowth, glioma cells were cultured in 2D within the well of a tissue culture plate, 
whilst the neurosphere was cultured on top of Alvetex® scaffold within the same well, this 
is described as 2D/3D conditioning of media (B), as the glioma cells and neurosphere are 
not in contact with one another.  
 
 
4.3 Results 
 
 4.3.1 Inhibition of Neurite Outgrowth by Aggrecan 
 
A number of methodologies were used throughout this chapter to induce neurite 
inhibition, by recapitulating certain aspects of glial scar signalling. The first of which 
involves the coating of 2D and 3D growth substrates with the CSPG aggrecan. This 
provides a non-permissive, inhibitory growth surface to study neurite inhibition along 
with mechanisms of recovery. Aggrecan induced neurite inhibition is evident in 2D 
culture, as demonstrated by Figure 4-9. A reduction in TUJ-1 positive (green) extensions 
can be observed from immunofluorescence images (Figure 4-9A) with increasing 
concentration of aggrecan coating (0.05 – 50 μgmL-1). This reduction in visible neurites is 
particularly apparent at high aggrecan concentrations such as 5 μgmL-1 (Figure 4-9Ae,f) 
and 50 μgmL-1 (Figure 4-9Ag,h).  
 
Quantification reveals that both the number of neurites per neurosphere (Figure 4-9B) 
and neurite density of each neurosphere (Figure 4-9C), decline in a dose dependant 
fashion with increasing aggrecan concentration. Similarly, neurite length shown in Figure 
4-9D, also appears to share a negative relationship with aggrecan concentration, however, 
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there appears to be an anomaly between points 0.5 μgmL-1 and 5 μgmL-1. Generally 
though, increasing concentration of aggrecan appears to have a negative effect upon 
neurite length and growth in 2D culture. 
 
To investigate the ability of aggrecan coatings to provide a non-permissive environment 
for neurite growth in 3D culture, Alvetex® Scaffold was coated with a range of 
concentrations (0.05 – 50 μgmL-1) of aggrecan. Neurospheres can be seen to remain on 
the top of the scaffold (Figure 4-10Aa,c,e,g) whilst TUJ-1 positive (green) neurites can be 
seen to have penetrated the depth of the 3D material (Figure 4-10Ab,d,f,h). Increasing 
aggrecan concentration resulted in a decrease in the number of neurites that are visible 
from the bottom view of the scaffold and at 50 μgmL-1 there are almost no visible neurites 
penetrating the depth of the scaffold. This observation is complemented by quantification 
(Figure 4-10B), which reveals that the number of neurites penetrating the scaffold 
decreases in dose dependent relationship with increasing aggrecan concentration.  
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 Fig 4-9: Culture of neurospheres on 2D 
inhibitory substrates, coated with the CSPG, 
aggrecan, inhibits neurite outgrowth. 
Representative confocal images of 
neurospheres cultured on an inhibitory 
substrate in 2D (A) stained for the pan-
neuronal marker TUJ-1 (green) and nuclei are 
stained blue. Scale bars: Aa,c,e,g: 200 μm 
Ab,d,f,h: 50 μm. Substrates were coated with a 
range of concentrations (0.05 – 50 µgmL-1) of 
aggrecan, a CSPG molecule, in addition to 
standard poly-D-lysine and laminin coating 
solution.  The number of neurites per 
neurosphere (B) (data represent mean ± SEM, 
n=21-27; between 7-9 neurospheres were 
analysed from each of 3 independently 
differentiated populations of neurospheres) 
decreases in a dose-dependent manner with 
increasing concentrations of aggrecan, as does 
neurite density (C) (data represent mean ± 
SEM, n=21-27; between 7-9 neurospheres were 
analysed from each of 3 independently 
differentiated populations of neurospheres) 
and the average length of neurites (D) (data 
represent mean ± SEM, n=130; a total of 130 
neurites were measured from 7-9 
neurospheres analysed from 3 independently 
differentiated populations of neurospheres) 
also generally decreases with increasing 
aggrecan concentration.  
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Fig 4-10: Culture of neurospheres on 3D inhibitory substrates, coated with the CSPG, aggrecan, inhibits neurite outgrowth. 
Representative confocal images of neurospheres cultured on an inhibitory 3D surface (A) stained for the pan-neuronal marker TUJ-1 (green) and nuclei are stained 
blue. Neurospheres can be observed from the top view of the scaffold (Aa,c,e,g) and neurites have visibly penetrated the 3D material, as seen from the bottom view 
(Ab,d,f,h). Scale bars: 200 μm. Substrates were coated with a range of concentrations (0.05 – 50 µgmL-1) of aggrecan, a CSPG molecule, in addition to standard poly-
D-lysine and laminin coating solution, and fewer neurites visibly penetrate the scaffold with increasing aggrecan concentration. Quantification of the number of 
neurites penetrating the scaffold (B) (data represent mean ± SEM, n=7-10; between 2-3 neurospheres were quantified per repeat within each independent cellular 
population tested, of which there were 3) reveals that neurite outgrowth is inhibited in a dose dependent manner with increasing aggrecan concentration.  
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4.3.1.1 Recovery of Aggrecan Induced Neurite Inhibition through 
Modulation of Rho A/ROCK Signaling  
 
As outlined in detail earlier within this chapter, CSPGs such as aggrecan are thought to 
induce a series of intracellular signalling events following receptor activation. This is 
thought to include activation of Rho A and ROCK, ultimately leading to cytoskeletal 
changes that induce growth cone collapse and neurite retraction26,33,39. To investigate the 
role of this signalling pathway in aggrecan-mediated neurite inhibition, Y-27632 an 
inhibitor of ROCK, and ibuprofen an inhibitor of Rho A, were added to the culture medium 
of neurospheres cultured on non-permissive aggrecan-coated growth substrates. 
 
 4.3.1.1.1 Inhibition of ROCK by Y-27632 
 
In 2D culture conditions, neurospheres were either cultured without aggrecan coating 
(Figure 4-11Aa,b) or upon non-permissive growth substrates coated with 50 μgmL-1 
aggrecan solution (Figure 4-11Ac-j). In addition to this, neurospheres were also cultured 
with growth medium containing a range of concentrations (0.5 – 15 μM) of Y-27632 
(Figure 4-11Ae-j). Significant neurite outgrowth can be observed from neurospheres 
cultured on permissive surfaces without aggrecan coating (Figure 4-11Aa,b), whereas 
those cultured on the non-permissive aggrecan coated surfaces (Figure 4-11Ac,d) 
generate a significantly reduced number of neurites. The addition of Y-27632 to the 
culture medium appears to rescue aggrecan-induced neurite inhibition in a dose 
dependant manner with the induction of extremely dense neurite outgrowth from 
neurospheres cultured with 15 μM Y-27632 (Figure 4-11Ai,j). However, neurites from 15 
μM Y-27632 treated neurospheres also appear extremely short compared those 
generated in the presence of lower concentrations of the molecule.  
 
The culture of neurospheres on substrates coated with 50 μgmL-1 aggrecan was found to 
significantly inhibit the number of neurites extended per neurosphere (Figure 4-11B) and 
addition of Y-27632 was found to rescue this inhibitory response. The addition of 0.5 μM 
Y-27632 to the culture medium was found to significantly enhance neurite outgrowth on 
aggrecan coated surfaces, restoring the number of neurites per neurosphere to control 
levels. Higher concentrations of Y-27632 (10 – 15 μM) actually resulted in an 
enhancement of neurite outgrowth, with the number of neurites per neurosphere 
surpassing the control levels.  
 
A similar trend is also observed in quantification of neurite density (Figure 4-11C), with 
aggrecan coating resulting in a significant inhibition in the neurite density of the 
neurospheres. This again, was rescued by Y-27632 treatment with 0.5 μM resulting in 
restoration of neurite density to control levels, whereas 10 – 15 μM treatment resulted in 
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an enhancement of neurite density. Neurite length (Figure 4-11D) is also significantly 
inhibited by 50 μgmL-1 aggrecan coating, and 0.5 μM Y-27632 also restores this inhibitory 
effect. However, as Y-27632 concentration increases from 0.5 μM to 15 μM, a dose 
dependent decrease in neurite length is observed. This has also been observed in the 
absence of an inhibitory stimulus as described in Chapter III. Therefore, although all 
concentrations of Y-27632 rescue aggrecan-induced inhibition of neurite length, a 
secondary relationship between Y-27632 and inhibition of neurite length is also evident 
from this quantification.  
 
Neurospheres cultured in 3D, were either cultured upon Alvetex® Scaffold alone (Figure 
4-12Aa,b) or coated with 50 μgmL-1 aggrecan (Figure 4-12Ac-j) with Y-27632 medium 
supplementation (Figure 4-12Ae-j). Neurospheres remain on top of the scaffold (Figure 4-
12Aa,c,e,g,i) with few TUJ-1 positive (green) neurites visibly radiating from the central 
neurosphere, as neurites penetrate the 3D material. However, addition of Y-27632 to the 
culture medium results in observation that more neurites appear to radiate from the 
neurosphere and traverse the surface of the scaffold itself. The bottom view of the scaffold 
(Figure 4-12Ab,d,f,h,j) highlights neurite penetration, as a number of TUJ-1 positive 
(green) neurites can be seen to have completely penetrated the 3D material. In the 
absence of aggrecan coating (Figure 4-12Aa,b) significant neurite outgrowth is visible 
from the bottom view of the scaffold, whereas very few neurites can be seen to have 
penetrated scaffolds coated with 50 μgmL-1 aggrecan. Addition of Y-27632 at a range of 
concentrations (0.5 – 15 μM) results in a large amount of neurite outgrowth visible from 
the underside of the scaffold (Figure 4-12Ae-j). 
 
Quantification further evidenced the findings observed from the immunofluorescence 
images, as the number of neurites penetrating each scaffold (Figure 4-12B) was reduced 
by aggrecan coating and enhanced by Y-27632 treatment. Y-27632 even at the lowest 
concentration tested (0.5 μM) was found to enhance neurite penetration to levels that 
surpass that of the control, with both 10 μM and 15 μM significantly enhancing the 
number of neurites that penetrate aggrecan-coated scaffold scaffolds. 
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Fig 4-11: Inhibition of ROCK by Y-27632 can 
overcome aggrecan-mediated neurite inhibition 
in 2D culture. 
Representative confocal images of neurospheres 
cultured on an inhibitory 2D substrate coated with 
50 μgmL-1 aggrecan (ACAN) (A). Neurite outgrowth 
is highlighted by the pan neuronal marker TUJ-1 
(green) and nuclei are stained in blue. Neurospheres 
cultured without aggrecan (Aa,b) have extensive 
neurite outgrowth radiating from the central 
aggregate, however neurospheres cultured on 2D 
plastic coated with aggrecan (Ac,d) have very few 
neurites protruding from the cell aggregate. The 
addition of Y-27632, a selective ROCK inhibitor (Ae-
j) recovers neurite outgrowth on aggrecan coated 
2D surfaces. Scale bars: (Aa,c,e,g,i): 200 μm 
(Ab,d,f,h,j): 50 μm. The number of neurites per 
neurosphere (B) (data represent mean ± SEM, n=9-
18; between 3-6 neurospheres were quantified per 
independent replicate, of which there were 3) was 
significantly decreased in the presence of aggrecan 
and addition of Y-27632 was able to overcome this 
inhibition, restoring neurite outgrowth to control 
levels and even enhancing neurite outgrowth at 
higher concentrations. Y-27632 was also able to 
restore neurite density (C) (data represent mean ± 
SEM, n=9-18; between 3-6 neurospheres were 
quantified per independent replicate, of which there 
were 3) on aggrecan coated surfaces and neurite 
length (D) (data represent mean ± SEM, n=110-784; 
in total between 110-784 individual neurites were 
measured from 3 replicates of neurospheres derived 
from independent pools of cells) was enhanced to 
greater than control levels with low concentrations 
(0.5 µM) of Y-27632, however this effect decreased 
with increasing concentrations of the molecule. One-
way ANOVA with Tukey’s multiple comparisons: * = 
p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Fig 4-12: Inhibition of ROCK by Y-27632 can overcome aggrecan-mediated inhibition of neurite outgrowth in 3D culture. 
Representative confocal images of neurospheres cultured on Alvetex® scaffold coated with 50 μgmL-1 aggrecan (ACAN). Neurospheres are visible from the top view 
of the scaffold (Aa,c,e,g,i) and TUJ-1 (green) positive neurites can be seen penetrating the scaffold depth from the bottom view of the scaffold (Ab,d,f,h,j). Scale bars: 
200 μm. The number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=6-7; 2-3 neurospheres were quantified from 3 independent replicates) 
is greatly inhibited in the presence of aggrecan and with the addition of 0.05 μM Y-27632, is recovered levels similar to that of the control. However when Y-27632 
concentration is increased, the number of neurites penetrating the scaffold increases to levels that surpass that of the control. One-way ANOVA with Tukey’s 
multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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4.3.1.1.2 Inhibition of Rho A by Ibuprofen 
 
To investigate the role of Rho A in CSPG-induced neurite inhibition, neurospheres were 
cultured on 2D surfaces coated with aggrecan and a range of concentrations of ibuprofen 
(10 – 500 μM) were added to the culture medium. Neurospheres were cultured on control 
substrates (Figure 4-13Aa,b) or non-permissive substrates coated with 50 μgmL-1 
aggrecan (Figure 4-13Ac-j). Neurospheres cultured upon aggrecan-coated surfaces 
(Figure 4-13Ac,d) appear to produce far fewer neurites than those cultured on control 
surfaces (Figure 4-13Aa,b). The addition of ibuprofen to the culture medium (Figure 4-
14Ae-j), resulted in the generation of more visible neurites than aggrecan-coating alone, 
with higher concentrations 100 μM – 500 μM of ibuprofen appearing to generate the most 
neurites.  
 
Neurospheres cultured on 50 μgmL-1 aggrecan coated surfaces produced significantly 
fewer neurites per neurosphere (Figure 4-13B) than those cultured on control surfaces. 
This effect was rescued by ibuprofen treatment with the number of neurites per 
neurosphere increasing in a dose dependent manner with ibuprofen concentration. 
Ibuprofen treatment of 100 μM and 500 μM resulted in the generation of a similar number 
of neurites as control cultures.  
 
The same effect is also observed in terms of neurite density (Figure 4-13C) with aggrecan 
coating significantly inhibiting neurite density compared with controls. Neurite density is 
partially restored with 10 μM ibuprofen treatment and higher concentrations of ibuprofen 
(100 μM – 500 μM) restores neurite density to similar levels as neurospheres cultured 
without aggrecan coating. Neurite length (Figure 4-13D) is slightly reduced by aggrecan 
coating, however, this is not statistically significant and 10 μM ibuprofen treatment has no 
effect upon neurite legnth. Higher concentrations of ibuprofen such as 100 μM and 500 
μM, enhance neurite length significantly compared to neurites generate on both 
permissive and non-permissive substrates alone. 
 
Neurospheres cultured in 3D remain on top of the scaffold (Figure 4-14Aa,c,e,g,i) whereas 
neurites penetrate the scaffold and are visible from below (Figure 4-14Ab,d,f,h,j). A large 
volume of neurites can be seen to have penetrated scaffolds coated with permissive, 
control proteins (Figure 4-14Aa,b), however, this is significantly reduced when scaffolds 
are coated with aggrecan (Figure 4-14Ac,d) and very few neurites are visible from the 
bottom view of the scaffold. More neurites have visibly penetrated aggrecan-coated 
scaffolds with increasing concentration of ibuprofen treatment. 
 
This is reflected in the quantification of the number of neurites that have penetrated the 
scaffold (Figure 4-14B) with each treatment condition. In the absence of aggrecan, a large 
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number of neurites penetrate the scaffold, however in the presence of aggrecan coating, 
this number is significantly reduced. Ibuprofen medium treatment increases neurite 
outgrowth within aggrecan-coated 3D scaffolds, however even the highest concentration 
(500  μM) of ibuprofen tested does not fully restore neurite growth. Treatment with 500 
μM ibuprofen results in a significant increase in neurite penetration compared with 
aggrecan coating without ibuprofen medium supplementation, however the number of 
neurites penetrating the scaffold is still significantly reduced compared with control 
cultures. Therefore ibuprofen partially restores aggrecan-induced inhibition of neurite 
growth in a 3D culture environment. 
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Fig 4-13: Ibuprofen overcomes aggrecan-
mediated inhibition of neurite outgrowth in 2D 
culture. 
Representative confocal images of neurospheres 
cultured on inhibitory 2D growth substrates coated 
with 50 μgmL-1 aggrecan (ACAN) and treated with 
ibuprofen (A). Scale bars: (Aa,c,e,g,i): 200 μm 
(Ab,d,f,h,j): 50 μm. Neurites are highlighted by 
staining for the pan-neuronal marker TUJ-1 (green) 
and nuclei are stained in blue. Neurospheres 
cultured without aggrecan (Aa,b) have a large 
amount of neurites radiating from the central cell 
aggregate, whereas those cultured on the inhibitory 
substrate have very few neurites protruding from 
the aggregate body (Ac,d). The number of neurites 
per neurosphere (B) (data represent mean ± SEM, 
n=9-27; between 3-9 neurospheres were quantified 
per independent replicate, of which there were 3) is 
greatly inhibited when neurospheres are cultured 
on inhibitory substrates, and the addition of 
ibuprofen is able to overcome such inhibition, 
restoring neurite outgrowth to levels similar to that 
of the control. Similarly, the density of neurites (C) 
(data represent mean ± SEM, n=9-27; between 3-9 
neurospheres were quantified per independent 
replicate, of which there were 3) is restored by 
ibuprofen in the presence of aggrecan and even 
enhanced to levels greater than the control by high 
concentrations of ibuprofen. Neurite length (D) 
(data represent mean ± SEM, n=154-845; in total 
between 154-845 individual neurites were 
measured from 3 replicates of neurospheres 
derived from independent pools of cells) however, 
is only enhanced by high concentrations of 
ibuprofen. One-way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001. 
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Fig 4-14: Ibuprofen overcomes aggrecan-mediated inhibition of neurite outgrowth in 3D culture. 
Representative confocal images of neurospheres cultured on 3D inhibitory growth substrates coated with 50 μgmL-1 aggrecan (ACAN) and treated with ibuprofen 
(A). Neurospheres can be visualised from the top view of the scaffold (Aa,c,e,g,i) and TUJ-1 (green) positive neurites can be observed to have penetrated the 3D 
material and are visible from the bottom view of the scaffold (Ab,d,f,h,j). Scale bars: 200 μm. The number of neurites penetrating the scaffold (B) (data represent 
mean ± SEM, n=3-9; 2-3 neurospheres were quantified from 3 independent replicates) is greatly inhibited when neurospheres are cultured on aggrecan-coated 
scaffolds and this effect is rescued in a dose dependent manner with increasing ibuprofen concentration. However, the number of neurites penetrating the scaffold, 
even at the highest concentration of ibuprofen tested, still does not reach the same level as those neurospheres cultured without aggrecan. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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4.3.2 Development of a Co-culture Model to More Accurately Reflect the in Vivo 
Environment of the Glial Scar 
 
Reactive astrocytes are the major cell type involved in neurite inhibition within the glial 
scar. They express GFAP and secrete CSPGs, which act through receptors to induce growth 
cone collapse and inhibition of neurite growth. To more accurately reflect the cellular 
interactions that occur in the glial scar, and provide an alternative system to investigate 
the process of CSPG-induced inhibition, a co-culture model was developed.  
 
This first required the characterisation and selection of a cell line that most accurately 
recapitulates the important aspects of reactive astrocytes that are involved in neurite 
inhibition i.e CSPG secretion. The chosen cell line was then carefully characterised to 
ensure the optimal set of growth conditions were used throughout the co-culture 
methodology and that expression of desired proteins remained constant when cultured in 
these conditions. A 2D co-culture model was then developed and applied to study the 
process neurite inhibition and inhibitors of CSPG-induced signalling were used to 
promote neurite recovery.  
 
  4.3.2.1 Characterisation and Selection of Glioma Cell Lines 
 
To select an appropriate glioma cell line that best reflects the characteristics of the 
reactive astrocytes found in the glial scar, two commonly used cell lines were 
characterised. U-118MG cells are a human glioblastoma cell line with mixed morphology, 
Figure 4-15A is a phase contrast micrograph of U-118MG cells cultured at confluence in 
2D. In 3D conditions, as shown by H&E staining (Figure 4-15B) U-118MG line the edges of 
the scaffold with cell layers visible on the top and bottom of the scaffold, and a small 
number of cells populate the centre of the scaffold.  
 
U-251MG cells are also a human glioblastoma cell line, however they are known to contain 
GFAP positive cells. Figure 4-15C is a phase contrast image that depicts the morphology of 
U-251MG cells at confluence in 2D culture. Unlike U-118MG cells, in 3D culture U-251MG 
cells do not form cell layers on the top and bottom of the scaffold, as the majority of cells 
populate the centre of the 3D material.  
 
Immunofluorescence staining highlights GFAP immunoreactivity (Figure 4-15E-H) in U-
251MG cells cultured in 2D (Figure 4-15G) but not in U-118MG cultured in any condition 
(as expected) or in 3D cultured U-251MG cells (Figure 4-15H). A small amount of positive 
immunostaining for the chondroitin sulphate (CS) epitope (Figure 4-15I-L), which is an 
epitope present on CSPG molecules, can be observed in 2D (Figure 4-15I) and 3D (Figure 
4-15J) cultures of U-118MG cells. However, there is no visibly apparent staining in 2D 
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cultures of U-251MG cells (Figure 4-15K) but perhaps the strongest staining is visible in 
3D cultures (Figure 4-15L) of U-251MG cells.  
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Fig 4-15: Characterisation and reactive 
marker expression in glioma cell lines 
cultured in 2D and 3D.  
Representative phase contrast images of 
confluent cultures of the glioma cell lines, U-
118MG (A) and U-251MG (C) cultured in 2D 
conditions. Representative H&E staining of U-
118MG and (B) U-251MG (D) cell lines 
cultured in 3D for 10 days within Alvetex® 
scaffold. Representative confocal images of U-
118MG and U-251MG cells cultured in 2D and 
3D with the reactive astrocyte marker, GFAP 
being highlighted in green and nuclei stained 
blue (E-H). Representative confocal images of 
chondroitin sulphate expression in U-118MG 
and U-251MG cells cultured in 2D and 3D (I-
L). U-251MG cells appear to express markers 
of reactive astrocytes found in the glial scar to 
a greater extent than U-118MG cells in 2D and 
3D culture conditions. 2D (M) and 3D (N) 
antibody controls show no positive staining. 
Scale bars: (A-D): 100 μm, (E,G,I,K,M): 20 μm, 
(F,H,J,L,N): 50 μm. 
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Immunofluorescence staining of the CSPG marker, chondroitin sulphate, highlights 
positive expression of CSPGs within cells. However as CSPGs are secreted molecules, this 
does not necessarily give an accurate reflection of the CSPG-content of the culture 
medium. For this reason an ELISA assay was used to determine the CSPG concentration of 
the culture medium from 2D and 3D cultures of each glioma cell line. Figure 4-16 
describes the data obtained from this assay, and although the results are not statistically 
significant, slight variances in the CSPG concentration of the culture medium can be noted. 
For example 2D cultures of U-118MG cells appear to contain a higher concentration of 
CSPGs than 2D cultures of U-251MG; however due to the lack of statistical support, little 
can be drawn from this. Similarly, 3D cultures of U-251MG appear to produce medium 
with a higher CSPG content than their 2D counterpart, which is supported by the 
immunofluorescence data described in Figure 4-15, however, again this is not statistically 
significant. The main observation made from this assay, therefore, is that both 2D and 3D 
cultures of U-118MG and U-251MG cells generate CSPG-containing medium.  
 
 
 
 
Fig 4-16: Characterisation of CSPG secretion from glioma cell lines cultured in 2D 
and 3D conditions.  
An ELISA analysis of the CSPG content of medium conditioned by the glioma cell lines U-
118MG and U-251MG for 10 days in 2D and 3D culture (data represent mean ± SEM, n=3; 
3 samples individual cell cultures were tested). Medium conditioned by U-118MG cells 
cultured in 2D was found to have a higher CSPG content than U-251MG conditioned 
medium. However, in 3D culture, medium conditioned by U-251MG cells, was found to 
contain a slightly higher concentration of CSPG molecules than U-118MG conditioned 
medium.   
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Therefore from both the immunofluorescence and ELISA data it was decided that the U-
251MG glioblastoma cell line was the most suitable to recapitulate aspects of reactive 
astrocyte signalling from the glial scar. U-251MG cells were found to positively stain for 
GFAP, a hallmark of reactive gliosis, whereas U-118MG cells do not express this marker. In 
addition to this, U-251MG cells were also found to highly express CSPGs in 3D culture. 
This is particularly important, as the main application of the co-culture model is to study 
the molecular signalling events that lead to CSPG-induced neurite inhibition.    
 
4.3.2.2 Analysis of Optimal Growth Conditions for U-251MG Glioma Cells 
 
 4.3.2.2.1 Optimisation of Growth Medium 
 
The guidelines outlined by the European collection of cell cultures (ECACC) for the culture 
of U-251MG cells describe the suitable culture medium as: Earle’s Minimum Essential 
Medium supplemented with 2 mM L-glutamine, 1 % non-essential amino acids, 1 mM 
sodium pyruvate and 10 % FBS (EMEM). However, the human pluripotent stem cell line, 
TERA2.cl.SP12, which the neurite outgrowth model is based upon, require culture 
medium of Dulbecco’s Modified Eagle’s Medium supplemented with 2 mM L-glutamine, 1 
mM sodium pyruvate and 10 % FBS (DMEM). Therefore, to combine both cell types in a 
co-culture model of neurite inhibition, one culture medium must be selected in which 
both cell types can be cultured without adverse effects upon protein expression and 
cellular phenotype. As the neurite outgrowth model had previously been optimised and 
developed using DMEM, it was decided to analyse the effect of this medium upon the 
glioma cell line. 
 
Figure 4-17 outlines the effect of each medium composition on U-251MG cellular growth 
and morphology over a 10-day time frame, which is the normal timescale of a neurite 
outgrowth study.  Phase contrast images of U-251MG cells cultured in EMEM in 2D over 
time (Figure 4-17Aa-c) show cell density increasing over the culture period, with cells 
appearing extremely sparse at day 2 post-seeing (Figure 4-17Aa) and extremely confluent 
at day 10 (Figure 4-17Ac). Phase contrast images of cells cultured in 2D in DMEM (Figure 
4-17Ag-i) however, appear less confluent compared with their EMEM counterpart. Cells 
cultured in 2D with DMEM at day 6 appear only 80 – 90 % confluent rather than the 
extremely dense 100 % confluent monolayer observed in EMEM cultures.  
 
A similar effect is noted in H&E stained 3D cultures (Figure 4-17Ad-f,j-l) with cell density 
appearing to increase over the culture period. However at day 10, cells cultured in EMEM 
(Figure 4-17Af) appear to change in morphology, with cells appearing more rounded and 
darkly stained, perhaps indicative of cellular death. This morphological change is not 
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noted in 3D DMEM cultures, with cells maintaining their healthy morphology even at day 
10 in culture. This apparent cell death could be induced as maximal confluency or 
competition for nutrients is reached in cell dense cultures, as cell proliferation appears to 
be enhanced in EMEM as oppose to DMEM.  
 
This effect upon cellular proliferation was further investigated by use of an MTT cell 
viability assay, that utilises precipitate formation measured as absorbance, as an indirect 
measure of cell viability. In 2D cultures (Figure 4-17B) grown in EMEM, absorbance, thus 
cell viability was found to increase over the 10-day culture period, however at day 10, 
absorbance was found to decrease slightly. This suggests a loss of cell viability toward the 
end of the culture period in 2D conditions with EMEM. However, when cells were cultured 
in 2D with DMEM, MTT absorbance increased steadily over the period, with no evident 
decrease in viability apparent over the course of the culture. Interestingly, MTT 
absorbance was found to be consistently higher in EMEM cultures than DMEM in 2D 
conditions, prior to the EMEM-induced reduction in cell viability. This consolidates the 
observations made based upon the phase contrast micrographs, that cells proliferate 
more quickly in EMEM, which perhaps also explains the reduction in viability noted at day 
10, as cells become over confluent and begin to die. 
 
MTT viability of cells cultured in 3D (Figure 4-17C) with EMEM decreases initially, before 
slowly beginning to increase and decreasing once again toward the end of the culture 
period. Again this reduction in viability is also evidenced in the H&E image of a 
representative day 10 culture, as morphological changes consistent with cellular death 
were apparent. Similarly, the viability of 3D-DMEM cultures was found to remain mostly 
constant throughout the culture period with an increase in viability around day 6. 
Generally the viability of 3D-DMEM-based cultures was good and consistently higher than 
EMEM cultures.  
 
Immunostaining highlights expression of GFAP (Figure 4-18A) and chondroitin sulphate 
(Figure 4-18B) in each culture medium and within 2D and 3D cultures. This reveals that 
less confluent 2D cultures maintained in DMEM (Figure 4-18Ab) express GFAP to a much 
greater extent than those fully confluent cultures maintained in EMEM (Figure 4-18Aa). 
This is similar to chondroitin sulphate expression, which appears enhanced in DMEM 
(Figure 4-18Bb) 2D cultures as opposed to EMEM (Figure 4-18Ba) cultures. However 
expression of GFAP is not evident in 3D cultures maintained with both media (Figure 4-
18Ac,d) and very little positive chondroitin sulphate staining is apparent with either 
medium type (Figure 4-18Bc,d). The chondroitin sulphate content of medium collected 
from each culture condition was analysed by ELISA (Figure 4-18D) and although the 
results obtained were not statistically significant, a slight increase in CSPG expression in 
3D DMEM-based cultures was noted.  
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Fig 4-17: The effect of different media 
conditions on the growth of U-251MG 
glioma cells. 
U-251MG glioma cells were cultured for 10 
days either in the recommended 
maintenance medium of EMEM 
(supplemented with 10 % FBS, 2 mM L-
glutamine, 1 % NEAA, 1 mM sodium 
pyruvate and 20 active units of penicillin 
and streptomycin) or DMEM (supplemented 
with 10 % FBS, 2 mM L-glutamine, and 20 
active units of penicillin and streptomycin). 
Representative phase contrast images (Aa-c, 
g-i) of U-251MG cultured in 2D and 
haematoxylin and eosin staining (Ad-f, j-l) of 
U-251MG cells grown in 3D within Alvetex® 
scaffold in both EMEM and DMEM. Scale 
bars: 100 μm. Cells cultured in EMEM 
appear to reach confluency earlier in culture 
than those cultured in DMEM. MTT cell 
viability analysis of cells cultured in 2D (B) 
and 3D (C) in both types of medium (data 
represent mean ± SEM, n=3; repeated with 3 
independent cultures).  
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Fig 4-18: The expression of reactive astrocyte 
markers in U-251MG glioma cells is dependent 
upon culture medium. 
Representative confocal images of U-251MG cells 
cultured in EMEM or DMEM for 10 days in both 
2D and 3D culture environments. Expression of 
GFAP (A, green) appears increased in 2D (Aa,b) 
cells cultured in DMEM rather than EMEM, 
whereas 3D cultures (Ac,d) do not appear to 
express GFAP in levels similar to 2D. Expression 
of chondroitin sulphate (B, green), a motif 
common to CSPGs, appears increased in cells 
cultured in 2D (Ba,b) in DMEM, rather than EMEM 
medium. 3D cultures (Ba,d) appear to express 
chondroitin sulphate (CS) to  a slightly greater 
extent when cultured in EMEM rather than 
DMEM. Hoechst stains nuclei blue and 2D (Ca) and 
3D (Cb) antibody controls show no positive 
staining. Scale bars: 20 μm. ELISA analysis (D) of 
the chondroitin sulphate content of culture 
medium from cells cultured in each growth 
medium (EMEM/DMEM) suggests that cells 
cultured, particularly in 3D, in DMEM secrete 
more CS containing molecules into the culture 
medium than cells cultured in EMEM (data 
represent mean ± SEM, n=3; medium from 3 
independent cultures per condition).  
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Therefore, EMEM was found to enhance proliferation of U-251MG cultures in comparison 
to DMEM, which is not suitable for this co-culture application as cells become over 
confluent and lose viability over the 10-day duration of a neurite outgrowth assay. 
However, the slower growth and enhanced viability in 3D culture of DMEM cultured cells, 
is more favourable for maintenance of U-251MG cells over the course of an assay and 
allows for the easy incorporation of the cells into the existing neurite outgrowth 
methodology. In addition to this, the enhanced expression of GFAP and CS observed in 
DMEM 2D cultures, suggests that when cultured at a lower cell density in DMEM, cells 
express more of the desired characteristics of native reactive astrocytes.  
 
4.3.2.2.2 Optimisation of Cell Seeding Density 
 
As U-251MG cells were found to express both GFAP and CS to a greater degree in DMEM-
based cultures that were less densely populated than their EMEM-based counterparts, it 
was hypothesised that cellular density (confluency) may play a role in the regulation of 
expression of these key proteins. For this reason, the expression of both GFAP and CS was 
measured by immunofluorescence in 2D and 3D cultures of varying densities (Figure 4-
19).  
 
Phase contrast micrographs reveal the morphology of U-251MG cells in 2D culture at sub-
confluency (Figure 4-19A) where large areas of unpopulated space can be seen and 
confluent cultures of densely packed cells (Figure 4-19B).  There appears to be increased 
immunoreactivity to both GFAP (Figure 4-19G,H) and CS (Figure 4-19M,N) in sub-
confluent 2D cultures compared with their confluent counterpart. This suggests that in 2D 
culture U-251MG cells express both GFAP and CSPGs to a greater extent when cells are 
less densely packed together. This further supports the use of DMEM to reduce cellular 
proliferation and maintain cells in a sub-confluent state, expressing GFAP and CS 
throughout the 10-day culture period.  
 
Furthermore, a variety of cell seeding densities (0.5 million – 3 million cells per scaffold) 
in 3D culture were also trialed, and expression of GFAP and CS was analysed. H&E images 
demonstrate increasing density of cells populating the scaffold in 3D culture (Figure 4-
19C-F) with increasing cell seeding density. There appears to be a thick cell-dense layer 
on top of scaffolds seeded with 3 million cells (Figure 4-19F), as not all cells penetrate and 
populate the 3D material. Little GFAP-positive staining is noted in 3D cultures, however, a 
small amount of positive staining is identifiable in cultures seeded with the lowest cell 
densities (0.5 – 1 million cells per scaffold) (Figure 4-19I-J), whereas no positive staining 
is evident in scaffolds seeded with 2 and 3 million cells (Figure 4-19K-L). Interestingly, the 
strongest, positive staining for CS expression is observed in cultures seeded with 0.5 
million cells (Figure 4-19O) and little positive staining is present in cultures seeded with a 
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larger number of cells (Figure 4-19P-R). However, expression of CS in cultures seeded 
with 3 million cells (Figure 4-19R) appears to form a gradient, with highest expression at 
the bottom of the scaffold and as cell density increases toward the top of the scaffold, 
where the thick cell layer is located, expression of CS becomes reduced.  
 
This proposed relationship between confluency and CSPG/GFAP expression was further 
evidenced by western blot analysis of protein expression from cells cultured in each 2D 
and 3D condition (Figure 4-20A). Versican is a CSPG known to be expressed by the glioma 
cell line U-251MG and due to alternative splicing, several isoforms of varying molecular 
weight exist (V0 – V4)376. Through western blotting it was determined that most versican 
isoforms (V1 – V4) are expressed much more highly in 3D culture than in 2D, and 
expression is maximal at lower seeding densities, decreasing with as cell density 
increases. However, the expression of V0 increased with seeding density, opposing the 
expression profile of the other isoforms and perhaps suggesting some reciprocal control 
mechanism. Similarly to versican, expression of GFAP was also found to decline with 
increasing cell density and expression was greater in 3D cultures, further confirming the 
immunofluorescence findings. β-actin was used as a loading control and little variation 
between lanes is evident. 
 
ELISA analysis of the CSPG content (Figure 4-20B) of medium generated from 3D cultures 
seeded with increasing cell densities (0.5 – 3 million cells per scaffold) reveals little 
difference in concentration between the conditions. However, it does appear that there 
may be a dose-dependent decrease in CSPG-content of the culture medium with 
increasing cell seeding density, but this is not statistically significant.  
 
Therefore, it appears that at low cell density U-251MG cells express protein markers 
consistent with reactive astrocytes found in the glial scar to a greater degree. This has 
been evidenced by a number of techniques including immunofluorescence, western 
blotting and ELISA and the outcome remains consistent. This is a consideration that must 
be taken into account during the development of a co-culture model, as a seeding density 
should be selected that allows for maximal expression of proteins of interest. In addition 
to this, the enhanced expression of GFAP and CSPGs observed in 3D culture, is also an 
interesting finding. This could be due to the increased surface area provided by the 3D 
scaffold, resulting in fewer cell-cell interactions and a reduced cellular density, in turn 
leading to enhanced expression of GFAP and CSPGs. This finding also supports the use of 
3D cell culture technology throughout this study to enhance the expression of such 
proteins in U-251MG cultures. 
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Fig 4-19: Immunostaining of 
reactive astrocyte markers 
in U-251MG glioma cells is 
confluency dependent.  
Representative phase contrast 
images of U-251MG cells 
cultured at low confluency (A) 
and high confluency in 2D (B). 
Representative haematoxylin 
and eosin staining of U-251MG 
cells cultured in 3D within 
Alvetex® Scaffold for 10 days at 
varying seeding densities (C-F). 
Representative confocal 
images of GFAP expression of 
U-251MG cells cultured in 2D 
(G,H) and 3D (I-L) culture at 
different levels of confluency. 
Representative confocal 
images of chondroitin sulphate 
(CS) expression, a motif 
common to CSPGs, in glioma 
cells cultured in 2D (M,N) and 
3D (O-R). Nuclei are stained by 
hoechst in blue and antibody 
controls (S,T) are negative for 
staining. Cells appear to 
express both GFAP and 
chondroitin sulphate more at 
lower confluency. Scale bars: 
(A-D): 100 μm, (G,H,M,N): 20 
μm, (I-L,O-R): 50 μm. 
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Fig 4-20: The expression of reactive astrocyte markers in 2D and 3D cultured U-251MG cells is dependent upon cellular confluency. 
Representative western blot analysis (A) of versican and GFAP expression with increasing confluency in 2D and 3D cultured U-251MG cells. Versican is a CSPG 
molecule and its isoforms (V1-4) along with GFAP are expressed more in 3D cultures that are seeded with less cells and expression decreases with increasing cell-
seeding density. These molecules are also expressed much less in 2D cultures than 3D cultures. However, the V0 isoform is expressed much more at higher seeding 
densities in a pattern that opposes the expression of V1-4. ELISA analysis (B) (data represent mean ± SEM, n=3; conditioned medium from 3 independent cultures) 
of the chondroitin sulphate content of medium conditioned by U-251MG cells cultured in 3D at a range (0.5 – 3 million) of seeding densities. Chondroitin sulphate 
secretion appears to be dependent upon confluency and its expression appears enhanced at lower seeding densities.  
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4.3.2.3 Application of a 2D Co-culture Glioma/Neurosphere Model to 
Investigate Neurite Inhibition 
 
Following the optimsation of each of the U-251MG growth parameters, a 2D co-culture 
model to study the process of CSPG-mediated neurite inhibition could finally be 
developed. This involved the seeding of U-251MG cells in 2D wells of standard tissue 
culture plates coated with poly-D-lysine and laminin as per the neurite outgrowth 
protocol. Glioma cells were allowed to adhere for 24 hours prior to the seeing of fully 
differentiated neurospheres for neurite outgrowth studies. Initially a variety of glioma cell 
seeding densities (10,000 – 40,000 cells per well of a 48-well tissue culture plate) were 
trialed to identify the optimal set of conditions to study neurite outgrowth (Figure 4-21A). 
 
Neurite outgrowth (TUJ-1 positive staining – green) can be seen to radiate from 
neurospheres cultured on glioma cell monolayers (GFAP positive staining – red) (Figure 
4-21A). Neurite outgrowth appears reduced with increasing U-251MG seeding density 
and neurites become extremely short and barely able to extend from the neurosphere at 
the maximum seeding density of 40,000 glioma cells per well (Figure 4-21Ai,j). This could 
either be due to CSPG-induced inhibition or mechanical blockage of neurites by the 
physical presence of glioma cells.  
 
Quantification of neurite outgrowth reveals a dose dependent inhibition in the number of 
neurites per neurosphere (Figure 4-21B) with increasing glioma cell seeding density. 
However, this is not statistically significant and there appears to be a potential anomalous 
point at 20,000 cells per well. This anomaly disappears when neurite growth is 
normalised to neurosphere size and expressed as neurite density (Figure 4-21C), in 
addition to this, differences between the glioma cell seeding densities also become 
statistically significant. Therefore the co-culture of neurospheres and glioma cells results 
in a statistically significant inhibition of neurite density. Neurite length (Figure 4-12D) 
however, is a lot more variable amongst the seeding densities tested with significant 
inhibition only observed with 20,000 and 40,000 cells per well and an apparent increase 
in neurite legnth with 10,000 U-251MG cells per well. 
 
 
 
 
 
 
 
 174 
 
 
Fig 4-21: Co-culture of neurospheres with U-
251MG glioma cells in 2D is inhibitory to 
neurite outgrowth. 
Representative confocal images of neurospheres 
co-cultured with U-251MG cells at varying seeding 
densities (A). Glioma cells were seeded at varying 
seeding densities 24 hours prior to the addition of 
neurospheres to the culture, to allow glioma cells 
to adhere and form a monolayer of cells. The pan-
neuronal marker, TUJ-1 (green), highlights neurite 
outgrowth, while U-251MG can be distinguished 
due to their positive expression of the 
intermediate filament protein, GFAP (red) and 
nuclei are highlighted in blue. Scale bars: 
(Aa,c,e,g,i): 200 μm (Ab,d,f,h,j): 50 μm. 
Quantification of the number of neurites per 
neurosphere (B) (data represent mean ± SEM, 
n=15-27; between 5-9 neurospheres were 
quantified from 3 independent replicates) at each 
seeding density indicates that increasing seeding 
density of glioma cells is gradually more inhibitory 
to neurite outgrowth. Neurite density (C) (data 
represent mean ± SEM, n=15-27; between 5-9 
neurospheres were quantified from 3 independent 
replicates), also gradually declines with increasing 
glioma cell seeding density and reaches a maximal 
state of inhibition at 30,000 cells per well of a 48-
well culture plate, as increasing the seeding 
density further does not impact neurite 
outgrowth. However, the average length of 
neurites (D) (data represent mean ± SEM, n=256-
461; in total between 154-845 individual neurites 
were measured from 3 replicates of neurospheres 
derived from independent pools of cells) was only 
found to be inhibited in the presence of 20,000 or 
40,000 glioma cells per well.  One-way ANOVA 
with Tukey’s multiple comparisons: * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Several approaches were then used to potentially recover neurite outgrowth in this 2D co-
culture model. This included growth medium supplementation with chondroitinase 
(Ch’ase), an enzyme known to break down CSPGs rendering them inactive, along with 
inhibitors of the downstream signalling pathway induced by CSPG-mediated receptor 
activation that leads to neurite inhibition. Y-27632 is a selective inhibitor of ROCK and 
ibuprofen is an inhibitor of Rho A both of which are known to be involved in CSPG-
mediated signalling downstream of receptor activation, and lead to changes in the actin 
cytoskeleton associated with neurite retraction. For this reason, Ch’ase, Y-27632 and 
ibuprofen were all added to the culture medium of 2D co-culture models to potentially 
induce neurite outgrowth within this inhibitory environment (Figure 4-22). 
 
A significant volume of neurites can be observed to radiate from neurospheres cultured in 
the absence of U-251MG cells (Figure 4-22Aa,b) whereas neurites become much shorter 
and struggle to develop and fully extend in the presence of glioma cells (Figure 4-11Ac,d). 
Although neurite outgrowth does not appear comparable with the monoculture control, 
the addition of Ch’ase (Figure 4-22Ae,f) to co-cultures does perhaps seem beneficial to 
neurite legnth. The addition of 10 μM Y-27632 (Figure 4-22Ag,h) to co-cultures appears to 
rescue the inhibitory phenotype induced by the glioma cells, as neurite outgrowth 
appears dense and neurites appear long. A similar result is noted with 500 μM ibuprofen 
treatment (Figure 4-22Ai,j), as again neurite outgrowth appears dense, although neurite 
legnth still appears to be impaired. Interestingly, in both Y-27632 and ibuprofen treated 
samples, it appears that the number of GFAP positive (red) glioma cells is reduced and 
their morphology appears unusual. This could suggest that inhibition of such an essential 
cellular pathway has adverse effects upon glioma cell structure and function.  
 
The number of neurites per neurosphere (Figure 4-22B) is significantly inhibited in co-
cultures with glioma cells. Ch’ase treatment was found to significantly enhance neurite 
number in co-cultures, restoring neurite outgrowth to a similar level as the monoculture 
control. Y-27632 treatment was not only found to restore the number of neurites per 
neurosphere to control levels, but also significantly enhance neurite outgrowth compared 
with control cultures. Ibuprofen treatment has a similar effect upon neurite number as Y-
27632, in that neurite outgrowth in co-cultures is enhanced to a level greater than that of 
monoculture, however this enhancement is not statistically significant in the case of 
ibuprofen treatment. 
 
Neurite density (Figure 4-22C) is similarly, significantly inhibited by glioma cell co-
culture, and restored to a level reminiscent of the control with Ch’ase treatment. Y-27632 
and ibuprofen were both found to not only recover neurite density but to significantly 
enhance neurite density in co-culture models compared with their monoculture control 
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counterpart. This action of Y-27632 and ibuprofen to restore neurite outgrowth could 
arise due to their apparent detrimental effect upon U-251MG glioma cells. There appears 
to be a reduced number of GFAP positive U-251MG cells visible in Y-27632 and ibuprofen 
treated cultures which could be due to cell-death, induced by inhibition of Rho A and 
ROCK signalling. This could give rise to reduced inhibitory action which could mediate the 
recovery in neurite outgrowth observed in these cultures, as oppose to a reduction in 
inhibitory signalling. However, this would not explain the increase in neurite density 
observed with both Y-27632 and ibuprofen treatment, which has also been observed in 
the absence of inhibitory stimulus as described in Chapter III. 
 
Neurite length (Figure 4-22D) is significantly inhibited by the presence of U-251MG cells. 
A partial, but significant recovery in neurite length is observed with Ch’ase treatment, and 
Y-27632 also partially restores neurite legnth, to a greater extent than Ch’ase. Ibuprofen 
treatment, however, further inhibits neurite legnth to a greater degree than co-culture 
alone. This perhaps is not surprising if the effect of ibuprofen upon neurite length in the 
absence of an inhibitory stimulus (as described in Chapter III) is considered.     
 
One criticism of this co-culture model is, perhaps, that direct contact between the glioma 
cells and neurites may lead to physical inhibition of neurite growth as oppose to solely 
CSPG-mediated inhibition, which is the interest of this study. This is true, and physical 
interactions between the glioma cells and neurites will impact neurite outgrowth. 
However, the ability of Ch’ase to restore neurite outgrowth to control levels in this system 
indicates that at least one component of the inhibition observed here is mediated by 
CSPGs.  
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Fig 4-22: Recovery of neurite outgrowth 
through inhibition of Rho A/ROCK 
signalling in a 2D co-culture system. 
Representative confocal images of 
neurospheres co-cultured with U-251MG cells 
(40,000 cells per well of a 48-well tissue 
culture plate) with the addition of 
chondroitinase, Y-27632 or ibuprofen to the 
culture medium (A). The pan-neuronal 
marker TUJ-1 highlights neurite outgrowth in 
green, while U-251MG cells are highlighted in 
red due to their GFAP expression and nuclei 
are stained blue.  Scale bars: (Aa,c,e,g,i): 200 
μm (Ab,d,f,h,j): 50 μm. Number of neurites per 
neurosphere (B) (data represent mean ± SEM, 
n=9-27; between 5-9 neurospheres were 
quantified from 3 independent replicates) and 
neurite density (C) (data represent mean ± 
SEM, n=9-27; between 5-9 neurospheres were 
quantified from 3 independent replicates) are 
significantly inhibited in the presence of U-
251MG cells which is recovered to a level 
similar to that of the control with the addition 
of chondroitinase and significantly enhanced 
with the addition of Y-27632 and ibuprofen to 
the culture medium. Neurite length (D) (data 
represent mean ± SEM, n=256-707; in total 
between 256-707 individual neurites were 
measured from 3 replicates of neurospheres 
derived from independent pools of cells) is 
significantly inhibited by the glioma cells, and 
although medium supplementation increases 
neurite length, under none of the conditions 
tested does it reach the same level as the 
control, in the absence of glioma cells.  One-
way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001, **** = p < 0.0001. 
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4.3.3 Investigation into the Effect of Rho A/ROCK Signaling on U-251MG Glioma Cells 
 
Unusual observations were made in reference to the morphology and confluency of 
glioma cells within the 2D co-culture system when treated with Y-27632 and ibuprofen. 
These treatments resulted in glioma cells losing their characteristic morphology and 
adopting a more stellate shape. In addition to this glioma cell monolayers appeared less 
dense, and fewer cells were observed. To investigate the cytotoxic effects of inhibition of 
Rho A and ROCK upon U-251MG dose responses with each molecule were conducted 
throughout a 10-day culture period. 
 
Confluency of U-251MG 2D monolayers incubated with a range of concentrations (0.5 – 50 
μM ) of Y-27632 can be observed within the phase contrast micrographs (Figure 4-23Aa-
d). Monolayers cultured without Y-27632 medium supplementation (Figure 4-23Aa) 
appear fully confluent and very densely packed together, whereas 50 μM treatment 
results in a less densely packed monolayer of cells that appear to extend long cytoplasmic 
processes. Apoptotic cell death was detected by use of a TUNEL assay (Figure 4-23Ae-i) 
which stains double stranded breaks in DNA, resulting in green staining within the nuclei 
of apoptotic cells (Figure 4-23Ai). Apoptotic cell death was not detectable within the 
range of Y-27632 concentrations tested, as no positive staining was detected (Figure 4-
23Ae-h). This suggests that the reduction in cell density observed within Y-27632 treated 
cultures is due to a reduction in cellular proliferation as oppose to an increase in cell 
death.  
 
To test this hypothesis, MTT cell viability assays were used to determine the effect of Y-
27632 concentration upon cellular viability (Figure 4-23B). Absorbance was found to 
decrease in a linear fashion with increasing Y-27632 concentration suggesting that at high 
concentrations, less metabolically active cells are present. This further evidences the 
observation made upon analysis of the phase contrast images, that at high concentrations 
of Y-27632, cultures contain fewer cells. To determine that this effect is due to slower 
proliferation over the course of the culture, rather than a loss of viability, MTT cell 
viability was coducted over the 10-day culture period (Figure 4-23C). Monolayers treated 
with 50 μM Y-27632 consistently produced an absorbance reading much less than that of 
their untreated counterpart, indirectly suggesting that less viable cells are present in Y-
27632 treated cultures. Furthermore, the absorbance reading of both treated and 
untreated cultures increases over the 10-day time frame. This suggests that within the 
limits of this assay, both treated and untreated cells have proliferated over the course of 
the culture period, however Y-27632 treated cells have proliferated more slowly.  
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Fig 4-23: Inhibition of ROCK reduces 
cell density, in the glioma cell line U-
251MG. 
Representative phase contrast images 
of U-251MG glioma cells cultured for 10 
days in the presence of a range of 
concentrations (0 – 50 μM) of the 
selective ROCK inhibitor, Y-27632 (Aa-
d). Cells appear extremely confluent at 
lower concentrations of the molecule; 
however, at higher concentrations cell 
density appears much less. 
Representative confocal images of 
TUNEL staining (Ae-h), indicate the 
presence of apoptotic cells by staining 
fragmented DNA green, as can be seen 
in the positive control (Ai).  There is no 
evidence of apoptotic cell death with 
any concentration of Y-27632 tested.  
Scale bars: (Aa-d): 100 μm, (Ae-i): 50 
μm. MTT cell viability data for U-251MG 
cells cultured with a range of 
concentrations (0 – 50 μM) Y-27632 for 
10 days (B) shows that with increasing 
concentration, cell viability decreases. 
MTT cell viability over the 10-day 
culture period (C) with and without 50 
μM Y-27632 treatment, shows that 
under both conditions cell viability 
increases over the culture period 
indicating that the cells are proliferating 
and not dying, however with Y-27632 
treatment, they appear to proliferate at 
a much slower rate.   
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Monolayers of U-251MG cells treated with a variety of concentrations of ibuprofen (50 – 
750 μM), also appear less confluent following a 10-day culture period. This effect can be 
observed in the phase contrast micrographs (Figure 4-24Aa-e) as untreated cultures 
appear extremely densely packed and confluent whereas cultures treated with high 
concentrations of ibuprofen (500 – 750 μM) appear significantly less confluent. Cultures 
treated with 500 μM (Figure 4-24Ad) ibuprofen appear significantly less dense compared 
with untreated monolayers and cultures treated with 750 μM (Figure 4-24Ae) ibuprofen 
appear sparsely populated with cells. 
 
As with Y-27632 treatment, a TUNEL assay (Figure 4-24Af-j) was used to determine the 
presence of apoptotic cells within the cultures and as with Y-27632, there was no 
evidence of cell death at any concentration of ibuprofen tested. To determine if the 
reduction in confluency was a reflection of reduced cellular proliferation, an MTT cell 
viability assay was used to determine the effect of ibuprofen concentration upon cellular 
behaviour (Figure 4-24B). Absorbance, and therefore viability, was found to decrease 
with increasing ibuprofen concentration in a dose dependent fashion. This suggests that a 
reduced number of cells are metabolically active in cultures treated with ibuprofen, 
confirming the phase contrast-based observations. As with Y-27632 treatment, an MTT 
measured time course (Figure 4-24C) was conducted on untreated and ibuprofen treated 
cultures, to determine if this effect was due to reduced proliferation. Although the 
viability of both populations of cells increases over the course of the culture period, 
suggesting cells are not actively proliferating, viability for ibuprofen treated cultures 
remains reduced in comparison to untreated cells. This suggests that ibuprofen reduces 
cellular proliferation as oppose to inducing cell death.  
 
There is no evidence of apoptotic cell death in cultures treated with both Y-27632 and 
ibuprofen even at high concentrations. This suggests that inhibition of Rho A and ROCK 
does not have a cytotoxic effect upon on the cells. Reduced confluency as observed 
through microscopy and reduced cell viability as measured by MTT assay, suggests that 
cellular proliferation is reduced with Y-27632 and ibuprofen treatment. 
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Fig 4-24: Inhibition of Rho A decreases proliferation of the glioma cell line, U-251MG.  
Representative phase contrast images of U-251MG glioma cells cultured for 10 days with a range of concentrations of the drug ibuprofen (0 – 750 μM), an 
inhibitor of Rho A signalling (Aa-e). Cells appear confluent at lower concentrations of ibuprofen and cell density appears to decrease at higher concentrations 
of the drug (500 – 750 μM). Representative confocal images of TUNEL staining (Af-j), hilights fragmented DNA (a result of apoptosis) in green, as can be seen 
in the positive control (Ak). There is no evidence of apoptotic cell death with any concentration of ibuprofen tested. Scale bars: (Aa-e): 100 μm, (Af-k): 50 μm. 
MTT cell viability data (B) suggests that as ibuprofen concentration increases, cell viability decreases, and as there is no evidence of cell death, this may be 
due to a decrease in proliferation. MTT cell viability over the 10 day culture period (C) with and without 750 μM ibuprofen treatment, shows that under both 
conditions cell viability increases, indicating that cells are proliferating rather than dying, however with ibuprofen treatment, they appear to proliferate at a 
much slower rate.    
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Expression of GFAP and CSPGs was analysed via immunofluorescence in U-251MG 
monolayers treated with Y-27632 and ibuprofen. Cultures were treated with a range of 
concentrations (0.5 – 50 μM) of Y-27632 (Figure 4-25A) for 10 days with GFAP positive 
staining (Figure 4-25Aa-d) appearing increased in cultures treated with 50 μM Y-27632. 
Monolayers treated with 50 μM Y-27632 appear much less confluent than their untreated 
counterpart and both staining for GFAP and CS appear enhanced in these treated cultures.  
Furthermore, treatment with a range of concentrations (50 – 750 μM) of ibuprofen 
(Figure 4-25B) resulted in little variations in GFAP (Figure 4-25Ba-e) and CS (Figure 4-
25Bf-j) expression. However, potentially more GFAP staining may be visible in cultures 
treated with 750 μM ibuprofen.  
 
This evidence suggests that inhibition of Rho A and ROCK, results in reduced proliferation 
of U-251MG as oppose to cytotoxicity, which leads to reduced confluency of cultures. As 
the effects of confluency upon GFAP and CS expression were explored in the previous 
section, it was evident that immunoreactivity of GFAP and CS appeared enhanced in sub-
confluent cultures. Reduced confluency of Y-27632 and ibuprofen treated cultures 
therefore could explain any enhanced GFAP and CS immunostaining observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 183 
 
Fig 4-25: Inhibition of Rho A/ROCK 
signalling in U-251MG glioma cells 
promotes expression of markers of 
reactivity. 
Representative confocal images of U-
251MG cells cultured for 10 days with a 
range of concentrations of the selective 
ROCK inhibitor, Y-27632 (A) or the 
inhibitor of Rho A, ibuprofen (B). 
Expression of the intermediate filament 
protein, GFAP (Aa-d, Ba-e), stained in 
green, appears to increase at higher 
concentrations of each molecule (5 – 50 μM 
Y-27632, 100 – 750 μM ibuprofen).  
Similarly expression of chondroitin 
sulphate (Ae-h, Bf-j), a marker for the 
inhibitory molecules, CSPGs, secreted by 
reactive astrocytes and stained in green, 
again appears to increase at the higher 
concentrations of each molecule, and 
expression appears to be greatest with 50 
μM Y-27632. This increase in expression of 
GFAP and chondroitin sulphate could be 
due to the decreased cell density of 
cultures treated with each molecule.  Scale 
bars: (Aa-d, Ba-e): 50 μm, (Ae-h, Bf-j): 20 
μm. 
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4.3.4 Investigation into the Paracrine Effect of Glioma Cell Secreted Soluble Inhibitory 
Factors upon Neurite Outgrowth 
 
 4.3.4.1 Conditioned Medium 
 
To overcome the restriction of physical neurite blockage observed in 2D co-culture, a 
conditioned medium experiment was devised to determine the effect on neurite 
outgrowth of soluble inhibitory molecules secreted by the glioma cells. To achieve this, U-
251MG cells were cultured in 2D (Figure 4-26Aa) or 3D (Figure 4-26Ba) conditions for 10 
days, before their culture medium was harvested. Conditioned medium was then mixed in 
a 50:50 ratio with fresh growth medium (Figure 4-26Ab,Bb) for use in 2D (Figure 4-
26Ac,Bc) and 3D neurite outgrowth assays (Figure 4-26Ad,Bd). This ensures that the pH 
and condition of the medium is suitable for neurosphere growth, as medium harvested 
from 10-day old glioma cell cultures, may contain too many metabolites and insufficient 
nutrients.  
 
Neurospheres were cultured in 2D or 3D with medium conditioned by 2D cultures of U-
251MG cells (Figure 4-27A). In the absence of conditioned medium, significant TUJ-1 
positive (green) neurite outgrowth visibly radiates from the central neurosphere in 2D 
cultures (Figure 4-27Ba,b), however neurite outgrowth appears reduced from 
neurospheres cultured in the presence of glioma cell conditioned medium (Figure 4-
27Bc,d). Ch’ase supplementation of conditioned medium (Figure 4-27Be,f) results in a 
similar level of neurite outgrowth as control cultures in 2D. Whilst addition of Y-27632 to 
the conditioned medium (Figure 4-27Bg,h) results in 2D neurite outgrowth that appears 
denser than control cultures and ibuprofen treatment (Figure 4-27Bi,j) also appears to 
restore neurite outgrowth to control levels.  
 
Neurospheres cultured in 3D with 2D glioma cell conditioned medium (Figure 4-27Bk-t) 
all remain on top of the scaffold (Figure 4-27Bk,m,o,q,s), whereas TUJ-1 positive (green) 
neurites penetrate the depth of the 3D material (Figure 4-27Bl,n,p,r,t). Significant neurite 
outgrowth can be seen to have penetrated the scaffold in control cultures (Figure 4-27Bl), 
whereas there is no evidence of neurite outgrowth from the underside of scaffolds 
cultured in 2D glioma cell conditioned medium (Figure 4-27Bn). Few TUJ-1 positive 
(green) neurites are visible from the bottom view of Ch’ase treated cultures (Figure 4-
27Bp) and a large number of neurites can be seen to have penetrated scaffolds treated 
with Y-27632 (Figure 4-27Br). Ibuprofen treatment (Figure 4-27Bt) also resulted in a 
small number of neurites that had visibly penetrated the 3D material. 
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Fig 4-26: A schematic depicting the 
use of U-251MG glioma cell 
conditioned medium in both 2D and 
3D neurite outgrowth assays.  
To investigate the effect of paracrine 
factors such as CSPGs secreted from U-
251MG glioma cells, medium 
conditioned by glioma cells was used in 
both 2D and 3D neurite outgrowth 
assays. U-251MG glioma cells were 
either cultured in 2D (A) or 3D (B) for 
10 days in DMEM (supplemented with 
10 % FBS, 2 mM L-glutamine, and 20 
active units of penicillin and 
streptomycin) with a 50 % media 
change on day 5 of culture. Following 
the 10 day culture period, media was 
removed from U-251MG cultures and 
mixed in a 1:1 ratio with fresh DMEM 
medium (b). This conditioned medium 
was then used in both 2D (c) and 3D (d) 
neurite outgrowth assays, with 
neurospheres being cultured in this 
medium for the 10 day neurite 
outgrowth period of culture. 
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Fig 4-27: Culture of neurospheres in medium 
conditioned by 2D cultured glioma cells is inhibitory 
to neurite outgrowth and can be overcome by 
modulation of Rho A/ROCK signalling.  
Conditioned medium was obtained from U-251MG glioma 
cells cultured in 2D conditions for 10 days, as depicted in 
schematic (A) for use in 2D and 3D neurite outgrowth 
assays. Representative confocal images of neurospheres 
cultured in 2D (Ba-j) or 3D (Bk-t) conditions with 2D 
glioma cell conditioned medium and medium 
supplementation with chondroitinase, Y-27632 or 
ibuprofen. Neurite outgrowth is highlighted in green by 
the pan neuronal marker; TUJ-1 and nuclei remain within 
the central body of the neurosphere and are stained in 
blue. Neurospheres cultured without conditioned 
medium have extensive neurite outgrowth radiating from 
the neurosphere in 2D (Ba,b) and penetrating the scaffold 
in 3D culture (Bk,l). Whereas with 2D conditioned 
medium, neurite outgrowth is visibly reduced in 2D 
culture (Bc,d) and no neurites can be seen to have 
penetrated the 3D material in 3D culture (Bm,n). 
Chondroitinase supplementation, an enzyme that breaks 
down inhibitory CSPGs in addition to conditioned 
medium treatment, appears to restore neurite outgrowth 
in 2D culture (Be,f) and more neurites can be seen to 
once again penetrate the scaffold in 3D culture (Bo,p). 
Similarly treatment with the selective ROCK inhibitor, Y-
27632, appears to restore neurite outgrowth in 2D 
culture (Bg,h) and a significant amount of neurites can be 
seen penetrating the scaffold in 3D culture (Bq,r). 
Ibuprofen, an inhibitor of Rho A signalling, has a similar 
effect to Y-27632 in 2D (Bi,j) and 3D (Bs,t) culture 
conditions.  Scale bars: (Ba,c,e,g,i,k-t): 200 μm, 
(B,b,d,f,h,j): 50 μm.  
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Medium conditioned by 3D cultured U-251MG cells (Figure 4-28A) was applied to 2D and 
3D cultured neurospheres during induction of neurite outgrowth. Neurospheres cultured 
in 2D without glioma cell conditioned medium (Figure 4-28Ba,b) project a large quantity 
of TUJ-1 (green) positive neurites; whilst neurites generated in conditioned medium 
(Figure 4-28Bc,d) appear extremely short and reduced in size. Treatment of neurospheres 
cultured in conditioned medium with the enzyme Ch’ase (Figure 4-28Be,f) results in 
neurite growth comparable to that of control cultures.  Treatment of 2D neurospheres 
cultured in conditioned medium with Y-27632 (Figure 4-28Bg,h), results in extremely 
dense neurite outgrowth and ibuprofen treatment (Figure 4-28Bi,j) also restores neurite 
outgrowth to a level that is comparable to the control.  
 
Neurospheres cultured in 3D with 3D glioma cell conditioned medium, remain on top of 
the scaffold (Figure 4-28Bk,m,o,q,s) whilst TUJ-1 positive (green) neurites penetrate the 
depth of the 3D material, as visible from the underside of the scaffold (Figure 4-
28Bl,n,p,r,s,t). A significant number of neurites are visible from the underside of cultures 
maintained without conditioned medium (Figure 4-28Bl), whereas no neurites visibly 
penetrate scaffolds cultured in glioma cell conditioned medium (Figure 4-28Bn). A small 
number of neurites visibly penetrate scaffolds in the presence of Ch’ase (Figure 4-28Bp). 
A large number of neurites are visible from the underside of scaffolds treated with Y-
27632 (Figure 4-28Br), perhaps even more than control cultures. Ibuprofen treatment 
(Figure 4-28Bt), however, results in few neurites visibly penetrating the 3D material.  
 
Quantification of the number of neurites generated per neurosphere (Figure 4-29A) from 
neurospheres cultured in 2D with conditioned medium and each treatment condition, 
reveals that neurite number is inhibited by both 2D and 3D glioma cell conditioned 
medium. Furthermore, 3D glioma cell conditioned medium inhibits neurite number to a 
greater degree than 2D conditioned medium albeit not statistically significantly. Ch’ase 
treatment partially restores the number of neurites per neurosphere in cultures treated 
with both 2D and 3D conditioned medium and Y-27632 treatment enhances neurite 
outgrowth in both cases, to a level that is greater than that of the control. Ibuprofen 
however, restores neurite outgrowth in the prescence of both 2D and 3D glioma cell 
conditioned medium to levels reminiscent of the control.  
 
A similar outcome is evident in terms of the neurite density of each neurosphere (Figure 
4-29B) cultured in 2D. Neurite density is inhibited in both 2D and 3D glioma cell 
conditioned medium and 3D conditioned medium inhibits neurite outgrowth in 2D to a 
greater extent than 2D conditioned medium. Ch’ase treatment restores neurite outgrowth 
in both cases to a level that is similar to the control and both Y-27632 and ibuprofen 
enhance neurite density in the presence of 2D and 3D conditioned medium to a level that 
surpasses that of the control. 
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Fig 4-28: Culture of neurospheres in medium 
conditioned by 3D cultured glioma cells is 
inhibitory to neurite outgrowth and can be 
overcome by modulation of Rho A/ROCK 
signalling.  
Conditioned medium was obtained from U-251MG 
glioma cells culture in 3D conditions for 10 days for 
use in 2D and 3D neurite outgrowth assays, as 
depicted in schematic (A). Representative confocal 
images of neurospheres cultured in 2D (Ba-j) or 3D 
(Bk-t) culture conditions with 3D glioma cell 
conditioned medium and supplementation with 
chondroitinase, Y-27632 or ibuprofen. Staining for 
the pan-neuronal marker TUJ-1 in green highlights 
neurite outgrowth and nuclei are highlighted in 
blue.  Neurospheres cultured without conditioned 
medium have extensive neurite outgrowth radiating 
from the neurosphere in 2D (Ba,b) and penetrating 
the scaffold in 3D culture (Bk,l). However, in the 
presence of conditioned medium, neurospheres 
cultured in 2D (Bc,d), appear to produce reduced 
neurite outgrowth. In 3D conditions (Bm,n) no 
neurites are visible from the bottom view of the 
scaffold. However, treatment with chondroitinase in 
addition to conditioned medium, appears to restore 
neurite outgrowth in 2D culture (Be,f) and more 
neurites can be seen to penetrate the scaffold in 3D 
culture (Bo,p). Similarly treatment with the 
selective ROCK inhibitor, Y-27632, appears to 
restore neurite outgrowth in 2D culture (Bg,h) and a 
significant number of TUJ-1 positive neurites can be 
seen to penetrate the scaffold in 3D culture (Bq,r). 
Ibuprofen, an inhibitor of Rho A signalling, has a 
similar effect an appears to restore neurite 
outgrowth in 2D (Bi,j) and 3D (Bs,t) culture 
conditions.  Scale bars: (Ba,c,e,g,i,k-t): 200 μm, 
(B,b,d,f,h,j): 50 μm. 
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Fig 4-29: Inhibition of neurite outgrowth from neurospheres cultured in U-251MG 
conditioned medium in 2D and 3D culture systems. 
Quantification of neurite number (A) (data represent mean ± SEM, n=9-18; between 3-6 
neurospheres were quantified per independent replicate, of which there were 3) and 
density (B) (data represent mean ± SEM, n=9-18; between 3-6 neurospheres were 
quantified per independent replicate, of which there were 3) from neurospheres cultured 
in 2D in medium conditioned by glioma cells cultured in 2D or 3D. Neurite length (C) (data 
represent mean ± SEM, n=52-100; in total between 52-100 individual neurites were 
measured from 3 replicates of neurospheres derived from independent pools of cells) is 
inhibited in neurospheres cultured in 2D with glioma cell conditioned medium. 
Quantification of neurite penetration through Alvetex® scaffold (D) (data represent mean 
± SEM, n=3-6; between 1-2 neurospheres were quantified from 3 independent replicates) 
from neurospheres cultured in 3D with glioma cell conditioned medium reveals that less 
neurites penetrate the scaffold in the presence of conditioned medium.. The protein 
concentration of 2D and 3D glioma cell cultures was determined by Bradford assay (E) 
(data represent mean ± SEM, n=3; lysates from 3 independent cultures) and normalised to 
the volume of conditioned medium generated by the cultures.  ELISA analysis (F) (data 
represent mean ± SEM, n=3; conditioned medium generated from 3 independent cultures) 
of the chondroitin sulphate content of 2D and 3D glioma cell conditioned medium reveals 
that 3D cultures generate containing a slightly higher concentration of chondroitin 
sulphate. Two-way ANOVA with Tukey’s multiple comparisons (A-D) and unpaired T-test 
(E-F). * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
 190 
The length of neurites (Figure 4-29C) generated from 2D cultured neurospheres is 
severely impaired from neurospheres cultured in glioma cell conditioned medium. This 
reduction in neurite length is restored upon treatment with Ch’ase, however both Y-
27632 and ibuprofen have little effect upon neurite length and in both cases 3D 
conditioned medium significantly impairs neurite length to a greater degree. 
 
Neurospheres cultured in 3D in the presence of glioma cell conditioned medium generate 
fewer neurites capable of traversing the depth of the 3D material (Figure 4-29D). Ch’ase 
treatment partially restores neurite penetration by 3D culture, whilst Y-27632 was found 
to have little effect upon 2D glioma cell conditioned medium samples, however 
significantly enhanced neurite penetration in the presence of 3D glioma cell conditioned 
medium. Ibuprofen treatment partially restored 3D neurite outgrowth from 2D 
conditioned medium samples and had little effect upon neurite penetration from 
neurospheres cultured with 3D conditioned medium. 
 
In terms of neurite number and density in 2D culture, and penetration in 3D culture, it 
appears that neurite growth is impaired to a greater degree in 3D glioma cell conditioned 
medium as oppose to 2D conditioned medium. This could be due to differences in cell 
number and density of the cultures, as 3D cultures may contain a larger number of CSPG 
secreting cells. To account for this a Bradford assay was used to determine the total 
protein concentration of both 2D and 3D cultures (Figure 4-29E), and as 2D and 3D 
cultures require different volumes of growth medium, total protein concentration was 
normalised to the volume of conditioned medium generated by each culture condition. 
 
This analysis resulted in a similar protein concentration per mL of conditioned medium 
for both 2D and 3D cultures, with slightly reduced (not statistically significant) protein 
content in 3D cultures. This suggests that both 2D and 3D cultures contain a similar 
number of cells, once normalised, and that 3D cultures perhaps contain slightly fewer 
cells, which may explain the enhanced inhibition as CSPG expression may be enhanced by 
reduced cell density in 3D cultures.  To confirm this, an ELISA was used to determine the 
absolute CSPG concentration of 2D and 3D glioma cell conditioned medium samples and 
found that 3D conditioned medium contained a slightly higher concentration of CSPGs 
than 2D conditioned medium, however this was not statistically significant.     
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 4.3.4.2 2D/3D Glioma Cell-Neurosphere Co-culture Model 
 
To further study the effects of soluble inhibitory factors secreted from glioma cells in a 
dynamic system, 3D culture technology was utilised to develop a co-culture model 
whereby each cell type is not in contact with the other. This culture system consisted of a 
monolayer of glioma cells cultured at the bottom of a well within a standard tissue culture 
plate whilst a neurosphere is cultured on top of Alvetex® scaffold suspended within the 
same well (Figure 4-30C). Any soluble inhibitory factors secreted by the glioma cell 
monolayer will enter the culture medium and interact with the neurites within the 
scaffold. This reduces the difficulties associated 2D co-culture and mechanical blockage of 
neurite outgrowth due to contact between the two cell types.  
 
Immunofluorescence analysis reveals that whilst neurospheres remain on top of the 
scaffold in each case (Figure 4-30Aa,d,g,j,m) neurites can be seen to have penetrated the 
entire 200 μm depth of the 3D material and are visible from the bottom view of the 
scaffold (Figure 4-30Ab,e,h,k,n) in some cases. Extensive neurite outgrowth can be seen to 
have penetrated scaffolds from neurospheres cultured in the absence of glioma cells 
(Figure 4-30Aa-c). The presence of U-251MG GFAP (green) positive glioma cells (Figure 4-
30Af) resulted in a lack of visible neurite outgrowth from the underside of the scaffold 
(Figure 4-30Ae).  
 
Treatment with Ch’ase resulted the generation of a significant number of neurites capable 
of penetrating the scaffold (Figure 4-30Ah) despite the presence of U-251MG cells (Figure 
4-30Ai). Treatment of cultures with Y-27632 resulted in significant neurite outgrowth as 
visible from the bottom view of the scaffold (Figure 4-30Ak) along with a detrimental 
effect upon U-251MG cell density (Figure 4-30Al) with monolayers appearing less 
confluent and cell morphology altered. Few neurites are visible from the underside of 
scaffolds treated with ibuprofen (Figure 4-30n), however more neurites are visible than 
in co-culture samples with no treatment (Figure 4-30e). Ibuprofen also has a similar effect 
upon U-251MG morphology and confluency (Figure 4-30o), as discussed earlier within 
this chapter. The recovery effect of Y-27632 and partial recovery effect of ibuprofen, is 
unlikely to be due to the reduced confluency of glioma cell monolayers in these cultures, 
as it has been identified earlier in this chapter that sub-confluent glioma cells express 
CSPGs to a greater degree than confluent monolayers. 
 
The number of neurites that penetrate the scaffold (Figure 4-30B) was quantified in each 
case and the incorporation of U-251MG cells into the model was found to reduce neurite 
inhibition by a large degree. Medium supplementation with Ch’ase was found to restore 
neurite penetration to a similar level as the control and Y-27632 treatment was found to 
significantly enhance neurite outgrowth compared with the control. Ibuprofen medium 
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treatment was found to partially restore neurite penetration. This quantification supports 
the observations made upon analysis of the immunofluorescent images. 
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Fig 4-30: Co-culture of U-251MG glioma cells and 
neurospheres that are not in contact is inhibitory to 
neurite outgrowth and can be overcome by 
modulation of the Rho A/ROCK pathway. 
Representative confocal images (A) of neurospheres 
cultured in 3D on top of Alvetex® scaffold and glioma 
cells cultured in 2D at the bottom of each well. 
Neurospheres can be observed from the top view of the 
scaffold (Aa,d,g,j,m) with neurites penetrating the depth 
of the 3D material and are visible from the underside of 
the scaffold (Ab,e,h,k,n). GFAP positive U-251MG 
(Ac,f,i,l,o) are visible within each culture well. The pan-
neuronal marker TUJ-1 is highlighted in green 
(Aa,b,d,e,g,h,j,k,m,n) as is the intermediate filament 
protein GFAP (Ac,f,i,l,o) and nuclei are highlighted in 
blue. Scale bars: (Aa,b,d,e,g,h,j,k,m,n): 200 μm, 
(Ac,f,i,l,o): 50 μm. Quantification of the number of the 
number neurites that have penetrated the scaffold (B) 
(data represent mean ± SEM, n=3-9; 1-3 neurospheres 
were quantified per independent replicate, of which 
there were 3) indicates that in the presence of U-251MG 
glioma cells, neurite outgrowth is greatly inhibited and 
with the addition of chondroitinase, an enzyme known 
to render CSPGs inactive, neurites penetrating the 
scaffold is restored to a similar level as the control. 
Addition of small molecule modulators of the 
Rho/ROCK pathway into this system also has a recovery 
effect on neurite outgrowth, with Y-27632 enhancing 
neurite outgrowth to a level that surpasses the control 
and ibuprofen restoring neurite levels to a similar level 
as the control. A schematic depicting U-251MG cells 
cultured in 2D at the bottom of the culture well and a 
neurosphere being cultured in 3D within Alvetex® 
scaffold in the same well (C). One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001. 
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4.4 Discussion 
 
Unlike other biological systems, the CNS has limited capacity for regeneration; therefore 
trauma to the brain and spinal cord can result in catastrophic injury220,306. The inability of 
neurons to regenerate and restore lost neuronal connections, particularly following 
traumatic spinal cord injury, forms a major obstacle in the treatment and restoration of 
function33,34,39,206,220. This occurs due to the formation of a glial scar that consists of 
multiple, interconnecting inhibitory pathways that act to impair the regeneration of lost 
neuronal circuitry33,34,39,206,220. This chapter outlines the application of a novel human 
pluripotent stem cell based model to study the molecular mechanisms that underpin 
neurite inhibition within the glial scar and describes several distinct methodologies used 
to induce neurite inhibition and promote recovery of neurite growth.  
  
 4.4.1 Aggrecan-Induced Neurite Inhibition 
 
The culture of neurons on non-permissive growth substrates coated with inhibitory 
molecules such as astrocyte-secreted CSPGs, is a strategy commonly used to induce 
neurite inhibition25,26,377–380.  Aggrecan is a member of the CSPG family that is also found in 
cartilage220,381–383 and is commonly used in vitro to induce neurite inhibition384,385. This 
chapter describes several methodologies used to induce and subsequently investigate the 
underlying mechanisms involved in CSPG-mediated neurite inhibition, the first of which 
involves a simple system of aggrecan coating. Both 2D and 3D growth substrates were 
coated with aggrecan to provide non-permissive growth environments for neurite 
development. This methodology successfully induced neurite inhibition in human stem 
cell derived neurites in a dose-dependent manner in both 2D and 3D culture systems.  
 
Furthermore, the signalling pathway by which CSPGs are thought to induce neurite 
inhibition, has previously been described to involve Rho A and ROCK activation 
downstream of receptor binding26,27,209,372. To investigate this in the context of specifically 
aggrecan-induced neurite inhibition, ibuprofen an inhibitor of Rho A and Y-27632 a ROCK 
inhibitor, were both shown to recover neurite growth on non-permissive aggrecan coated 
growth substrates. This supports evidence outlined in the literature that implicates Rho A 
and ROCK signalling in downstream CSPG induced signal transduction.  
 
However, although aggrecan coating of growth substrates is a simple and effective 
methodology that can be used to study CSPG-induced neurite inhibition, it is not 
necessarily physiologically representative in terms of neurite inhibition within the glial 
scar. Aggrecan is a CSPG, and does induce neurite inhibition in vitro, however, there is 
little evidence that aggrecan is secreted or over-expressed following spinal cord injury 
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and Lemons et al even describe a significant reduction in aggrecan levels in the spinal 
cord post-injury386.  
 
This aggrecan-based model of neurite inhibition is also extremely simple, which may be 
an advantage for some applications, but does not provide an accurate representation of 
the cocktail of CSPGs secreted by reactive astrocytes following injury387,388. A simplified 
model of inhibition such as this may be beneficial in some circumstances such as 
investigations into generic CSPG signalling mechanisms or screening of compounds for 
the ability to overcome CSPG-mediated inhibition in an industrial or academic setting. 
However, to better recreate the complex nature of CSPG-mediated inhibition in the 
context of the glial scar, a co-culture model was developed to incorporate CSPG secreting 
cells into the culture system.  
 
 4.4.2 Co-culture of Glioma Cells and Neurospheres in 2D Culture 
 
To better recapitulate the complex cellular microenvironment encountered by damaged 
neurons in the injured spinal cord, a co-culture model was developed to incorporate cells 
that express similar CSPGs to the reactive astrocytes of the glial scar. Reactive astrocytes 
are the major cellular component of the glial scar and upon injury to the spinal cord, 
astrocytes upregulate the intermediate filament protein GFAP and secrete significant 
quantities of CSPGs that inhibit neurite extesion33,39,220. In vivo following injury, evidence 
suggests that reactive astrocytes secrete a number of CSPGs including: NG2, neurocan, 
brevican, phosphacan and versican, which form an inhibitory matrix following SCI387,388. 
 
In the interest of developing a fully human-based model of neurite inhibition and to 
maintain medical relevance, human glioma cell lines were characterised and considered 
for use in this model. Alternatively, to avoid the use of neoplastic cells, primary animal 
derived reactive astrocytes could have been considered for use in this model, however 
introducing cells from a different species may have consequences in terms of cross-
species reactivity of CSPGs.  
 
The human gliomablastoma cell line U-251MG was selected for use in this co-culture 
model as there is an abundance of evidence throughout the literature that describes the 
expression of CSPGs from this cell line including versican and phosphacan389–392, and it is 
also well documented that this cell line contains GFAP positive cells393–396.  Unlike 
aggrecan, both versican and phosphacan are known to be upregulated and actively 
secreted in the injured spinal cord387, therefore U-251MG cells both secrete CSPGs and 
express GFAP similarly to the reactive astrocytes found in the glial scar. Characterisation 
described throughout this chapter also confirms that U-251MG cultures express both 
GFAP and CSPGs, and specific expression of all versican isoforms was confirmed by 
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western blot. Therefore it was determined that U-251MG cells have similar properties to 
the reactive astrocytes of the glial scar making them a suitable candidate for use in this co-
culture model. 
 
The co-culture model described in this chapter involved the seeding of U-251MG cells in 
2D as a monolayer culture, allowing the cells to populate the microenvironment for 24 
hours before seeding a mature neurosphere on top of the monolayer for neurite 
outgrowth studies. However, neurite inhibition within this system may not be solely 
mediated by chemical factors such as CSPGs and their downstream signalling pathways, 
because the glioma cells and neurites are in contact with one another which may result in 
a physical inhibition of neurite extension. Reactive astrocytes in the glial scar in vivo form 
long cytoskeletal processes that interweave, resulting in a meshwork that mechanically 
blocks the growth of neurites33,39,220,293. Although this aspect of the co-culture model 
represents a mechanism of neurite inhibition that occurs in vivo, this is not the objective 
of this study. The objective of this study is to identify the molecular signalling events 
involved in CSPG-mediated inhibition, which may be masked or complicated by the 
physical interactions involved between the cell types in this co-culture model.  
 
However, chondroitinase, an enzyme that degrades CSPGs reducing their function312–
314,343,344,355, was found to restore neurite outgrowth in this 2D co-culture model to a level 
comparable with that of neurospheres cultured alone. This suggests that actually a large 
proportion of the neurite inhibition observed in this model, is mediated by CSPGs and the 
physical interaction of the glioma cells and neurons has little impact on neurite 
outgrowth. Similarly, both inhibitors of Rho A and ROCK signalling were also found to 
restore some aspects of neurite outgrowth in this co-culture system. This again, could 
suggest that physical inhibition may play only a minor role in inhibition within this model 
or perhaps the neurite enhancing effects of Y-27632 and ibuprofen, as discussed in 
Chapter III, may drive neurite growth despite the nature of the physical interactions 
between cell types. 
 
Although mechanical inhibition of neurite outgrowth by reactive astrocytes is an 
important component of the glial scar, the main focus of this study is chemical induced 
neurite inhibition mediated by CSPGs. This co-culture model is perhaps suitable for the 
study of physical cellular interactions between neurites and reactive astrocytes; however, 
its application to study CSPG-mediated inhibition is limited. For this reason, other culture 
methodologies were explored such as the use of glioma cell conditioned medium to 
investigate the effect of soluble inhibitors of neurite outgrowth only, removing any 
inhibitory effect mediated by cellular physical interaction.  
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 4.4.3 Effect of Glioma Cell Conditioned Medium on Neurite Outgrowth 
 
In order to further improve and build upon the 2D co-culture model developed within this 
chapter, several methodologies were implemented to examine glioma cell-induced neurite 
inhibition-mediated by soluble, secreted molecules only. U-251MG cells have previously 
been described to secrete CSPGs such as versican into their growth medium389,390, which 
in addition to the ELISA analysis of glioma cell conditioned medium described within this 
chapter, suggests that U-251MG cells secrete soluble CSPG molecules just as reactive 
astrocytes secrete CSPGs into the extracellular space within the glial scar. Therefore, a 
number of experiments were devised to investigate the inhibitory ability of glioma cell 
conditioned medium in terms of neurite outgrowth, reducing the limitations of the 
previously described 2D co-culture model. 
 
 The effect of conditioned medium harvested from 2D and 3D cultures of U-251MG cells 
upon neurite outgrowth was determined, as 3D cultures had been demonstrated to more 
positively stain for the CSPG motif CS, than 2D cultures. Therefore, it was hypothesised 
that 3D cultures of U-251MG cells secrete CSPGs to a greater extent than 2D cultures, and 
potentially may induce neurite inhibition to a greater extent. Both 2D and 3D glioma cell 
conditioned medium was found to be inhibitory to 2D and 3D cultured neurites and in 
some aspects of neurite outgrowth, 3D conditioned medium was found to induce neurite 
inhibition to a greater extent. ELISA analysis confirmed that CSPGs were present in the 
conditioned medium, however a full analysis of the CSPG content of the conditioned 
medium would be beneficial, to determine the content and ratio of a variety of CSPG 
molecules within the medium.  
 
In addition to the use of previously conditioned medium, a dynamic co-culture model was 
also developed that allowed U-251MG cells to simultaneously condition medium whilst 
neurites develop. This involved the culture of U-251MG cells as a monolayer at the bottom 
of a culture well, whilst neurospheres were cultured on Alvetex® scaffold suspended 
within the same well. This allowed U-251MG to gradually condition the growth medium 
throughout the course of the culture period, exposing neurites to a time-dependent 
gradient of CSPG secretion, similar to the in vivo environment that forms post-spinal cord 
injury.  
 
This methodology avoids the problem that arises during the conditioning of growth 
medium, in that U-251MG culture depletes nutrients from the medium whilst also 
generating metabolites that may be toxic and reducing the pH of the medium. This may 
have detrimental effects upon neuronal survival and neurite generation, whereas if U-
251MG and neurospheres are cultured in the same system, medium quality can be better 
managed. However, this system also has the disadvantage of glioma cell death when 
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screening potential drugs that may be cytotoxic. This chapter describes the ability of 
particular molecules to restore neurite growth in the presence of inhibitory stimuli 
(ibuprofen and Y-27632), however such molecules were also found to impact glioma cell 
growth and morphology. The combination of both neurospheres and glioma cells within 
the same culture system may reduce the ability of the model to screen cytotoxic 
compounds, as they may induce glioma cell death reducing CSPG secretion within the 
model. In this case pre-conditioned medium may be a more useful tool to study the ability 
of compounds to overcome CSPG-mediated inhibition without impacting CSPG secretion 
and viability of the glioma cells themselves. Therefore, the suitability of each conditioned 
medium model for the desired application should be considered prior to use. 
 
 4.4.4 Methods of Recovery of Neurite Outgrowth 
 
The main aim of this chapter was to induce neurite inhibition in human derived neurites, 
to then identify methods that are able to recover neurite growth. This is important to 
identify key signalling pathways involved in CSPG-mediated inhibition in the glial scar and 
this also demonstrates the potential screening application of inhibition models, to help 
identify molecules that may be beneficial in the treatment of SCI.  
 
CSPGs are secreted by reactive astrocytes in the glial scar; they then induce neurite 
inhibition in neighbouring neurons through the activation of cell surface receptors 
including LAR and PTPσ318–320. Receptor activation is thought to induce a signalling 
cascade that leads to activation of Rho A and ROCK, resulting in actin filament 
stabalisation and growth cone collapse27,365,366,372,373. The use of many small molecules to 
intervene and inhibit this signalling pathway has been examined within this chapter, as 
summarised in Figure 4-31. This has particularly focused on the inhibition of Rho A and 
downstream ROCK to prevent neurite collapse through destabilisation of the actin 
cytoskeleton.  
 
Chondroitinase (Ch’ase) is an enzyme that cleaves GAG side chains from CSPG molecules, 
preventing their structural interaction with cell surface receptors, subsequently inhibiting 
signal transduction at the ligand-receptor binding stage343. Ch’ase has been well 
characterised in terms of promoting functional recovery in animal models312,313,344,345,355 of 
SCI and is also known to promote axonal regeneration in vitro397. For this reason Ch’ase 
was added to the culture medium of both 2D co-culture and conditioned medium systems 
with the view to promote neurite growth in the presence of inhibitory CSPGs. In most 
systems Ch’ase was found to restore neurite outgrowth to control levels, which suggests 
that Ch’ase may reduce the function of CSPGs in culture supporting evidence outlined in 
the primary literature. Furthermore, this also suggests that the neurite inhibition 
observed both in 2D co-culture and conditioned medium models, is induced by CSPG-
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action, as recovery is demonstrated with Ch’ase supplementation. Therefore, neurite 
regeneration-induced by Ch’ase treatment, not only demonstrates a potential recovery 
mechanism but also contributes toward model validation. 
 
CSPG-mediated receptor activation is thought to lead to the activation of Rho A, which has 
consequences upon the actin cytoskeletal leading to neurite inhibition365. Ibuprofen is an 
NSAID and also an inhibitor of Rho A that has been documented to promote functional 
recovery following SCI28,30,31,372. Although there is a large body of evidence that ibuprofen 
treatment leads to recovery in functional deficit post-SCI368,369, there are only a small 
number of studies that identify the ability of ibuprofen to induce axonal regeneration in 
vitro31. This chapter describes the use of ibuprofen treatment to consistently promote 
neurite outgrowth both in 2D and 3D models of neurite inhibition. Ibuprofen was found to 
either partially or fully restore neurite outgrowth in all the models of inhibition described 
in this chapter including aggrecan-coating, 2D co-culture and conditioned medium 
systems. This, along with evidence outlined in literature, supports the role of Rho A in 
CSPG-mediated inhibition of neurite outgrowth and identifies the neuroregenerative 
properties of ibuprofen. 
 
The proposed pathway by which CSPGs elicit neurite inhibition states that Rho A 
activation leads to activation of downstream ROCK which in turn determines actin 
dynamics resulting in neurite inhibition26,27. Y-27632 is a selective inhibitor of ROCK and 
has been used to promote neurite growth in many systems, both without the presence of 
an inhibitory stimulus and in neurite inhibition studies. Numerous studies, both in 
vivo209,398–400 and in vitro23,27,204, identify the beneficial effects of Y-27632 following spinal 
cord injury in terms of neurite sprouting and functional recovery. This chapter documents 
the ability of Y-27632 to not only overcome neurite inhibition in the many models 
described herein, but also to enhance neurite outgrowth regardless of the inhibitory 
stimulus. In all models of inhibition described in this chapter, and in both 2D and 3D 
culture systems, Y-27623 was found to consistently enhance neurite growth to levels 
greater than the control. Very impressive neurite outgrowth was observed both in 2D and 
3D neurite outgrowth assays that incorporate this molecule. The enhanced potency of Y-
27632 compared with ibuprofen, is perhaps due to the efficiency at which each molecule 
inhibits its target. 
 
Therefore, Ch’ase, Y-27632 and ibuprofen have all been demonstrated to overcome 
neurite inhibition in the models described within this chapter. This suggests a pivotal role 
for Rho A and ROCK signalling in CSPG-mediated signal transduction which is supported 
by a large body of primary literature. Furthermore, this has been demonstrated in an 
aggrecan-based model of neurite inhibition in addition to several more complex glioma 
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cell-based models of neurite inhibition, which demonstrates the reliability and 
reproducibility of these findings.  
 
 
 
Fig 4-31: Overview of CSPPG-mediated neurite inhibition and methods of recovery.  
Schematics depicting the molecular mechanisms that underpin CSPG-mediated inhibition 
in the glial scar and mechanisms to inhibit the process and restore neurite growth. 
Chondroitinase breaks down CSPGs rendering them unable to activate their receptors, 
ibuprofen inhibits Rho A downstream of receptor activation and Y-27632 inhibits ROCK, 
all of which are capable of restoring neurite growth in the inhibitor glial scar. 
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 4.4.5 Expression of Reactive Astrocyte Markers by Glioma Cells is Confluency 
Dependent 
 
Primary astrocytes, when harvested from animal models and cultured in vitro generally 
adopt a reactive phenotype, upregulate GFAP and form complex cytoplasmic 
projections192,351,401 . This may be the desirable astrocytic phenotype for studies that 
require astrocytes to become reactive, such as glial scar interactions, however methods to 
maintain a more non-reactive astrocyte phenotype have been developed192,351. 
Particularly, more physiologically relevant 3D cell culture technology has been used to 
maintain primary astrocytes in vitro in a less-reactive state. Solid scaffolds such as 
Alvetex® scaffold192, hydrogels351 and nanofiber scaffolds401 have all been demonstrated 
to promote a non-reactive phenotype in primary astrocytes cultured in vitro. This led to 
the hypothesis that cell-cell interactions and culture confluency may regulate the 
expression of reactive astrocyte markers in cultured cells in vitro.  
 
The majority of studies focus on the reactive phenotype of primary astrocyte cultures, and 
little characterisation as to the expression of GFAP and CSPGs has been carried out in 
established glioma cell lines. However, due to the effect of 3D cell culture technology on 
primary cultures, it may be hypothesised that 3D cell culture technology may possibly 
reduce the expression of GFAP and CSPGs in glioma cell lines also. Data outlined in this 
chapter actually describes enhanced expression of CSPGs and GFAP, when U-251MG cells 
are cultured in Alvetex® scaffold, particularly at lower seeding densities. Expression of 
reactive astrocyte markers is enhanced in 3D culture compared with 2D and is also 
enhanced in sub-confluent rather than confluent cultures.  
 
Therefore, this suggests that expression of GFAP and CS is confluency dependent, 
implicating the role of cell-cell contacts in the phenotype of glial cells in vitro. However, 
expression of such markers in glioma cells opposes the expression profiles documented in 
primary cell cultures, suggesting that the neoplastic nature of glioma cell lines impacts 
cellular phenotype.  
 
4.4.6 Inhibition of Rho A and ROCK Signalling Reduces Glioma Cell Proliferation 
 
Inhibition of Rho A and ROCK through small molecule modulators was used to restore 
neurite growth in the presence of inhibitory U-251MG glioma cells. However, the effect of 
such molecules on the glioma cells themselves resulted in some interesting observations. 
Application of both Y-27632 and ibuprofen resulted in morphological changes in the 
glioma cells, which was particularly apparent in Y-27632 cultures, as cells adopted a 
clearly more stellate morphology. This has also been observed in primary astrocytes, 
which adopt a flat polygonal morphology upon in vitro culture but can be induced by Y-
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27632 to form stellate structures with complex cellular processes402–405. The effect of Y-
27632 induction of astrocytic process formation has been utilised by Holtje et al to 
promote wound closure following injury404. This highlights the importance of 
understanding such basic, fundamental processes including control of actin dynamics in 
detail, and devising innovative, novel applications of such knowledge.  
 
Treatment of U-251MG cells with ibuprofen and Y-27632 to inhibit Rho A and ROCK 
respectively, appeared to result in a reduction of cellular proliferation. This was measured 
by MTT assay, which is a metabolic assay that indirectly measures cellular viability 
through metabolic behaviour. It therefore does not give an accurate representation of 
cellular proliferation and to confirm this effect, more direct studies are required.  
 
However, the effects of Rho A/ROCK inhibition in primary astrocyte cultures, 
partocicularly Y-27632 treatment has previously been documented by Yu et al to promote 
proliferation of spinal cord-derived astrocytes406. Although Y-27632-mediated inhibition 
of ROCK has been documented to promote proliferation of primary astrocytes, inhibition 
of ROCK has been well documented in other cell types to reduce cellular proliferation406. 
In particular, proliferation of glioblastoma cell lines including the U-251MG line as 
discussed in this chapter, has previously been described to be inhibited by the selective 
ROCK inhibitor, Y-27632407,408. These findings have even led to the consideration of 
inhibition of Rho A and ROCK as a suitable therapeutic strategy in the treatment of 
malignant glioblastomas, particularly to reduce tissue invasion and prevent cancer 
progression. This supports the findings outlined in this chapter that suggest inhibition of 
Rho A and ROCK may reduce cell proliferation in U-251MG cells. 
 
Furthermore, increased expression of both GFAP and CS was documented upon induction 
by Y-27632 and ibuprofen. This was thought to be a consequence of the reduced 
proliferative capacity of the cells, leading to less confluent cultures and as described 
earlier U-251MG cells were found to express these markers to a greater extent at reduced 
cell density. However, a study by Chan et al does document the ability of Y-27632-induced 
inhibition of ROCK to induce a reactive phenotype, resulting in enhanced expression of 
these markers in primary astrocyte cultures409.  
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4.5 Key Findings 
 
 Growth substrates coated with CSPGs (aggrecan) were inhibitory to neurite 
outgrowth in 2D and 3D culture.  
 
 Aggrecan-mediated neurite inhibition was overcome by inhibition of Rho A 
(ibuprofen) or inhibition of ROCK (Y-27632) in 2D and 3D culture systems.  
 
 The glioma cell line, U-251MG, was found to express GFAP and CSPGs reminiscent 
of the reactive astrocytes that contribute toward glial scarring post-SCI.  
 
 Expression of GFAP and CSPGs in U-251MG cells was found to be dependent upon 
cellular density and culture parameters. Inhibition of Rho A (ibuprofen) or ROCK 
(Y-27632) enhanced expression of both GFAP and CSPGs, and also reduced 
cellular proliferation. 
 
 A 2D co-culture model combining U-251MG cells and human stem cell-derived 
neurospheres was developed. However, this method of co-culture had significant 
limitations, although recovery of neurite growth was evident when treated with 
Ch’ase, Y-27632 or ibuprofen.  
 
 Glioma cell conditioned medium containing secreted CSPG molecules, was used to 
successfully induce neurite inhibition from human-derived neurospheres. This 
inhibitory response was overcome by Ch’ase, Y-27632 and ibuprofen treatment.  
 
 A dynamic co-culture model was developed whereby; glioma cells were cultured 
at the bottom of the culture well, whilst neurospheres were cultured in 3D in the 
same well. This resulted in inhibition of neurite outgrowth that was overcome by 
Ch’ase, Y-27632 and ibuprofen treatment.   
 
 
 
 
 
 
 
 
 
 
 204 
4.6 Conclusions 
 
This chapter has involved the development of several different methodologies used to 
induce neurite inhibition and study the interactions in the glial scar. These range from 
simple CSPG coatings, to complex co-culture models, the suitability of which depends 
upon the application for which it is intended. More simple models such as the aggrecan-
induced model of inhibition described within this chapter are useful to give insight into 
specific CSPG-mediated signalling pathways, however do not accurately reflect the 
complex environment that forms post-SCI. More complex models such as the conditioned 
medium and co-culture models described in this chapter are helpful in the study of 
complex interactions that occur following injury to the spinal cord, however their 
complexity may impede the successful dissection of clear molecular signalling.  
 
In addition to models of inhibition, this chapter also discusses the signalling mechanisms 
involved in CSPG-mediated neurite inhibition with particular focus on Rho A and ROCK 
signalling. Inhibitors of Rho A and ROCK signalling can be used to overcome CSPG-
mediated inhibition and provide not only a potential therapeutic target but also help 
provide a more detailed view of the signalling pathway that leads to growth cone collapse 
and neurite inhibition.  
 
Understanding the Rho A signalling pathway is not only important in the development of 
neural regeneration strategies but also in the development of therapeutic applications in 
the context of other pathologies. This chapter describes the ability of the selective ROCK 
inhibitor, Y-27632 to reduce cellular proliferation of the glioma cell line U-251MG, this in 
turn has implications in the treatment of malignant gliomas, as such molecules could be 
used to reduce cell proliferation and thus cancer progression. Inhibition of ROCK can 
potentially provide a strategy to reduce tumour progression and invasion, along with 
identifying key signalling pathways involved in this process. 
 
Furthermore, this chapter describes an application of the novel human stem cell derived 
model of neuritogenesis described in Chapter III to study the process of neurite inhibition 
that occurs following spinal cord injury. In addition to this, applications such as 
investigations into the signalling pathways involved in CSPG-mediated neurite inhibition 
and screening of molecules to overcome inhibitory stimulation have also been described. 
Therefore this model could provide a 3D and therefore more physiologically relevant in 
vitro model of neurite growth and inhibition that may be beneficial in the screening of 
drugs, to identify candidate compounds that promote neurite regeneration.  
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4.7 Future Directions 
 
Future work building upon the data described in this chapter could include the following: 
 
 The inhibitory effects of glioma cell-deposited ECM could be investigated by 
culturing U-251MG cells in Alvetex® scaffold for a desired culture period. Cells 
could then be lysed leaving only the secreted ECM that coats the remaining 
scaffold. Neurospheres cultured on top of the scaffold to determine the effect of 
the deposited ECM on neurite growth. 
 
 Other modulators of Rho A and ROCK signalling could be used to potentially 
achieve neurite recovery in the inhibitory models outlined in this chapter. These 
could include fasudil and C3 transferase, which have been well documented in by 
many studies to promote neurite regeneration.  
 
 A complex analysis of U-251MG conditioned medium could be conducted to 
identify both neurite promoting and inhibitory constituents of the medium. This 
could be achieved through mass spectroscopy and additional ELISA assays to 
determine the composition of the conditioned medium.  
 
 The co-culture model described in this chapter that separates glioma cells from 
neurospheres and was used to assess the effect of soluble inhibitory molecules 
upon neurite outgrowth could be further enhanced. The glioma cells in this model 
are cultured in 2D at the bottom of the culture well, however to further improve 
the model, glioma cells could be cultured in 3D within an Alvetex® membrane at 
the bottom of the well to further enhance the secretion of CSPGs.  
 
 
 
 
 
 
 
 
 
 
 
 
 206 
Chapter V: Investigation into the Role of β-amyloid in 
Neurite Inhibition within Alzheimer’s Disease 
 
5.1 Introduction 
 
Neurodegenerative diseases including Alzheimer’s and Parkinson’s disease are 
characterised by a loss of neuronal connectivity. Inhibition of neurite development is one 
of multiple pathogenic mechanisms that lead to a reduction in connectivity in these 
diseases. Therefore, the example of neurodegeneration, highlights the need for reliable, 
physiologically relevant and robust in vitro models to both study the complex molecular 
signalling pathways involved in neurite inhibition, and to screen the ability of molecules 
to overcome inhibitory influences.  
 
 5.1.1 Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease and 
perhaps one of the most devastating diagnoses a patient and their family can receive410. 
The incidence of AD is increasing, reflecting an ageing population and in 2009 there were 
35.6 million cases of AD recorded world wide with this number expected to more than 
double by 2050411. As of yet there is no complete cure for AD and other forms of dementia, 
however, there has been a great deal of research in this area with a focus on 
understanding the molecular pathophysiology of the disease subsequently leading to 
rational therapeutic design412–418.   
 
The main clinical characteristics of AD involve the decline of memory initially as a loss of 
episodic memory411. This results in the inability of a patient to recall recent events such as 
autobiographical activities411. Understanding the molecular events that lead to disease 
progression and pathogenesis, can help discover points at which treatments can 
intervene, preventing this episodic memory loss and relieving the symptoms of the 
disease.  
 
5.1.2 Pathophysiology of Alzheimer’s Disease 
 
In 1907, Alois Alzheimer first identified two pathological anomalies in the brain of a 
female dementia patient410. These two lesions represent the hallmark features of the 
disease and their observation postmortem is still required for a confirmed AD diagnosis 
today410. Generation of proteinaceous aggregates is common to the pathogenesis of many 
neurodegenerative diseases including AD264. The brains of AD patients in addition to 
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displaying synapse loss, include two hallmark lesions, extracellular senile plaques 
containing aggregated β-amyloid peptides and intracellular neurofibrillary tangles (NFTs) 
composed of hyperphosphorylated forms of the microtubule-associated protein Tau264.  
 
There is a growing body of evidence that implicates these protein aggregates in the onset 
and progression of AD and understanding their development and interactions may be 
essential in the identification of successful drug candidates264. However, AD is a multi-
faceted disease with many contributing pathogenic mechanisms, including synapse loss, 
inflammatory responses and oxidative stress which along with proteinaceous aggregate 
deposition all play a role in the development and progression of the disease410. Therefore, 
the development of successful drug candidates to treat AD has been difficult, as all of the 
aforementioned mechanisms should be taken into consideration during the development 
of such therapeutics. 
 
 
 
 
 
Fig 5-1: Pathological hallmarks of Alzheimer’s disease. 
The two major, most well characterised hallmarks of AD include the extracellular 
accumulation of β-amyloid as plaques and the intracellular accumulation of 
hyperphosphorylated tau as neurofibrillary tangles. 
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5.1.2.1 β-amyloid Generation and Senile Plaque Formation 
 
β-amyloid (Aβ) is produced by the proteolytic cleavage of the parental amyloid precursor 
protein (APP) via the sequential action of secretase enzymes410. There are three families 
of secretase enzymes: α-, β- and γ-secretases all of which contain proteolytic enzymes. For 
example, ADAM9, ADAM10 and ADAM17 are metalloproteinase enzymes that have α-
secretase activity419,420. Similarly β-site APP-cleaving enzyme 1 (BACE1) is an integral 
membrane protein that belongs to the β-secretase category421,422 and γ-secretase exists as 
a complex of enzymes including presenilin 1 and 2 (PS1 and PS2), nicastrin, anterior 
pharynx defective and presenilin enhancer 2262,423.  
 
The cleavage and enzymatic processing of APP can be separated into amyloidgenic and 
non-amyloidgenic processing (see Figure 5-2). The non-amyloidgenic pathway is the most 
prevalent method of APP processing and involves the cleavage of APP 83 amino acids 
from the C-terminus by α-secretase410. This produces a large N-terminal ectodomain 
(sAPPα) that is secreted into the ECM along with an 83 amino acid long C-terminal 
fragment (C83) that is retained in the membrane410,424. C83 is then cleaved by γ-secretase 
producing a short p3 fragment. Cleavage by α-secretase occurs within the Aβ region; 
therefore prevents the formation of Aβ specieis410,424. 
 
Alternatively the amyloidgenic pathway of APP cleavage leads to the generation of Aβ 
species associated with AD pathogenesis. The initial proteolysis within this pathway is 
mediated by β-secretase, as oppose to α-secretase at a location 99 amino acids from the C-
terminus410,424,425. This results in the release of sAPPβ into the ECM whilst a 99 amino acid 
C-terminal stub (C99) remains within the membrane. Subsequent cleavage of C99 by γ-
secretase between residues 39 and 43, results in the generation of Aβ species, of which 
the 40-residue length peptide (Aβ40) is the most prevelant410,424,425. A small proportion (~ 
10 %) of total Aβ is made up of the 42-residue variant (Aβ42), which is more hydrophobic 
and more readily forms insoluble fibrils and aggregates compared with Aβ40410,426. For this 
reason Aβ42 is the predominant Aβ species associated with senile plaque formation and 
AD pathogenesis is associated with an increase in the ratio Aβ42 relative to Aβ40, which is 
even used as a diagnostic biomarker in CSF analysis426–434. 
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Fig 5-2: Proteolytic processing of amyloid precursor protein (APP).  
A schematic that depicts two forms of APP proteolytic cleavage including the abundant 
non-amyloidgenic pathway and Aβ generation through the amyloidgenic pathway. Non-
amyloidgenic cleavage involves the action of α-secretase that cleaves APP within the Aβ 
domain, giving rise to soluble sAPPα and membrane bound C83. Amyloidgenic processing 
however, first involves the action of β-secretase that releases soluble sAPPβ whilst C99 
remains within the plasma membrane. γ-secretase then acts upon the remaining C99 
liberating Aβ species. AD is associated with an increase in amyloidgenic processing of APP 
and the buildup of Aβ deposits. 
 
 
Familial forms of AD are generally associated with mutations involved in the processing of 
APP for example mutations in APP435–437, PS1 and PS2438 are associated with autosomal 
dominant early-onset AD439. One mutation in APP known as the Swedish mutation 
(APPSwe) is the result of a double amino-acid change that leads to increased cleavage of 
APP by β-secretase440. Mutations in the presenilins such as PS1M146V result in increased 
levels of Aβ42 therefore enhanced aggregation and incidence of senile plaques410. 
Increased dosage of APP is also associated with dementia as patients with Down’s 
syndrome often experience Aβ accumulation early in life. This is because the APP gene 
resides on chromosome 21, which Down syndrome patients have three copies of441–443.  
 
The central role of Aβ formation in the pathophysiology of AD has resulted in numerous 
attempts at therapeutic intervention444. Inhibition of the secretase enzymes thus 
prevention of Aβ formation has been a common strategy in the design of AD drugs. 
However, inhibition of γ-secretase resulted in reduced Aβ levels in the brain445 but was 
associated with a cognitive decline at clinical trial in the treatment group263. This was 
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later thought to be due to the wide range of protein targets of γ-secretase with over 100 
targets having now being identified446–450. β-secretase inhibition has been regarded with 
more success, as reduction in Aβ concentration within the CSF of patients was noted 
without any obvious detrimental effects418. However, one β-secretase inhibitor clinical 
trial was halted due to hepatotoxicity444,451–453. Other therapeutic strategies that target Aβ 
accumulation include stimulation of the non-amyloidgenic pathway444, aggregation 
inhibitors454,455, immunotherapy456 and promotion of Aβ clearance457,458.  
 
Although Aβ appears to play a central role in the pathogenic molecular mechanisms 
involved in AD progression, early thoughts that Aβ deposits were the driving force of the 
disease are now beginning to be rejected459. In the early 1990s the amyloid cascade 
hypothesis was first suggested and involves the theory that Aβ formation and aggregation 
occurs in a linear pathway resulting in the gradual accumulation and aggregation of the 
peptide in the brain460. Amyloid deposition was thought to drive inflammation and 
oxidative stress, leading to neuronal injury and loss460. However, recently many experts in 
the field openly dismiss the amyloid cascade hypothesis, as emerging studies reveal that 
AD is a complex disease involving many interacting cellular imbalances in processes such 
as autophagy, lysosomes, mitochondria, DNA damage etc459,461. Nevertheless, Aβ 
production is still thought to be an important factor in the development of the disease but 
must be considered in conjunction with other factors as oppose to a single driving force. 
 
5.1.2.2 Abnormal Phosphorylation of Tau 
 
Tau is a microtubule associated protein (MAP) found in the axons of neurons and is 
involved in the stabalisation of microtubules (MTs)264. There are six major isoforms of tau 
found within the human brain, all of which are derived from a single gene by alternative 
splicing and contain a MT-binding domain comprised of repeats of a highly conserved 
tubulin-binding motif462. Each tau isoform differs in terms of the number of tubulin-
binding repeats and in the presence of either one or two 29 amino acid long inserts at the 
N-terminal domain, however this is not instrumental in MT-binding463. Although the 
primary function of tau is known to be stabalisation of MTs, other binding partners such 
as RNA464 and PS1465 have been identified suggesting that tau may be prone to 
heterogenous interactions and may even play a role in protein misfolding and 
aggregation264.   
 
The role of tau in MT-binding is regulated post-translationally by serine/threonin-
directed phosphorylation that modulates MT-binding affinity in a dynamic 
equilibirum264,466–468, as shown in Figure 5-3. This is thought to be important during 
development, as phosphorylation of tau during development is much higher than in the 
adult brain, which is usually characterised by a considerably lower tau phosphorylation 
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state264,469–471. The role of tau in the stabalisation of MT is essential to the normal 
functioning of the neuron as the MT network is involved in maintaining the correct 
morphology of the cell, which is particularly important in neurons as their morphology is 
essential to their function and connectivity particularly as neurons span large distances in 
the body264. The MT-network, thus tau, is also essential in the transport of cellular cargo 
including signalling molecules, trophic factors, organelles and other essential cellular 
components264. Therefore, correct functioning of tau is essential to ensure proper axonal 
transport, which in turn impacts the function and viability of neurons along with their 
highly extended processes.  
 
 
 
 
 
 
 
Fig 5-3: Dynamic equilibrium of tau phosphorylation in microtubule homeostasis. 
A schematic representation of tau (red) binding to microtubules (MTs, blue) in its 
unphosphorylated state (A) which is essential for MT integrity, although hinders the 
movement of cargo along MTs. Phosphorylation of tau (B) results in MT detachment and a 
dynamic equilibrium of tau phosphorylation (C) ensures effective axonal transport is 
maintained. 
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In AD and other taupathies the equilibrium of tau binding to MTs is disrupted resulting in 
high levels of unbound tau, which increases the likelihood of pathogenic conformational 
changes resulting in tau aggregation and fibrillisation264. Aggregation of tau first begins 
with the abnormal disengagement of tau from MTs that can be a result of many factors, 
including hyperphosphorylation264,472–475. This results in a high cytosolic concentration of 
unbound tau, increasing the likelihood of misfolding and rendering tau more likely to 
undergo aggregation264. Small intracellular deposits of tau then form, known as pre-
tangles that are non-fibrillary and do not contain β-sheets264. A structural rearrangement 
of pre-tangles is then required for the formation of paired helical filaments that self-
assemble to form neurofibrillary tangles (NFTs): intracellular inclusions associated with 
neurodegeneration264. 
 
In AD the highest concentration of aggregated tau (~ 95 % of total tau) is found within the 
dystrophic neurites of the neuron264. Therefore it is though that tau pathology can lead to 
abnormal cytoskeletal structure and function that can compromise axonal transport 
leading to synaptic dysfunction, neurodegeneration and loss of functional neurites264.  In 
addition to this, tau is also thought to contribute to AD pathology through interactions 
with Aβ, which remain poorly understood and of which there are three proposed models 
of interaction411, as summarised in Figure 5-4.  One model suggests that Aβ is the driving 
force that stimulates hyperphosphorylation of tau411. This is supported by the fact that Aβ 
deposition in APP transgenic mice was observed to lead to hyperphorphorylation of tau, 
whereas in tau transgenic mice Aβ aggregation was not noted476,477. Furthermore 
intracranial injection of synthetic Aβ into tau transgenic mice was found to enhance NFT 
formation478.  
 
Another model of tau/Aβ driven pathology suggests that both Aβ and tau act through 
different mechanisms to have a synergistic, complimentary effect411. For example, 
mitochondrial dysfunction and oxidative stress are thought to play an important role in 
AD progression and tau is known to impair complex I of the respiratory chain, whilst Aβ is 
known to block complex IV-dependent respiration479–482. Therefore, both Aβ and tau 
impair mitochondrial function but through distinct mechanisms. The final school of 
thought states that tau may play a secondary role in Aβ-mediated toxicity411. This theory 
was founded on the evidence that in the tau knockout, transgenic neurons were protected 
from Aβ induced cell death in culture483, therefore it was hypothesised that tau was 
simply a mediator of the negative effects of Aβ.  
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Fig 5-4: Proposed models of tau and β-amyloid interaction in Alzheimer’s disease pathogenesis. 
A schematic describing three potential modes of Aβ and tau interactions in the development of AD pathology. Aβ deposition may drive hyperphosphorylation of tau 
resulting in neurotoxicity (A) or tau may mediate the toxic effects of Aβ, therefore disease progression is dependent upon tau presence (B). Alternatively tau and Aβ 
may independently target cellular processes amplifying the toxic effect of the other (C). 
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There is an abundance of contradictory evidence as to the role of Aβ and tau aggregation 
in the onset and progression of AD, however both are thought to play a central role in the 
development of the disease. This highlights the complex nature of neurodegenerative 
diseases involving interplay between multiple pathogenic mechanisms that should always 
be considered in the development of disease models and potential therapeutics.  
 
5.1.3 Neurite Outgrowth and Alzheimer’s Disease 
 
One of the major hallmarks of AD, other than the accumulation of proteinaceous 
aggregates, is the loss of neuronal connectivity. This occurs due to synaptic loss484–488 and 
the inhibition of neurite growth411, which are essential in the formation of neuronal 
connections. The molecular mechanisms that underpin neurite inhibition within the brain 
of AD patients remain relatively unknown. However in vitro studies have interestingly 
revealed opposing functions of APP and Aβ in neurite outgrowth and survival. APP has 
been found by many studies to enhance neurite development489–491 whereas Aβ has been 
found to have inhibitory effects upon neurite growth36,40. Understanding the molecular 
signalling events that underpin these processes may be essential in revealing the 
underlying pathogenic mechanisms involves in AD progression and in the development of 
novel therapeutics with the aim of restoring lost neuronal connections in the brain of 
patients with AD.  
 
5.1.3.1 APP and Neurite Outgrowth 
 
The amyloid precursor protein (APP) is perhaps one of the most studied proteins to date, 
due to its central role in the generation of Aβ and the significance of this in AD pathology. 
However, its role in many biological processes appears complex as APP has been found to 
exhibit both neurotoxic and neuroprotective effects with functions including cell 
adhesion, acting as a cell surface receptor, synapse formation and cell division492. 
However, many studies have struggled with identifying the exact functions of APP, as 
many experimental models involving over- or under-expression of APP result in varied 
expression of many proteolytic products, which may impact experimental outcomes492.    
 
One of the most widely studied functions of full length-APP is its ability to induce neurite 
outgrowth and synaptogenesis, particularly in the developing brain. Expression of APP in 
the developing chick brain is thought to coincide with the developmental period 
associated with maximal neurite outgrowth and synaptogenesis, suggesting a potential 
role of APP in nervous system development493. Many in vitro cell-based neuronal models 
have been used to identify the neurite promoting properties of APP, which were first 
identified in the 1990s490,494.  However, since the identification of the role of APP in 
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stimulation of neurite outgrowth, little has been uncovered of the underlying molecular 
mechanisms that drive this function. 
 
Proposed mechanisms by which APP may enhance neurite generation include: 
enhancement of cellular adhesion495, interactions with integrins496 and ECM 
components497 along with mediation of the effects of NGF498. Although the specific 
mechanisms of APP induction of neurite outgrowth remain undetermined, studies such as 
that of Allinquant et al highlight the importance of APP function in this key developmental 
process499. Alliquant et al demonstrate the ability of anti-sense oligonucleotides to block 
APP expression in embryonic cortical neurons in vitro resulting in a reduction in axonal 
and dendritic outgrowth499. 
 
Therefore although the exact molecular mechanisms remain largely unknown, APP is 
thought to play an integral role in neurite outgrowth during development. This raises 
interesting questions in the loss of neuronal connectivity associated with AD such as a 
potential link between increased amyloidgenic processing and a reduction in 
neuritogenesis and synaptogenesis. In addition to this the opposing effects of Aβ upon 
neurite outgrowth further implicate impaired neuritogenesis in the pathophysiology of 
AD. 
 
5.1.3.2 β-amyloid Peptides and Neurite Outgrowth 
 
The role of Aβ species in neurite outgrowth, unlike that of APP, is thought to be negative 
with many studies evidencing the inhibitory qualities of Aβ36,40. Several in vitro cell-based 
models have analysed the effects of Aβ upon neurite outgrowth, which provide the 
advantage of a simplified system to study the impact of Aβ alone as opposed to, the 
complex interacting pathways involved in AD pathogenesis that may also impact neuronal 
connectivity.  
 
Petratos et al describe the exogenous addition of Aβ species to the culture medium of SH-
SY5Y cells with the resultant neurite outgrowth being inhibited by both Aβ40 and Aβ42 
supplementation compared with controls36. Interestingly, this study found that neurite 
outgrowth was inhibited to a greater degree by Aβ40 than the more insoluble and 
aggregate-prone Aβ4236. In a similar study Postuma et al examined the ability of Aβ species 
to induce neurite inhibition in primary neuronal cultures with Aβ presented to cells 
bound to the growth substrate40. This study determined that substrate-bound Aβ 
inhibited neurite outgrowth to a greater extent than soluble Aβ supplementation of 
culture medium and that when bound to the growth substrate Aβ42 inhibited neurite 
outgrowth to a greater extent than Aβ4040.   
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The inhibitory function of Aβ is supported by observations of dystrophic growth cones 
within the brain of patients with AD. As neurites pass through Aβ-rich deposits such as 
senile plaques, they adopt a curvature and their morphology becomes dystrophic500,501. 
Furthermore, transgenic animal models of AD have been used to observe dendritic 
abnormalities associated with Aβ deposition and in a comparison with human 
postmortem AD brain, several dendritic abnormalities were identified502. These 
morphological abnormalities include spine loss, shaft atrophy, bending, branch breaking 
and sprouting502. A study by Jin et al identifies the ability of soluble Aβ dimers isolated 
from AD brain tissue to induce neurite degeneration503. This study has the advantage of 
applying naturally occurring Aβ peptides to primary cell cultures as opposed to synthetic 
forms of the peptides used in other studies and similarly it evidences abnormal neurite 
development in the presence of Aβ.   
 
Therefore, many techniques both in vitro and in vivo have been used to evidence the role 
of Aβ in neurite inhibition and dysfunction. This change in morphology associated with Aβ 
deposition and inhibition of growth has a striking impact on neuronal connectivity and 
signal transduction along with synapse formation500. Such changes in neuronal 
connectivity may have a negative impact on memory function and may be involved in the 
clinical onset of symptoms in conjunction with other pathogenic factors. Therefore, 
although there is a large body of evidence to support the role of Aβ in inhibition of neurite 
outgrowth, the molecular mechanisms that drive this process must now be uncovered to 
aid in the development of therapeutics and to further our understanding of the process. 
 
5.1.3.2.1 Interactions Between β-amyloid and the Nogo Receptor 
 
Inhibitory molecule-mediated signal transduction plays a huge role in the inability of 
neurons to regenerate following traumatic injury to the CNS (as reviewed in Chapter IV). 
The Nogo receptor (NgR) present on neurons, initiates an intracellular signalling cascade 
upon ligand binding that results in neurite dystrophy and growth cone collapse39. In the 
injured spinal cord NgR ligands include myelin inhibitors such as Nogo, OMGP and MAG 
along with CSPGs secreted from reactive astrocytes39. Interestingly there is emerging 
evidence to suggest NgR plays a role in AD pathophysiology as both APP and Aβ have been 
found to bind to the receptor504–506.  
 
Numerous studies have determined the ability of both APP and Aβ to bind to the NgR, 
however the ability of Aβ to activate this receptor and its downstream signalling events is 
still remains unclear. It has been reported by Park et al that whilst Aβ binds to NgR, 
disruption of NgR expression in transgenic mouse models results in increased Aβ 
deposition and dystrophic neurites504. Similarly, this study also discusses that 
overexpression of NgR results in decreased Aβ production in cultured cells504. This 
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evidence may suggest that Aβ binds to but does not activate NgR, and NgR simply 
sequesters Aβ preventing it from performing its neurodegenerative functions.   
 
However, a study by Knowles et al describes the role of p75, which is a constituent of the 
NgR complex, in Aβ mediated neuritic dystrophy507,508. This study determined that 
primary neuronal cultures obtained from p75 knockout transgenic mice, were protected 
against the deleterious effects of Aβ on neurite growth507. Similarly, transgenic knockout 
mice exhibited a significant reduction in neuritic dystrophy and a complete reversal of 
cholinergic neurite degeneration compared to wild type507. This evidence supports the 
role of p75, thus the NgR signalling complex in Aβ-mediated inhibition of neurite 
outgrowth.  
 
An interesting treatment approach has been developed based upon the finding of Aβ-NgR 
binding. This is explored in another study by Park et al that utilises subcutaneous delivery 
of NgR to improve spatial memory in a transgenic mouse model of AD509.  This is thought 
to improve the clinical symptoms of AD through both sequestering of Aβ and blocking the 
function of secretase enzymes involved in amyloidgenic processing, therefore 
overexpression of NgR has also been associated with a decreased production of Aβ 
species505,506. This highlights the necessity of understanding the molecular mechanisms 
that underpin such processes to identify potential therapeutic interventions aimed at 
restoring normal physiological functions. 
 
5.1.3.2.2 The Role of Rho A & ROCK Signaling in β-amyloid-mediated 
Neurite Inhibition 
 
The common neurite inhibitory signalling pathway, as discussed in Chapter IV in the 
context of spinal cord injury, involves receptor activation that leads to activation of Rho A 
and downstream ROCK that impacts the actin cytoskeleton resulting in growth cone 
collapse and neurite inhibition. This signalling pathway is also thought to mediate the 
inhibitory effects of Aβ, however whether it is initiated by NgR activation still remains 
unclear. Petratos et al describe the role of Rho A signalling in Aβ-mediated inhibition 
using a cell-based in vitro neurite outgrowth model36. Aβ induction of neurite inhibition 
was found to result in an increase in GTP-bound active Rho A and the selective ROCK 
inhibitor, Y-27632 was found to restore neurite outgrowth in the presence of Aβ40 to 
control levels36. 
 
However, this study also suggests that other mechanisms may be involved in Aβ-mediated 
inhibition, including microtubule involvement36. Collapsin response mediator protein-2 
(CRMP-2) phosphorylation is activated by ROCK and associated with inhibition of tubulin 
polymerisation and therefore microtubule elongation. Petratos et al also describe the 
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increased expression of CRMP-2 upon Aβ treatment in SH-SY5Y model neurons along with 
in vivo observations of increased CRMP-2 and GTP-Rho A in the region of amyloid 
deposits36. This suggests that Aβ induces inhibition of neurite outgrowth through multiple 
mechanisms including activation of Rho A leading to actin stabalisation and neurite 
retraction along with activation of CRMP-2 and inhibition of microtubule 
polymerisation510.    
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Fig 5-5: Proposed mechanism of Aβ-mediated neurite inhibition in Alzheimer’s disease. 
A schematic depicting the events that may lead to Aβ-induced inhibition of neurite outgrowth and decreased neuronal connectivity in AD. Aβ is known to bind to 
the NgR receptor, however, it is not known whether or not it activates the receptor. Rho A and ROCK activation have been implicated in the inhibition of neurite 
growth via Aβ as they have in many other inhibitory mechanisms. It is therefore hypothesised that Aβ acts through the NgR to activate Rho A and downstream 
ROCK which results in stabalisation of the actin cytoskeleton resulting in growth cone collapse and neurite retraction. Activation of ROCK is also thought to lead to 
phosphorylation of CRMP-2 that induces depolymerisation of microtubules and also contributes toward inhibition of neurite outgrowth. 
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5.1.4 iPSC Technology and Alzheimer’s Disease Modelling 
 
The underlying pathophysiological mechanisms that are involved in onset of AD and its 
clinical symptoms are extremely complex. The clinical manifestations of AD are thought to 
be driven by a number of interacting mechanisms including: abnormal protein 
homeostasis and accumulation, oxidative stress, mitochondrial dysfunction, inflammation, 
and loss of neuronal connectivity511–514. For this reason the development of accurate in 
vitro disease models is extremely challenging, as many factors should be considered in the 
development of such models.  
 
Advancements in induced pluripotent stem cell (iPSC) technology offer novel 
opportunities to study cellular responses and establish therapeutic strategies against 
complex, multi-faceted diseases such as AD. Takuya et al initially describe the isolation of 
AD-patient specific iPSCs along with their use in modelling neurodegeneration in 2011157. 
This study describes the isolation of fibroblasts from autosomal-dominant early-onset 
familial AD patients with mutations in PS1 (A246E) and PS2 (N141I) along with their 
subsequent reprogramming to form a population of disease-specific iPSCs157. The patient-
specific iPSCs were then induced to differentiate toward a neural lineage and the 
subsequent neurons were characterised as expressing a higher ratio of Aβ42:Aβ40 
representative of the diseased state157.  
 
Since the first isolation of AD-patient derived iPSCs by Takuya et al in 2011, many other 
groups have developed similar lines with APP236,237,515 and PS1 mutations235 along with 
lines from patients with sporadic forms of AD237,515. In depth characterisation of such cell 
lines has revealed that in vitro models can replicate the increased levels of Aβ42, 
hyperphosphorylated tau236 and oxidative stress237, associated with AD-progression. 
Applications of such unique models have also been demonstrated. For example Sproul et 
al used iPSC-derived neural progenitors from a patient with a mutation in PS1 to identify 
novel candidate genes that may be implicated in sporadic AD235.   
 
Patient specific in vitro models such as these offer novel systems to study the complex 
pathophysiological mechanisms that underpin neurodegenerative diseases, whilst also 
offering more a more physiologically relevant platform with which to screen potential 
drugs. This technology also has implications in terms of personalised medicine, as patient-
specific in vitro models can be developed for the purpose of drug screening, with better 
predicative value in order to determine if a specific treatment regime may be suitable on 
an individual basis.   
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5.1.5 Conclusions 
 
AD is the commonest form of dementia and is a growing burden associated with an ageing 
population. It is a complex, multi-faceted degenerative disease that results in a loss of 
neuronal connectivity associated with synaptic dysfunction and neurite inhibition. 
Accumulation of Aβ as extra-cellular senile plaques is a hallmark of AD that is associated 
with neurite dystrophy and growth cone collapse in vivo. Similarly, many studies have 
used in vitro cell-based models to dissect the molecular signalling involved in Aβ-
mediated neurite inhibition and have determined the involvement of Rho A, ROCK and 
CRMP-2 along with the actin and microtubule components of the cytoskeleton. Aβ-
mediated neurite inhibition in AD is thought to share similarities with neurite inhibition 
that occurs following SCI with the NgR receptor and its downstream signalling cascade 
being implicated in both pathologies.  
 
Understanding the molecular mechanisms that underpin Aβ-mediated inhibition may help 
elucidate potential therapeutic targets, therefore reliable in vitro neuronal models are 
essential to uncover the signalling pathways involved in such complex diseases. This 
chapter describes the application of a novel, 3D human-derived in vitro model of neurite 
outgrowth and its application to study the process of Aβ-mediated neurite inhibition 
along with methods of recovery through inhibition of Aβ-mediated signalling. This 
chapter also highlights the use of iPSC-based patient-derived models of neuritogenesis 
AD-specific neuritic abnormalities and signalling.  
 
 5.1.5.1 Chapter Aims 
 
This chapter aims to investigate the role of Aβ-mediated signalling in the process of 
neurite inhibition that occurs within AD, through the use of a novel 3D model of human 
neuritogenesis. Several different methodologies were applied to study this process 
including the use of synthetic Aβ-peptides to coat growth substrates or supplement 
culture medium along with AD-patient specific iPSC-derived neuroprogenitor cells. 
Furthermore, this chapter examines the role of the NgR along with downstream Rho A 
and ROCK in the inhibition of human model neurites along with the application of 
inhibitors of each of these molecules to the in vitro system with the aim of overcoming Aβ-
mediated inhibition. This demonstrates the ability of such in vitro models to be used as 
drug screening tools or to help identify modulators of specific signalling pathways to 
overcome the inhibitory properties of Aβ, along with the development of a patient-specific 
model that may have implications in the field of personalised medicine.  
 
We hypothesise that adding Aβ species to our current EC cell-based models (2D/3D) of 
neurite outgrowth will result in a reduction in neurite outgrowth, based upon evidence 
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described throughout the literature. We also hypothesise that inhibition of Rho A 
(ibuprofen) and inhibition of ROCK (Y-27632) will overcome Aβ-mediated inhibition, in a 
similar manner as CSPG-mediated inhibition discussed in Chapter IV. This hypothesis, 
again, is based upon evidence previously discussed in the primary literature that suggests 
Aβ-mediated inhibition is controlled through a RhoA/ROCK dependent mechanism. In this 
chapter, we will also discuss the ability of AD-model neurons to form neurites in a novel 
iPSC-based in vitro model, and we hypothesise that due to an increased ratio of Aβ42:Aβ40, 
their ability to form neurites will be reduced. 
 
 5.1.5.2 Chapter Objectives 
 
 Investigate the ability of substrate bound Aβ peptides to inhibit neurite 
outgrowth in human-derived neurons. 
 
 Investigate the ability of soluble Aβ peptides presented in culture medium to 
inhibit neurite outgrowth from human stem cell-derived neurons.  
 
 Characterise the effects of “ageing” Aβ peptides upon peptide aggregation.  
 
 Determine the effect of a variety of Aβ40:Aβ40 ratios upon neurite outgrowth in 2D 
culture. 
 
 Assess the ability of ROCK inhibition (Y-27632) in overcoming Aβ-mediated 
neurite inhibition in 2D and 3D culture. 
 
 Analyse the ability of Rho A inhibition by ibuprofen to overcome Aβ-mediated 
neurite inhibition in 2D and 3D culture. 
 
 Determine the role of NgR in Aβ signalling by the use of NEP 1-40 to potentially 
overcome Aβ-mediated neurite inhibition in 2D and 3D culture. 
 
 Investigate the ability of soluble Aβ to inhibit neurite outgrowth in WT iPSC-
derived neurons in 2D and 3D culture. 
 
 Characterise WT and AD-patient obtained iPSC-derived neuroprogenitor cells in 
2D culture. 
 
 Determine the ability of AD-patient derived neuroprogenitor cells to form 
neurites in 2D and 3D culture systems. 
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 Investigate the effect of Rho A (Y-27632) and ROCK (ibuprofen) inhibition upon 
AD-patient derived neurites.  
 
5.2 Materials & Methods 
 
 5.2.1 Ageing of β-amyloid Peptides 
 
A well-established technique of ageing β-amyloid peptides (Aβ40 and Aβ42) was employed 
to promote aggregation of the peptides, so that in culture they are presented to neurites 
as aggregated masses similar to the senile plaques of AD. Peptides were incubated at 37 °C 
for 24 hours to promote aggregation prior to use in a neurite outgrowth assay. 
 
 5.2.2 Protein Aggregation Assay 
 
The PROTEOSTAT® Protein Aggregation Assay (Enzo, Exeter, UK) was used to measure 
aggregation of β-amyloid peptides. Manufacturer’s instructions were followed; briefly, 
Aβ40 and Aβ42 peptides were diluted in their respective vehicles to a stock concentration 
of 50 μgmL-1. Proteostat detection solution was then prepared by adding 1.5 μL of 
detection reagent to 3 μL of 10 x assay buffer and 25.5 μL of DMSO to give a final volume 
of 30 μL. To each well of a black walled microtitre plate (ThermoFisher), 2 μL of 
protoestat detection solution was added, along with 98 μL of 50 μgmL-1 protein solution. 
The plate was then incubated at room temperature for 15 mins before being analysed 
using the Biotek Synergy H4 fluorescent plate reader with excitation of 550 nm and 
emission of 600 nm. 
 
5.2.3 Coating of Growth Substrates with β-amyloid Peptides for Neurite Outgrowth 
Studies 
 
Growth substrates were coated with Aβ peptides prior to seeding of neurospheres. 24 
hours preceding the end of differentiation of human pluripotent stem cell aggregates, 48-
well tissue culture plates were coated with poly-D-lysine and laminin coating solution 
containing Aβ peptides. Aβ40 and Aβ42 were reconstituted in their respective vehicles at a 
concentration of 1 mgmL-1 and the desired volume of peptide was added to 10 μgmL-1 
poly-D-lysine and laminin coating solution to achieve a final concentration of 0.05 – 50 
μgmL-1. For example, for a final concentration of 50 μgmL-1, 1 mL of 1 mgmL-1 Aβ stock 
solution would be added to 19 mL of 10 μgmL-1 poly-D-lysine and laminin coating 
solution. Aβ containing coating solution was then added at a volume of 150 μL per well to 
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a 48-well tissue culture plate and incubated overnight at room temperature before being 
washed twice in PBS prior to neurosphere seeding for neurite outgrowth. 
 
 5.2.4 Addition of Ratios of β-amyloid Peptides to Neurite Outgrowth Cultures 
 
To investigate the effect of varying ratios of Aβ42:Aβ40 on neurite outgrowth from stem cell 
derived neurospheres, both peptides were added to the culture medium for the duration 
of the neurite outgrowth period. The final concentration of both peptides remained 
constant at 1 μM, so that any effect observed was not that of varying total peptide 
concentration. The amount of Aβ40 and Aβ42 making up the final concentration of 1 μM 
changed relative to each other. Table 5–1 contains the volume of each peptide for the 
respective ratios of  Aβ42:Aβ40. 
 
Ratio of 
Aβ42:Aβ40 
Aβ42 
Concentration 
[μM] 
Aβ40 
Concentration 
[μM] 
1:10 0.1 0.9 
1:5 0.17 0.83 
1:1 0.5 0.5 
5:1 0.83 0.17 
10:1 0.9 0.1 
 
Table 5-1: Concentrations of Aβ Peptides per Aβ42:Aβ40 Ratio. 
Varying ratios of Aβ42 and Aβ40 were added to neurosphere culture medium for the 10-
day neurite outgrowth period, resulting in a total concentration of 1 μM. 
 
 5.2.5 Culture of Alzheimer’s Phenotype Cells 
 
ReproNeuro AD-mutation cells (ReproCELL) are neural progenitors derived from iPSCs 
transfected with a mutation in the presenilin 1 (PS1) gene. PS1 is one of the core proteins 
of the γ-secretase enzyme that is involved in amyloidgenic processing of APP and 
production of Aβ species. ReproNeuro AD-mutation cells have a mutation (P117L) in the 
PS1 gene and exhibit an increased ratio of Aβ42:Aβ40. 
 
ReproNeuro AD-Patient 1 cells (ReproCELL) are neural progenitors differentiated from 
iPSCs derived from a patient with AD. These cells have a mutation in the presenilin 2 
(PS2) gene (R62H), another of the core proteins that make up the γ-secretase enzyme and 
mutations in both PS1 and PS2 have been identified as pathogenic loci involved in early 
onset, autosomal dominant AD. 
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Both ReproNeuro AD-mutation and ReproNeuro AD-patient 1 cells were cultured as 2D 
monolayers and spheroids for use in 2D and 3D neurite outgrowth assays. They were 
cultured in the same manner as ReproNeuro cells described in section 2.2.10 Culture of 
ReproNeuro Cells, and ReproNeuro cells acted as a wild type control. 
 
5.3 Results 
 
5.3.1 The Role of β-amyloid peptides in Inhibition of Neurite Outgrowth 
 
To explore the ability of Aβ species to induce neurite inhibition in human pluripotent 
stem cell-derived model neurites, 2D growth substrates were coated with a range of 
concentrations (0.05 – 50 μgmL-1) of peptides (Aβ40, Aβ42, aged Aβ40 and aged Aβ42). 
Peptides were aged at 37 °C to promote their aggregation, and produce peptide 
aggregates similar to the hallmark senile plaques of AD36,40,516. Immunofluorescence 
images (Figure 5-6A) depict TUJ-1 positive (green) neurite outgrowth from neurospheres 
cultured on each of the Aβ coated substrates. Most notably perhaps, neurospheres 
cultured on 5 μgmL-1 Aβ40 (Figure 5-6Ac) appear to produce significantly shorter neurites 
than other conditions tested. Similarly, increasing the peptide concentration of the coating 
solution to 50 μgmL-1 Aβ40 (Figure 5-6Ad) resulted in neurite outgrowth appearing less 
uniform around the neurosphere. High concentrations (5 – 50 μgmL-1) of Aβ42 and aged 
Aβ40 coating also result in a reduction in neurite length. 
 
Quantification of the average number of neurites generated per neurosphere (Figure 5-
6B) revealed a dose dependent inhibition induced by all peptides tested.  Interestingly, 
Aβ42 induced inhibition to the greatest degree, followed by Aβ40, with the aged peptides 
having the least effect upon neurite outgrowth.  A similar trend is evident from 
quantification depicting the neurite density of the neurospheres (Figure 5-6C), as coatings 
containing all peptides tested resulted in a dose dependent inhibition in neurite growth. 
Again, Aβ42 induced neurite inhibition to the greatest degree, closely followed by Aβ40 and 
the aged peptides had the least effect upon neurite density.  
 
Generally neurite length (Figure 5-6D) was inhibited by all Aβ species with Aβ42 coating 
resulting in a large reduction in neurite length. The length of neurites generated from 
those neurospheres cultured on Aβ40 coated substrates appeared a lot more variable and 
whilst both aged peptides induced a clear inhibition of neurite length, their effect was not 
as significant as fresh Aβ42 coating. 
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Fig 5-6: Substrate bound β-
amyloid peptides are inhibitory 
to 2D neurite outgrowth. 
Representative confocal images of 
neurospheres cultured on 2D 
growth substrates coated with Aβ 
peptides (A). Neurites are 
highlighted in green, stained for the 
pan-neuronal marker TUJ-1 and 
nuclei are stained in blue. Scale 
bars: 200 μm. The number of 
neurites per neurosphere (B) (data 
represent mean ± SEM, n=8; 
neurite outgrowth from a total of 8 
neurospheres was quantified from 
3 independent replicates) and 
neurite density (C) (data represent 
mean ± SEM, n=8; neurite 
outgrowth from a total of 8 
neurospheres was quantified from 
3 independent replicates) both 
decline with Aβ concentration for 
all peptides tested, including 
peptides that were aged at 37 °C to 
promote aggregation. Neurite 
length (D) (data represent mean ± 
SEM, n=60; a total of 20 neurites 
were quantified from 1-2 
neurospheres per independent 
replicate, of which there were 3) is 
similarly inhibited with increasing 
Aβ concentration with Aβ40 and 
aged Aβ42 having the greatest 
inhibitory effect.  
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The effect upon neurite outgrowth of the soluble addition of Aβ species to the culture 
medium was also analysed by supplementing culture medium with 1 μM of each peptide 
(Aβ40, Aβ42, aged Aβ40 and aged Aβ42). Immunofluorescence images (Figure 5-7A) 
highlighting TUJ-1 positive (green) neurite outgrowth show that neurospheres cultured 
with exogenous Aβ species (Figure 5-7Ab-e) appear to generate less neurites than the 
vehicle matched control (Figure 5-7Aa). Particularly, Aβ40 treated neurospheres (Figure 5-
7Ab) appear to produce fewer neurites, whilst Aβ42 treated neurospheres (Figure 5-7Ac) 
appear to produce much shorter neurites than the control. Aged peptides (Figure 5-7Ad,e) 
appear to have less effect on neurite outgrowth than their fresh counterparts; however, 
neurite outgrowth surrounding aged Aβ40 treated neurospheres (Figure 5-7Ad) appears 
less uniform.   
 
The number of neurites per neurosphere (Figure 5-7B) is significantly inhibited by the 
addition of all Aβ species to the culture medium. However, Aβ40 was found to have the 
largest impact on neurite number, significantly reducing neurite number to a greater 
degree compared with Aβ42. Fresh Aβ42, along with both aged Aβ40 and aged Aβ42 were 
found to have a similar effect upon neurite number. A similar effect was observed when 
this was normalised to neurosphere size and expressed as neurite density (Figure 5-7C). 
All Aβ species were found to significantly reduce neurite density, with Aβ40 inducing 
neurite inhibition to the greatest degree. Aβ42 was found to not be as inhibitory as Aβ40 
when presented to cells as soluble mediators in the culture medium and both aged 
peptides had the least effect upon neurite density. 
 
Interestingly the action of Aβ species upon neurite length (Figure 5-7D) differs from that 
of both neurite number and density. Although all peptides were found to significantly 
inhibit neurite length, Aβ42 was actually found to induce inhibition to the greatest degree, 
unlike its effects upon neurite number and density. Aged Aβ40 had a similar effect upon 
neurite length as the fresh Aβ40 peptide and aged Aβ42 also had a similar effect to the fresh 
Aβ42 peptide and in both cases Aβ42 was found to significantly induce neurite inhibition to 
a greater degree than its Aβ40 counterpart. 
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Fig 5-7: Media soluble β-amyloid peptides are inhibitory to neurite outgrowth in 2D culture. 
Representative confocal images of neurospheres cultured in 2D in medium supplemented with 1 μM Aβ peptides (A). TUJ-1 (green) positive neurites can be 
seen extending from the central aggregate, where nuclei (blue) remain. Scale bars: 200 μm. Quantification of the number of neurites per neurosphere (B) (data 
represent mean ± SEM, n=9; 3 individual neurospheres were quantified from 3 independent replicates) and neurite density (C) (data represent mean ± SEM, 
n=9; 3 individual neurospheres were quantified from 3 independent replicates) are inhibited in the presence of all Aβ peptides, with Aβ40 having the greatest 
inhibitory effect. Similarly, all Aβ peptides were found to be inhibitory to neurite length (data represent mean ± SEM, n=23-104; between 23-104 neurites were 
measured from 3 neurospheres per independent replicate, of which there were 3), with the greatest inhibitory effect being observed with Aβ42 and aged Aβ42. 
One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Ageing Aβ peptides at 37 °C is a well-documented methodology to promote their 
aggregation36,40,516. This is often used to present the peptides to cells as protein 
aggregates, reminiscent of the peptide plaques that are a hallmark of AD. To characterise 
the effect of the ageing process upon the peptides, a protein aggregation assay (Figure 5-
8) was conducted to measure the level of peptide aggregation in both fresh and aged 
peptides. The basis of this assay was to fluorescently label protein aggregates, therefore 
net fluorescence intensity correlates with protein aggregation517–519. Little aggregation 
was observed in both fresh and aged Aβ40 samples, whilst aggregation noted in Aβ42 
samples exceeds that of the positive control and assay limits. Although both aged Aβ42 and 
fresh Aβ42 peptides exhibited large amounts of peptide aggregation, ageing of the peptide 
at 37 °C did enhance this process, albeit not statistically significantly. 
 
 
 
Fig 5-8: Characterisation of the ability of 37 °C incubation to promote Aβ 
aggregation. 
The PROTEOSTAT® protein aggregation assay was used to characterise the effects of a 
well-established “ageing” procedure used to promote peptide aggregation. Aβ peptides 
were incubated at 37 °C to promote aggregation for 24 hours and then analysed using the 
PROTEOSTAT® assay, which detects peptide aggregation as fluorescent signal. Net 
fluorescence intensity is a measure of peptide aggregation, and very little aggregation was 
observed in Aβ40 samples. A large amount of aggregation was observed in the longer, 
more insoluble, Aβ42 peptide and which was enhanced by the “ageing” procedure (data 
represent mean ± SEM, n=3, repeated 3 times with different samples of peptide).  
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To better recreate physiological conditions, several Aβ42:Aβ40 ratios were tested (Figure 
5-9), as a defining characteristic of AD is an increase in the ratio of Aβ42 to Aβ40438,444. A 
range of ratios were tested including those high in Aβ40 (1:10) and those high in Aβ42 
(10:1) with 1:10 simulating the Aβ mix of healthy brain426 and Aβ peptides were added to 
the culture medium of 2D models at a concentration of 1 μM. 
 
Neurite outgrowth visible from neurospheres via immunofluorescence analysis (Figure 5-
9A) appears to be reduced in those cultures treated with ratios higher in Aβ42 than Aβ40 
(Figure 5-9Ak-n) with Aβ42 supplementation alone (Figure 5-9Ao,p) resulting in sparse 
neurite outgrowth and neurites that appear extremely short. All peptides tested appear to 
reduce neurite outgrowth compared with the control (Figure 5-9Aa,b), however those 
treated with higher ratios of Aβ42 appear to generate the least neurites.  
 
Supplementation of the culture medium with all peptide mixes tested resulted in a 
significant reduction in the number of neurites generated per neurosphere (Figure 5-9B), 
with variable results between the ratios tested. There was not a clear relationship 
between neurite number and Aβ42 content of the peptide mixes tested, although, all Aβ 
conditions were inhibitory. A similar result was obtained in terms of neurite density 
(Figure 5-9C), as all peptide mixes induced a significant reduction in the density of neurite 
outgrowth. However, no clear relationship between the Aβ42 content of the culture 
medium and inhibition of neurite density was identified.  
 
Medium supplementation with all peptide mixes resulted in a significant reduction in 
neurite length (Figure 5-9C), with the exception of Aβ40 supplementation alone, which 
resulted in a slight, insignificant increase in neurite length compared with the control. All 
ratios of peptides tested resulted in a significant reduction in neurite length, however 
ratios higher in Aβ42 inhibited neurite length to the greatest degree and were even found 
to be more inhibitory than Aβ42 treatment alone.  
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Fig 5-9: Ratio of Aβ40 to Aβ42 in culture medium impacts neurite outgrowth in 2D culture. 
Representative confocal images of neurospheres cultured in 2D (A) in media supplemented with Aβ40 and Aβ42 at varying ratios making up a total concentration of 1 μM. Neurites are 
highlighted by positive TUJ-1 (green) staining and Hoechst stains nuclei blue. Scale bars: (Aa,c,e,g,i,k,m,o): 200 μm (Ab,d,f,h,j,l,n,p): 50 μm. The number of neurites per neurosphere (B) 
(data represent mean ± SEM, n=18-32; 6-11 individual neurospheres were quantified from 3 independent replicates) and the average neurite density of the neurospheres (C) (data 
represent mean ± SEM, n=18-32; 6-11 individual neurospheres were quantified from 3 independent replicates) both are significantly inhibited with the addition of all Aβ conditions. The 
average length of neurites (D) (data represent mean ± SEM, n=369-615; between 369-615 neurites were measured from 6-11 neurospheres per independent replicate, of which there 
were 3) is significantly decreased with the addition of increased Aβ42:Aβ40 (5:1, 10:1), a phenotype of Alzheimer’s disease.  One-way ANOVA with Tukey’s multiple comparisons: * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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5.3.2 Modulation of the Rho A/ROCK Pathway to overcome β-amyloid Mediated Neurite 
Inhibition 
 
Activation of the Rho A/ROCK signalling cascade is thought to be responsible for the 
effects mediated by Aβ upon neurite growth510. For this reason the ROCK inhibitor Y-
27632 and ibuprofen an inhibitor of Rho A, were both added to the culture medium of 2D 
and 3D neurite outgrowth assays with the aim of providing recovery from the Aβ-
mediated effects upon neurite growth.  
 
  5.3.2.1 Inhibition of ROCK by Y-27632 
 
The culture medium of 2D neurite outgrowth models was supplemented with Aβ40 to 
induce neurite inhibition or Aβ40 in combination with 10 μM Y-27632 to potentially 
restore neurite growth in the presence of inhibitory Aβ species. Extensive neurite growth 
can be seen to radiate from vehicle treated neurospheres (Figure 5-10Aa,b), whereas 
fewer TUJ-1 positive projections visibly extend from neurospheres treated with 1 μM Aβ40 
(Figure 5-10Ac,d). Neurospheres cultured in medium supplemented with both 1 μM Aβ40 
and 10 μM Y-27632 (Figure 5-10Ae,f) appear to generate a large number of densely 
packed neurites that perhaps seem a little short compared with the control neurites. 
 
Treatment with Aβ40 alone resulted in a significant inhibition in the average number of 
neurites (Figure 5-10B) generated by each neurosphere. The addition of Y-27632 to the 
culture medium, however did not just result in a recovery of neurite number, but 
significantly enhanced the number of neurites generated by each neurosphere even 
compared with control cultures. This was supported by quantification of neurite density 
(Figure 5-10C) that also revealed a significant inhibition in neurite growth when 
neurospheres were treated with Aβ40 and significant enhancement of neurite density with 
Y-27632 supplementation.  
 
No significant inhibition in neurite length (Figure 5-10D) was detectable with Aβ40 
treatment alone, however combination treatment with Aβ40 and Y-27632 resulted in a 
significant reduction in neurite length compared with both control and Aβ40 treated 
neurites. This effect is similar to Y-27632 treatment in the absence of an inhibitory 
stimulus as described in Chapter III.  
 
In 3D culture, neurospheres remained on top of the scaffold (Figure 5-11Aa,c,e) whereas 
TUJ-1 positive (green) neurites can be visualised from the bottom view of the scaffold 
(Figure 5-11Ab,d,f) having penetrated the entire 200 μm depth of the 3D material. 
Extensive neurite outgrowth can be seen from the underside of control scaffolds (Figure 
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5-11Ab), whereas, significantly fewer neurites can be seen to have penetrated the scaffold 
with Aβ40 treatment (Figure 5-11Ad). Combination treatment with Y-27632 and Aβ40 
resulted in a large number of neurites visible from the bottom of the scaffold (Figure 5-
11Af), which actually appears greater that the neurite outgrowth visible from control 
cultures.  
 
Quantification of neurite penetration (Figure 5-11B) confirms this, as neurite penetration 
is significantly reduced with Aβ40 treatment alone, in comparison to control cultures. 
Treatment with both Aβ40 and Y-27632 resulted in a significant increase in neurite 
penetration compared with both control cultures and Aβ40 supplementation alone. This 
supports the 2D culture findings that Y-27632 treatment not only recovers Aβ40-mediated 
inhibition of neurite growth, but also enhances neurite outgrowth to levels that are 
greater than the control. 
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Fig 5-10: Inhibition of ROCK by the small 
molecule inhibitor, Y-27632, can recover Aβ 
mediated inhibition of neurite outgrowth in 
2D culture. 
Representative confocal images of neurospheres 
cultured in 2D (A) without medium 
supplementation (Aa,b), with the addition of  1 μM 
Aβ40 (Ac,d) and with the addition of  1 μM Aβ40 
and 15 μM Y-27632 (Ae,f). TUJ-1 (green) positive 
neurites extend from the central neurosphere 
where nuclei (blue) remain. Scale bars: Aa,c,e: 200 
μm Ab,d: 50 μm. Quantification of the number of 
neurites per neurosphere (B) (data represent 
mean ± SEM, n=9-18; 3-6 individual neurospheres 
were quantified from 3 independent replicates.) 
show neurite inhibition in the presence of  Aβ40 
alone and with the addition of Y-27632 the 
number of neurites is enhanced, even surpassing 
that of the control. A similar response is observed 
with neurite density (C) (data represent mean ± 
SEM, n=9-18; 3-6 individual neurospheres were 
quantified from 3 independent replicates) with Y-
27632 not only recovering neurite density, but 
enhancing it to levels greater than the control. 
Neurite length however (D) (data represent mean 
± SEM, n=200-605; between 200-605 neurites 
were measured from 3-6 neurospheres per 
independent replicate, of which there were 3) is 
not found to be significantly inhibited with the 
addition of Aβ40, however, when Y-27632 is added 
to the culture, neurite length is significantly 
reduced. One-way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001. 
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Fig 5-11: Inhibition of ROCK by the small molecule inhibitor, Y-27632, can recover Aβ mediated neurite inhibition in 3D culture. 
Representative confocal images of neurospheres on top of Alvetex® scaffold (Aa,c,e) and TUJ-1 (green) positive neurites penetrating the depth of the 3D material, as 
visible from below (Ab,d,f) with nuclei being highlighted in blue. Neurospheres were cultured without medium supplementation (Aa,b), with the addition of 1 μM 
Aβ40 to the culture medium (Ac,d) or with the addition of 1 μM Aβ40 and 15 μM Y-27632 (Ae,f) to the culture medium. Scale bars: 200 μm. The number of neurites 
penetrating the 3D material (B) (data represent mean ± SEM, n=5-16; between 2-5 neurospheres were quantified per independent replicate, of which there were 3) 
is significantly inhibited by the addition of Aβ40 to the culture medium and this effect is not only recovered by Y-27632, but neurite outgrowth is enhanced to levels 
greater than the control. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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  5.3.2.2 Inhibition of Rho A by Ibuprofen 
 
To investigate the role of Rho A in Aβ-mediated inhibition of neurite outgrowth, 
neurosphere cultures were supplemented with Aβ40 in combination with a range of 
concentrations of ibuprofen (10 – 500 μM). Neurite outgrowth can be seen to radiate from 
neurospheres cultured in 2D (Figure 5-12A) with significant neurite outgrowth visible 
from neurospheres cultured without Aβ40 medium supplementation (Figure 5-12Aa,b). 
The addition of 1 μM Aβ40 to the culture medium resulted in neurite outgrowth appearing 
less dense around the neurosphere (Figure 5-12Ac,d). Ibuprofen supplementation in 
addition to Aβ40 treatment resulted in densely packed neurites more reminiscent of the 
control, with high concentrations of ibuprofen such as 100 μM (Figure 5-12Ag,h) and 500 
μM (Figure 5-12Ai,j) resulting in extremely dense neurite outgrowth.  
 
The average number of neurites (Figure 5-12B) generated per neurosphere was 
significantly inhibited by the addition of Aβ40 to the culture medium. This inhibitory effect 
was rescued in a dose dependent manner with increasing ibuprofen concentration. High 
concentrations of ibuprofen including 100 μM and 500 μM also resulted in a significant 
increase in the number of neurites generated per neurosphere compared with the control. 
Similarly to neurite number, neurite density (Figure 5-12C) is also inhibited by Aβ40 
supplementation and rescued in a dose dependent manner with increasing ibuprofen 
concentration. Treatment with 100 μM ibuprofen in addition to Aβ40 resulted in a similar 
neurite density as the control, however treatment with 500 μM ibuprofen resulted in a 
significant increase in neurite density, enhancing neurite outgrowth compared with 
control cultures. 
 
Addition of Aβ40 to the culture medium of 2D neurite outgrowth cultures resulted in a 
significant inhibition in neurite length (Figure 5-12D). This reduction in length was 
rescued by 10 μM ibuprofen treatment, restoring neurite length to a similar level as the 
control. Treatment with 100 μM ibuprofen also rescued Aβ40-induced inhibition of neurite 
length and resulted in a slight increase in neurite length compared with 10 μM ibuprofen 
treatment. However, 500 μM ibuprofen treatment resulted in a significant reduction in 
neurite length compared with 100 μM. This ibuprofen-induced reduction in neurite length 
has also been noted in the absence of an inhibitory stimulus, as described in Chapter III. 
 
In 3D culture, neurospheres remain on top of the scaffold (Figure 5-13Aa,c,e,g,i) whereas 
TUJ-1 positive (green) neurites can be seen from the bottom view of the scaffold (Figure 
5-13Ab,d,f,h,j) having penetrated the entire depth of the 3D material. Significant neurite 
outgrowth can be observed on the underside of control scaffolds cultured without 
medium supplementation (Figure 5-13Ab), whereas fewer neurites have visibly 
penetrated the scaffold in cultures treated with Aβ40 (Figure 5-13Ad). Few neurites are 
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visible on the underside of scaffolds treated with Aβ40 and 10 μM ibuprofen (Figure 5-
13Af), however 100 – 500 μM ibuprofen treated cultures (Figure 5-13Ah,j) appear to have 
generated a similar number of neurites as control cultures. 
 
Significantly fewer neurites penetrated the scaffold (Figure 5-13B) with Aβ40 medium 
supplementation compared with control cultures. Treatment of cultures with 10 – 100 μM 
ibuprofen resulted in a slight increase in neurite penetration, however, treatment with 
500 μM ibuprofen resulted in a significant increase in neurite outgrowth, restoring 
neurite growth to a level similar to that of the control. 
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Fig 5-12: Recovery of Aβ mediated neurite 
inhibition in 2D culture by ibuprofen, an 
inhibitor of Rho A. 
Representative confocal images of 
neurospheres (A) cultured without Aβ40 (Aa,b) 
with the addition of 1 μM Aβ40 to the culture 
medium and the addition of varying 
concentrations (0 – 500 μM) of ibuprofen (Ac-
j). Neurites are TUJ-1 positive and highlighted 
in green with nuclei stained blue and restricted 
to the cell aggregate body. Scale bars: 
(Aa,c,e,g,i): 200 μm (Ab,d,f,h,j): 50 μm. Both the 
number of neurites per neurosphere (B) (data 
represent mean ± SEM, n=9-27; 3-9 individual 
neurospheres were quantified from 3 
independent replicates) and neurite density 
(C) (data represent mean ± SEM, n=9-27; 3-9 
individual neurospheres were quantified from 
3 independent replicates) are significantly 
inhibited in the presence of Aβ40, this 
inhibitory effect is rescued in a dose dependent 
manner with increasing ibuprofen 
concentration.  Similarly, neurite length (D) 
(data represent mean ± SEM, n=232-938; 
between 232-938 neurites were measured 
from 3-9 neurospheres per independent 
replicate, of which there were 3) is inhibited 
with the addition of Aβ40 and subsequently 
rescued by supplementation with ibuprofen in 
a dose dependent manner until 500 μM 
ibuprofen is reached and the effect is lost. One-
way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001, **** = p < 0.0001. 
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Fig 5-13: Recovery of Aβ mediated neurite inhibition in 3D culture by ibuprofen, an inhibitor of Rho A. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold (Aa,c,e,g,i) with TUJ-1 (green) positive neurites penetrating the depth of 
the 3D material and are visible from below the scaffold (Ab,d,f,h,j). Nuclei are highlighted in blue. Neurospheres were cultured without media supplementation 
(Aa,b) or with the addition of 1 μM Aβ40 in combination with varying concentrations (0 – 500 μM) of ibuprofen (Ac-j). Scale bars: 200 μm. Quantification of the 
number of neurites penetrating each scaffold (B) (data represent mean ± SEM, n=8-9; between 2-3 neurospheres were quantified per independent replicate, of 
which there were 3) demonstrates significant inhibition with the addition of Aβ40 to the culture medium, an effect that is rescued in a dose dependent manner with 
addition of the drug ibuprofen. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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5.3.3 Investigation into the Role of the Nogo Receptor in β-amyloid Mediated Inhibition 
of Neurite Outgrowth 
 
A number of studies have identified the ability of Aβ to structurally interact with the Nogo 
receptor (NgR), however it is not yet known if Aβ actually activates the receptor504–506. 
Activation of NgR in the glial scar results in the activation of Rho A and ROCK, ultimately 
leading to actin filament stabalisation and neurite retraction324,368,400. The evidence 
previously described in this chapter suggests that both activation of Rho A and ROCK are 
involved in Aβ-mediated neurite inhibition, therefore, it can be hypothesised that 
activation of the signalling pathway may be induced by NgR-Aβ binding and subsequent 
activation of the receptor. To test this hypothesis an NgR antagonist (NEP 1-40) was 
added to both 2D and 3D neurite outgrowth culture systems to determine the ability of 
NgR antagonism to recover the neurite inhibitory effects of Aβ.    
 
Neurospheres cultured in 2D conditions without Aβ supplementation (Figure 5-14Aa,b) 
generate a significant quantity of TUJ-1 positive (green) neurites that radiate from the 
central neurosphere. The number of neurites generated by neurospheres cultured with 1 
μM Aβ40 medium supplementation (Figure 5-14Ac,d), appears to be reduced in 
comparison to untreated neurospheres. Aβ treated neurospheres appear to generate 
fewer, shorter neurites than their untreated counterparts. Supplementation of the culture 
medium with 1 μM NEP 1-40 in addition to 1 μM Aβ40 (Figure 5-14Ae,f) resulted in 
significant neurite outgrowth, with a large number of TUJ-1 positive (green) neurites 
extending from the central neurosphere in a similar manner to untreated neurospheres. 
 
The average number of neurites per neurosphere (Figure 5-14B) is significantly inhibited 
by the addition of Aβ40 to the culture medium. Supplementation of medium with Aβ40 and 
NEP 1-40, resulted in a significant enhancement in neurite number compared with Aβ40 
treatment alone. However the number of neurites generated from Aβ40 and NEP 1-40 
treated neurospheres was still significantly reduced in comparison to control 
neurospheres. This is partial recovery of neurite outgrowth by NEP 1-40 treatment is 
further supported by quantification of neurite density (Figure 5-14C). Neurite density is 
significantly inhibited by Aβ40 treatment, and significantly enhanced by NEP 1-40 
treatment in comparison to Aβ40 alone. However, again Aβ40 and NEP 1-40 treatment still 
results in a significantly reduced neurite density compared with control neurospheres.  
 
Similarly to the other aspects of neurite outgrowth measured, neurite length (Figure 5-
14D) is also significantly inhibited by the presence of Aβ40. However, interestingly NEP 1-
40 supplementation actually enhanced the inhibitory effects of Aβ40, resulting in further 
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inhibition of neurite length that was statistically significant compared with both control 
and Aβ40-alone treated neurospheres.  
 
In 3D culture, neurospheres are situated on top of the scaffold (Figure 5-15Aa,c,e), 
whereas neurites are visible from the bottom view (Figure 5-15Ab,d,f) of the scaffold, 
having completely penetrated and exited the 3D material. Extensive neurite outgrowth 
can be observed from the underside of scaffolds cultured without medium 
supplementation (Figure 5-15Ab), whereas few TUJ-1 positive (green) projections are 
visible from Aβ40 treated cultures (Figure 5-15Ad). Treatment with both Aβ40 and NEP 1-
40 (Figure 5-15Af) resulted in a significant number of neurites visible from the underside 
of the scaffold, similar in number to control cultures. Significantly fewer neurites 
penetrated the scaffold (Figure 5-15B) and were found to exit the scaffold in Aβ40 treated 
cultures. Although, NEP 1-40 treatment resulted in a slight increase in neurite 
penetration, this value did not differ significantly from either control of Aβ40 treated 
cultures.  
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Fig 5-14: Partial recovery of Aβ 
mediated neurite inhibition in 2D 
culture by NEP 1-40, a Nogo receptor 
antagonist. 
Representative confocal images (A) of 
neurospheres cultured in 2D without Aβ40 
(Aa,b) with the addition of 1 μM Aβ40 alone 
(Ac,d) or in combination with 1 μM NEP 
(Ae,f) to the culture medium. Neurite 
outgrowth is highlighted in green by 
staining for the pan-neuronal marker TUJ-
1 and nuclei are stained blue. Scale bars: 
200 μm. Quantification of number of 
neurites per neurospheres (B) (data 
represent mean ± SEM, n=15-18; 5-9 
individual neurospheres were quantified 
from 3 independent replicates) and 
neurite density (C) (data represent mean ± 
SEM, n=15-18; 5-9 individual 
neurospheres were quantified from 3 
independent replicates) demonstrate the 
ability of Aβ40 to inhibit neurite outgrowth. 
The Nogo receptor antagonist peptide, 
NEP 1-40, is able to partially overcome 
Aβ40 mediated inhibition, however, NEP 
does not recover neurite outgrowth to 
control levels. Neurite length (D) (data 
represent mean ± SEM, n=213-653; 
between 213-653 neurites were measured 
from 5-9 neurospheres per independent 
replicate, of which there were 3), however, 
is inhibited by the presence of Aβ40 and 
NEP. One-way ANOVA with Tukey’s 
multiple comparisons: * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 5-15: Partial recovery of Aβ mediated neurite inhibition by NEP 1-40, a Nogo receptor antagonist, in 3D culture. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold (Aa,c,e) with TUJ-1 (green) positive neurites penetrating the depth of the 
scaffold and are visible from below the scaffold (Ab,d,f). Nuclei are highlighted in blue. Neurospheres were cultured without supplementation (Aa,b) or with the 
addition of 1 μM Aβ40 alone (Ac,d) or in combination with 1 μM NEP (Ae,f) to the culture medium. Scale bars: (Aa,c,e): 200 μm (Ab,d,f): 50 μm. Quantification of the 
number of neurites penetrating the 3D material (B) (data represent mean ± SEM, n=4-6; between 1-2 neurospheres were quantified per independent replicate, of 
which there were 3) reveals that Aβ40 significantly inhibits the number of neurites penetrating the material and NEP partially restores this, however not to the 
same levels as the control. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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5.3.4 Investigation the Inhibitory Effects of Exogenous β-amyloid in an iPSC-based Model 
of Neurite Outgrowth  
 
To further investigate the role of Aβ in neurite inhibition, the iPSC ReproNeuro model 
system was also applied to examine the ability of exogenous addition of Aβ to inhibit 
neurite outgrowth. Conducting the same experiments in another model system helps to 
confirm the previous findings and provide robust and reproducible data. 
 
ReproNeuro-derived neurospheres were cultured in 2D without treatment (Figure 5-
16Aa,b) with 1 μM Aβ40 alone (Figure 5-15Ac,d), or in combination with 10 μM Y-27632 
(Figure 5-15Ae,f) or 100 μM ibuprofen (Figure 5-15Ag,h). Neurite outgrowth from Aβ40-
treated neurospheres appears less dense and less consistent compared with untreated 
neurite outgrowth. Treatment with Y-27632 in addition to Aβ40 results in significant 
neurite generation with neurite growth appearing more dense that in control cultures. 
Similarly, neurospheres treated with Aβ40 in combination with ibuprofen also appear to 
generate a large number of neurites comparable to control cultures. 
 
Although the number of neurites generated per neurosphere (Figure 5-16B) was reduced 
by Aβ40 treatment, this inhibition was not statistically significant. Both Y-27632 and 
ibuprofen treatment resulted in a significant enhancement in neurite number compared 
with Aβ40 treatment alone, and even resulted in the production of a greater number of 
neurites compared with control cultures. However, when this was normalised to 
neurosphere size and expressed as neurite density (Figure 5-16C), the inhibitory action of 
Aβ40 became statistically significant. Both Y-27632 and ibuprofen treatment significantly 
enhanced neurite density compared with Aβ40 treatment alone, restoring neurite density 
to a similar, slightly enhanced level compared with the control.  
 
Neurite length (Figure 5-16D) was significantly inhibited by Aβ40 treatment in comparison 
to the vehicle treated control. This inhibition of neurite length was successfully recovered 
by Y-27632 treatment, which resulted in a significant enhancement in neurite length 
compared with Aβ40 treatment alone. However, ibuprofen treatment resulted in a further 
significant inhibition in neurite length compared with all conditions tested. 
 
ReproNeuro-derived neurospheres cultured in 3D remained on top of the scaffold (Figure 
5-17Aa,c,e,g), with penetration of neurites visible from the bottom view of the scaffold 
(Figure 5-17Ab,d,f,h). Vehicle treated control neurospheres (Figure 5-17Aa,b) resulted in 
complete penetration of the 3D material with a large number of neurites can visible from 
the bottom of the scaffold. Treatment with Aβ40 (Figure 5-17Ac,d) however, resulted in 
few visible neurites radiating from the neurosphere on top of the scaffold, and no neurites 
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had visibly penetrated the depth of the scaffold itself.  Treatment with Y-27632 in 
addition to Aβ40 (Figure 5-17Ae,f) resulted in restoration of neurite outgrowth from the 
neurosphere situated on top of the scaffold, and few neurites had visibly penetrated the 
scaffold, however this neurite growth was still reduced in comparison to the control. 
Treatment with ibuprofen and Aβ40 (Figure 5-17Ag,h), resulted in penetration of neurites 
as visible from the bottom view of the scaffold. All test conditions induced a significant 
inhibition in the number of neurites that penetrated the scaffold (Figure 5-17B), with Y-
27632 and ibuprofen treatment only partially enhancing neurite penetration compared 
with Aβ40 alone.   
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Fig 5-16: Exogenous addition of Aβ40 is 
inhibitory to neurite outgrowth from 
iPSC-derived neurospheres in 2D 
culture. 
Representative confocal images (A) of 
ReproNeuro derived neurospheres 
cultured in 2D (Aa,b) with the addition of 
1 μM Aβ40 to the culture medium (Ac,d) 
and with further supplementation of Y-
27632 (Ae,f) and ibuprofen (Ag,h). Scale 
bars: 100 μm. Neurite outgrowth is 
highlighted by staining for the pan-
neuronal marker TUJ-1 (green) and 
nuclei are stained in blue. Quantification 
of the number of neurites per 
neurosphere (B) (data represent mean ± 
SEM, n=3-9; 1-3 individual neurospheres 
were quantified from 3 independent 
replicates) and neurite density (C) (data 
represent mean ± SEM, n=3-9; 1-3 
individual neurospheres were quantified 
from 3 independent replicates) reveal 
that addition of Aβ40 to the culture 
medium is inhibitory to neurite 
outgrowth and both Y-27632 and 
ibuprofen can overcome this inhibition 
to control levels. Neurite length (D) (data 
represent mean ± SEM, n=57-213; 
between 57-213 neurites were measured 
from 1-3 neurospheres per independent 
replicate, of which there were 3) is 
inhibited with Aβ40 supplementation and 
restored to normal levels by Y-27632 
however, not by ibuprofen. One-way 
ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001. 
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Fig 5-17: Exogenous addition of Aβ40 is inhibitory to neurite outgrowth from iPSC-derived neurospheres in 3D culture. 
Representative confocal images (A) of ReproNeuro derived neurospheres cultured in 3D (Aa,b) with the addition of 1 μM Aβ40 to the culture medium (Ac,d) and 
with further supplementation of Y-27632 (Ae,f) and ibuprofen (Ag,h). Neurospheres remain on top of the scaffold (Aa,c,e,g) whilst TUJ-1 (green) positive neurites 
penetrate the depth of the scaffold, as visible from the bottom view of the scaffold (Ab,d,f,h). Nuclei are stained blue. Scale bars: 100 μm. Quantification of the 
number of neurites penetrating the 3D material (B) (data represent mean ± SEM, n=3; due to limited cell availability 3 neurospheres from 1 population of cells were 
quantified) demonstrates the ability of Aβ40 to induce neurite inhibition in a 3D environment, with partial recovery induced by Y-27632 and ibuprofen. One-way 
ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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5.3.5 Investigation into the Neurite Outgrowth Properties of Alzheimer’s Disease 
Phenotype Cells  
 
Alzheimer’s disease model neuroprogenitor cells are available from the ReproNeuro 
range, and produce an increased ratio of Aβ42:Aβ40 consistent with pathological 
abnormalities found within the brain of Alzheimer’s disease patients212. There are two 
types of AD phenotype cells, the first of which is termed AD-patient 1, and is derived from 
an iPSC line established from an AD patient. This cell line contains a mutation (R62H) in 
presenilin 2 (PS2) a component of the γ-secretase complex that is involved in APP 
processing and Aβ species generation212. The second AD-model cell type is known as AD-
mutation and involved the derivation of an iPSC line from a healthy individual which was 
then transfected with a known AD-associated mutation (P117L) of presenilin 1 (PS1), 
another component of the γ-secretase complex212. A schematic depicting the derivation of 
each AD-phenotype ReproNeuro cell type is outlined in Figure 5-18. 
 
 
 
Fig 5-18: Schematic depicting the origin of each ReproNeuro AD-phenotype cell line.  
ReproNeuro cells act as the wild type control for each AD-phenotype cell line and are 
derived from a healthy individual. ReproNeuro AD-patient 1 are derived from somatic 
cells from an AD patient with a mutation in PS2 (R62H), reprogrammed into iPSCs and 
subsequently differentiated to generate disease-specific neuroprogenitor cells. 
ReproNeuro AD-mutation cells were formed from an iPSC line derived from a healthy 
individual and subsequently transfected with a mutation in PS1 (P117L) and 
differentiated into neuroprogenitor cells that express a higher ratio of Aβ42:Aβ40. 
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Initially, to characterise the growth of each ReproNeuro cell type, cells were cultured as 
2D monolayers as per the manufacturer’s instructions. Phase contrast images (Figure 5-
19A-C) reveal that a significant number of cells in wild type cultures have not adhered to 
the growth substrate (Figure 5-19A), this could be due to a loss of viability upon cellular 
revival from cryopreservation. Patient-derived cells appear from phase contrast analysis 
(Figure 5-19B) to contain a mixed population of different cell types with most cells 
appearing to adopt a large, flattened glial-like morphology. Monolayer culture of the 
mutation cell line, however, resulted in the formation of a vast neuronal network with an 
array of projections and connections (Figure 5-19C).  
 
Immunofluorescence analysis of these cultures, highlighting expression of the pan-
neuronal marker TUJ-1 (green) revealed that wild type cultures generated few neurites 
(Figure 5-19D). Although patient cultures (Figure 5-19E) also resulted in the formation of 
a small number of neurites, cultures also contained a large number of other cell types 
appearing with varied morphology, suggesting that cultures are not pure. As observed via 
phase contrast microscopy, immunofluorescence staining of mutation monolayers (Figure 
5-19F) reveals a large number of TUJ-1 positive processes that interconnect forming a 
large neuronal network.   
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Fig 5-19: Neurite outgrowth from 2D monolayers of iPSC derived, Alzheimer’s disease phenotype cells. 
Representative phase contrast images (A-C) of ReproNeuro, iPSC derived neuroprogenitor cells, cultured for 14 days on ECM coated glass coverslips. ReproNeuro (A,D) 
cells are the isogenic control for the two Alzheimer’s phenotype cell types (B-F). ReproNeuro AD-Patient 1 (B,E) are neuroprogenitor cells derived from iPSCs from an 
Alzheimer’s disease patient with a mutation in presenilin 2. ReproNeuro AD-Mutation (C,F) are iPSC derived neuroprogenitor cells, transfected with a mutation in 
presenilin 1. Presinilin is a subunit of the γ-secretase enzyme involved in the amyloidgenic processing and generation of Aβ. Representative confocal images (D-F) of 
TUJ-1 (green) positive neurons in 14-day-old cultures of ReproNeuro cells. Nuclei are highlighted in blue. Scale bars: (A-C): 100 μm (D-F): 50 μm. Patient derived cells 
appear to be a more heterogeneous mix of cell types than the other two cellular populations, as under both phase contrast and immunofluorescence, larger cells are 
clearly visible in addition to neurons. A significant number of neurons and neuritic extensions are visible in mutation cultures with the formation of complex neuronal 
networks. 
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Each ReproNeuro cell type was then cultured as neurospheres in 2D to analyse the radial 
extension of neurites from the central cellular mass. Neurites from each cell type were 
visible under phase contrast (Figure 5-20Aa,c,e), however, similar to monolayer cultures, 
patient-derived neurospheres do not appear to contain a pure population of 
neuroprogenitor cells. Patient-derived neurospheres (Figure 5-20Ac), extend not only 
neurites, but cell bodies with varied morphology, from the central cellular mass.  
 
Immunofluorescence staining (Figure 5-20Ab,d,f) highlighting TUJ-1 (green) positive 
neurite outgrowth, revealed significant neurite extension from wild type neurospheres 
(Figure 5-20Ab). Patient-derived neurospheres (Figure 5-20Ad), on the other hand, not 
only generate a significant number of neurites, but a mixture of cell types can be observed 
with TUJ-1 positive cell bodies appearing to migrate outward from the neurosphere. 
Mutation-derived neurospheres (Figure 5-20Af) produce significant neurite outgrowth 
with little evidence of cellular migration; however, neurite outgrowth around the 
perimeter of the neurosphere appears less consistent than wild type neurite outgrowth.  
 
Both the number of neurites per neurosphere (Figure 5-20B) and neurite density (Figure 
5-20C) reveal a similar trend in that both variables are significantly inhibited in patient 
and mutation cells. Neurite outgrowth was significantly inhibited in the patient-derived 
cell line compared with mutation and wild type cells. Neurite length (Figure 5-20D), 
however, exhibits a different correlation with cell type. Both patient and mutation cells 
produce significantly shorter neurites than wild type cells, with patient-derived cells 
producing the longest neurites. A similar correlation was observed in quantification of 
cellular migration (Figure 5-20E), as a large number of nuclei were found to lie outside of 
the cellular aggregate in patient-derived cultures, but not in wild type or mutation 
cultures.  
 
In 3D culture, all neurosphere bodies remain on top of the scaffold (Figure 5-21Aa-c) 
whereas TUJ-1 positive (green) neurites grow into the 3D material and penetrate the 
entire depth to emerge from the bottom of the scaffold (Figure 5-21Ad-f). Few neurites 
can be observed from the bottom view of wild type neurospheres (Figure 5-21Ad), 
whereas a large number of neurites have visibly penetrated the scaffold in patient-derived 
cultures (Figure 5-21Ae), and again only a small amount of penetration is visible in 
mutation cultures (Figure 5-21Ag). This was confirmed by quantification of neurite 
penetration (Figure 5-21B), which established that a large number of neurites had 
penetrated the scaffold from patient-derived cultures compared with both wild type and 
mutation.  
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Fig 5-20: Reduced of 2D neurite outgrowth in 
neurospheres formed from Alzheimer’s 
phenotype iPSC derived neuroprogenitor cells. 
Representative phase contrast (Aa,c,e) and confocal 
(Ab,d,f) images of neurospheres formed from 
ReproNeuro, iPSC derived neuroprogenitor cells. Both 
phase contrast and immunofluorescence (staining for 
the pan-neuronal marker TUJ-1, green and nuclei are 
highlighted in blue) analysis demonstrate significant 
neurite outgrowth from the central cellular aggregate. 
Many short neurites can be observed to radiate from 
wild type neurospheres (Aa,b), whereas patient 
derived neurospheres (Ac,d) appear to have a mixed 
population of cells protruding from the cellular 
aggregate. Neurospheres derived from mutation cells 
(Ae,f), also appear to have many short neurites, 
similar to wild type cultures. Scale bars: 100 μm. 
Quantification of the number of neurites per 
neurosphere (B) (data represent mean ± SEM, n=11-
15; 3-5 individual neurospheres were quantified from 
3 independent replicates) and neurite density (C) 
(data represent mean ± SEM, n=11-15; 3-5 individual 
neurospheres were quantified from 3 independent 
replicates) reveals that neurite outgrowth was 
significantly inhibited in neurospheres derived from 
both patient and mutation cells. However, the average 
neurite length (D) (data represent mean ± SEM, 
n=173-516; between 173-516 neurites were 
measured from 3-5 neurospheres per independent 
replicate, of which there were 3) was significantly 
enhanced in neurites from patient derived 
neurospheres and neurites from both patient and 
mutation neurospheres were significantly longer than 
from wild type neurospheres. Similarly, the number of 
nuclei that have appeared to migrate from the central 
cellular aggregate (E) (data represent mean ± SEM, 
n=3) is significantly greater in patient derived 
neurospheres than any other condition tested, 
similarly to neurite length. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 5-21: Increase of neurite outgrowth in 3D culture by neurospheres formed from iPSC derived Alzheimer’s phenotype neuroprogenitor cells.  
Representative confocal images of neurospheres formed from ReproNeuro, iPSC derived neuroprogenitor cells and subsequently cultured in 3D (A). Neurite 
outgrowth is highlighted by staining for the pan-neuronal marker TUJ-1 (green) and nuclei are stained blue. Nuclei generally remain within the cellular aggregate 
as visible from the top view of the scaffold (Aa-c), whereas neurites are visible from the bottom view of the scaffold (Ad-f), as they have penetrated the entire depth 
of the 3D material. Scale bars: 100 μm. Quantification of the number of neurites that have penetrated the scaffold for each cell type (B) (data represent mean ± SEM, 
n=3-6; due to limited cell availability 1-2 neurospheres from 1 population of cells were quantified) reveals that a much larger number of neurites penetrate the 
scaffold from neurospheres derived from patient cells rather than the wild type or mutation cells. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 
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5.3.6 The Effect of Rho A/ROCK Inhibition on Neurite Outgrowth From Alzheimer’s 
Disease Phenotype Cells  
 
To further understand the mechanisms governing Aβ-mediated inhibition of neurite 
growth, the effect of Rho A inhibition by ibuprofen and ROCK inhibition by Y-27632 was 
investigated in these AD-phenotype cell lines.  
 
 5.3.6.1 ReproNeuro AD-Patient 1 
 
ReproNeuro patient-derived cells were cultured as neurospheres in 2D with a range of 
concentrations (0.5 – 15 μM) of Y-27632 (Figure 5-22Ac-k). Significant neurite outgrowth 
can be observed from wild type derived cultures (Figure 5-22Aa,b), along with patient-
derived cultures (Figure 5-22Ac,d). However patient-derived neurospheres appear to 
produce fewer neurites and contain a more heterogenous population of cell types. 
Addition of Y-27632 to the culture medium of patient-derived cells resulted in a slight 
increase in visible neurite outgrowth, and a reduction of visible cell bodies outside of the 
neurosphere was particularly evident at 15 μM Y-27632 treatment (Figure 5-22Aj,k). 
 
The number of neurites per neurosphere (Figure 5-22B) was reduced in patient-derived 
cells compared with wild type. This inhibition was rescued with 0.5 μM Y-27632 
treatment, which restored neurite number to control levels. Treatment with higher 
concentrations of Y-27632, however, resulted in a significant enhancement in the number 
of neurites generated per neurosphere compared with control, wild type cultures. Neurite 
number was also enhanced by 15 μM Y-27632 treatment, however the number of neurites 
generated by 15 μM treated neurospheres was reduced compared with those treated with 
10 μM Y-27362.    
 
A similar result was obtained from quantification of neurite density (Figure 5-22C), as 
neurite outgrowth from patient-derived neurospheres was significantly reduced 
compared with wild type neurospheres. This inhibitory effect was recovered by treatment 
with 0.5 μM Y-27632, whilst higher concentrations of Y-27632 such as 10 μM and 15 μM 
significantly enhanced neurite density compared with the wild type, control.  
 
Neurite length (Figure 5-22D) was significantly enhanced in patient-derived cultures 
compared with wild type, and inhibited in a dose dependent manner by Y-27632 
treatment. Although all treatment conditions produced significantly longer neurites than 
wild type cultures, Y-27632 treatment did have an inhibitory effect upon neurite length 
with 15 μM treatment resulting in significantly shorter neurites than 0.5 μM treatment. A 
similar effect is noted in terms of cellular migration (Figure 5-22E) from each 
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neurosphere. Significantly more nuclei were located outside of each neurosphere in 
patient-derived cultures than wild type, and Y-27632 treatment induced a dose 
dependent decrease in the number of nuclei that lie outside of each neurosphere, with 
both 10 μM and 15 μM Y-27632 resulting in a statistically significant inhibition of 
migration.  
 
In 3D culture, all neurospheres remained on top of the scaffold (Figure 5-23Aa,c,e,g,i) and 
more neurites visibly radiated from the central cellular point in patient-derived cultures. 
A similar number of neurites appear visible from the underside of wild type (Figure 5-
23b) and patient-derived cultures (Figure 5-23Ad) with Y-27632 treatment (Figure 5-
23Af,h,j) appearing to enhance the number of neurites visible from the bottom view of 
each scaffold. Quantification of neurite penetration (Figure 5-23B) confirms this 
observation, as slightly more (but not statistically significant) neurites penetrate the 
scaffold in patient-derived cultures as oppose to wild type cultures. Y-27632 treatment 
was also found to enhance neurite penetration and 0.5 μM and 15 μM Y-27632 
significantly enhanced neurite penetration compared with wild type cultures. 
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Fig 5-22: Restoration of neurite outgrowth from 
Alzheimer’s disease patient derived neurospheres 
cultured in 2D with treatment with the ROCK 
inhibitor, Y-27632. 
Representative confocal images of ReproNeuro derived 
neurospheres cultured in 2D for 24 hours to induce 
neurite outgrowth (A) with a range of concentrations (0 
– 15 μM) of Y-27632.  Staining for the pan-neuronal 
marker TUJ-1 in green highlights neurite outgrowth and 
nuclei are highlighted in blue. Significant neurite 
outgrowth can be observed from wild type neurospheres 
(Aa,b), whereas patient derived neurospheres (Ac,d) 
appear to produce a reduced number of neurites that are 
longer, which appears to be enhanced and restored to 
normal levels with Y-27632 treatment (Ae-k). Scale bars: 
100 μm. Quantification of the number of neurites per 
neurosphere (B) (data represent mean ± SEM, n=6-18; 2-
6 individual neurospheres were quantified from 3 
independent replicates) and the neurite density (C) (data 
represent mean ± SEM, n=6-18; 2-6 individual 
neurospheres were quantified from 3 independent 
replicates) show that neurite outgrowth is inhibited in 
patient derived neurospheres and can be enhanced by 
treatment with Y-27632. 0.5 μM Y-27632 treatment 
restored neurite outgrowth to a similar level as wild type 
and 10 – 15 μM enhanced neurite outgrowth to a level 
that surpasses that of the wild type. However, neurite 
length (D) (data represent mean ± SEM, n=81-319; 
between 81-319 neurites were measured from 3-6 
neurospheres per independent replicate, of which there 
were 3.) is significantly enhanced in patient derived 
neurospheres compared with the control, and increasing 
Y-27632 concentration acts to inhibit neurite length. 
However, even at 15 μM Y-27632 length is still 
significantly enhanced compared with wild type. 
Similarly to length, cellular migration (E) (data represent 
mean ± SEM, n=3-6) is enhanced in patient derived 
neurospheres compared with wild type and is inhibited 
with increasing Y-27632 concentration.  One-way 
ANOVA with Tukey’s multiple comparisons: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 5-23: Enhancement of neurite outgrowth from Alzheimer’s disease patient derived neurospheres cultured in 3D with ROCK inhibitor, Y-27632.  
Representative confocal images of ReproNeuro derived neurospheres cultured in 3D for 10 days to induce neurite outgrowth (A) with a range of concentrations (0 
– 15 μM) of the ROCK inhibitor, Y-27632. Neurospheres can be seen from the top view of the scaffold, with neurite outgrowth highlighted by green staining for the 
pan-neuronal marker TUJ-1 and nuclei are stained blue (Aa,c,e,g,i), significant neurite outgrowth can be observed from the underside of the scaffold (Ab,d,f,g,j) and 
appears to be enhanced in patient derived samples with Y-27632 treatment.  Scale bars: 100 μm. Quantification of the number of neurites penetrating the scaffold 
(B) (data represent mean ± SEM, n=3-6; due to limited cell availability 3-6 neurospheres from 1 population of cells were quantified) reveals that more neurites 
penetrate the 3D material from AD patient rather than WT-derived neurospehres. Neurite outgrowth from patient derived neurospheres was also further enhanced 
by addition of Y-27632 to the culture medium with the highest concentration (15 μM) Y-27632 producing significantly more neurites that have penetrated the 3D 
material compared with untreated patient derived samples. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p 
< 0.0001. 
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To identify the role of Rho A in Aβ-mediated inhibition, 2D ReproNeuro cultures were 
treated with a range of concentrations (10 – 500 μM) of ibuprofen. Less visible neurites 
were evident in cultures of patient-derived cells (Figure 5-24Ac,d) compared with wild 
type cultures (Figure 5-24Aa,b), although neurites did appear longer. Treatment with high 
concentrations (100 – 500 μM) of ibuprofen appear to enhance the number of TUJ-1 
positive (green) neurites radiating from patient-derived neurospheres, with the 
generation of particularly dense neurite outgrowth from neurospheres treated with 500 
μM ibuprofen (Figure 5-24Ai,j). 
 
The number of neurites per neurosphere (Figure 5-24B) was significantly inhibited in 
patient-derived cultures compared with wild type cultures. This inhibitory effect was 
rescued by ibuprofen treatment, with 10 μM ibuprofen restoring neurite number to a 
similar level as the wild type control. Treatment with 100 μM ibuprofen significantly 
enhanced neurite number compared with untreated patient-derived samples and 500 μM 
ibuprofen significantly enhanced the number of neurites generated from patient-derived 
neurosphere in comparison with wild type neurite outgrowth.  
 
A similar result was obtained in terms of neurite density (Figure 5-24C), as neurite 
density was significantly reduced in patient-derived cultures compared with wild type. 
Ibuprofen treatment induced a dose dependent increase in neurite density, with 100 μM 
ibuprofen treatment resulting in a neurite density similar to that of the wild type control. 
Treatment with 500 μM ibuprofen also significantly enhanced neurite density from 
patient-derived cells.  
 
Neurite length (Figure 5-24D) was significantly enhanced in patient-derived cultures, and 
ibuprofen treatment had little effect upon neurite length. However, cellular migration 
from the central neurosphere (Figure 5-24E) was significantly enhanced in patient-
derived cultures compared with wild type cells. Ibuprofen treatment reduced cellular 
migration in a dose dependent manner and treatment with 500 μM ibuprofen significantly 
reduced cellular migration compared with untreated patient-derived neurospheres. 
 
In 3D culture, neurospheres remain on top of the scaffold (Figure 5-25Aa,c,e,g,i) and more 
neurites visibly radiate from the neurosphere itself in patient-derived cultures. The 
bottom view of the scaffold (Figure 5-25Ab,d,f,h,j) reveals neurite penetration and it can 
be seen that more neurites penetrate the depth of the 3D material in patient-derived 
cultures (Figure 5-25Ad,f,h,j) as oppose to wild type (Figure 5-25Ab). It also appears that 
particularly high concentrations of ibuprofen such as 500 μM may enhance neurite 
penetration in 3D culture (Figure 5-15Aj). Quantification of neurite penetration (Figure 5-
25B) confirms this observation, and reveals that a large number of neurites penetrate the 
scaffold from patient-derived neurospheres as oppose to wild type. It also appears that 
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ibuprofen increases neurite penetration in a dose dependent manner, however this is not 
statistically significant. 
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Fig 5-24: Recovery of neurite outgrowth from Alzheimer’s disease patient derived neurospheres cultured in 2D through inhibition of Rho A by ibuprofen.  
Representative confocal images (A) of ReproNeuro Alzheimer’s disease patient derived neurospheres cultured in 2D for 24 hours  with a range of concentrations (0 – 500 μM) of 
ibuprofen. TUJ-1 (green) positive neurites can be seen radiating from the central cellular aggregate with nuclei (blue) generally remaining within the cell mass of the neurosphere. 
Scale bars: 100 μm. Quantification of the number of neurites per neurosphere (B) (data represent mean ± SEM, n=3-18; 1-6 individual neurospheres were quantified from 3 
independent replicates) and neurite density (C) (data represent mean ± SEM, n=3-18; 1-6 individual neurospheres were quantified from 3 independent replicates) reveals that neurite 
outgrowth is inhibited in Alzheimer’s disease patient derived cells compared with wild type, and this is rescued in a dose dependent manner by increasing ibuprofen concentration, 
with the highest concentration tested (500 μM) enhancing neurite outgrowth to levels greater than that of the wild type.  However, neurite length (D) (data represent mean ± SEM, 
n=62-319; between 62-319 neurites were measured from 1-6 neurospheres per independent replicate, of which there were 3) is significantly greater in those neurites produced from 
patient derived neurospheres than wild type, and this is not affected by ibuprofen concentration. Migration of cells from the neurosphere body (E) (data represent mean ± SEM, n=3-6; 
1-6 individual neurospheres were quantified from 3 independent replicates) is significantly greater in patient derived samples compared with wild type and this is inhibited in a dose 
dependent fashion with increasing ibuprofen concentration.  One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 5-25: Recovery of neurite outgrowth from Alzheimer’s disease patient derived neurospheres cultured in 3D through inhibition of Rho A by 
ibuprofen.  
Representative confocal images (A) of ReproNeuro Alzheimer’s disease patient derived neurospheres cultured in 3D for 10 days with a range of concentrations (0 – 
500 μM) of ibuprofen. Neurospheres can be seen from the top view of the scaffold (Aa,c,e,g,i) with neurites stained green and  nuclei stained blue. TUJ-1 positive 
neurites can be seen from the bottom view of the scaffold (Ab,d,f,h,j) having penetrated the entire depth of the 3D material. Scale bars: 100 μm. Quantification of the 
number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=3-6; due to limited cell availability 1-2 neurospheres from 1 population of cells 
were quantified) reveals that more neurites penetrate the scaffold from patient derived neurospheres than wild type, and this is slightly enhanced by high 
concentrations (100 – 500 μM) of ibuprofen. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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 5.3.6.2 ReproNeuro AD-Mutation 
 
ReproNeuro mutation-derived neurospheres were cultured in 2D with a range of 
concentrations (0.5 - 15 μM) of Y-27632. Significant neurite growth developed from wild 
type-derived neurospheres (Figure 5-26Aa,b). However, neurite outgrowth from 
mutation-derived neurospheres (Figure 5-26Ac,d) appears less dense and uniform 
around the neurosphere compared with wild type control. Treatment with increasing 
concentrations of Y-27632 (Figure 5-26Ac-j) appears to enhance visible neurite growth 
from mutation-derived neurospheres, and neurites appear particularly long with 0.5 μM 
Y-27632 treatment (Figure 5-26Ae,f). 
 
The number of neurites generated per neurosphere (Figure 5-26B) was significantly 
reduced in mutation cultures compared with wild type. Y-27632 treatment enhanced 
neurite number in a dose dependent manner with the lowest concentration tested, 0.5 μM 
Y-27632, leading to a significant enhancement in neurite number compared with 
mutation alone. Treatment with the highest concentration of Y-27632 tested, 15 μM, led 
to a significant increase in neurite number from mutation-derived neurospheres 
compared with wild type-derived neurospheres.  
 
Neurite density (Figure 5-26C) is also significantly reduced in mutation-derived cultures 
in comparison with wild type cultures. Y-27632 treatment enhances neurite density in a 
dose dependent manner and 15 μM Y-27632 enhances neurite density even compared to 
wild type cultures. Neurite length (Figure 5-26D) is significantly enhanced in mutation-
derived cultures and Y-27632 treatment results in an inhibition in length. However, even 
with Y-27632-induced inhibition of length, all mutation-derived neurospheres generate 
neurites that are significantly longer than wild type-derived neurites. Migration of cells 
from the central body of the neurosphere (Figure 5-26E) is reduced in mutation cultures 
compared with wild type cells and Y-27632 inhibits cellular migration in a dose 
dependent fashion.  
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Fig 5-26: Recovery of neurite outgrowth from 
Alzheimer’s disease mutation neurospheres 
cultured in 2D through inhibition of ROCK by 
Y-27632.  
Representative confocal images (A) of 
neurospheres derived from ReproNeuro mutation 
Alzheimer’s disease phenotype cells, cultured in 
2D for 24 hours with a range of concentrations (0 
– 15 μM) of the selective ROCK inhibitor Y-27632. 
Neurites are stained for the pan-neuronal marker 
TUJ-1 in green and nuclei are stained blue and 
generally remain within the cellular aggregate. 
Scale bars: 100 μm. The number of neurites per 
neurosphere (B) (data represent mean ± SEM, 
n=6-18; 2-6 individual neurospheres were 
quantified from 3 independent replicates) and 
neurite density (C) (data represent mean ± SEM, 
n=6-18; 2-6 individual neurospheres were 
quantified from 3 independent replicates) are both 
inhibited in mutation derived neurospheres 
compared with wild type, an effect that is rescued 
with increasing Y-27632 concentration and even 
enhanced to levels greater than that of the wild 
type. Neurite length (D) (data represent mean ± 
SEM, n=84-319; between 84-319 neurites were 
measured from 2-6 neurospheres per independent 
replicate, of which there were 3) however, is 
enhanced in mutation derived neurospheres 
compared with wild type, an effect that is reduced 
by Y-27632 treatment. Migration of cells from the 
neurosphere (E) (data represent mean ± SEM, 
n=3-6; 2-6 individual neurospheres were 
quantified from 3 independent replicates) is 
reduced in neurospheres derived from mutation 
cells compared with wild type, and migration is 
inhibited further by treatment with Y-27632. One-
way ANOVA with Tukey’s multiple comparisons: * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Mutation-derived neurospheres were also cultured in 2D with a range of concentrations 
of ibuprofen (10 – 500 μM). Immunofluorescence analysis of the pan-neuronal marker 
TUJ-1 (green) reveals that mutation-derived neurospheres (Figure 5-27Ac,d) clearly 
produce fewer neurites that are less densely packed than wild type control cultures 
(Figure 5-27Aa,b). Ibuprofen treatment appears to enhance neurite growth producing 
more a uniform extension of neurites from the body of the neurosphere with neurite 
outgrowth also appearing denser. This is particularly apparent with 500 μM ibuprofen 
treatment (Figure 2-27Ai,j). 
 
The number of neurites produced per neurosphere (Figure 5-27B) is reduced in 
mutation-derived cultures and enhanced in a dose dependent manner with ibuprofen 
treatment. Treatment with 10 μM ibuprofen resulted in the generation of a similar 
number of neurites as the wild type control, whereas treatment with 500 μM ibuprofen 
resulted in a significant enhancement in neurite growth compared with the wild type 
control. Neurite density (Figure 5-17C) is also reduced in mutation-derived cultures 
compared with wild type and is enhanced by ibuprofen in a dose dependent manner. 
Treatment with 10 μM ibuprofen significantly increased neurite density compared with 
untreated mutation control cultures and treatment with 500 μM ibuprofen treatment 
significantly enhanced neurite density compared with the wild type control.  
 
Neurite length (Figure 5-27D) is significantly enhanced in mutation-derived cultures 
compared with wild type control and ibuprofen treatment consistently reduced neurite 
length. Although, ibuprofen treatment resulted in a reduction in neurite length, all 
mutation samples both untreated and ibuprofen treated resulted in significantly enhanced 
neurite length compared with the wild type control. Cellular migration (Figure 5-17E) was 
reduced in mutation cells and further inhibited by ibuprofen treatment in a dose 
dependent manner as 500 μM ibuprofen resulted in a significant reduction in cellular 
migration compared with wild type cultures.  
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Fig 5-27: Recovery of neurite outgrowth from Alzheimer’s disease mutation neurospheres cultured in 2D through inhibition of Rho A by ibuprofen.  
Representative confocal images (A) of neurospheres derived from ReproNeuro mutation, Alzheimer’s phenotype cells, cultured in 2D for 24 hours with a range of concentrations (0 – 
500 μM) of ibuprofen, an inhibitor of Rho A. Neurites are highlighted in green by staining for the pan-neuronal marker, TUJ-1 and nuclei are stained blue. Scale bars: 100 μm. The 
number of neurites per neurosphere (B) (data represent mean ± SEM, n=6-18; 2-6 individual neurospheres were quantified from 3 independent replicates) and neurite density (C) 
(data represent mean ± SEM, n=6-18; 2-6 individual neurospheres were quantified from 3 independent replicates) are both decreased in mutation derived neurospheres compared with 
wild type, however this effect is rescued by treatment with ibuprofen and at 500 μM, is even enhanced to a level that is greater than wild type. Neurite length (D) (data represent mean ± 
SEM, n=79-319; between 79-319 neurites were measured from 2-6 neurospheres per independent replicate, of which there were 3.) is enhanced in mutation-derived neurospheres 
compared with wild type, however this is slightly inhibited by the addition of ibuprofen to the culture medium. Migration of cells from the neurosphere (E) (data represent mean ± SEM, 
n=3-6; 2-6 individual neurospheres were quantified from 3 independent replicates) is inhibited in mutation derived neurospheres compared with wild type, and is further inhibited by 
ibuprofen, particularly at high concentrations (500 μM). One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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In 3D culture neurospheres remain situated on top of the scaffold (Figure 5-28Aa,c,e,g) 
whilst TUJ-1 positive (green) neurites are visible from the bottom view of the scaffold 
(Figure 5-18Ab,d,f,h) having completely penetrated the 3D material. A significant number 
of neurites can be visualised from the underside of both wild type (Figure 5-28Ab) and 
mutation (Figure 5-28Ad) cultures and Y-27632 treatment appears to result in an 
increase in the number of neurites visible from the bottom of the scaffold (Figure 5-18Af).  
 
The number of neurites that had penetrated the scaffold (Figure 5-28B) from both wild 
type and mutation cultures were similar. However Y-27632 and ibuprofen treatment both 
enhanced the number of neurites that penetrated the scaffold from mutation cultures, 
resulting in an increased level of 3D neuritogenesis compared with wild type control 
cultures.  
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Fig 5-28: Enhancement of neurite outgrowth from Alzheimer’s disease mutation derived neurospheres cultured in 3D by inhibition of Rho A and ROCK 
signalling.  
Representative confocal images (A) of neurospheres derived from ReproNeuro mutation, Alzheimer’s phenotype cells, cultured in 3D for 10 days with 15 μM Y-
27632, a selective ROCK inhibitor or 500 μM ibuprofen, an inhibitor of Rho A. Neurospheres remain on top of the scaffold, as can be seen from the top view 
(Aa,c,e,g) while TUJ-1 positive (green) neurites penetrate the entire depth of the scaffold, visible from the bottom view of the scaffold (Ab,d,f,h), with nuclei being 
stained blue. Scale bars: 100 μm. Quantification of the number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=3-6; due to limited cell 
availability 3-6 neurospheres from 1 population of cells were quantified) reveals little difference between wild type and mutation derived neurospheres with both 
Y-27632 and ibuprofen supplementation enhancing the number of neurites penetrating the scaffold from mutation derived neurospheres. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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 5.3.6.3 Summary 
 
A further comparison of each ReproNeuro cell type with each medium supplementation 
regime was conducted. Analysis of the number of neurites generated per neurosphere 
(Figure 5-29A) in 2D culture found that neurite number was reduced in patient and 
mutation samples compared with wild type. Y-27632 treatment was found to enhance 
neurite number from all cell types and restored neurite number to a level that was similar 
to wild type in patient-derived cells. Similarly, ibuprofen treatment resulted in similar 
number of neurites per neurosphere from all cell types. Neurite density (Figure 5-29B) of 
2D cultures was significantly reduced in both patient and mutation-derived cells 
compared with control. This significant difference was reduced by both Y-27632 and 
ibuprofen treatment, restoring neurite density to a similar level as the wild type.   
 
The length (Figure 5-29C) of neurites generated in 2D was significantly enhanced in 
patient-derived compared with wild type cells and mutation-derived cells also produced 
significantly longer neurites than their wild type counterparts, however mutation-derived 
neurites were significantly shorter than patient-derived neurites. Y-27632 and ibuprofen 
treatment had little effect upon neurite length. Similarly, the migration of cells from 
neurospheres (Figure 5-29D) in 2D culture was also significantly enhanced in patient-
derived cultures with all medium supplementation. However, Y-27632 treatment did 
reduced migration in all cell types.  
 
Neurite outgrowth in 3D culture (Figure 5-29E) varies little between the cell lines with Y-
27632 treatment inducing a slight increase in neurite penetration whereas; ibuprofen 
treatment only induces an increase in patient-derived neurites.  
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Fig 5-29: Comparison of the effect of ROCK and Rho A inhibition on Alzheimer’s phenotype and wild type derived neurospheres cultured in 2D and 3D.  
Quantification of neurite outgrowth from wild type, Alzheimer’s disease patient and mutation derived neurospheres treated with an inhibitor of ROCK, Y-27632 and an inhibitor of 
Rho A, ibuprofen. Number of neurites per neurosphere (A) (data represent mean ± SEM, n=9; 3 individual neurospheres were quantified from 3 independent replicates) cultured in 
2D and treated with Y-27632 and ibuprofen. The neurite density (B) (data represent mean ± SEM, n=9; 3 individual neurospheres were quantified from 3 independent replicates) 
of neurospheres cultured in 2D for 24 hours is inhibited in patient and mutation derived neurospheres compared with wild type, an effect that is rescued with both Y-27632 and 
ibuprofen treatment, aThe length (C) (data represent mean ± SEM, n=100; 100 neurites were measured from 3 neurospheres per independent replicate, of which there were 3) of 
neurites generated from 2D cultured neurospheres for 24 hours is greatly enhanced in patient derived neurospheres followed by mutation and wild type, a trend that is conserved 
with Y-27632 and ibuprofen treatment. Migration of cells (D) (data represent mean ± SEM, n=3; 1 individual neurosphere was quantified per independent repeat) from 
neurospheres cultured in 2D, is significantly enhanced in patient derived neurospheres than wild type or mutation, an effect that is maintained with both Y-27632 and ibuprofen 
treatment. The number of neurites penetrating the scaffold (E) (data represent mean ± SEM, n=3; due to limited cell availability 1-2 neurospheres from 1 population of cells were 
quantified) of neurospheres cultured in 3D is greater in patient derived neurospheres than wild type or mutation, an effect that is enhanced by Y-27632 and ibuprofen treatment.  
Two-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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5.4 Discussion 
 
 5.4.1 β-amyloid-mediated Neurite Inhibition In Vitro 
 
This chapter explores the role of Aβ in neurite inhibition through the use of several in 
vitro systems. The first of which involved the coating of growth substrates with Aβ 
peptides, which has previously been demonstrated to induce neurite inhibition in primary 
neurons by Postuma et al40. However, Postuma et al only analysed the effect of Aβ species 
upon neurite length, whereas data outlined in this chapter addresses the impact of Aβ-
coating upon many aspects of neurite outgrowth including number, density and length. 
The data described in this chapter outlines an inhibitory relationship between all Aβ-
species and neurite growth; however, it was found that the coating of growth substrates 
with the Aβ42 peptide resulted in the largest reduction in neurite length. This finding is 
supported by Postuma et al who demonstrate the ability of Aβ42 coatings to induce 
inhibition of neurite of neurite length to a greater degree than Aβ4040.  
 
A study by Petratos et al also describes the ability of Aβ species to inhibit neurite growth 
in a SH-SY5Y model of neuritogenesis, when added exogenously to the culture medium36. 
This was further evidenced by data presented in this chapter as culture medium 
supplementation with both Aβ40 and Aβ42 resulted in significant reductions in neurite 
growth. Interestingly, Petratos et al found that Aβ40, which is less prone to fibril formation 
and senile plaque generation, actually resulted in the largest reduction in neurite 
outgrowth within this model36. The data outlined in this chapter supports this finding as 
Aβ40 was found to induce the largest reductions in neurite number and density. However 
Aβ42 was found to have the largest impact on neurite length. This highlights an advantage 
of this stem cell-derived, neurosphere-based model of neurite outgrowth, as multiple 
variables and aspects of neurite outgrowth can be quantified. This gives a better 
indication as to the effect of a molecule upon neurite outgrowth because several aspects 
of neurite growth can be quantified including number, density and length, rather than 
relying on quantification of one variable alone.   
 
Ageing of Aβ peptides through incubation at 37 °C is a common strategy to promote 
peptide aggregation and to present the peptides to cell cultures in a manner more 
befitting of the senile plaques encountered by cells in the brain of Alzheimer’s disease 
patients516,520,521. However, throughout this chapter it was found that aged Aβ species 
impacted neurite growth the least, with fresh peptides actually inducing inhibition to a 
greater extent than their aged counterparts. This was also the case in Petratos et al’s 
study, which found that the aged Aβ42 peptide was a less potent inhibitor of neurite 
growth than its fresh peptide counterpart36. This study hypothesised that the reduction in 
potency of aged peptides could be due to over aggregation, as large insoluble aggregates 
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may be generated that are unable to interact with cells. The level of peptide aggregation 
was then characterised by atomic force microscopy (AFM), which confirmed this 
hypothesis36. A similar finding is outlined in the protein aggregation assay data detailed in 
this chapter, as ageing of the Aβ42 peptide resulted in such a high result that it exceeded 
the assay range. Therefore, it could be hypothesised that the reduced effects of aged 
peptides upon neurite outgrowth may be due to over aggregation of Aβ42.  
 
The substrate bound and medium supplementation approaches used to investigate Aβ-
induced neurite inhibition in this chapter, provide simple, robust models of Aβ-cellular 
interaction. However, in the brain of both healthy individuals and AD-patients, a variety of 
different Aβ species exist, whereas, these models only involve the presentation of one 
type of Aβ peptide to neurites. Therefore to better recapitulate the in vivo environment, a 
variety of Aβ42:Aβ40 ratios were added to the culture medium of neurite outgrowth assays, 
as an increased level of Aβ42 in comparison to Aβ40 is a hallmark of AD426–428. In the 
healthy adult brain the Aβ composition is thought to be 10 parts Aβ40 for every 1 part 
Aβ42, whereas this ratio can differ up to 10-fold in the brains of AD-patients426. For this 
reason a variety of Aβ ratios ranging from 1:10 to 10:1 were tested to investigate the 
ability of neurites to grow in these culture conditions. Although there was little 
correlation between Aβ ratio and neurite number or density, neurite legnth was 
significantly inhibited by ratios higher in Aβ42 than Aβ40, consistent with the AD-
phenotype.  
 
A number of methodologies have been used to determine the role of Aβ species in neurite 
growth and development, all of which consistently provide evidence that Aβ42 has a 
significant impact upon neurite length. Although Aβ40 is less closely linked to senile 
plaque development and protein aggregation as Aβ42 the data outlined in this chapter still 
found a correlation between neurite inhibition and Aβ40 treatment through a number of 
model systems.  
 
 5.4.2 Neurite Inhibition in Alzheimer’s Disease Phenotype Cells 
 
iPSC technology offers the ability to develop physiologically relevant in vitro models of 
complex diseases that otherwise would be studied in much more simplified systems. AD 
model cells were first isolated in 2011 by Yagi et al from patients with early-onset familial 
AD and mutations in the genes for PS1 and PS2157. PS1 and PS2 form the γ-secretase 
complex involved in Aβ generation from APP, mutations of which lead to increased 
production of amyloidgenic species411,461. The iPSC AD-model line derived by Yagi et al 
was differentiated to form neuronal cultures that express higher ratios of Aβ42:Aβ40 
indicative of AD157. The ReproNeuro AD-model neurons described in this chapter are 
similar to those described by Yagi et al in that they were derived from iPSC lines 
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developed from an AD-patient with a mutation in PS2 (R62H) or transfected with a 
similar mutation in PS1 (P117L)212, resulting in an increased Aβ42:Aβ40 ratio438.   
 
ReproNeuro patient and mutation derived AD-model cells provide a more physiologically 
relevant in vitro system to investigate the process of Aβ-mediated inhibition compared 
with the more simple models described in this chapter that rely upon synthetic peptides. 
Both AD patient and mutation lines were found to produce fewer neurites with less dense 
neurite outgrowth than the wild type ReproNeuro line. However, cultures of patient cells 
produced significantly longer neurites than wild type cultures. One reason for this, could 
be that, as observed in 2D monolayer cultures patient-derived cells were a mixed 
population containing other cell types, which was also evident in neurosphere cultures.  
 
Excessive cellular migration was observed in 2D neurosphere cultures of patient-derived 
cells, perhaps a result of the heterogenous cell population, which may provide a more 
permissive substrate for neurite development. One hypothesis is that neurites may grow 
over other cell types more easily than the plastic growth substrate resulting in their 
increased length, or that the population of cells may contain glial cells that provide 
neurotrophic support to the developing neurites522–524. However, it does appear that 
patient-derived cells are inherently different from wild type perhaps in more ways than 
just Aβ secretion and a thorough characterisation and evaluation of the cell types is 
required. 
 
When patient and mutation-derived neurospheres were cultured in the 3D neurite 
outgrowth model using Alvetex® scaffold, it appeared that ReproNeuro AD-Patient cells 
generated more neurites capable of traversing the depth of the scaffold. If this result is 
considered alone, it might be thought that neurite outgrowth from patient-derived cells is 
enhanced, however, when taken into consideration with the 2D data, a more reliable 
picture of the neurite generating capability of patient-derived cells forms. Neurite length 
was enhanced from patient derived cells in 2D culture; therefore more neurites were 
capable of spanning the 200 μm depth of the scaffold. This may not be a true reflection of 
the neurite outgrowth capabilities of each cell type and highlights a limitation of the 3D 
model system in that only those neurites that are longer than 200 μm are quantified. 
Therefore, although a 3D culture environment provides a more physiologically 
representative model of neurite development, 3D and 2D obtained data should be closely 
considered together, as the 2D outgrowth model measures more variables and may be 
more sensitive to changes in neurite outgrowth between experimental conditions.  
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 5.4.3 Proposed Mechanism of β-amyloid-mediated Neurite Inhibition 
 
Petratos et al’s study into the neurite inhibitory properties of Aβ, implicates Rho A and 
ROCK signalling in this process and found that the selective ROCK inhibitor, Y-27632 was 
able to overcome Aβ-induced inhibition36. For this reason, ibuprofen an inhibitor of Rho A 
and Y-27632 an inhibitor of ROCK, were both used with the aim of reducing the inhibitory 
effect of Aβ upon neurite outgrowth. Various concentrations of Y-27632 and ibuprofen 
were used to overcome Aβ-induced inhibition in both the exogenous addition of Aβ to the 
culture medium, and AD phenotype cell models of neurite inhibition described throughout 
this chapter.  
 
On the whole both Y-27632 and ibuprofen treatment was able to overcome Aβ-induced 
neurite inhibition in both 2D and 3D culture systems. However, Y-27632 and ibuprofen 
treatment often has unusual effects upon neurite legnth both in the presence and absence 
of an inhibitory stimulus, as described in Chapter III. This could be due to some kind of 
reciprocal control of neurite number and length, perhaps as inhibition of Rho A and ROCK 
results in the destabilisation of actin filaments, this may restrict filament length and 
therefore neurite elongation. Variable results in terms of neurite length in 2D often 
transcend into unexpected results in 3D culture due to the aforementioned limitations of 
the 3D-culture assay.  
 
The ability of Y-27632 and ibuprofen to overcome Aβ-mediated neurite inhibition in these 
systems, suggests that Rho A and ROCK activation are integral signalling pathways 
involved in this process. In addition to this, Aβ is also known to bind to the NgR504–506,509, 
activation of which leads to Rho A and ROCK stimulation, although it is not confirmed that 
Aβ binding results in receptor activation324,325,331,332. Therefore, one proposed mechanism 
of action is that, Aβ-binding activates NgR leading to Rho A and ROCK activation resulting 
in neurite inhibition and growth cone collapse, similar to the signalling pathway evoked 
by inhibitory molecules within the glial scar (outlined in Figure 5-30).  
 
To test this hypothesis, the NgR antagonist Nogo extracellular peptide (NEP 1-40), was 
added to inhibition models to potentially overcome Aβ-mediated inhibition, implicating 
receptor activation in the downstream signalling pathway. NEP 1-40 is an NgR 
competitive antagonist comprised of the first 40 amino acids of the Nogo-66 molecule, 
which binds to the leucine-rich region of the receptor blocking the inhibitory effects of 
Nogo-66. Therefore if NEP 1-40 was able to promote recovery of neurite outgrowth in the 
presence of Aβ, it might suggest that receptor activation is involved in the molecular 
pathway stimulated by Aβ that leads to neurite inhibition. However, the data only 
demonstrates a partial recovery of Aβ-induced inhibition with NEP 1-40 supplementation 
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in all model systems, suggesting that NgR activation may be one of multiple pathways 
involved. 
 
 
 
 
Fig 5-30: A schematic summary describing the molecular mechanisms of Aβ-
induced neurite inhibition with mechanisms of recovery. 
Aβ is thought to bind to the NgR resulting in activation of Rho A and ROCK signalling that 
ultimately results in changes in actin dynamics leading to growth cone collapse and 
neurite inhibition. NEP 1-40 is a receptor antagonist peptide thought to block NgR 
signalling, providing recovery and restoring neurite outgrowth in the presence of Aβ. 
Ibuprofen inhibits Rho A downstream of NgR signalling and Y-7632 inhibits ROCK 
downstream of Rho A, both of which lead to inhibition of NgR-mediated intracellular 
signalling and restoration of neurite outgrowth. 
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5.5 Key Findings 
 
 Aβ species were inhibitory to neurite outgrowth both in substrate bound and 
soluble forms.  
 
 High ratios of Aβ42:Aβ40 reminiscent of AD were particularly inhibitory to neurite 
length in 2D culture.  
 
 Inhibition of Rho A (ibuprofen) and ROCK (Y-27632), was able to overcome Aβ-
mediated inhibition in 2D and 3D culture.  
 
 The NgR antagonist NEP 1-40 was able to partially restore neurite outgrowth, 
despite the presence of inhibitory Aβ.  
 
 AD model iPSC-derived neurons produced fewer, longer neurites than their WT 
counterparts.  
 
 AD patient-derived neurons appeared to be a heterogenous mix of neurons and 
glial cells.  
 
 Inhibition of Rho A and ROCK was able to restore neurite outgrowth to WT levels 
in AD phenotype cell lines.  
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5.6 Conclusion 
 
This chapter has involved the evaluation of the role of Aβ in neurite outgrowth in several 
different in vitro systems. These range from simple Aβ coating of growth substrates to 
complex iPSC-based diseased models, the suitability of which depends upon the 
application for which it is intended. More simple models of inhibition such as Aβ medium 
supplementation are useful to provide insight into specific underlying molecular 
mechanisms, however do not accurately reflect the complex in vivo environment. More 
complex models such as Aβ ratio administration and the use of disease model cells 
described within this chapter have useful applications in the understanding of complex 
pathways involved in AD pathogenesis, however their complexity may inhibit the 
successful identification of key signalling pathways.  
 
In addition to the identification of the neurite inhibitory properties of Aβ, this chapter also 
discusses the potential signalling mechanisms that result in neurite inhibition as 
stimulated by Aβ. In particular, this has focussed on the Rho A and ROCK signalling 
pathway, inhibitors of which have been used to restore neurite growth in the presence of 
inhibitory Aβ species. This provides a therapeutic target in that attenuation of Rho 
A/ROCK signalling could provide a potential strategy to induce neural regeneration within 
neurodegenerative diseases. Furthermore, this chapter also identifies NgR as a potential 
receptor through which Aβ elicits it neurite inhibitory signalling, in addition to other 
potential pathways.  
 
This chapter has also describes the development of a novel neurosphere-based neurite 
outgrowth model utilising AD disease model neuroprogenitor cells. This methodology 
could also be adapted for use with other disease model cell types including Parkinson’s 
disease, to provide more information as to the development of neurites within these 
complex diseases. There are also personalised medicine implications as iPSC lines could 
be generated on a patient-specific basis and used within this neurite outgrowth assay 
with the application of screening potential drugs for the promotion of regeneration.   
 
 
 
 
 
 
 
 
 
 
 277 
5.7 Future Directions 
 
Future work building upon the data described in this chapter could include the following: 
 
 Receptor-binding studies could be conducted to determine the ability of Aβ to 
bind and activate NgR within this model.  
 
 AFM analysis could be used to further characterise the aggregation properties of 
each Aβ species.  
 
 To further validate the proposed mechanism of Rho A and ROCK activation 
leading to growth cone collapse, other modulators of Rho A and ROCK signalling 
could be used to potentially recover neurite growth in the presence of Aβ. These 
might include C3 transferase and fasudil, which have been well documented to 
promote neurite regeneration.  
 
 Other signalling mechanisms involving other aspects of the cytoskeleton could be 
explored including the involvement of the microtubule and intermediate 
filament-based cytoskeletal components.  
 
 Genotypic analyses could be used to determine any differences between the wild 
type, patient and mutation-derived ReproNeuro cell types other than mutation in 
PS1 and PS2. 
 
 The fundamental methodology developed within this chapter involving iPSC-
derived AD model neurons could be applied to study the process of neurite 
development in other neurodegenerative diseases such as Parkinson’s disease.  
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 Chapter VI: Application of Biomimetic Surfaces to Study the 
Role of Extracellular Molecules in Neurite Outgrowth and 
Inhibition 
 
6.1. Introduction 
 
Previously, we have described how 3D technology can be used to enhance current in vitro 
models of neurite outgrowth (Chapter III), providing a more physiologically relevant 
situation to study developing neurites. In this chapter, we build on this, by using protein 
surface technology to recapitulate the native biochemical environment which developing 
neurites are exposed to in vivo. This not only helps to better represent the developmental 
process of neurite generation but also helps standardise this model of neurite outgrowth, 
providing a more reliable screening tool for the identification of 
degeneration/regeneration-promoting molecules. This combination of technologies helps 
to further enhance the novel model of human neurite outgrowth described in Chapter III.  
 
6.1.1 The Role of the Extra-Cellular Matrix in Neurite Outgrowth 
 
During neuritogenesis the ECM plays a pivotal role in providing adhesion points to 
maturing neurons and neurites whilst also providing neuritic growth cues along with 
forming a permissive environment for neuron maturation525. Guidance cues such as those 
provided by the ECM are essential for the correct development of a functional neural 
network526. Cues from the ECM are transmitted to the developing neuron by integrin 
receptors found at the developing growth cone and provide specific binding sites for ECM 
components and modulate cellular responses to guidance cues526. Interactions between 
integrins and specific biochemical signatures within the ECM results in axonal outgrowth 
and pathfinding behaviour essential for the correct assembly of the nervous system.   
 
The ECM consists of a heterogenous mix of glycoproteins and proteoglycans that from the 
external microenvironment which a cell is exposed to526. The ECM often includes 
components such as laminin, fibronectin, collagen, tenascin and heparan sulphate 
proteoglycans (HSPGs), which are secreted by neurons and their supporting cells into the 
interstitial space. Large ECM proteins often form an immobilised, self-assembled, rigid 
scaffold that physically supports cellular adhesion and provides traction forces526. Both 
the mechanical and biochemical properties of the ECM influence cellular behaviour and 
this should be taken into consideration in the development of in vitro models. 
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Different constituents of the ECM have been reported to positively and negatively effect 
axonal growth in vitro and in vivo and some ECM proteins also work cooperatively with 
soluble growth factors to impact axonal outgrowth11. Collagens are expressed throughout 
the nervous system and have been demonstrated to play essential roles in axon guidance, 
pathfinding, target recognition and sprouting526–532. Interestingly, a C. elegans collagen 
type XV/XVIII mutant model results in disruption of normal motoneuron migration and 
motor axon guidance533, highlighting the important role of collagens in neurite outgrowth. 
Laminins are perhaps the most widely studied ECM component in terms of neurite 
outgrowth promoting properties that include regulation of neuron adhesion, motility and 
differentiation526, which will be discussed in detail in 6.1.2 Laminin Promotes Neurite 
Generation.  
 
Tenascins are a family of oligomeric glycoproteins that mediate neuronal-glial 
interactions and can be both inhibitory to neurite outgrowth or neurite promoting534–539. 
Tenascins consist of varying numbers of functional domains that have differential effects 
upon neurite outgrowth540. The EGF-like region of TN-R is inhibitory to neurite outgrowth 
and exhibits anti-adhesive properties, whereas, FN-II domains of TN promote adhesion 
and neurite outgrowth541. The role of fibronectin in neurite development, however, is 
thought to be more simple than that of tenascin and supportive in nature526. The functions 
of fibronectin within the nervous system involve promotion of neuronal survival, 
differentiation and morphogenesis, which have been evidenced in a number of in vitro 
cell-based studies273,274,542–547.  
 
  6.1.1.1 Integrin Receptors and Neurite Outgrowth 
 
Integrins are a family of receptors that are heterodimeric and consist of an α and β 
subunit, of which there are known to be eighteen different α subunits and eight different β 
subunits with 24 combinations of integrin complexes526.  The role of integrin receptors is 
to promote cellular-ECM interactions. In the nervous system high integrin expression is 
observed during development548–551 whilst in the mature nervous system progenitor and 
stem cells express high levels of integrins552,553. This is due to the integral role of integrins 
in mediation of the effects of the ECM upon neurite outgrowth, promoting neuronal 
migration and axonal generation during development526.  
 
Within the neuronal growth cone, integrins interact with the ECM to form adhesion 
complexes that form within filopodial and lamellipodial protrusions and remain in a fixed 
position during neurite elongation554–557. Adhesion complexes contain components such 
as integrins, paxillin and viniculin similarly to fibroblast focal adhesion complexes. 
Viniculin and paxillin are adaptor proteins that form a link between the actin 
cytoskeleton, one of the driving forces in neurite growth, and the extracellular 
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environment in the form of integrin-generated signals557. Adhesions have been observed 
by Robles and Gomez to cluster along bundles of actin filaments suggesting that external 
stimuli from the ECM via integrin mediated signalling, impacts neuritogenesis through an 
actin dependent mechanism557.  
 
Other signalling molecules found within adhesion complexes at the neuronal growth cone 
include non-receptor tyrosine kinases (NTKs), focal adhesion kinase (FAK) and Src207,557–
560. These kinases modulate the downstream signalling of a number of receptors and 
interact with several signalling pathways to control cellular motility and neurite 
elongation. Downstream signalling of integrin activation includes the Rho family of 
GTPases such as Rac 1 and Rho A. Integrin activation and its downstream events result in 
Rac 1 activation and Rho A inhibition, which promotes actin polymerisation and growth 
cone advancement284,561. However, this signalling pathway exists in a balance with Rho A 
and ROCK activation leading to increased actomyosin contractility and growth cone 
collapse, as shown in Figure 6-1, which is important during development to promote 
growth cone stalling or turning526. This balance may exist through the binding of growth 
promoting or inhibitory ligands to integrins or as a result of re-association of FAK-
associated protein complexes526.  
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Fig 6-1: Integrin mediated control of neurite outgrowth. 
A schematic depicting the role of ECM-integrin interactions and their role in neurite development and inhibition. Integrin signalling is mediated by a Src-FAK 
complex that promotes neurite extension through activation of Rac 1 and inhibition of Rho A. However, shifting the balance toward Rho A activation and away from 
Rac 1 activity results in a reduction in actin polymerisation and enhancement of actomyosin contractility resulting in growth cone collapse and axon retraction. 
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6.1.2 Laminin Promotes Neurite Generation 
 
Laminin is a major component of the ECM in most physiological systems. It particularly is 
abundant in both the mature and developing nervous system. Laminins are 
heterotrimeric glycoproteins and consist of α, β and γ chains that are organised in a 
characteristic cruciform structure (Figure 6-2)526. At the moment, five different α, three β 
and three γ chains have been identified that combine to give over 15 different 
combinations of laminin isoforms526,530,531. Plantman et al determined in DRG model 
neurons that specific integrin complexes are responsible for the neurite outgrowth 
promoting effects of each laminin isoform562. This study identified the role of integrins 
α3β1 and α7β1 in mediating neurite growth on laminin-1 and -2 substrates and integrin 
α6β1 was found to be responsible for induction of neurite growth on substrates of 
laminin-8 and -10562.  
 
 
 
 
 
 
Fig 6-2: Cruciform structure of laminin.  
A schematic depicting the molecular structure of laminin, consisting of three interweaving 
chains: α, β and γ.  
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Many in vitro neuronal culture models have documented the neurite enhancing effects of 
laminin, with identification of specific neurite promoting domains. Specifically the 
“IKVAV” domain of the α1-chain has been well documented to have neurite induction 
qualites271,272,563,564, as demonstrated by Nomizu et al who use a synthetic peptide 
analogue to investigate the neurite promoting effects of the “IKVAV” domain564. Similarly, 
Adams et al describe the role of “IKVAV” as a guidance cue and observed growth cone 
turning with neurites preferentially extending along a gradient of the substrate bound 
peptide271. The domain “IKVSV” similar to the widely studied “IKVAV” motif has also been 
described to promote cell attachment and neurite outgrowth by Nomizu et al564. This 
suggests that a subtle change of one amino acid to the sequence does not greatly affect the 
biological function of the molecule in terms of neurite outgrowth at the concentrations 
tested within this investigation.  
 
Previously “IKVAV” was thought to be the active site of laminin, and the sequence 
responsible for its neurite induction qualities, however, it was then discovered that a 
range of amino acid sequences were capable of neurite induction. Liesi et al identified the 
“RNIAEIIKDI” motif as playing an important role in neurite elongation and cell 
adhesion275. This was investigated through a competition assay whereby primary rat 
cerebellar neurons were cultured on a substrate coated with laminin and a synthetic 
peptide containing the “RNIAEIIKDI” sequence was added to the culture medium275. This 
resulted in the synthetic peptide competing for cellular binding against the laminin 
coating; therefore, fewer cells adhered to the growth substrate and developed neurites275.  
In addition to this Liesi et al also demonstrate the neurite promoting properties of 
“RNIAEIIKDI” in a traditional neurite outgrowth assay on growth substrates coated with 
the synthetic peptide275.  
 
Therefore, laminin has been well documented to enhance neurite outgrowth, playing an 
important role in vivo during neuronal development and also forming the basis of many in 
vitro cell culture substrates to enhance neuronal cultures. Specific neurite-promoting 
domains of laminin have been identified with “IKVAV” perhaps being the most widely 
studied, however more amino acid sequences are being uncovered to determine the 
specific molecular events that lead to laminin induction of neurite outgrowth. This is 
important as inhibition of laminin attachment and signalling is thought to be one of the 
mechanisms by which neurite outgrowth is inhibited in the injured spinal cord.   
  
6.1.3 The Role of Laminin in Neurite Inhibition 
 
The neurite enhancing properties of laminin are thought to be impaired in the glial scar 
that arises following spinal cord injury resulting in inhibition of neurite growth (for a 
comprehensive review of glial scar signalling see Chapter IV). Inhibitory molecules such 
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as those found on damaged myelin and CSPGs secreted from reactive astrocytes are 
thought to impair laminin-receptor binding, reducing the sensitivity of neurons to 
laminin-induced neurite generation.  
 
McKeon et al describe the culture of neurons upon glial scar tissue containing CSPGs, 
derived from injured rats317. Treatment with chondroitinase ABC, led to an increase in 
neurite outgrowth upon the inhibitory substrate, however this recovery effect was 
reversed when blocking antibodies to the laminin β2 chain were applied317. This suggests 
that recovery and growth of neurites within the injured spinal cord is dependent upon the 
presence of laminin and that CSPGs may act as inhibitors of laminin mediated growth. 
Similarly, Friedlander et al discuss the ability of CSPGs to inhibit ECM-neuronal 
interactions through binding to N-CAM adhesion molecules261. N-CAM and Ng-CAM are 
adhesion molecules with important roles in neuronal development and are known to bind 
laminin565,566. Friedlander et al identify the ability of CSPGs to bind to both N-CAM and Ng-
CAM inhibiting the ECM-neuronal interactions and resulting in neurite inhibition261,315.    
 
Similarly, the regenerative capacity of the PNS compared with the CNS is thought to be 
attributed to the laminin content of the ECM. Myelin inhibitors of neurite growth found in 
the injured central nervous system such as MAG have also been identified in the PNS, 
which was initially thought of as unusual due to the regenerative capacity of the PNS567–
569. However, a study by David et al describes the ability of laminin to overcome MAG 
mediated neurite inhibition and the differences between the ECM content of the PNS and 
CNS, resulted in the observation that the inability of CNS neurons to regenerate may be 
due to an absence of laminin in the ECM570.  
 
Understanding the interactions between the ECM and developing neurons is important to 
help unveil the developmental events that result in neuronal maturation. Due to its role in 
neurite inhibition, understanding the specific role of laminin in neurite outgrowth may be 
an important factor in the development of therapeutics and to increase our understanding 
of the events that occur following injury to the nervous system. 
 
6.1.4 In Vitro ECM Coatings 
 
As discussed previously (Chapter I), to create in vitro models that best reflect the in vivo 
system, each aspect of the cellular microenvironment should be considered161. This 
includes the biochemical composition of the ECM and is the reason why many cell-based 
models include the coating of growth substrates with ECM components161. ECM coating 
procedures usually require incubation of growth substrates with solutions containing the 
desired molecule, which then adsorb onto the growth surface571,572. 
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Most neuronal-based culture models require coating of growth substrates with laminin 
prior to cellular seeding to ensure correct neuronal development and neuritogenesis573–
579. For example, a neurite outgrowth assay described by Smit et al based on PC12 cells, 
requires different ECM coatings to promote either cellular proliferation or 
differentiation580. To induce neuritogenesis within this assay Transwell™ 3D culture 
inserts were coated with laminin to promote neurite growth, which can then be 
quantified. Protocols such as this harness the neurite promoting properties of laminin to 
enhance their models and provide a more physiologically relevant environment for 
neurite development by recapitulating the biochemical environment of the developing 
nervous system. 
 
6.1.5 Biomimetic Surfaces 
 
In vitro tissue and disease modelling is beginning to increase in popularity due to the 
ethical issuesand regularions associated with animal models. Therefore, there is a great 
deal of interest in recapitulating the native cellular microenvironment to produce the 
most physiologically relevant models possible. This includes recreating cellular-matrix 
interactions that are paramount to so many cellular functions. Presentation of ECM-
molecules to cells within culture systems can be achieved in many ways, including the use 
of ECM-based hydrogels such as collagen gels, traditional ECM adsorption coating or the 
use of biomimetic surfaces581.  
 
Biomimetic surfaces mimic many aspects of the ECM in tissues and can provide 
biochemical cues and cell-matrix interactions to promote tissue growth and formation581. 
There are two design strategies usually employed to produce functional biomimetic 
biomaterials, one of which involves the incorporation of soluble bioactive molecules such 
as growth factors into the biomaterial that are released over time to modulate tissue 
formation582–584. Another methodology involves the incorporation of peptide motifs or 
whole molecules by chemical or physical modification to present the bioactive sequences 
to cells cultured on the surface of the material585–588. There are many factors to consider in 
the design of biomimetic surfaces such as, concentration and spatial distribution of 
modified bioactive molecules, which must be optimised to produce the best possible 
growth surface581. 
 
Identification of specific bioactive domains within ECM-molecules that are responsible for 
receptor interaction, has allowed the generation of biomaterials containing just the 
bioactive sequence. The use of short bioactive peptides as oppose to whole ECM 
molecules is beneficial, as native ECM proteins are able to randomly fold which may 
inhibit presentation of the receptor-binding domain581. Short peptide sequences however, 
are more stable during the modification and coating process therefore in most cases the 
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modified peptide is available for cell binding581. Furthermore, the large-scale production 
of short peptide chains is more economically favourable and results in the same biological 
effect, as the active sequence of the molecule is presented581.  
 
Perhaps the most commonly used peptide incorporated into such systems is the “RGD” 
domain derived from fibronectin and laminin589–593. “RGD” is a motif heavily involved in 
cell adhesion and is incorporated into many biological surfaces to render surfaces 
adhesive that are usually inherently non-adhesive to cells594–596. Similarly, specific 
domains from laminin have been identified and incorporated into biomaterials to produce 
permissive growth environments for neuronal development and neurite extension. These 
include the “IKVAV”, “RNIAEIIKDI” and “YIGSR” laminin domains that induce neural 
differentiation and development in desired systems597–599.  
 
Peptides such as these have been immobilised on a series of materials including 
glass600,601, quartz602, metal oxide603 and polymers604,605, a number of coupling techniques 
have also been employed. One immobilisation technique involves the use of reactive 
moieties on the surface of the material (usually NH2) that react with functional groups 
such as COOH on the bioactive peptide581. Another approach can be the use of bi-
functional long spacer arm cross linkers that can immobilise the bioactive peptide to the 
growth surface whilst enabling the peptide to move flexibly within the culture 
enrionment602. A photochemical immobilisation method has been employed to couple 
peptides to polymer substrates that lack appropriate functional groups606. 
 
Biomimetic materials such as these provide a more physiological relevant 
microenvironment for the culture of cells, which has application purposes in the field of 
tissue engineering for both transplantation or in vitro tissue modelling581. Modified 
bioactive growth surfaces can also be used to elucidate cellular responses to specific 
biochemical cues, to help gain understanding into the downstream signalling events 
initiated by cell-matrix interactions607. Similarly, surfaces such as these provide 
opportunities to study cellular behaviour in a defined manner such as the effect upon 
cellular function of density and spatial distribution of bioactive domains581.  
 
 6.1.5.1 OrlaSURF Platform 
 
The OrlaSURF platform is a method of peptide immobilisation to provide biomimetic 
surfaces for cell culture and tissue engineering purposes. Initially optimised on gold 
surfaces the technology involves the use of an engineered N-terminal transmembrane 
domain from Esherichia coli outer membrane protein, Omp A608–610. Specific bioactive ECM 
motifs are then engineered into the flexible outer loops of Omp A and the protein attaches 
to the biomaterial through a single cysteine residue608–610. This results in the formation of 
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an orientated peptide monolayer. The space between the peptide motifs can then be filled 
using thiolipids or thioalkanes to ensure the active motifs are exposed. This technology 
results in stable, orientated monolayers of peptides, displaying the motifs of interest in a 
functional conformation and alleviating the many problems associated with adsorption 
coating608–610.  
 
OrlaSURF technology is now used to produce commercially available functionalised cell 
culture growth substrates that overcome some of the problems associated with other 
coating methods611. Orla surfaces contain peptide motifs displayed in the precise 
orientation for cellular engagement resulting in high levels of reproducibility and 
functionality, as shown in Figure 6-3612. The technology is based on the combination of 
robust bacterial proteins and thiliolipids, involving a surface-binding unit (SBU) that 
connects target proteins/motifs to growth surfaces.612 This allows for flexible engineering, 
as target peptides can be presented in a number of orientations such as loops, linear 
motifs or full-length peptides611. This technology can be used to functionalise a range of 
surfaces including gold, plastics, glass, polymers and metal oxides, along with offering the 
ability to produce heterogenous multi-protein surfaces or homogenous single-protein 
surfaces611.  
 
 
Fig 6-3: Comparison of traditional adsorption coating of growth substrates with the 
OrlaSURF platform.  
A schematic depicting the differences between traditional adsorption coating of growth 
substrates with ECM molecules and application of OrlaSURF, which immobilises peptide 
sequences in the correct orientation to interact with cells. OrlaSURF also allows for the 
presentation of whole ECM-proteins or smaller peptide motifs displayed in a loop or 
linear fashion. 
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Adsorption OrlaSURF 
Lack of orientation Precise orientation 
Denaturation Structurally intact 
Poor functionality Functionality retained 
Inaccessible active sites Accessible active sites 
Poor reproducibility Excellent reproducibility 
 
Table 6-1: Advantages of OrlaSURF platform over traditional adsorption coating. 
OrlaSURF immobilies specific peptide domains onto cell culture growth substrates in the 
correct orientation to interact with cells. This has advantages over traditional adsorption 
coating of growth substrates including enhanced reproducibility and functionality. 
 
This technology has previously been used to enhance cell adhesion upon substrates 
coated with various ECM-molecules. Cooke et al describe the culture of PC12 cells upon 
growth substrates coated by adsorption technique with collagens, fibronectin and laminin 
in comparison to substrates coated using an Omp A immobilisation technique610. It was 
found that cells were able to attach to growth substrates coated via Omp A and that each 
ECM molecule had varying effects upon cellular adhesion610.  
 
Another study by Cooke et al describes an application of this technology to investigate the 
ability of ECM-derived motifs to induce neuronal differentiation and neurite outgrowth in 
PC12 cells613. This study was able to identify specific neurite enhancing motifs and 
compare the ability of several ECM-derived amino acid sequences to induce 
neuritogenesis613. Sequences derived from collagen I and IV were found to enhance the 
number of neurites per cell and mean neurite length whereas a laminin motif “YIGSR” was 
found to enhance branching613. This demonstrates the application of such technology to 
study the important role of specific ECM-constituents in neuronal and neurite 
development. 
 
6.1.6 Conclusions 
 
The ECM provides biochemical cues that contribute toward the cellular 
microenvironment and recreating such cues is an important factor in the development of 
tissues and cell based models in vitro. Recapitulating aspects of the cellular 
microenvironment is important in ensuring that cellular behaviour is as similar to their in 
vivo counterpart as possible, therefore producing physiologically relevant and reliable in 
vitro models. The role of the ECM is particularly important in neuronal development, as 
integrin-ECM mediated signal transduction is important in the stimulation of neurite 
extension and guidance. Understanding the role of specific ECM-components in neurite 
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development such as laminin and its active domains has implications in the development 
of potential therapeutic interventions. For example, CSPG-mediated glial scar signalling 
may be targeted, as one mechanism of action of CSPGs is thought to be inhibition of 
laminin signalling. Furthermore, biomimetic surfaces offer novel, robust and reproducible 
bioactive growth substrates that enable investigations into the role of ECM-specific 
peptide domains in cellular processes. Initial studies have shown the application of 
OrlaSURF technology to study the role of ECM-derived motifs in the process of neuronal 
and neurite development. This caims to address the role of the ECM, with particular focus 
on the role of laminin, in neurite development and the application of OrlaSURF to study 
the process of neurite inhibition and recovery. 
 
 6.1.6.1 Chapter Aims 
 
This chapter aims to investigate the role of the ECM in the process of neurite 
development, along with the specific role of laminin in neuritogenesis. This chapter 
discusses the ability of several ECM-derived peptide motifs from collagen, laminin and 
fibronectin to induce neuritogenesis, along with identifying specific laminin domains that 
actively in the induce neuritogenesis. A comparison of traditional laminin adsorption 
coating and OrlaSURF laminin coating is also discussed within this chapter along with 
multiple analytical methodologies to compare the different coating techniques. 
Additionally this chapter also aims to provide a potential application of biomimetic 
surfaces in the study of myelin-induced neurite inhibition, a component of the glial scar 
that follows spinal cord injury.  
 
To investigate this process, this chapter describes the coating of surfaces via OrlaSURF 
with known inhibitors of neurite outgrowth including OMGP and Nogo (for a detailed 
review of Nogo and OMGP induced signalling see Chapter IV), and the ability of 
modulators of Rho A and ROCK to overcome myelin-induced inhibition. The aim of this is 
to help elucidate the molecular mechanisms that underpin myelin-mediated neurite 
inhibition and to provide a potential application of this technology as a screening tool to 
identify the ability of compounds to overcome inhibitory stimuli.   
 
We hypothesise that growth substrate coated laminin-derived domains will enhance 
neurite outgrowth in this model, as there is a wealth of evidence described in the 
literature that support the role of laminin in neurite development. We also hypothesise 
that coating of growth substrates with Nogo and OMGP found in the glial scar will 
negatively impact neurite outgrowth. This inhibition should be recovered through 
application of NEP 1-40, ibuprofen and Y-27632, to intervene at each stage of the 
downstream signalling cascade, activated by Nogo and OMGP. This will provide a 
potential application of the model to be used as a screening tool, either to detect 
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compounds capable of induction of inhibition or recovery of neurite outgrowth. Overall 
this chapter aims to functionalise Alvetex® scaffold to provide a biochemically favourable 
environment for the development of neurons and to produce a physiologically relevant 
model of neurite development and inhibition.  
 
 6.1.6.2 Chapter Objectives 
 
 Investigate the role of collagen, fibronectin and laminin-derived sequences in the 
induction of neurite outgrowth in 2D and 3D culture.  
 
 Determine the ability of Orla poly-D-lysine and laminin coating to induce neurite 
outgrowth compared with the standard coating solution of poly-D-lysine and 
laminin used to develop this human stem cell-derived model of neurite 
outgrowth.  
 
 Investigate the potential of laminin to enhance neurite outgrowth in a dose-
dependent manner. 
 
 Compare the effect of whole molecule laminin adsorption and Orla laminin 
coating on neurite outgrowth in 2D and 3D culture. 
 
 Determine the ability of a range of laminin-derived domains to induce neurite 
outgrowth in 2D and 3D culture. 
 
  Analyse the ability of OMGP and Nogo coatings to induce neurite inhibition in 2D 
and 3D culture. 
 
 Determine the ability of Rho A (ibuprofen) and ROCK inhibition (Y-27632) to 
overcome inhibition of neurite outgrowth mediated by the myelin inhibitors 
found in the glial scar (OMGP, Nogo).  
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6.2 Materials & Methods 
 
6.2.1 Seeding of Neurospheres on Orla Surfaces 
 
Cell culture growth surfaces coated using OrlaSURF technology (Orla Protein 
Technologies, Newcastle, UK) were used to culture neurospheres and to assess the impact 
of varying extracellular molecules on neurite outgrowth, including those found in the 
ECM. For 2D neurite outgrowth studies, neurospheres were seeded into 6-well tissue 
culture plates (Orla Protein Technologies) coated with a peptide of interest, which do not 
require any additional treatment. For 3D neurite outgrowth studies, neurospheres were 
seeded onto 6-well Alvetex® Scaffold (ReproCELL Europe) coated with a peptide of 
interest (Orla Protein Technologies). Coated Alvetex® Scaffolds were prepared by ethanol 
washing to ensure a hydrophilic surface for cell attachment and media permeation; this 
was achieved through briefly dipping the scaffold in 70 % ethanol for 10 seconds, 
followed by 2 washes in PBS. Neurospheres were seeded onto both 2D and 3D surfaces as 
described in 2.2.6.2 Seeding of Neurospheres for Neurite Outgrowth Assays. 
 
6.2.2 Coating of Growth Substrates with Laminin from Engelberth-Holm-Swarm 
Murine Sarcoma Basement Membrane      
 
Alvetex® Scaffold 12-well format inserts (Reinnervate) were prepared by plasma 
treatment using the K1050X Plasma Asher at a power level of 40 W, for 5 mins. Treated 
scaffolds and conventional 48-well tissue culture treated plates were coated overnight at 
room temperature with varying concentrations (0.05 – 50 µgmL-1) laminin coating 
solution. Coating solution was prepared by adding the desired volume of 1 mgmL-1 
Laminin from Engelberth-Holm-Swarm murine sarcoma basement membrane to PBS 
without Ca++, Mg++ to achieve the preferred concentration of coating. For example, to 
achieve a coating concentration of 50 µgmL-1, 0.5 mL of 1 mgmL-1 Laminin from 
Engelberth-Holm-Swarm murine sarcoma basement membrane was added to 9.5 mL PBS. 
To each well of a 48 well tissue culture plate, 150 μL coating solution was added and 300 
μL coating solution was added to each Alvetex® Scaffold. Following overnight incubation 
at room temperature, coating solution was removed and growth substrates were washed 
three times with PBS and stored in PBS prior to neurosphere seeding.  
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Sequence Molecule Product Code 
MNYYSNS Collagen IV ORLA165 
RGDS Fibronectin ORLA153 
YIGSR Laminin β1 ORLA163 
IKVAV Laminin α1 ORLA162 
IKVSV Laminin α2 ORLA189 
VRWGMQQIQLVV Laminin α5 ORLA230 
DITYVRLKF Laminin γ1 ORLA236 
RNAIAEIIKDI Laminin γ1 ORLA239 
- Nogo (Loop Configuration) ORLA51 
- Nogo (Linear Configuration) ORLA53 
- OMGP ORLA52 
 
Table 6-2: Orla motifs used to study the process of neurite development and 
inhibition.  
A range of peptide sequence domains used throughout this project from extracellular 
proteins. The OrlaSURF platform was used to coat growth substrates with these domains 
and present them to cells. This includes domains derived from components of the ECM 
such as laminins and also inhibitory molecules found on myelin debris of particular 
importance in glial scar signalling, such as OMGP and Nogo.   
 
 
6.3 Results 
 
6.3.1 Examining the Role of the Extra-Cellular Matrix in Neurite Outgrowth 
 
To investigate the role of particular ECM-derived amino acid sequences in neurite 
development, fully matured neurospheres were cultured on 2D surfaces coated using Orla 
technology with a selection of domains. Immunofluorescence images highlighting TUJ-1 
expression (green) reveal neurite outgrowth radiating from the central neurosphere 
(Figure 6-4Aa-d). Few neurites radiate from neurospheres cultured on the FLAG, control 
substrate (Figure 6-4Aa) whereas significant neurite outgrowth is visible from 
neurospheres cultured on ECM-coated surfaces (Figure 6-4Ab-d). Neurites generated 
from neurospheres cultured on collagen IV coated substrates appear shorter in length 
than those cultured on surfaces coated with the laminin YIGSR domain.  
 
The number of neurites per neurosphere (Figure 6-4B) was enhanced by all ECM-derived 
domains tested; however, only fibronectin and laminin-derived domains induced a 
significant enhancement in neurite number compared to FLAG. Fibronectin coating 
resulted in the generation of significantly more neurites than collagen IV and a laminin-
derived coating resulted in significantly more neurites than fibronectin. Similarly, neurite 
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density (Figure 6-4C) was significantly enhanced by all ECM domains tested, with again 
the laminin-derived YIGSR being responsible for the greatest generation of neurites. A 
similar trend was apparent in terms of neurite length (Figure 6-4D), as all ECM-derived 
domains induced a significant enhancement in neurite length and the laminin-derived 
YIGSR domain was responsible for the greatest enhancement in neurite length.  
 
Neurospheres were also cultured in 3D on Alvetex® Scaffold coated using Orla technology 
with each ECM-derived domain. Neurospheres remain on top of the scaffold (Figure 6-
5Aa,c,e,g,i) and TUJ-1 positive (green) neurites penetrate the depth of the 3D material and 
are visible from the bottom view of the scaffold (Figure 6-5Ab,d,f,h,j). Uncoated Alvetex® 
Scaffold (Figure 6-5Aa,b) from the same batch as those coated with Orla domains, was 
tested and few neurites were visible from the underside of the scaffold. Similarly, 
scaffolds coated with control FLAG peptide (Figure 6-5Ac,d), also generated few neurites 
as visible from the bottom view of the scaffold. Orla coating with all the ECM-domains 
tested (Figure 6-5Ae-j) resulted in a greater number of neurites that were visible from the 
bottom view of the scaffold, with the laminin YIGSR domain in particular appearing to 
have the most positive effect upon neurite penetration.  
 
A similar number of neurites were found to penetrate the scaffold (Figure 6-5B) in 
cultures based on uncoated scaffolds and control FLAG coated scaffolds. Coating of 3D 
growth substrates with ECM-derived sequences, resulted in a significant increase in 
neurite penetration compared with both the uncoated and FLAG controls. Similarly to 2D 
culture, the fibronectin-derived domain induced neurite growth to a significantly greater 
degree than collagen IV and the laminin-derived motif induced neurite outgrowth to a 
significantly greater extent than fibronectin.  
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Fig 6-4: The ECM component, laminin β-1 has neurite enhancing effects in 2D culture. 
Representative confocal images (A) of 2D neurite outgrowth from neurospheres cultured on Orla surfaces coated with either the control peptide Flag (Aa), a collagen IV motif 
(Ab), a fibronectin motif (Ac) or a laminin motif (Ad). Neurites are highlighted by expression of the pan-neuronal marker TUJ-1 (green) and nuclei are stained blue. Scale bars: 
200 μm. The number of neurites per neurosphere (B) (data represent mean ± SEM, n=33-45; 11-15 individual neurospheres were quantified from 3 independent replicates) is 
significantly enhanced by the coating of growth substrates with Orla ECM motifs compared with the control peptide and the Orla laminin β-1 motif was found to enhance the 
number of neurites per neurosphere to the greatest extent. A similar pattern is observed in the neurites density (C) (data represent mean ± SEM, n=33-45; 11-15 individual 
neurospheres were quantified from 3 independent replicates) of the aggregates, with the coating of growth substrates with ECM molecules enhancing nerite outgrowth, and 
laminin β-1 having the largest effect.  Neurite length (D) (data represent mean ± SEM, n=476-1340; between 476-1340 neurites were measured from 11-15 neurospheres per 
independent replicate, of which there were 3) is also enhanced by ECM coating, again being enhanced to the highest degree by the laminin β-1 motif. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 6-5: The ECM component, laminin β-1 has neurite enhancing effects in 3D culture. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold (Aa,c,e,g,i) coated with Orla ECM motifs. TUJ-1 (green) positive neurites 
have penetrated the entire depth of the 3D material (Ab,d,f,h,j) whereas nuclei (blue) are restricted to the cellular aggregate. Neurospheres were cultured on 
Alvetex® scaffold without protein coating (Aa,b), coated with the control peptide (Flag Ac,d) or coated with motifs from collagen IV (Ae,f), fibronectin (Ag,h) or 
laminin β-1 (Ai,j). Scale bars: 200 μm. The number of neurites penetrating each scaffold (B) (data represent mean ± SEM, n=13-15, 4-5 individual neurospheres 
were quantified from 3 independent replicates) is significantly enhanced with Orla protein coating and enhanced to the greatest degree by coating with the laminin 
β-1 motif. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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The ReproNeuro, iPSC-derived model of neuritogenesis, as described in Chapter III, is 
based upon the coating of growth substrates with particular ECM-derived products. It is 
recommended that ReproNeuro Glu cells are cultured on substrates coated with 
“ReproCoat” a coating mixture containing an unknown concentration of both laminin and 
fibronectin; however, the TERA2.cl.SP12 model of neuritogenesis involves the coating of 
growth substrates with 10 μgmL-1 laminin and poly-D-lysine. To compare the ability of 
each coating solution to induce neurite extension, ReproNeuro Glu-derived neurospheres 
were cultured on 2D substrates coated with each ECM-derived mixture using the 
traditional adsorption coating technique.  
 
Immunofluorescence analysis (Figure 6-6A) reveals significant neurite outgrowth from 
neurospheres cultured on substrates coated with each solution. However, neurites appear 
longer and more curved when cultured on substrates coated with ReproCoat (Figure 6-
6Aa) compared with poly-D-lysine and laminin coating (Figure 6-6Ab). Both the number 
of neurites (Figure 6-6B) and neurite density (Figure 6-6C) are similar from neurospheres 
cultured on each coating. However, neurite length (Figure 6-6D) is significantly enhanced 
on surfaces coated with ReproCoat as opposed to poly-D-lysine and laminin, perhaps 
suggesting a role for fibronectin in neurite elongation and extension. 
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Fig 6-6: ECM coating impacts neurite outgrowth from neurospheres formed from iPSC derived neuroprogenitor cells in 2D culture. 
Representative confocal images (A) of ReproNeuro Glu derived neurospheres cultured on 2D substrates coated with either ReproCoat (Aa) – a mixture of 
fibronectin and laminin coating solution, or 10 μgmL-1 poly-D-lysine and laminin coating solution (Ab) for 10 days. TUJ-1 (green) positive neurites radiate from the 
central cellular aggregate and nuclei are stained in blue.  Scale bars: 200 μm. Quantification of the number of neurites (B) and neurite density (C) (data represent 
mean ± SEM, n=3; due to limited cell availability 3 neurospheres from 1 population of cells were quantified) reveals little difference between the two coating 
solutions, however ReproCoat significantly enhances neurite length (D) (data represent mean ± SEM, n=3) when compared to poly-D-lysine and laminin coating 
solution. Unpaired T-test: *** = p < 0.001 
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The original TERA2.cl.SP12 model of neurite outgrowth developed in Chapter III involves 
the adsorption coating of 2D and 3D growth substrates with 10 μgmL-1 laminin and poly-
D-lysine solution. To test the ability of Orla technology to enhance neurite outgrowth 
compared with this standard model, neurospheres were cultured on 2D growth surfaces 
coated with various combinations of the laminin YIGSR domain and poly-D-lysine. 
Significant TUJ-1 positive (green) neurite outgrowth is evident from neurospheres 
cultured on surfaces coated with the conventional coating solution (10 μgmL-1 laminin 
and poly-D-lysine) (Figure 6-7Aa,b). Whereas, neurospheres cultured on Orla surfaces 
coated with either a mixture of 50 % YIGSR – 50 % Flag (Figure 6-7Ac,d) or 50 % poly-D-
lysine – 50 % Flag (Figure 6-7Ae,f) resulted in fewer, shorter neurites and neurite 
outgrowth was less uniform.  However, the coating of growth substrates with an Orla 50 
% YIGSR – 50 % poly-D-lysine mix (Figure 6-7Ag,h), resulted in significant neurite 
outgrowth, which appeared dense and neurites appeared longer than those generated 
from neurospheres on traditional adsorption coated surfaces. 
 
The number of neurites per neurosphere (Figure 6-7B) generated from neurospheres 
cultured on adsorption-coated poly-D-lysine and laminin surfaces was significantly 
enhanced compared with both 50 % Flag Orla mixes. Similarly, the number of neurites 
generated on Orla poly-D-lysine and laminin coating was significantly enhanced 
compared with both 50 % Flag Orla mixes. Both adsorption and Orla poly-D-lysine and 
laminin coatings generated a similar number of neurites per neurosphere that did not 
differ significantly.  
 
The neurite density (Figure 6-7C) of neurospheres cultured on adsorption-coated poly-D-
lysine and laminin-coated surfaces was significantly enhanced compared with all other 
conditions tested. Orla poly-D-lysine and laminin coating resulted in a significantly 
enhanced neurite density compared with either 50 % Flag Orla mixes. Neurite length 
(Figure 6-7D) was also enhanced by surfaces adsorption-coated with poly-D-lysine and 
laminin compared to both 50 % Flag Orla mixes. However, Orla laminin and poly-D-lysine 
coating resulted in significantly longer neurites than any other condition tested, including 
adsorption coating.  
 
Neurospheres were also cultured in 3D on Alvetex® scaffolds coated with poly-D-lysine 
and laminin, adsorption and Orla coatings. Neurospheres remain on top of the scaffold 
(Figure 6-8Aa,c,e,f), whereas TUJ-1 positive (green) neurites are visible from the 
underside of the scaffold (Figure 6-8Ab,d,f,h). Significant neurite outgrowth can be 
observed from adsorption-coated cultures (Figure 6-8Aa,b) whereas few neurites are 
visible from the underside of 50 % Flag Orla mix-coated scaffolds (Figure 8-6c-f). 
Significant neurite outgrowth is also visible from the underside of scaffolds coated with 
Orla poly-D-lysine and laminin (Figure 6-8Ag,h).  
 299 
The number of neurites penetrating the scaffold (Figure 6-8B) is significantly enhanced in 
cultures coated with Orla poly-D-lysine and laminin compared with any other condition 
tested. Adsorption poly-D-lysine and laminin coating results in increased neurite 
penetration compared with both 50 % Flag Orla mixes, however Orla poly-D-lysine and 
laminin coating results in the greatest number of neurites having penetrated the scaffold.  
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Fig 6-7: Coating of 2D growth substrates with 
Orla laminin β-1 and poly-D-lysine motifs 
enhances neurite length compared with 
adsorption coating.  
Representative confocal images (A) of 
neurospheres cultured on 2D surfaces coated in 
the traditional adsorption manner with 10 
μgmL-1 poly-D-lysine and laminin coating 
solution (Aa,b) or with laminin β-1 (Ac,d), poly-
D-lysine (Ae,f) or a combination of laminin and 
poly-D-lysine (Ag,h) Orla motifs. Neurite 
outgrowth is highlighted in green through 
staining for the pan-neuronal marker, TUJ-1 and 
nuclei are highlighted in blue. Scale bars: 200 
μm. The number of neurites per neurosphere 
(B) (data represent mean ± SEM, n=17-18; 5-6 
individual neurospheres were quantified from 3 
independent replicates) and neurite density (C) 
(data represent mean ± SEM, n=17-18; 5-6 
individual neurospheres were quantified from 3 
independent replicates) are both enhanced by 
the combination of Orla motifs as oppose to each 
motif displayed separately. However neurite 
outgrowth is not induced to the same level as 
that of the traditional adsorption coating. 
Neurite length (D) (data represent mean ± SEM, 
n=118-492; between 118-492 neurites were 
measured from 5-6 neurospheres per 
independent replicate, of which there were 3), is 
significantly enhanced by the mixture or Orla 
laminin and poly-D-lysine motifs compared with 
each motif-displayed separately and compared 
with traditional adsorption coating. One-way 
ANOVA with Tukey’s multiple comparisons: * = 
p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Fig 6-8: Coating of 3D growth substrates with Orla laminin β-1 and poly-D-lysine motifs enhances neurite outgrowth compared with adsorption coating 
Representative confocal images (A) of neurospheres cultured on Alvetex® scaffold coated in the traditional adsorption manner with 10 μgmL-1 poly-D-lysine and 
laminin coating solution (Aa,b) or with laminin β-1 (Ac,d), poly-D-lysine (Ae,f) or a combination of laminin and poly-D-lysine (Ag,h) Orla motifs. Neurospheres 
remain on top of the scaffold (Aa,c,e,g) whilst TUJ-1 (green) positive neurites penetrate the 3D material and are visible from below (Ab,d,f,h). Nuclei are stained 
blue.  Scale bars: 200 μm. Quantification of the number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=5-6; 1-2 individual neurospheres 
were quantified from 3 independent replicates) reveals that neurite outgrowth from scaffolds coated with the mixture of Orla laminin and poly-D-lysine motifs is 
enhanced compared with each motif displaced separately and compared with traditional adsorption coating. One-way ANOVA with Tukey’s multiple comparisons: * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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6.3.1.1 Investigation into the Neurite Enhancing Properties of Laminin 
 
To focus on the specific neurite enhancing properties of laminin and its specific domains, 
a dose response was conducted on 2D Orla-coated surfaces. Growth substrates were 
coated with various combinations of the “YIGSR” domain and control, Flag peptide to 
investigate the nature of laminin-induced neurite outgrowth. Few neurites radiated from 
neurospheres cultured on Flag control surfaces (Figure 6-9Aa,b), with a slight increase in 
visible neuritogenesis from 25 % and 50 % laminin mixes (Figure 6-9Ac-f).  Neurite 
outgrowth from 75 % laminin “YIGSR” (Figure 6-9Ag,h) coated surfaces appears more 
uniform and dense compared with Flag control coating alone and neurite outgrowth 
appears the most uniform from neurospheres cultured on substrates coated with 100 % 
“YIGSR” (Figure 6-9Ai,j). 
 
The number of neurites generated per neurosphere (Figure 6-9B) was enhanced in a dose 
dependent manner with increasing YIGSR content of the growth substrate coating 75 % 
and 100 % “YIGSR” coatings induced a significant increase in the number of neurites 
generated from neurospheres, compared with control and 25 % “YIGSR” coatings. 
Similarly, neurite density (Figure 6-9C) is also enhanced in a dose dependent manner with 
increasing YIGSR content of the Orla coating. Both 75 % and 100 % “YIGSR” coatings were 
found to enhance neurite density significantly compared with FLAG.  
 
Neurite length (Figure 6-9D) again, was enhanced by the laminin “YIGSR” domain content 
of the growth substrate coating in a dose dependent manner. Orla coatings containing the 
highest content of the “YIGSR” domain (75 – 100 %) resulted in the growth of neurites 
with significantly enhanced length compared with FLAG and other conditions tested such 
as 25 % laminin coating.    
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Fig 6-9: Coating of 2D growth substrates 
with the Orla laminin β-1 motif enhances 
neurite outgrowth in a dose dependent 
manner. 
Representative confocal images (A) of 
neurospheres cultured on 2D substrates 
coated with an increasing content of the Orla 
laminin β-1 motif mixed with the control 
peptide, flag. Neurites are positive for TUJ-1 
(green) and nuclei are stained blue and 
remain in the central body of the cellular 
aggregate.  Scale bars: 200 μm. Both the 
number of neurites per neurosphere (B) 
(data represent mean ± SEM, n=18; 6 
individual neurospheres were quantified 
from 3 independent replicates) and the 
neurite density (C) (data represent mean ± 
SEM, n=18; 6 individual neurospheres were 
quantified from 3 independent replicates) 
are enhanced in a dose dependent manner 
with increasing laminin β-1 coating content. 
Similarly, the average length of neurites (D) 
(data represent mean ± SEM, n=224-419; 
between 224-419 neurites were measured 
from 6 neurospheres per independent 
replicate, of which there were 3) is also 
enhanced by increasing laminin β-1 content 
of the substrate coating. Therefore, the Orla 
laminin β-1 motif has neurite enhancing 
properties in 2D culture. One-way ANOVA 
with Tukey’s multiple comparisons: * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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In order to compare Orla laminin coatings directly with traditional adsorption coatings, a 
2D laminin adsorption dose response was carried out. This involved the culture of 
neurospheres on 2D growth substrates coated with laminin from Engelberth-holm-swarm 
murine sarcoma basement membrane, in a traditional adsorption fashion. A range of 
concentrations of laminin coatings (0.5 – 50 μgmL-1) were tested and at the lowest 
concentrations 0.5 – 1 μgmL-1 (Figure 6-10Aa-d), neurite outgrowth was not very uniform, 
with whole areas of the neurosphere free from outgrowth. This improved with increasing 
laminin concentration with 50 μgmL-1 (Figure 6-10Ak,l) laminin coating resulting in more 
uniform neurite outgrowth and neurites appeared longer.  
 
Both the number of neurites per neurosphere (Figure 6-10B) and neurite density (Figure 
6-10C) increased in a dose dependent manner with increasing laminin concentration.  
Similarly, neurite length (Figure 6-10D) also generally increased with increasing laminin 
coating concentration, however the data point at 10 μgmL-1 perhaps appears to be 
unusually high and could be anomalous.  
 
To compare the Orla “YIGSR” laminin motif with the laminin adsorption coating, two 
distinct methods of comparison were employed. The first of which involves the plotting of 
the Orla YIGSR dose response side-by-side with the adsorption dose response (Figure 6-
11A-C) for each variable measured within the 2D neurite outgrowth assay (i.e neurite 
number (Figure 6-11A), neurite density (Figure 6-11B) and neurite length (Figure 6-
11C)). This method of comparison was termed the “Estimated Method”, as the two dose 
responses can be compared by reading from the graph the laminin concentration that 
each Orla coating is equivalent to. This produces an equivalent range of laminin 
concentrations for each Orla substrate, for example 100 % Orla “YIGSR” coating produces 
a response in terms of neurite number that lies between 10 – 20 μgmL-1 laminin 
adsorption coating.  
 
Another method of comparison employed to compare Orla and adsorption laminin 
coatings involved the use of the laminin adsorption dose response as a standard curve 
(Figure 6-11D-F). A linear regression was fitted through each data set (blue line) and the 
equation of the line of best fitted was calculated. From this the unknown laminin 
concentration (x) could be calculated for each Orla “YIGSR” dose, from the known 
response (y) in terms of neurite number (Figure 6-11D), neurite density (Figure 6-11E) 
and neurite length (Figure 6-11F). This method of comparison was termed the “Numerical 
Method” and a range of equivalent laminin concentrations were also obtained from the 
analysis of each measure of 2D neurite outgrowth.   
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Fig 6-10: Conventional laminin 
coating of 2D growth substrates 
enhances neurite outgrowth in a dose 
dependent manner. 
Representative confocal images (A) of 
neurospheres cultured on 2D substrates 
coated with a range of concentrations 
(0.5 – 50 μgmL-1) of laminin from 
Engelbreth-Holm-Swarm murine 
sarcoma basement membrane. TUJ-1 
(green) positive neurites can be seen to 
extend radially from the central cellular 
aggregate with nuclei (blue) remaining 
within the body of cellular mass. Scale 
bars: (Aa,c,e,g,i,k): 200 μm (Ab,d,f,h,j,l): 
50 μm. The number of neurites per 
neurosphere (B) (data represent mean ± 
SEM, n=18-27; 6-9 individual 
neurospheres were quantified from 3 
independent replicates) and the neurite 
density (C) (data represent mean ± SEM, 
n=18-27; 6-9 individual neurospheres 
were quantified from 3 independent 
replicates) gradually increases in a dose 
dependent fashion with increasing 
laminin coating concentration. Neurite 
length (D) (data represent mean ± SEM, 
n=66-100; between 66-100 neurites 
were measured from 6-9 neurospheres 
per independent replicate, of which 
there were 3) also has a positive 
correlation with laminin coating 
concentration.  
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Fig 6-11: Comparison of Orla laminin β-1 coating with conventional laminin coating in 2D culture. 
Neurite outgrowth from neurospheres cultured on 2D substrates coated with either the Orla laminin β-1 motif or with laminin from Engelbreth-Holm-Swarm 
murine sarcoma basement membrane was compared using two different methodologies. Neurite number, density and length were all compared either using 
an estimation method (A,B,C) or numerical method (D,E,F) of comparison. The estimation method of comparison involved plotting the Orla and conventional 
coating data side by side on the same graph, enabling the concentration of laminin coating solution that each Orla value was equivalent to, to be read from the 
graph. The numerical method of comparison involved using a dose response of neurite outgrowth against conventional laminin coating concentration (taken 
from Fig 6-7) as a standard curve. A linear regression was then fit to the standard curve and the linear equation could then be derived. Each equation was then 
rearranged to make x the subject and y (the average neurite number, density or length for each Orla laminin condition) could then be substituted into the 
equation to find the laminin concentration that each Orla condition was equivalent to. 
 
 
 307 
 
Therefore, from each method of comparison, a range of laminin concentrations was 
obtained based on the analysis of each variable measured in 2D culture (Table 6-3). One 
limitation of the “estimated method” of comparison was that neurite length from the Orla 
surfaces surpassed the maximal concentration of adsorption laminin tested (50 μgmL-1), 
whereas the numerical method allows for extrapolation, providing a more accurate 
representation of each concentration.  
 
 
 
 
Table 6-3: Summary of Orla laminin β-1 coating and conventional laminin coating 
comparison in 2D. 
The laminin concentration that each Orla laminin β-1 condition is equivalent to in 2D as 
derived from both the estimated method and numerical method of comparison. 
 
 
 
A laminin adsorption dose-response was also carried out in 3D culture, again to allow for 
a comparison between Orla “YIGSR” and traditional whole molecule adsorption coating. 
As in all 3D neurite outgrowth assays, neurospheres remained on top of the scaffold 
(Figure 6-12Aa,c,e,g,i,k), whereas TUJ-1 positive (green) neurites penetrate the depth of 
the 3D material as visible from the underside of the scaffold (Figure 6-12Ab,d,f,h,j,l). Few 
neurites are visible from the bottom view of scaffolds coated with low concentrations of 
laminin (0.5 – 10 μgmL-1), whereas significant neurite outgrowth can be observed in 3D 
cultures coated with 20 – 50 μgmL-1. Quantification of the number of neurites penetrating 
each scaffold (Figure 6-12B) reveals that neurite penetration increases in a dose 
dependent manner with increasing laminin concentration, with 5 – 50 μgmL-1 laminin 
coating evoking the largest response in neurite growth in 3D culture.  
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Fig 6-12: Conventional laminin coating of 3D growth substrates enhances neurite outgrowth in a dose dependent manner. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold (Aa,c,e,g,i,k) coated in a range of concentrations (0.5 – 50 μgmL-1) of 
laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane.  TUJ-1 (green) positive neurites can be seen to have penetrated the scaffold depth 
and are visible from the underside of the scaffold (Ab,d,f,h,j,l) while nuclei (blue) remain within the central body of the neurosphere. Scale bars: 200 μm. The 
number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=9; 3 individual neurospheres were quantified from 3 independent replicates) 
increases in a dose dependent manner with increasing laminin concentration.  
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Similarly to 2D culture, both the “Estimated” (Figure 6-13A) and “Numerical” (Figure 6-
13B) methods of comparison were employed to compare 3D neurite outgrowth on 
scaffolds coated with Orla “YIGSR” and traditional laminin adsorption coating. From the 
estimation method of comparison it was determined that the “YIGSR” domain resulted in 
a neurite outgrowth response similar to 1 – 5 μgmL-1 laminin adsorption coating (Table 6-
4), and from the numerical method, it was calculated that 3D neurite outgrowth on 
scaffolds coated with “YIGSR” was equivalent to 5.33 μgmL-1 laminin coating (Table 6-4). 
Therefore, a similar result was obtained from both methods of comparison, suggesting 
that results obtained from this comparison of laminin coatings, are reliable and robust.  
 
 
 
 
 
 
 
Fig 6-13: Comparison of Orla laminin β-1 coating with conventional laminin coating 
in 3D culture. 
Neurite outgrowth from neurospheres cultured on Alvetex® scaffold coated either with 
Orla laminin β-1 or with laminin from Engelbreth-Holm-Swarm murine sarcoma 
basement membrane was compared using two different methodologies. The number of 
neurites penetrating the scaffold for each concentration of conventional laminin coating 
solution was plotted side by side with the number of neurites penetrating the scaffold 
when coated with Orla laminin β-1. The concentration of laminin coating solution 
equivalent to the same level of neurite outgrowth as the Orla laminin β-1 motif was then 
read from the graph, this is the estimation method of comparison (A). However, in the 
numerical method of comparison, a line of best fit was fitted through the points of the 
dose response between conventional laminin coating concentration and the number of 
neurites penetrating the scaffold (taken from Fig 6-10), an equation for the line was then 
derived. This equation was then rearranged to make x the subject and y (the average 
number of neurites penetrating the scaffold for Orla laminin β-1) was then substituted 
into the equation to calculate the equivalent concentration of laminin coating solution. 
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Table 6-4: Summary of Orla laminin β-1 coating and conventional laminin coating 
comparison in 3D. 
The laminin concentration that the Orla laminin β-1 coating is equivalent to in 3D as 
derived from both the estimated method and numerical method of comparison. 
 
 
The impact of several other Orla laminin-derived domains on neurite outgrowth was 
tested in 2D culture, including the “IKVAV” motif of laminin α1 that has been well 
documented to promote neurite outgrowth. Neurospheres were cultured on 2D tissue 
culture plastic coated with each Orla laminin-derived domain and significant neurite 
outgrowth can be seen to radiate from neurospheres cultured on most laminin-coated 
substrates (Figure 6-14A). However, some laminin-derived domains such as 
“VRWGMQQIQLVV” (Figure 6-14Ag,h) and “DITYVRLKF” (Figure 6-14k,l) appear to 
produce less neurites than the control FLAG coating  (Figure 6-14Aa,b).  
 
The number of neurites generated per neurosphere (Figure 6-14B) is enhanced by most 
laminin-derived amino acid sequences, with the exception of “VRWGMQQIQLVV” and 
“DITYVRLKF” which resulted in a reduction in neurite number compared with control 
FLAG. However, only the “IKVAV” motif resulted in a signficiant increase in neurite 
outgrowth compared with the control coating. The impact of each laminin-derived 
domain on neurite density (Figure 6-14C) was similar to the impact of each domain upon 
neurite number. Most laminin-derived domains resulted in a small increase in neurite 
density; however, both “VRWGMQQIQLVV” and “DITYVRLKF” resulted in a reduction in 
neurite density compared with FLAG.  
 
Furthermore, neurite length (Figure 6-14D) differs little between each laminin coating 
with only the “YIGSR” domain resulting in a massive enhancement of neurite length. 
“IKVAV” also results in a smaller enhancement of neurite length, which is significant 
compared with control neurites. 
 
Neurospheres were also cultured in 3D upon Alvetex® Scaffold coated with the same Orla 
laminin-derived motifs that were used for 2D neurite outgrowth assays. Neurospheres 
remained on top of each scaffold (Figure 6-15Aa,c,e,g,i,k,m), whereas TUJ-1 positive 
neurites (green) can be seen to have penetrated and exited each scaffold, as visible from 
the bottom view of the scaffold (Figure 6-15Ab,d,f,h,j,l,n). Fewer neurites are visible from 
the bottom view of scaffolds coated with “DITVRLKF” (Figure 6-15Ak,l) than the other 
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conditions tested, with “IKVAV” (Figure 6-15Ac,d) and “IKVSV” (Figure 6-15Ae,f) coatings 
resulting in a large number of visible neurites from the bottom view of each scaffold. 
 
The number of neurites penetrating the scaffold (Figure 6-15B) in the case of each Orla 
coating was significantly enhanced compared with FLAG by the “RNAIAEIIKDI” motif only. 
Both “IKVAV” and “IKVSV” motifs resulted in a slight increase in neurite outgrowth within 
3D culture, however, “VRWGMQQIQLVV”, “YIGSR” and “DITYVRLKF” motifs induced 
neurite outgrowth to a similar level as the control FLAG surface.  
 
A comparison between each Orla laminin-derived motif and whole molecule laminin 
adsorption coating for 2D and 3D neurite outgrowth was carried out. This involved the 
use of both “Estimated” (Figure 6-16) and “Numerical” methods of comparison to produce 
a range of equivalent laminin concentrations based on the variety of aspects of 2D and 3D 
neurite outgrowth measured (i.e number of neurites per neurosphere (Figure 6-16A), 
neurite density (Figure 6-16B), neurite length (Figure 6-16C) and 3D neurite outgrowth 
(Figure 6-16D)). The “YIGSR” and “RNAIAEIIKDI” domains performed particularly well in 
terms of most aspects of neurite outgrowth, resulting in a similar level of neurite 
outgrowth as high concentrations of laminin adsorption coating (Table 6-5). Again, the 
“Numerical” method of comparison resulted in a more accurate range of laminin 
concentrations; however, both methodologies produce similar numerical values. 
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Fig 6-14: Identification of neurite 
promoting domains of laminin in 2D 
culture. 
Representative confocal images of 
neurospheres cultured on 2D Orla 
substrates coated with a range of laminin 
domains (A). Neurite outgrowth is 
highlighted by positive staining for TUJ-1 
(green) and nuclei are stained in blue. Scale 
bars: (Aa,c,e,g,i,k,m): 200 μm (Ab,d,f,h,j,l,n): 
50 μm Quantification of the number of 
neurites per neurosphere (B) (data 
represent mean ± SEM, n=15; 5 individual 
neurospheres were quantified from 3 
independent replicates) and neurite density 
(C) (data represent mean ± SEM, n=15; 5 
individual neurospheres were quantified 
from 3 independent replicate) reveals that 
some motifs such as “IKVAV” and “IKVSV” 
enhance neurite outgrowth, whereas others 
such as “VRWGMQQIQLVV” and 
“DITYVRLKF” are inhibitory to neurite 
outgrowth. Similarly, the average length of 
neurites (D) (data represent mean ± SEM, 
n=184-354; between 184-354 neurites 
were measured from 5 neurospheres per 
independent replicate, of which there were 
3) reveals that “YIGSR” clearly impacts 
neurite length to a greater degree than the 
other motifs tested. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Fig 6-15: Identification of neurite promoting domains of laminin in 3D culture. 
Representative confocal images of neurospheres cultured on top of Alvetex® scaffold coated using Orla technology with a range of laminin domains (A). 
Neurospheres reside on top of the scaffold (Aa,c,e,g,i,k,m) whilst TUJ-1 positive neurites (green) penetrate the depth of the scaffold and are visible from the 
underside (Ab,d,f,h,j,l,n). Scale bars: 200 μm. Quantification of the number of neurites penetrating the scaffold (B) (data represent mean ± SEM, n=9; 3 individual 
neurospheres were quantified from 3 independent replicates) reveals enhancement of neurite outgrowth by “IKVAV”, “IKVSV” and “RNAIAEIIKDI” motifs. . One-way 
ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
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Fig 6-16: Comparison of Orla laminin 
motifs with laminin coated dose response 
using the estimated method of comparison.  
A side-by-side comparison of traditional 
laminin adsorption coating and each Orla 
laminin motif to determine the range of 
laminin coating that each motif is equivalent 
to in terms of number of neurites per 
neurosphere (A), neurite density (B), neurite 
length (C) and the number of neurites 
penetrating the scaffold in 3D culture (D).  
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Table 6-5: Comparison of Orla laminin motifs with traditional adsorption coating of 
laminin using the estimated and numerical methods of comparison.  
A table comparing the range of laminin concentrations which each motif is equivalent to 
in terms of neurite number, density, length and penetration in 3D culture. The estimated 
method involves the side-by-side plotting of each data set adjacently (Figure 6-16) 
whereas the numerical method involves the analysis of a regression plotted through a 
laminin standard curve (Figure 6-11).  
 
 
6.3.2 Inhibition of Neurite Outgrowth by Myelin Inhibitors found in the Glial Scar 
 
To further investigate the molecular mechanisms that underpin neurite inhibition in the 
glial scar that forms following spinal cord injury, in addition to investigations outlined in 
Chapter IV, Orla surface technology was also used to functionalise 2D and 3D growth 
substrates with inhibitory molecules found in the glial scar. The myelin inhibitors of 
neurite outgrowth such as Nogo and OMGP, are found on myelin debris in the glial scar 
and activate NgRs to induce activation of Rho A and ROCK which ultimately leads to 
remodelling of the actin cytoskeleton along with inhibition of neurite growth and 
extension (reviewed by Figure 6-17)32,309,323–325,327,331,614.  
 
Therefore, to produce a more standardised model of neurite inhibition, to investigate the 
potential downstream signalling mechanisms involved in myelin-induced inhibition, 2D 
growth substrates were coated with OMGP and Nogo motifs to assess their effects upon 
neurite outgrowth. Neurospheres cultured on control surfaces (Figure 6-18Aa,b) generate 
a significant number of neurites that radiate from the central neurosphere, whereas, those 
cultured on OMGP (Figure 6-18Ac,d) coated 2D surfaces generate very few neurites. 
Similarly, neurite outgrowth from neurospheres cultured on substrates coated with Nogo 
in its traditional loop configuration (Figure 6-18Ae,f) is much less uniform with whole 
areas of the neurosphere free from neurite outgrowth. The Nogo sequence was also 
presented to cells in a linear configuration to determine if the loop structure is essential 
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for function, the linear Nogo sequence (Figure 6-18Ah,g) resulted in extension of few TUJ-
1 positive (green) extensions. Similarly, a 50:50 coating mix of the two Nogo 
configurations (Figure 6-18Ai,j) resulted in the extension of few; short neurites compared 
with neurospheres cultured on FLAG coated surfaces. 
 
 
 
 
 
Fig 6-17: Myelin-induced inhibition of neurite outgrowth in the glial scar. 
Inhibitory molecules such as Nogo-66, MAG and OMGP present on myelin debris released 
from damaged neurons induce growth cone collapse and neurite retraction in the glial 
scar. This is achieved through activation of the Nogo receptor (NgR) which leads to 
activation of the Rho A and ROCK signalling pathway. Activation of ROCK results in 
stabalisation of actin filaments and growth cone collapse, leading to the inability of 
neurons to regenerate neuritic processes.   
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The number of neurites per neurosphere (Figure 6-18B) was significantly reduced by the 
coating of growth substrates with each inhibitory motif compared with the control, FLAG 
coating. The Nogo linear configuration was also found to significantly reduce the number 
of neurites generated per neurosphere compared with both OMGP and Nogo loop motifs. 
Neurite density (Figure 6-18C) was also significantly reduced by all inhibitory coatings, 
with the Nogo linear domain inducing neurite inhibition to the greatest extent and 
significantly reducing neurite outgrowth further than OMGP.  
 
Similarly to neurite number and density, neurite length (Figure 6-18D) was also 
significantly inhibited compared with control FLAG, by all inhibitory coated surfaces. The 
Nogo loop domain also significantly inhibited neurite length to a greater degree than 
OMGP or the 50:50 Nogo Mix coatings.  
 
In 3D culture, neurospheres remained on top of Alvetex® scaffold (Figure 6-19Aa,c,e,g,i) 
with TUJ-1 positive (green) neurites penetrating the scaffold and exiting from the bottom 
of the 3D material (Figure 6-19Abd,f,h,j). Significant neurite penetration can be observed 
from the underside of FLAG-coated (Figure 6-19Aa,b) scaffolds whereas few neurites 
visibly penetrate the inhibitory-coated materials (Figure 6-19c-j).  Quantification reveals 
that neurite penetration (Figure 6-19B) is reduced by coating of the 3D growth 
environment with each myelin inhibitory molecule, with only the 50:50 mix of each Nogo 
configuration inducing a significant reduction in neurite outgrowth compared with FLAG.  
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Fig 6-18: Orla motifs found on inhibitory 
molecules within the glial scar, induce 
neurite inhibition in 2D culture. 
Representative confocal images (A) of 
neurospheres cultured on 2D surfaces 
coated with a control motif (Aa,b), an OMGP 
motif (Ac,d), a Nogo motif in a loop (Ae,f) or 
linear configuration (Ag,h) and a mixture of 
the two Nogo configurations (Ai,j). Neurite 
outgrowth is highlighted in green by 
positive expression of the pan-neuronal 
marker TUJ-1 and nuclei are stained in blue. 
Scale bars: (Aa,c,e,g,i): 200 μm (Ab,d,f,h,j): 
50 μm. Neurite number (B) (data represent 
mean ± SEM, n=9; 3 individual neurospheres 
were quantified from 3 independent 
replicates), density (C) (data represent 
mean ± SEM, n=9; 3 individual neurospheres 
were quantified from 3 independent 
replicates) and length (D) (data represent 
mean ± SEM, n=118-492; between 118-492 
neurites were measured from 3 
neurospheres per independent replicate, of 
which there were 3) are all inhibited by the 
inhibitory motifs with length being inhibited 
to a greater degree by the Nogo loop 
configuration and number/density being 
inhibited a greater degree by the Nogo 
linear configuration. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Fig 6-19: Orla motifs found on inhibitory molecules within the glial scar, induce neurite inhibition in 3D culture.  
Representative confocal images (A) of neurospheres cultured on Alvetex® scaffold coated with a control motif (Aa,b), an OMGP motif (Ac,d), a Nogo motif in a loop 
(Ae,f) or linear configuration (Ag,h) and a mixture of the two Nogo configurations (Ai,j). Neurospheres remain on top of the scaffold (Aa,c,e,g,i) and TUJ-1 (green) 
positive neurites penetrate the 3D material and are visible from below (Ab,d,f,h,j). Nuclei are stained blue. Scale bars: 200 μm. Quantification of the number of 
neurites penetrating the 3D material (B) (data represent mean ± SEM, n=5-6; 1-2 individual neurospheres were quantified from 3 independent replicates) reveals 
that all motifs inhibit neurite outgrowth compared with the control flag peptide and the mixture of the two Nogo domains inhibits neurite outgrowth to the greatest 
degree. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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6.3.2.1 Recovery of Myelin-induced Neurite Inhibition through Modulation 
Nogo Receptor Signalling 
 
Inhibition of several aspects of NgR signalling has been demonstrated to restore 
functional recovery in animal models of SCI. For this reason, small molecule inhibitors 
have been added to the culture medium of 2D and 3D neurite outgrowth assays based on 
growth substrates coated with Orla inhibitory motifs (Nogo/OMGP). This demonstrates 
the potential application of this model to be used a screening tool to investigate the ability 
of small molecules to overcome myelin-induced neurite inhibition. The small molecules 
tested in this chapter include the selective ROCK inhibitor – Y-27632, inhibitor of Rho A – 
ibuprofen and an NgR antagonist – NEP 1-40. All of which inhibit either NgR signalling 
directly (NEP 1-40)336,357 or downstream signal transduction (Y-2763223,204,209,366 and 
ibuprofen30,284,365,368,372) with the aim of restoring normal neurite outgrowth.   
 
   6.3.2.1.1 Recovery of Nogo-mediated Inhibition 
 
Neurospheres cultured in 2D on control FLAG-coated substrates (Figure 6-20Aa,b) 
generate a significant volume of TUJ-1 positive (green) neurites. However, neurospheres 
cultured on Nogo-coated substrates (Figure 6-20Ac,d) generate very few visible neurites. 
Supplementation of the culture medium with 10 μM Y-17632 (Figure 6-20Ae,f) resulted in 
the generation of a large number of neurites with neurite outgrowth appearing enhanced 
compared to that generated from the control surface. Treatment with 100 μM ibuprofen 
(Figure 6-20Ag,h) resulted in the generation of a similar number of neurites as the control 
surface, as did treatment with 1 μM NEP 1-40 (Figure 6-20Ai,j). 
 
The number of neurites per neurosphere (Figure 6-20B) was reduced by Nogo coating 
alone and with the addition of Y-27632 to the culture medium; neurite number was 
significantly enhanced compared with both Nogo coating and FLAG coating without 
medium supplementation. Similarly, ibuprofen treatment significantly enhanced neurite 
number compared with Nogo coating alone, and slightly enhanced neurite outgrowth 
compared with the control FLAG substrate. NEP 1-40 supplementation restored neurite 
number to a similar level as the control FLAG-coated surface.  
 
A similar trend was observed in terms of the density of neurite outgrowth (Figure 6-20C), 
which was significantly inhibited by Nogo coating. Neurite density was also significantly 
enhanced by the addition of Y-27632 to the culture medium both compared to FLAG and 
Nogo-coated substrates. Ibuprofen treatment significantly enhanced neurite density 
compared with Nogo and restored neurite density to a similar level as the control FLAG 
coating. Similarly, NEP 1-40 treatment also restored neurite density to a similar level as 
the control.  
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Neurite length (Figure 6-20D) was also reduced by Nogo coating and was significantly 
enhanced by Y-27632 treatment compared with FLAG coating alone. Ibuprofen treatment 
however, further inhibited neurite length compared with Nogo coating alone and NEP 1-
40 treatment had little effect upon neurite length.  
 
Neurospheres were also cultured in 3D on Alvetex® scaffold coated with Flag (Figure 6-
21Aa,b) or Nogo (Figure 6-21Ac,d) and supplemented with Y-27632 (Figure 6-21Ae,f), 
ibuprofen (Figure 6-21Ag,h) or NEP 1-40 (Figure 6-21i,j). Neurite outgrowth is visible 
from the underside of scaffolds coated with the control FLAG peptide, whereas, little to no 
neurite outgrowth is visible from the bottom view of scaffolds coated with the Orla Nogo 
motif. Treatment with 10 μM Y-27632 resulted in a large enhancement of neurite 
outgrowth, with a huge network of intertwining neurites becoming visible from the 
bottom view of the scaffold. Both ibuprofen and NEP 1-40 treatment resulted in neurite 
penetration through the inhibitory 3D growth matrix; however, enhancement comparable 
to that of Y-27632 was not observed.  
 
Quantification of the number of neurites penetrating each scaffold (Figure 6-21B) reveals 
that neurite penetration in 3D culture was inhibited by Nogo coating of Alvetex® scaffold. 
Treatment with Y-27632 significantly enhanced neurite penetration compared with both 
FLAG and Nogo coatings alone, whilst, ibuprofen and NEP 1-40 treatment restores neurite 
penetration in the inhibitory growth environment, to a similar level as control FLAG.  
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Fig 6-20: Recovery of Orla Nogo 
mediated neurite inhibition through 
inhibition of Nogo receptor signalling 
and its downstream pathway in 2D 
culture. 
Representative confocal images of 
neurospheres cultured on Orla inhibitory 
surfaces coated with Nogo (A) and media 
supplementation with 15 μM Y-27632 (a 
selective ROCK inhibitor) (Ae,f), 500 μM 
ibuprofen (inhibitor of Rho A) (Ag,h) or 1 
μM NEP 1-40 (Nogo receptor antagonist 
peptide) (Ai,j). Scale bars: (Aa,c,e,g,i): 200 
μm (Ab,d,f,h,j): 50 μm. Quantification of the 
number of neurites per neurosphere (B) 
(data represent mean ± SEM, n=15; 5 
individual neurospheres were quantified 
from 3 independent replicates) and neurite 
density (C) (data represent mean ± SEM, 
n=15; 5 individual neurospheres were 
quantified from 3 independent replicates) 
demonstrates the ability of Nogo to induce 
neurite inhibition, which is recovered by 
each media supplement. Neurite length (D) 
(data represent mean ± SEM, n=45-391; 
between 45-391 neurites were measured 
from 5 neurospheres per independent 
replicate, of which there were 3) is 
enhanced by Y-27632 and inhibited in all 
other conditions. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
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Fig 6-21: Recovery of Orla Nogo mediated neurite inhibition through inhibition of Nogo receptor signalling and its downstream pathway in 3D culture. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold coated with an Orla Nogo motif and culture medium supplemented with 15 
μM Y-27632 (a selective ROCK inhibitor) (Ae,f), 500 μM ibuprofen (inhibitor of Rho A) (Ag,h) or 1 μM NEP 1-40 (Nogo receptor antagonist peptide) (Ai,j). 
Neurospheres remain on top of the scaffold with nuclei being stained blue (Aa,c,e,g,i) whereas TUJ-1 positive neurites (green) penetrate the depth of the 3D 
material  (Ab,d,f,h,j ). Scale bars: 200 μm. Quantification of the number of neurites penetrating the 3D material (B) (data represent mean ± SEM, n=9; 3 individual 
neurospheres were quantified from 3 independent replicates) reveals that ibuprofen and NEP 1-40 recover Nogo-mediated inhibition to a level that is similar to the 
control and Y-27632 enhances neurite outgrowth to a level greater than the control. One-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001. 
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   6.3.2.1.2 Recovery of OMGP-mediated Inhibition 
 
Neurospheres were also cultured in 2D on growth substrates coated with the control 
FLAG (Figure 6-22Aa,b) and inhibitory OMGP (Figure 6-22Ac,d) sequences with Y-27632 
(Figure 6-22Ae,f), ibuprofen (Figure 6-22Ag,h) or NEP 1-40 (Figure 6-22Ai,j) 
supplementation. Significant neurite outgrowth visibly radiated from neurospheres 
cultured on FLAG control substrates, whereas very little neurite outgrowth was visible 
from neurospheres cultured on OMGP coated surfaces. Supplementation with 10 μM Y-
27632 resulted in a significant enhancement in neurite generation compared with both 
FLAG and OMGP coatings. Treatment with 100 μM ibuprofen or 1 μM NEP 1-40 resulted in 
neurite outgrowth that appeared similar to that obtained from FLAG coatings. 
 
The number of neurites generated per neurosphere (Figure 6-22B) was significantly 
inhibited by OMGP coating. This was also significantly enhanced by Y-27632 culture 
medium supplementation compared with all other conditions tested. Ibuprofen treatment 
resulted in a slight enhancement of neurite number on the inhibitory coating and NEP 1-
40 treatment resulted in the generation of a similar number of neurites to the control 
FLAG coating. Neurite density (Figure 6-22C) quantification revealed a similar trend in 
that OMGP coating significantly inhibited neurite density compared with FLAG. Y-27632 
treatment also significantly enhanced neurite density compared with all other conditions 
tested, whilst ibuprofen and NEP 1-40 treatment rescued neurite density to a similar level 
as the FLAG control. 
 
Similarly, neurite length (Figure 6-22D) was also significantly reduced when 
neurospheres were cultured on OMGP coated surfaces, compared with FLAG. This 
reduction in neurite length was rescued to a similar level as the control by Y-27632 
treatment, however ibuprofen and NEP 1-40 had little beneficial effect upon rescue of 
neurite length on OMGP coated surfaces. 
 
Neurospheres cultured in 3D on Alvetex® scaffold coated with the control FLAG sequence 
(Figure 6-23Aa,b) generate significant neurite outgrowth as visible from the underside of 
the scaffold, as the neurites have penetrated the entire depth of the 3D material. However, 
few neurites are visible from the underside of OMGP coated scaffolds (Figure 6-23Ac,d) 
and 10 μM Y-27632 resulted in a large volume of neurites visible from the underside of 
the scaffold (Figure 6-23Ae,f). Treatment with both 100 μM ibuprofen (Figure 6-23Ag,h) 
and 1 μM NEP 1-40 (Figure 6-23i,j) resulted in more neurites that had visibly penetrated 
the scaffold than OMGP coating alone. 
 
The number of neurites that penetrated the 3D material (Figure 6-23B) was reduced by 
OMGP coating of the scaffold, and significantly enhanced by Y-27632 treatment compared 
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with all other conditions tested. Treatment with ibuprofen had little effect on neurite 
penetration within this inhibitory 3D microenvironment, whereas, NEP 1-40 treatment 
resulted in a similar level of neurite penetration as FLAG cultures. 
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Fig 6-22: Recovery of Orla OMGP mediated 
neurite inhibition through inhibition of 
Nogo receptor signalling and its 
downstream pathway in 2D culture. 
Representative confocal images of 
neurospheres cultured on Orla inhibitory 
surfaces coated with OMGP (A) and media 
supplementation with 15 μM Y-27632 (a 
selective ROCK inhibitor) (Ae,f), 500 μM 
ibuprofen (inhibitor of Rho A) (Ag,h) or 1 μM 
NEP 1-40 (Nogo receptor antagonist peptide) 
(Ai,j). Scale bars: (Aa,c,e,g,i): 200 μm 
(Ab,d,f,h,j): 50 μm. Quantification of the 
number of neurites per neurosphere (B) (data 
represent mean ± SEM, n=15; 5 individual 
neurospheres were quantified from 3 
independent replicates) and neurite density (C) 
(data represent mean ± SEM, n=15; 5 individual 
neurospheres were quantified from 3 
independent replicates) demonstrates the 
ability of OMGP to induce neurite inhibition, 
which is recovered by Y-27632 and partially 
recovered by ibuprofen and NEP 1-40. Neurite 
length (D) (data represent mean ± SEM, n=36-
425; between 36-425 neurites were measured 
from 5 neurospheres per independent 
replicate, of which there were 3) is enhanced 
by Y-27632 and partially recovered by 
ibuprofen and NEP 1-40. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Fig 6-23: Recovery of Orla OMGP mediated neurite inhibition through inhibition of nogo receptor signalling and its downstream pathway in 3D culture. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold coated with an Orla OMGP motif and culture medium supplemented with 
15 μM Y-27632 (a selective ROCK inhibitor) (Ae,f), 500 μM ibuprofen (inhibitor of Rho A) (Ag,h) or 1 μM NEP 1-40 (Nogo receptor antagonist peptide) (Ai,j). 
Neurospheres remain on top of the scaffold with nuclei being stained blue (Aa,c,e,g,i) whereas TUJ-1 positive neurites (green) penetrate the depth of the 3D 
material  (Ab,d,f,h,j ). Scale bars: 200 μm. Quantification of the number of neurites penetrating the 3D material (B) (data represent mean ± SEM, n=9; 3 individual 
neurospheres were quantified from 3 independent replicates) reveals that ibuprofen has no effect on neurite outgrowth whereas NEP 1-40 recovers OMGP-
mediated inhibition to a level that is similar to the control and Y-27632 enhances neurite outgrowth to a level greater than the control. One-way ANOVA with 
Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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   6.3.2.1.3 Recovery of OMGP/Nogo-mediated Inhibition 
 
In addition to this, the effect of 2D and 3D growth substrates coated with a 50:50 mixture 
of Nogo and OMGP inhibitory motifs upon neurite outgrowth was also examined. In 2D 
culture neurospheres were cultured on FLAG control coated substrates (Figure 6-24Aa,b) 
and significant neurite outgrowth was observed. Neurospheres were also cultured on 
growth substrates coated with a mixture of both OMGP and Nogo motifs (Figure 6-
24Ac,d), which resulted in the generation of neurites that appeared shorter and neurite 
outgrowth that appeared less dense compared with control FLAG coating. Cultures were 
also treated with 10 μM Y-27632 (Figure 6-24Ae,f), which resulted in extremely dense 
neurite outgrowth with neurites appearing much longer than from any other culture 
condition. Furthermore, cultures were also treated with 100 μM ibuprofen (Figure 6-
24Ag,h) and 1 μM NEP 1-40 (Figure 6-24Ai,j) which resulted in neurite outgrowth similar 
to that of neurospheres cultured on FLAG control substrates. 
 
The number of neurites generated per neurosphere (Figure 6-24B) was significantly 
inhibited by the OMGP and Nogo coating mixture. This inhibitory effect was recovered by 
medium supplementation with ibuprofen and NEP 1-40, restoring neurite outgrowth to a 
similar level as the control FLAG substrate. However, as with the other inhibitory coatings 
tested, Y-27632 treatment resulted in an enhancement of neurite number of OMGP and 
Nogo coated surfaces. Y-27632 significantly enhanced neurite number compared with 
both FLAG and Nogo/OMGP coated substrates alone. A similar effect was also observed in 
terms of neurite density (Figure 6-24C), as Nogo/OMGP coating resulted in a significant 
inhibition in neurite density, which was recovered by both ibuprofen and NEP 1-40 and 
enhanced by Y-27632 treatment.  
 
Neurite length (Figure 6-24D) was also significantly inhibited compared to FLAG by OMGP 
and Nogo coating. This effect was partially restored by Y-27632 treatment, and 
completely restored by NEP 1-40 treatment. However, ibuprofen treatment had little 
effect upon neurite length in this model of neurite inhibition.  
 
Neurospheres were also cultured in 3D on scaffolds coated with Nogo and OMGP. In all 
cases neurospheres remained on top of the scaffold (Figure 6-25Aa,c,e,g,i), whilst TUJ-1 
positive (green) neurites were visible from the bottom view of the scaffold (Figure 6-
25Ab,d,f,h,j) having penetrated the depth of the 3D material. Significant neurite outgrowth 
can be visualised from the underside of scaffolds coated with the control FLAG sequence 
(Figure 6-25Aa,b), whereas no neurites have visibly penetrated the scaffold coated with 
the inhibitory Nogo and OMGP mixture (Figure 6-25Ac,d). Treatment with 10 μM Y-27632 
(Figure 6-25Ae,f) resulted in significant neurite outgrowth, with a large interconnecting 
network of neurites visible from the bottom of the scaffold. Both 100 μM ibuprofen 
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(Figure 6-25Ag,h) and 1 μM NEP 1-40 (Figure 6-25Ai,j) treatment resulted in a significant 
amount of neurite penetration into the 3D scaffold. 
 
The number of neurites penetrating the scaffold (Figure 6-25B) was quantified in each 
case, and it was found that Nogo and OMGP coating reduced neurite penetration 
compared with the FLAG coating alone. Treatment with Y-27632 significantly enhanced 
neurite penetration compared with all other conditions tested. Ibuprofen treatment 
resulted in a partial recovery of neurite outgrowth within the inhibitory 3D growth 
environment, whereas, NEP 1-40 treatment restored neurite outgrowth to a similar level 
as the control. 
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Fig 6-24: Recovery of Orla OMGP:Nogo 
mediated neurite inhibition through 
inhibition of Nogo receptor signalling and its 
downstream pathway in 2D culture. 
Representative confocal images of 
neurospheres cultured on Orla inhibitory 
surfaces coated with a 50:50 mixture of nogo 
and OMGP motifs (A) along with media 
supplementation of 15 μM Y-27632 (a selective 
ROCK inhibitor) (Ae,f), 500 μM ibuprofen 
(inhibitor of Rho A) (Ag,h) or 1 μM NEP 1-40 
(nogo receptor antagonist peptide) (Ai,j). Scale 
bars: (Aa,c,e,g,i): 200 μm (Ab,d,f,h,j): 50 μm. 
Quantification of the number of neurites per 
neurosphere (B) (data represent mean ± SEM, 
n=15; 5 individual neurospheres were 
quantified from 3 independent replicates) and 
neurite density (C) (data represent mean ± SEM, 
n=15; 5 individual neurospheres were 
quantified from 3 independent replicates) 
demonstrates the ability of the inhibitory 
substrate induced neurite inhibition, which is 
recovered by all media supplements tested. 
Neurite length (D) (data represent mean ± SEM, 
n=74-426; between 74-426 neurites were 
measured from 3 neurospheres per 
independent replicate, of which there were 3) 
from neurospheres cultured upon the inhibitory 
substrate is enhanced by Y-27632 and NEP 1-
40. One-way ANOVA with Tukey’s multiple 
comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001. 
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Fig 6-25: Recovery of Orla OMGP:Nogo mediated neurite inhibition through inhibition of Nogo receptor signalling and its downstream pathway in 3D 
culture. 
Representative confocal images (A) of neurospheres cultured on top of Alvetex® scaffold coated with an 50:50 mixture of Orla OMGP and Nogo motifs with culture 
medium supplemented of 15 μM Y-27632 (a selective ROCK inhibitor) (Ae,f), 500 μM ibuprofen (inhibitor of Rho A) (Ag,h) or 1 μM NEP 1-40 (Nogo receptor 
antagonist peptide) (Ai,j). Neurospheres remain on top of the scaffold with nuclei being stained blue (Aa,c,e,g,i) whereas TUJ-1 positive neurites (green) penetrate 
the depth of the 3D material  (Ab,d,f,h,j). Scale bars: 200 μm. Quantification of the number of neurites penetrating the 3D material (B) (data represent mean ± SEM, 
n=9; 3 individual neurospheres were quantified from 3 independent replicates) reveals that ibuprofen has no effect on neurite outgrowth whereas NEP 1-40 
recovers OMGP-mediated inhibition to a level that is similar to the control and Y-27632 enhances neurite outgrowth to a level greater than the control. One-way 
ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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   6.3.2.1.4 Summary 
 
In order to ensure a fair comparison between all of the inhibitory and recovery conditions 
tested, each data set obtained from each inhibitory condition was plotted together to give 
an overall summary as to the data collected. The number of neurites generated per 
neurosphere in 2D culture (Figure 6-26A) was inhibited by all inhibitory coatings 
compared with FLAG and both OMGP and OMGP/Nogo significantly inhibited neurite 
number compared to FLAG. All supplementation with small molecule inhibitors of the 
NgR signalling pathway resulted in a reduction in variation between the inhibitory 
coatings, with no significant difference between each coating and FLAG. Therefore, it can 
be determined that each small molecule inhibitor (Y-27632, ibuprofen and NEP 1-40) 
successfully restored neurite number on each inhibitory substrate.  
 
Similarly to neurite number, neurite density (Figure 6-26B) from 2D cultures was also 
reduced by all inhibitory coatings and significantly reduced by both OMGP and 
Nogo/OMGP coatings. Supplementation with Y-27632 resulted in less variation between 
the growth substrates, therefore Y-27632 treatment can be said to restore neurite density 
in the presence of these inhibitory stimuli. Although ibuprofen treatment in some cases 
did not restore neurite density to the same level as that of FLAG, there was found to be no 
statistically significant difference between each substrate. NEP 1-40 treatment also 
resulted in no statistically significant difference between each growth substrate except for 
the Nogo/OMGP coating, which resulted in significantly reduced neurite density 
compared to FLAG coating supplemented with NEP 1-40.  
 
The length (Figure 6-26C) of neurites generated in 2D culture was always significantly 
inhibited on surfaces coated with Nogo and OMGP compared with the control FLAG 
growth substrate. Y-27632 treatment enhanced neurite length on Nogo-coated 2D 
surfaces, however even Y-27632 treatment did not rescue neurite length on OMGP and 
OMPG/Nogo coated surfaces. Ibuprofen and NEP 1-40 treatment also did not rescue 
neurite length on inhibitory-coated 2D surfaces.  
 
In 3D culture, neurite penetration (Figure 6-26D) was inhibited by coating with all 
inhibitory molecules compared to control FLAG coating. Y-27632 treatment restored 
neurite penetration to a similar level within scaffolds coated with all molecules tested. 
Ibuprofen treatment resulted in restoration in neurite penetration with Nogo coating but 
not with OMGP or Nogo/OMGP coatings. NEP 1-40 treatment restored neurite penetration 
to control levels with all coatings. 
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Fig 6-26: Comparison of Orla inhibitory motifs and methods of recovery. 
Quantification of the number of neurites per neurosphere (A) (data represent mean ± 
SEM, n=15; 5 individual neurospheres were quantified from 3 independent replicates), 
neurite density (B) (data represent mean ± SEM, n=15; 5 individual neurospheres were 
quantified from 3 independent replicates), neurite length (C) (data represent mean ± SEM, 
n=36-426; between 36-426 neurites were measured from 5 neurospheres per 
independent replicate, of which there were 3) and neurite penetration in 3D (D) (data 
represent mean ± SEM, n=9; 3 individual neurospheres were quantified from 3 
independent replicates) from neurospheres cultured on each Orla inhibitory surface.  
Two-way ANOVA with Tukey’s multiple comparisons: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001. 
 
 
6.4 Discussion 
 
 6.4.1 The Role of the ECM in Neurite Development 
 
The extracellular microenvironment has a large impact on cellular behaviour, for example 
the biochemical composition of the ECM influences many biological functions. This is the 
case in terms of neurite outgrowth, as ECM composition and integrin receptor expression 
both vary throughout development and have been linked to the reduced regenerative 
capacity of the adult CNS. The main aim of this chapter was to utilise novel protein surface 
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technology in collaboration with Orla Protein Technologies to further enhance the human 
pluripotent stem cell derived model of neuritogenesis described in Chapter III.  
 
The ability of various ECM-derived amino acid sequences to induce neuritogenesis was 
tested in both 2D and 3D culture systems. This included the “MNYYSNS” domain of 
collagen IV, which was found to slightly enhance neurite outgrowth but its effects were 
limited compared with other ECM-derived motifs tested. This is consistent with other 
primary studies that have described the ability of “MNYYSNS” to promote neurite 
outgrowth in a PC12 model of neurite outgrowth but reduce neural differentiation and 
TUJ-1 expression in stem cell/neuroprogenitor derived models of neuritogenesis613. Here, 
we describe that this collagen IV-derived motif has a subtle yet significant impact on 
neurite outgrowth that could be due to the promotion of cellular adhesion610.  Some in 
vitro models of neurite outgrowth incorporate collagen IV to biochemically promote 
neuritogenesis529, however, the data detailed in this chapter suggest that other ECM-
derived motifs may be more suitable for this purpose.   
 
Similarly, the “RGDS” sequence derived from fibronectin was also found to have a positive 
effect upon neurite outgrowth. Again, this is consistent with published data, as this 
fibronectin-derived domain has also been previously documented to promote 
enhancement of neurite length613. The  “RGD” motif itself has also been widely 
documented to promote neurite outgrowth from cultured neurons in vitro and is often 
incorporated into culture systems to promote neurite generation547,615. “RGD” is also a 
component of the laminin α chain and has been implicated in the neurite promoting 
effects of laminin in addition to fibronectin615; however, laminin has also been found to 
induce neurite outgrowth through a non-RGD-dependent mechanism, suggesting a role 
for other domains in neurite generation616,617.   
 
The primary function of the “YIGSR” domain of laminin is thought to be cell adhesion 
rather than neurite stimulation598,618,619. However, cellular adhesion and neurite 
generation are closely linked in vitro620,621 and use of the “YIGSR” domain has been 
demonstrated to guide neurite outgrowth in 3D cultures622,623. The “YIGSR” motif of the 
laminin-β1 chain acts through the non-integrin receptor 67LR and has been implicated in 
axonal guidance and chemoattraction624.  Previous studies have demonstrated that the 
“YIGSR” domain enhances both neurite length and branching in vitro which supports the 
evidence outlined in this chapter, that “YIGSR” can promote neuritogenesis in 2D and 3D 
culture and to a greater extent than collagen IV and fibronectin derived domains. This 
data suggests that laminin may play a more integral role in the developmental process of 
neuritogenesis than other ECM-derived components.   
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Both fibronectin and laminin-derived domains were found to enhance neurite outgrowth 
through a study that involved the combination of a novel EC cell-based model of 
neuritogenesis and Orla protein surface technology. However, the effect of both 
fibronectin and laminin on neurite outgrowth was also investigated using a novel iPSC-
based model of neuritogenesis. This involved the assessment of the effect of adsorption 
coatings on neurite development. ReproCoat is the recommended coating solution for this 
cell type and includes fibronectin and laminin at unknown concentrations, and the effect 
of this coating solution upon neurite outgrowth was compared with the standard poly-D-
lysine and laminin coating used throughout this project. ReproCoat resulted in 
significantly longer neurites that radiate and appeared to curve from the central 
neurosphere. This data may suggest that fibronectin has some involvement in neurite 
guidance and extension. 
 
The EC cell-based model of neuritogenesis described and characterised in detail in 
Chapter III involved the coating of 2D and 3D growth substrates with 10 μgmL-1 poly-D-
lysine and laminin solution. To further improve this model and enhance its robust and 
reproducible nature, Orla technology was utilised to produce 2D and 3D functionalised 
growth substrates containing a 50:50 mix of poly-D-lysine and laminin (YIGSR). This 
resulted in a significant enhancement of neurite length in 2D culture and neurite 
penetration in 3D culture.  
 
Incorporating Orla coated growth substrates into the standard methodology of this model 
not only enhances neurite growth in 2D and 3D but also is advantageous in terms of 
reducing the use of animal-derived products within the model. Laminin from Engelbreth-
Holm-Swarm murine sarcoma basement membrane is usually used for adsorption coating 
of growth substrates in the model, however, as this is an animal-derived product there are 
disadvantages associated with its use. Animal derived products can introduce unwanted 
variability into a model system625, and the elimination of the use of murine-derived 
laminin in this system, produces a more standardised model for use in industrial 
applications including drug screening. 
 
Furthermore, this chapter describes the use of Orla Protein Technology to coat 2D and 3D 
growth substrates with specific peptide sequences, in an active configuration to promote 
cellular interaction. This helps to recreate the biochemical microenvironment that a cell is 
exposed to in vitro and in combination with 3D cell culture technology is able to produce a 
more physiologically relevant model of neuritogenesis, producing data that more 
accurately reflects the in vitro process of neurite development. 
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 6.4.2 Specific Laminin Domains Promote Neurite Outgrowth 
 
The Laminin-I domain “YIGSR” was found to enhance neurite outgrowth to the greatest 
degree in 2D and 3D culture, compared with both fibronectin and collagen IV domains. 
For this reason, it was decided to focus investigations on the neurite promoting effects of 
laminin, particularly as laminin is commonly used in neuroscience research626–629. This 
initially involved assessing the effect of varying doses of “YIGSR” upon neurite outgrowth 
in 2D culture. From this, it became apparent that “YIGSR” had a dose-dependent effect 
upon all variables: neurite number, density and length, enhancing each aspect of neurite 
outgrowth with increasing “YIGSR” content of the growth substrate coating.  
 
To further investigate the role of laminin in neurite development, the ability of other 
motifs to induce neuritogenesis in 2D and 3D culture was also evaluated. This study found 
that the “IKVAV” motif of the α1 chain and the similar “IKVSV” motif of the α2 chain 
successfully induced a greater number of neurites than other laminin-derived sequences 
tested. This is supported by evidence described throughout the literature, as “IKVAV” and 
“IKVSV” have both been shown to induce neurite development in several model 
systems271,563,564,599, potentially through a β1 integrin dependent mechanism630–632.  
 
Other laminin-derived domains tested include the larger “VRWGMQQIQLVV” sequence of 
the α5 chain, which was found to inhibit some aspects of neurite outgrowth and have no 
effect upon others. This sequence is from the LG4 domain of α5, which has previously 
been shown to enhance neurite outgrowth in vitro633.  However the α5 laminin chain is 
expressed only at low levels in the adult brain and is mostly expressed in tissues 
including: bone marrow, pancreas, lung and heart634. This could suggest that the α5 chain 
is not involved in neuritogenesis or neuronal homeostasis to the same extent as other 
laminin components. 
 
In addition to this, sequences from the laminin γ1 chain including “DITYVRLKF” and 
“RNAIAEIIKDI” were also screened. Both sequences have been implicated in cell adhesion 
and neurite outgrowth in vitro previously635, however the data described in this chapter 
reveals that neither sequence impacts neurite length significantly; however 
“RNAIAEIIKDI” does enhance neurite number and density in 2D culture and penetration 
into the scaffold in 3D culture. The distinct effects upon neurite density and length of 
“RNAIAEIIKDI” could support the hypothesis that neurite protrusion and elongation are 
supported by different signalling events. This was first hypothesised in Chapter III, due to 
the effects of the selective ROCK inhibitory, Y-27632, enhancing neurite number and 
density but inhibiting neurite length. 
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The Orla SURF platform offers several advantages over conventional adsorption coating 
including, reduction in the use of animal-derived products, excellent reproducibility, good 
availability of active sites and precise orientation of peptide motifs. Each laminin-derived 
Orla motif was compared with a standard dose-response of conventional adsorption 
coating with laminin from engelbreth-holm-swarm (EHS) murine sarcoma basement 
membrane. This comparison allowed for the determination of a concentration of EHS 
laminin coating equivalent to each Orla motif, which evokes the same response in terms of 
neurite generation. This comparison was achieved for all variables (neurite number, 
density, length and 3D penetration), resulting in an equivalent range of laminin 
concentrations. 
 
Laminin from EHS contains laminin-1 (α1β1γ1)636; therefore all of the sequences 
investigated in this study, apart from “IKVSV” and “VRWGMQQIQLVV” are present in the 
coating. This offers a direct comparison between whole molecule adsorption and Orla 
coating of the specific active sequence for most motifs assessed. Two methods of 
comparison were employed, the “Estimated” method involving side-by-side plotting to 
compare each data set and the “Numerical” method involving the use of the adsorption 
dose-response as a standard curve for each variable. This comparison resulted in a range 
of equivalent laminin concentrations for each motif from each method of comparison. The 
ranges obtained from the “Estimated” method of comparison are much broader than those 
obtained from the “Numerical” method, for example, for “DITYVRLKF” the “Estimated” 
method of comparison resulted in 1 – 5 μgmL-1 whereas the “Numerical” method of 
comparison resulted in 0 – 0.407 μgmL-1.  
 
Generally, comparison of most Orla motifs resulted in quite a vast range of laminin 
concentrations; however, the “YIGSR” motif resulted in neurites as long as those produced 
by 129 μgmL-1 EHS adsorption coating in 2D culture. This suggests that the same response 
in terms of neurite outgrowth, as extremely high concentrations of EHS adsorption 
coating, can be obtained by Orla coating with an active domain. This has many advantages 
such as standardising a model for industrial applications along with a reduction in coating 
time and reduction in the use of expensive coatings.  
 
 6.4.3 Modelling Myelin-Induced Neurite Inhibition in the Glial Scar In Vitro 
 
The glial scar is an inhibitory environment that arises following SCI and prevents the 
regeneration of neurons and restoration of neural networks. One of the inhibitory 
mechanisms that contributes to the inability of neurites to grow and restore lost neural 
connections, involves the release of inhibitory molecules present on myelin debris from 
damaged neurons. These include the Nogo molecule consisting of an amino-terminal 
domain (amino-Nogo) and a 66 amino acid loop domain (Nogo-66), both known to elicit 
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neurite inhibition33,34,39,220. Oligodendrocyte myelin glycoprotein (OMGP) is also an 
inhibitor of neurite outgrowth found on myelin debris33,34,39,220, and along with Nogo-66 
activates the Nogo receptor (NgR), which acts through co-receptors (p75324,327,328,331,508, 
TROY329,637 and LINGO1329,330,638) to induce growth cone collapse and neurite retraction. 
Activation of NgR results in activation of Rho A and ROCK, which impacts actin dynamics 
resulting in neurite inhibition32,309,322,366,368,400.  
 
This chapter evaluated the use of Orla functionalised surfaces to study the molecular 
signalling events that underpin myelin-induced inhibition in the glial scar. To achieve this, 
2D and 3D growth substrates were coated with Orla Nogo-66 and OMGP proteins. The 66-
amino acid sequence of Nogo, known to interact with the NgR, was exposed to cells either 
as a loop structure (Nogo Loop) or as a linear sequence (Nogo Linear), as previous reports 
suggest that the loop configuration is essential for function639–641. Here we demonstrate 
that both Nogo configurations along with OMGP coatings inhibit neurite outgrowth in 2D 
and 3D culture systems with little difference in the level of inhibition between each motif. 
However, we do demonstrate that the Nogo-66 linear sequence, can elicit an inhibitory 
response contrary to popular opinion. 
 
Orla functionalised inhibitory surfaces such as these provide opportunities to model and 
study the process of neurite inhibition that occurs following injury to the CNS. 
Applications for such a standardised model include the screening of small molecules to 
overcome inhibitory responses or a tool to investigate the molecular signalling events that 
drive the inhibitory response. Orla functionalised inhibitory surfaces offer a simplistic 
model of myelin-inhibition that can be used to dissect the underlying signalling pathways 
involved in this process. 
 
  6.4.3.1 Inhibition of NgR Receptor Signalling can Restore Neurite  
  Outgrowth in the Presence of Myelin Inhibitors 
 
Both OMGP and Nogo-66 are known to induce inhibition through the binding and 
activation of the Nogo receptor (NgR)310,328,639,640. This results in activation of Rho A and 
ROCK signalling, which ultimately impacts actin dynamics resulting in growth cone 
collapse and neurite retraction32,322,331. For this reason, several compounds that inhibit 
each stage of this signalling cascade were added to the model system with the aim of 
overcoming myelin-induced inhibition in each case (summarised in Figure 6-27). This not 
only demonstrates the potential application of this model as a drug screening system that 
could be used to identify regeneration-promoting compounds, but also provides more 
evidence building on existing knowledge as to the downstream signalling events that 
mediate inhibition.  
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The NgR antagonist peptide, NEP 1-40, mimics the first 40 amino acids of the Nogo-66 
loop structure blocking receptor-ligand binding and has previously been shown to 
promote functional recovery in SCI models336,357. Data presented in this chapter describes 
the ability of NEP 1-40 to overcome OMGP and Nogo induced inhibition, restoring neurite 
outgrowth to control levels in 2D and 3D culture systems. This suggests that the neurite 
inhibition observed in this model is induced through the function of NgR, as expected. 
This helps to characterise the model, as NEP 1-40 treatment resulted in neurite recovery, 
as expected, suggesting that Nogo and OMGP are binding to NgR on the surfaces of 
developing neurites resulting in neurite inhibition, and when the function of this receptor 
is blocked, neurite growth is restored. 
 
Activation of NgR is thought to lead to activation of Rho A and ibuprofen is a molecule 
known to inhibit Rho A and provide a beneficial response following SCI30,368. For this 
reason, ibuprofen was also tested in this model, to determine if Rho A activation was 
involved in myelin-induced inhibition and to determine the potential beneficial effect of 
ibuprofen upon neurite outgrowth in the presence of OMGP and Nogo. Ibuprofen 
treatment was found to have varying results depending on the variable measured, in some 
cases ibuprofen restored neurite outgrowth on the inhibitory substrates and in others 
only a partial restoration of neurite outgrowth was observed, but on the whole ibuprofen 
generally had a positive effect upon neurite outgrowth in this inhibitory system. This 
suggests that Rho A activation is an important event in the transmission of inhibitory 
signalling. 
 
Rho A activation leads to activation of ROCK which ultimately results in the cytoskeletal 
changes associated with neurite inhibition. The selective ROCK inhibitor, Y-27632, is 
commonly used to overcome neurite inhibition and promote neurite outgrowth in other 
model systems26,27,204,209, and was applied to this myelin-based model of inhibition to 
determine the role of ROCK in myelin-induced inhibition. The ROCK inhibitor was able to 
overcome and further enhance neurite outgrowth in all conditions and systems tested. 
This suggests that activation of ROCK is essential in the induction of neurite inhibition by 
OMGP and Nogo and also demonstrates a methodology that could be used to further 
enhance neurite outgrowth in this model.  
 
Therefore, not only has neurite inhibition been achieved through the coating of 2D and 3D 
growth substrates with functional myelin-derived molecules, but recovery of neurite 
outgrowth has also been established through modulation of NgR and its downstream 
signalling. This provides a potential application for this model of inhibition as a drug 
screening tool that can be used to identify the ability of specific compounds to overcome 
myelin-induced inhibition or to further dissect the molecular signalling events involved in 
myelin-induced inhibition, building on data described within this chapter. 
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Fig 6-27: Schematic depicting mechanisms of recovery of myelin-induced neurite 
inhibition.  
Myelin inhibitors of neurite outgrowth, including Nogo-66 and OMGP act through the NgR 
to induce Rho A and ROCK signalling events, leading to inhibition of neurite regeneration. 
This signalling process can be inhibited at various stages such as inhibition of receptor 
activation by the NgR antagonist peptide, NEP 1-40. Similarly, Rho A can be inhibited by 
ibuprofen and ROCK can be inhibited by Y-27632, all of which lead to recovery of neurite 
growth by reducing NgR activation and its downstream signalling cascade. 
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6.5 Key Findings 
 
 ECM surface coatings enhanced neurite outgrowth in both 2D and 3D culture 
systems.  
 
 Laminin-derived motifs enhanced neurite outgrowth to the greatest degree, 
compared with collagen and fibronectin-derived motifs. 
 
 Orla poly-D-lysine and laminin coating, enhanced neurite length in 2D and 
penetration in 3D culture, compared with the traditional coating solution used in 
methodology.  
 
 Laminin-derived motifs enhanced neurite outgrowth in a dose dependent 
manner.  
 
 A variety of laminin-derived sequences induced neurite outgrowth (“IKVAV”, 
“IKVSV”), whereas others reduced neurite outgrowth (“DITYVRLKF”).   
 
 Myelin-associated proteins expressed within the glial scar (Nogo, OMGP) 
inhibited neurite outgrowth in 2D and 3D culture.  
 
 Inhibition of NgR activation (NEP 1-40), Rho A (ibuprofen) and ROCK (Y-27632), 
restored neurite outgrowth despite inhibitory coatings (Nogo, OMGP).  
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6.6 Conclusion 
 
This chapter has involved the utilisation of Orla protein surface technology to identify 
extracellular protein domains involved in neurite growth and inhibition. This initially 
involved identification of ECM-derived sequences that were able to promote neurite 
growth, before focussing on the specific role of laminin in neurite generation. The specific 
role of laminin-derived amino acid sequences in neurite development was identified and 
compared with published data in other model systems. This suggests that specific 
laminin-receptor interactions are responsible for neurite induction and may be involved 
in the developmental process of neuritogenesis.  
 
In addition to this, a comparison between traditional adsorption laminin coating and each 
Orla laminin-derived domain was conducted to determine the neurite promoting ability of 
each motif compared with established methodologies. This varied enormously depending 
upon the variable of interest and Orla surfaces were found to enhance neurite length to 
the greatest degree with the “YIGSR” domain inducing a similar length of neurite as 129 
μgmL-1 laminin coating, which would be very expensive to replicate using the traditional 
adsorption technique. In addition to being a more economical basis for a model, the Orla 
coating procedure also offers a more standardised alternative to traditional coating 
methodologies. This is particularly important depending on the specific application of the 
model.  
 
Furthermore, this chapter also describes the potential application of this model to study 
the process of neurite inhibition that occurs in the glial scar following SCI. This involved 
the coating of growth substrates with Orla inhibitory molecules including OMGP and 
Nogo. Not only is this useful in the study of the molecular processes that underpin myelin-
induced neurite inhibition, but this inhibitory model is also suitable for the screening of 
potential compounds that are able to restore neurite regeneration in this inhibitory 
environment. Functionalisation of 2D and 3D growth substrates restores aspects of the in 
vivo biochemical environment, providing a more physiologically relevant 
microenvironment to study many aspects of cell biology.   
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6.7 Future Directions 
 
Future work building upon the data described in this chapter could include the following: 
 
 Investigate the ability of growth substrates coated with mixtures of each laminin 
domain to induce neurite outgrowth. A variety of combinations of laminin-
derived amino acid sequences could be used to optimise the most effective Orla 
substrate in terms of neurite generation.  
 
 A thorough analysis of the expression of specific integrins and laminin receptors 
in this EC cell-based model of neuritogenesis could be conducted. This could help 
support the fact that certain motifs had a large impact on neurite growth. This 
may help understand the receptor-based signalling pathways involved in neurite 
development and how the transmission of biochemical cues from the 
extracellular environment can induce intracellular changes that result in neurite 
generation. 
 
 Laminin blocking antibodies could be added to cultures based on laminin coated 
growth substrates to confirm that laminin-receptor binding is responsible for 
neurite induction. 
 
 In terms of neurite inhibition and the downstream signalling of NgR, expression 
analyses (such as Western Blot) of components in the Rho A and ROCK signalling 
cascade could be conducted. For example, the upregulation of Rho A in its active 
form within the inhibitory model may provide evidence of the downstream 
signalling events following NgR activation.  
 
 Soluble NgR as a means of reducing receptor activation by sequestering 
inhibitory ligands has been demonstrated in other models of SCI and glial 
scarring. This could also be demonstrated to overcome inhibition in the model of 
myelin-induced inhibition to further evidence the role of NgR in Nogo and OMGP 
signal transduction within this model. 
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Chapter VII: Discussion 
 
7.1 Introduction 
 
This thesis has aimed to develop a novel human-derived model of neurite outgrowth, 
suitable for investigation into the molecular mechanisms that underpin neurite growth 
and inhibition, in a variety of neurological pathologies. This model was then used to 
investigate the molecular signalling events that govern inhibition of neurite outgrowth 
following SCI and in AD.  
 
3D cell culture technology was employed in combination with protein surface technology 
to provide the most physiologically representative model of neuritogenesis. This system 
was then applied to study neurite inhibition using several inhibition models ranging from 
simple (growth substrate coating, exogenous peptide supplementation) to complex (co-
culture, disease model cells).  
 
In addition to this, several methods of recovery were employed, to determine the 
molecular signalling events involved in neurite inhibition, whilst also demonstrating a 
potential application of the model as a drug-screening tool.  The model of neurite 
outgrowth described herein, has future applications ranging from academic interest 
including identification of specific signalling mechanisms involved in neurite growth and 
development, along with industrial applications including drug discovery, personalised 
medicine and neurotoxicity screening. 
 
7.2 Development of Novel Human Models of Neurite Outgrowth 
 
The initial stage of this project was to develop a robust and reproducible model of neurite 
outgrowth that could be applied to study neurite development and inhibition. Initially, an 
EC cell-based model of neuritogenesis was developed using TERA2.cl.SP12 human 
pluripotent stem cells. This cell type was selected, as neurite outgrowth from TERA2 EC 
cells has been well documented for many years66,67,69,71,144,148. In addition to this, the cell 
line is human derived, therefore its use in the study of human disease and medical 
applications, is more appropriate as it overcomes any physiological discrepancies 
associated with inter-species variation71,146.  
 
Retinoic acid is a potent morphogen involved in neuronal differentiation in vitro and has 
many applications in vitro to promote differentiation of human pluripotent stem 
cells9,45,48,56. However, its use in vitro is limited due to its ability to readily break down 
when exposed to light and heat81. For this reason, the stable, synthetic retinoid compound, 
 345 
EC2382,84 was used to induce singificant neuritogenesis within this model, producing a 
more reliable and reproducible model of neuritogenesis149. 
 
Furthermore, previous advances in induction of neurite outgrowth from TERA2.cl.SP12 
spheroid structures148, provided a solid foundation with which to begin development of 
the neurite outgrowth assay described within this thesis along with the development of a 
standard operating procedure outlining the methodology (Appendix I). Radial neurite 
outgrowth from a central cellular mass, allows for more accurate neurite quantification 
and a sampling method of quantification was developed to further enhance efficiency and 
accuracy of this process (Fig. 3-3). In addition to this, neurite outgrowth from this model 
was characterised and found to share similarities with neurite outgrowth during in vitro 
development (Fig. 3-4), suggesting that neurites generated in this manner have 
physiological relevance and can be used reliably to investigate the process of human 
neuritogenesis.  
 
Therefore, the initial stage of this project was to develop a novel in vitro model of neurite 
outgrowth capable of applications including the investigation into inhibitory mechanisms. 
The EC-derived model of neuritogenesis described within Chapter III, is robust, 
reproducible and amenable to high-throughput screening, therefore suitable for both 
academic and industrial applications. This is particularly important as inability of neurites 
to regenerate is implicated in a wide variety of neurological conditions33–36,38,39,42,43,220,441. 
Therefore, there is need for a reliable in vitro model to investigate the molecular 
processes governing neurite inhibition and to screen compounds that may be able restore 
neurite growth in inhibitory situations. 
 
In addition to this a novel iPSC-derived model of neuritogenesis was also developed, 
based upon the same spheroid culture and radial neurite outgrowth principles as the EC-
derived model. Although the EC-derived model has advantages including that it is robust, 
reproducible, simple and cheap to maintain, this iPSC-derived model adds another 
dimension to neurite development. iPSC technology is more expensive and perhaps less 
robust due to problems with cellular viability, than the EC-derived model but has distinct 
advantages in other areas of interest. These include the use of disease model iPSC-derived 
cell types, as demonstrated with AD-model cells in Chapter V. iPSC-derived disease model 
cells exist for a number of other neurodegenerative diseases including Parkinson’s 
disease Huntington’s disease - neurodegenerative diseases where neurite growth and 
inhibition may be of particular interest158,642–646.  
 
Although the iPSC-derived model of neurite outgrowth lacks some of the advantages of 
the EC-derived model, it does possess its own range of distinct advantages. For example, 
personalised medicine is a rapidly growing field of research and this model could be used 
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to generate patient-specific neurite outgrowth models capable of screening drugs or other 
compounds for effectiveness120,647–649.  
 
 7.2.1 Development of a Physiologically Relevant 3D Model of Neurite Outgrowth 
 
To further improve these novel models of human neurite outgrowth, 3D cell culture 
technology was combined with both models to produce a more physiologically relevant 
model of human neuritogenesis. In embryonic development, developing neurites 
experience a 3D ECM environment and it is well established that the extracellular 
microenvironmental cues experienced by cells in culture impacts their structure and 
function161,162,572. For this reason Alvetex® scaffold, a 3D porous, polystyrene scaffold, was 
used to translate both EC and iPSC-derived models into a 3D culture environment. 
 
A large number of drugs tested in vitro fail when their testing progresses into animal 
models169,191. One reason for this is that the 2D in vitro culture environment is so far 
removed from the in vivo physiological microenvironment, that cells behave differently in 
culture169,191. For this reason, many industrial assays are now being developed using 3D 
cell culture technology to provide a more reliable and physiologically relevant assay with 
better predictive value. The neurite outgrowth assays described in Chapter III were 
applied to 3D culture systems to further enhance their reliability and relevance. 
 
To better re-create the geometry and topographical cues experienced by developing 
neurites in vivo, mature neurospheres (either EC or iPSC based) were cultured on top of 
Alvetex® scaffold and neurites penetrated the 3D material. This served as a method of 
quantification and the number of neurites per neurosphere was analysed in each assay. 
However, although 3D culture provides a more favourable environment, similar to the in 
vivo environment and it has even been evidenced that Alvetex® scaffold enhances 
neuritogenesis in a similar model147,150, there are some disadvantages associated with this 
3D model. For example, the method of quantification relies on neurites having penetrated 
the 200 μm depth of the 3D material, therefore is a reflection of both neurite length and 
number of neurites generated. However, this reduces assay sensitivity as many neurites 
may not reach the length of 200 μm required for quantification.  
 
This particularly became apparent when investigating the induction of neurite outgrowth 
from AD-model cells in Chapter V. Neurite outgrowth from AD-patient neurospheres 
cultured in 2D revealed a significant impairment in neurite density and enhancement in 
neurite length, however, neurite penetration in 3D culture was enhanced, reflecting the 
2D result of neurite length and not density. For this reason both 2D and 3D assays were 
carried out for each investigation detailed in this thesis, and the results of both were 
analysed and considered for each situation. In addition to this, 2D culture analyses more 
 347 
variables including neurite length, number and density, therefore differential effects upon 
neurite length and number can be identified.  
 
Other limitations of this model include the fact that the polystyrene scaffold described 
throughout this project recapitulates only the native geometry of developing neurites, as 
opposed to other aspects of the in vivo microenvironment. For example, to create a truly 
physiologically relevant model, all aspects of the cellular microenvironment need to be 
modeled including, substrate stiffness, oxygen and nutrient availability, cell-to-cell 
interations, and cell-to-matrix interactions. Therefore, this model improves on currently 
widely adopted techniques to provide a more physiologically relevant model of 
neuritogenesis, but itself is not a completely physiologically relevant model. However, 
despite these limitations, the 3D model of neurite outgrowth described herein, still is an 
advanced model compared with current techniques and as demonstrated throughout this 
thesis has a wide range of applications. 
 
Applications of these 3D models have been outlined throughout this whole thesis, 
particularly to study the process of neurite inhibition in the glial scar (Chapter IV) and 
Alzheimer’s disease (Chapter V). During the course of these studies neurite outgrowth 
was successfully inhibited and then recovered through the application of small molecules 
and use of inhibitory coatings. This provides potential applications for such models in 
terms of drug screening, by identifying the ability of molecules of interest to overcome 
inhibitory signalling and to screen molecules for neurotoxicity (summarised in Figure 7-
1). 
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Fig 7-1: Application of 3D neurite outgrowth model to screen the ability of 
compounds to overcome inhibitory stimuli. 
A schematic depicting the use of the novel 3D neurite outgrowth assay, developed within 
this thesis to study neurite inhibition and recovery. Neurospheres (blue) sit on top of 
Alvetex® scaffold (grey) whilst neurites (green) penetrate the 3D material. Upon addition 
of inhibitory molecules such as CSPGs (aggrecan), myelin inhibitors (Nogo, OMGP), glioma 
cells and β-amyloid peptides, neurites retract and no longer completely penetrate the 3D 
material. Molecules that reduce inhibitory signalling were then added to the model, such 
as Y-27632, ibuprofen, Ch’ase and NEP 1-40, to promote neurite regeneration, restoring 
neurite penetration into the 3D material, despite the presence of inhibitory stimuli.  
 
 
7.3 Neurite Inhibition in the Glial Scar 
 
Following SCI a series of events occur that lead to the formation of an inhibitory 
environment, preventing the growth of neurites and the restoration of lost neuronal 
connections leading to functional deficit33,34,39,220. These events include the release of 
CSPGs from reactive astrocytes and release of myelin debris from damaged 
neurons33,34,39,220. CSPGs and inhibitory molecules such as Nogo, MAG, and OMGP from 
myelin debris interact with receptor complexes to activate Rho A and ROCK signalling that 
ultimately impacts actin dynamics and results in growth cone collapse and neurite 
retraction33,34,39,220.  
 
Several methodologies to study the process of neurite inhibition in the context of the glial 
scar were employed, ranging from simple to more complex models of inhibition, 
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depending on its intended use. Simple, inhibitory coatings were employed such as the 
CSPG aggrecan (Chapter IV) and functionalisation of growth substrates with myelin 
inhibitors (Chapter VI) to provide non-permissive growth substrates that induce neurite 
inhibition. These novel 2D and 3D inhibitory growth surfaces provide basic models that 
can be used to study the process of neurite inhibition that occurs in the glial scar following 
SCI.  
 
Signalling pathways involving both CSPG and myelin-induced inhibition are thought to be 
very similar. Although CSPGs act through receptors including LAR319,348 and PTPσ318–320 
and NgR3321, whilst myelin inhibitors act through the NgR1 receptor complex32,324,329,331, 
signalling downstream of receptor activation is thought to be the same in each case. This 
includes Rho A activation that leads to activation of ROCK, resulting in stabalisation of 
actin filaments followed by growth cone collapse and neurite inhibition25–
27,31,366,368,372,398,636. Therefore in each case, inhibitors of Rho A and ROCK were applied to 
these systems to overcome the inhibitory response. Both the inhibitor of Rho A, 
ibuprofen30,368 and inhibitor of ROCK, Y-2763223,286 were able to overcome both CSPG and 
myelin-induced inhibition, further evidencing the role of Rho A signalling in the inhibitory 
response and identifying the regeneration promoting properties of Y-27632 and 
ibuprofen. In addition to this, in the case of myelin-induced inhibition (described in 
Chapter VI) the NgR1 antagonist peptide NEP 1-40336,357 was also used to restore neurite 
outgrowth in the presence of inhibitory stimuli.  
 
Simple growth substrate inhibitory coatings such as aggrecan, Nogo and OMGP, provide 
basic, robust models to study the process of neurite inhibition and to screen molecules. 
Robust and standardised models (in the case of Orla inhibitory coatings) such as these are 
of particular value within the biotechnology industry, with particular applications of drug 
screening and molecular identification. However, they do not represent the complex 
inhibitory environment that cells experience within the glial scar. For this reason a more 
complex co-culture model of neurite inhibition was developed to better recapitulate the 
mixture of inhibitory molecules present within the in vivo glial scar. 
 
To better re-create the complex mixture of inhibitory signals involved in glial scar 
signalling and to focus on CSPG-mediated inhibition, a co-culture model was developed 
that included a glioma cell line known to express similar proteins as reactive astrocytes 
involved in glial scar development393–396. Several approaches were used to combine 
neurosphere and glioma cell culture, including a traditional 2D co-culture model involving 
monolayer culture of glioma cells with a neurosphere cultured on top. This particular 
method of co-culture has the disadvantage of providing physical contact between the two 
cell types that could contribute toward the inhibitory response observed. The aim of this 
co-culture methodology was to study CSPG-induced neurite inhibition, therefore this 2D 
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co-culture was not suitable. However, physical inhibition of neurite outgrowth by a 
reactive astrocyte meshwork is a means of inhibition that contributes toward glial 
scarring33,34,39,220, therefore, this co-culture model could be used to investigate this 
process. 
 
To further build on this co-culture methodology and to eliminate physical contact 
between the cell types, glioma cell conditioned medium was focused upon. This involved 
either the application of growth medium-derived from glioma cell cultures or the culture 
of glioma cells as a monolayer and neurospheres cultured within the same environment 
suspended in Alvetex® scaffold. These experiments allowed the effects of soluble 
mediators on neurite outgrowth to be examined, eliminating the aspect of physical 
inhibition.  
 
In all of the co-culture/conditioned medium experiments, Y-27632, ibuprofen and 
chondroitinase were able to rescue neurite growth (Chapter IV). This suggests that the 
neurite inhibition observed in these models is induced by CSPGs and further evidences 
the role of Rho A and ROCK signalling in CSPG-mediated inhibition. This, in combination 
with the recovery of neurite growth observed on inhibitory growth substrates (aggrecan 
and myelin-inhibitors) provides compelling evidence as to the role of Rho A and ROCK 
activation in neurite inhibition within the glial scar along with the potential use of 
ibuprofen and Y-27632 to overcome this inhibitory response. 
 
7.4 Neurite Inhibition in Alzheimer’s disease 
 
One of the main hallmarks of Alzheimer’s disease (AD) is the aberrant processing and 
extracellular accumulation of β-amyloid (Aβ) peptides in the form of senile 
plaques410,422,444,460,461,482,510. Neurites that pass through senile plaques lose their 
characteristic morphology, becoming dystrophic and abnormal500,502. This inhibition in 
neurite growth is thought to contribute toward a lack of neural connectivity associated 
with memory loss and disease progression500,502. For this reason, the ability of Aβ species 
to induce neurite inhibition was tested by he models of neurite outgrowth outlined in this 
project. 
 
Consistent with primary literature, data outlined in this thesis found both Aβ40 and Aβ42 
species to be inhibitory to neurite development when bound to growth substrates and 
soluble within culture medium35,36. These inhibitory models, similar to the aggrecan-
based model of CSPG-mediated inhibition, are simple and provide modest systems to 
dissect the molecular signalling events involved in the inhibitory process. However, in vivo 
neurons are exposed to a number of Aβ peptides, therefore to better recapitulate the in 
vivo system, the effects of various ratios of Aβ42:Aβ40 upon neurite outgrowth was 
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examined. This also allows for the modelling of various stages of disease progression as 
the ratios tested range from healthy brain levels to advanced disease levels426. All ratios 
tested were found to be inhibitory to neurite outgrowth, further evidencing the neurite 
inhibitory effects of Aβ. 
 
Although adding ratios of Aβ peptides to the culture medium better recreates the 
physiological environment experienced by neurons in the brain of patients with AD, it is 
still an extremely simple system aimed at modelling a multi-faceted exceptionally 
complex diseased state. Therefore to better model this complex neurodegenerative 
disease, the iPSC-derived model of neuritogenesis was applied to generate a disease-
specific model of neurite outgrowth. ReproNeuro AD-model neuroprogenitor cells with 
mutations in PS1 and PS2 associated with aberrant Aβ production were used to develop 
an AD-specific model of neurite outgrowth157,235,237. These cell types endogenously 
produce a high ratio of Aβ42:Aβ40, characteristic of AD and provide a more complex, 
disease-specific model to study neurite inhibition and outgrowth.  
 
This model was used to study the differences in neurite outgrowth between healthy 
individuals and those with an AD-associated mutations and found that neurite density 
was impaired in patient-derived samples. However, neurite length was enhanced in 
patient-derived samples, a result that was attributed to the heterogeneous nature of the 
cultures. This AD-specific model of neurite outgrowth based upon iPSC-technology has 
many potential applications, including personalised medicine, drug screening and 
identification of specific cellular signalling pathways involved in neurite development and 
inhibition.  
 
Furthermore, in both simple and complex models of Aβ-mediated neurite inhibition, Rho 
A and ROCK inhibition restored neurite outgrowth to control levels. This suggests that 
Rho A and ROCK activation is involved in Aβ-mediated neurite inhibition, consistent with 
evidence throughout the literature36,510. Y-27632 and ibuprofen, inhibitors of ROCK and 
Rho A respectively were found to have a positive effect upon neurite outgrowth in the 
presence of inhibitory Aβ species and in AD-model neurites, which suggests that these 
compounds may have beneficial effects in restoring neural connectivity in AD. This in vitro 
finding is consistent with in vivo evidence provided by Lim et al that suggests that 
ibuprofen could be beneficial in restoring neurite growth and reducing inflammation in a 
mouse model of AD650. 
 
However, the mechanism by which Aβ activates Rho A and ROCK still remains unclear. Aβ 
is known to structurally interact with the NgR504,505,509, a receptor heavily implicated in 
glial scar signalling activated by both CSPGs and myelin-associated inhibitory molecules, 
however it is not known if Aβ binding results in receptor activation. Therefore 
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experiments described within this thesis (Chapter V) aimed to identify the role of NgR in 
Aβ-mediated neurite inhibition by using the NgR receptor antagonist NEP 1-40336,357 to 
rescue neurite outgrowth in the presence of inhibitory Aβ species. However, this was not 
the case, and neurite outgrowth was not fully restored by NEP 1-40 treatment, although 
partial recovery was evident. This suggests that Aβ induces neurite inhibition by multiple 
mechanisms, one of which may be NgR activation, however NgR activation is not the sole 
mechanism responsible for Aβ-mediated inhibition. Aβ-mediated neurite inhibition 
shares many similarities with glial scar signalling including the involvement of NgR in 
addition to Rho A and ROCK activation, a common pathway in CSPG and myelin-induced 
inhibition. 
 
7.5 Similarities between the Glial Scar and Alzheimer’s disease 
 
The loss of neuronal connections leading to functional defects is involved in the 
pathogenic mechanisms that underpin many neurological disorders including trauma, in 
the form of SCI33,34,39,220 and neurodegenerative diseases, including AD36,40. In both of 
these pathological states an inhibitory environment forms leading to the inability of 
neurites to restore lost neuronal connections resulting in functional deficits. Neurite 
inhibition can be triggered by a number of stimuli such as inhibitory 
proteoglycans27,318,319,348 or peptides36,40, but ultimately results in a reduction of neuronal 
connectivity. 
 
In the glial scar, inhibitory molecules such as CSPGs secreted by reactive astrocytes and 
myelin inhibitors released from damaged neurons bind to receptors including the NgR, 
which leads to Rho A and ROCK activation, impacting the actin cytoskeleton and resulting 
in growth cone collapse26,27,33,34,39,209,220,317,348,378, as evidenced throughout this thesis 
(Chapters IV & VI). However, in AD it is the amyloidgenic Aβ peptides that are thought to 
induce neurite inhibition and similarly to glial scar signalling, and are thought to induce 
activation of Rho A and ROCK36,510, consistent with data outlined in this thesis (Chapter 
IV). Again, similarly to glial scar signalling, Aβ is known to interact with NgR, however it is 
not known if the peptide activates the receptor504,505,509. Delivery of soluble NgR has 
resulted in functional recovery in AD-animal models along with a reduction in Aβ 
deposition509; this suggests that the soluble NgR is capable of sequestering Aβ and 
reducing its inhibitory action. This is consistent with the role of Aβ as a ligand for NgR and 
in combination with data described in Chapter V, suggests that NgR may be one of 
multiple mechanisms implicated in the inhibitory action of Aβ.  
 
In addition to receptor-mediated signalling and its downstream pathway, the inhibitory 
events that underpin neurite inhibition in the glial scar and AD also share similarities in 
other respects. Astrocyte activation is a major consequence of SCI and results in the 
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secretion of inhibitory molecules such as CSPGs in addition to providing mechanical 
inhibition in the form of an astrocytic meshwork that physically blocks neurite 
extension33,34,39,220,293,347. Astrocyte activation has also been identified in AD as a 
consequence of Aβ accumulation651. This again, suggests common pathological 
mechanisms that contribute toward the inhibitory environments in both glial scar and AD 
situations. This also suggests that CSPG-induced inhibition may contribute toward the 
reduction in neural connectivity associated with AD, as reactive astrocytes are known to 
secrete inhibitory molecules. 
 
Therefore, the similarities and common signalling mechanisms involved in neurite 
inhibition in both AD and the glial scar highlight the importance of fully elucidating the 
molecular mechanisms that underpin neurite inhibition. Understanding the detailed 
inhibitory mechanisms that underpin the inability of neurites to grow in one diseased 
state may help improve understanding of the process in other pathological contexts, as 
this process appears to be common to many neurological disorders.  
 
7.6 Biomimetic Growth Surfaces and Neurite Outgrowth 
 
In addition to the development and application of neurite outgrowth models to 
understand the process of neurite inhibition following SCI and in AD, this thesis also 
examined the use of biomimetic growth substrates to further enhance the EC-derived 
model of neuritogenesis. The OrlaSURF platform has many distinct advantages compared 
to traditional adsorption coating of growth substrates, as specific biologically active 
domains are attached to growth surfaces in a precise and functional orientation610,611,613. 
This produces a more standardised culture environment, eliminating the use of more 
variable animal derived coatings625. In addition to this, coating 2D and 3D growth surfaces 
helps better re-create the biochemical physiological microenvironment161. 
 
This technology was used to study the role of ECM proteins in neurite development, as in 
vivo the ECM is thought to be an important factor in the development and elongation of 
neurites526,530. This process is particularly important, as inhibitory mechanisms, such as 
CSPG-mediated inhibition, are thought to block ECM-neurite binding, contributing to the 
inhibitory response311,652 and variations in integrin expression are thought to be 
responsible for the reduction of regenerative capacity in the adult CNS364,537,552,562. The 
data outlined in this thesis found that the laminin β1 “YIGSR” domain, enhanced neurite 
outgrowth to a greater degree than collagen IV and fibronectin-derived domains. This is 
consistent with evidence throughout the literature, as the role of laminin in neurite 
development is well documented187,562,624,626,627. 
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For this reason, the specific role of laminin in neurite generation was focused upon. This 
involved the screening of many laminin-derived motifs, including those from α1, α2, α5, 
β1, γ1 and γ1 chains. This allowed for the identification of specific neurite promoting 
domains and the data obtained was consistent with previous, documented literature as 
the “IKVAV” domain of laminin α1271,563,564,598 generally enhanced neurite outgrowth to 
the greatest degree, however “YIGSR” of laminin β1 had the greatest impact on neurite 
length279,598,622,624.  
 
In addition to ECM focused investigations, this technology was also used to study the role 
of myelin-induced inhibition in the glial scar. Growth surfaces were functionalised with 
Nogo and OMGP, inhibitory molecules present on myelin debris33,34,39,220, released from 
damaged neurons, to model the process of neurite inhibition, which impedes regeneration 
in the injured spinal cord. Inhibitors of down stream myelin-induced signalling such as Y-
27632, an inhibitor of ROCK and ibuprofen an inhibitor of Rho A, in addition to NEP 1-40, 
a NgR antagonist, were able to recover neurite outgrowth on these inhibitory surfaces. 
This, in addition to data outlined in Chapters IV & V, provides strong evidence as to the 
role of Rho A and ROCK signalling as a common mechanism responsible for neurite 
inhibition in many systems. Furthermore, this also demonstrates an important application 
of this inhibitory model, as a potential screening tool that could be used to identify 
molecules capable of overcoming myelin-inhibitory signalling.  
 
The OrlaSURF platform standardises growth substrate coating, compared with adsorption 
coating that limits the accessibility of active domains to the cells. This has distinct 
advantages, particularly in this model, as functionalisation with poly-D-lysine and laminin, 
replacing the standard ECM coating that this model relies on, not only enhances neurite 
outgrowth but also standardises the model itself609,610,612,625. This is beneficial in terms of 
industrial applications, and produces a more robust assay capable of screening potential 
neurotoxic compounds within an industrial setting. Furthermore, data outlined within 
this thesis also demonstrates the functionalisation of growth substrates with inhibitory 
molecules found within the glial scar following SCI, this provides the basis of an inhibitory 
model that has been successfully shown to induce neurite inhibition, which can be 
recovered through inhibition of NgR and its downstream signalling pathway. This 
standardised, inhibitory model could provide the basis for an assay capable of identifying 
regeneration promoting compounds (outlined in Figure 7-2). 
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Fig 7-2: Potential application of 3D Orla-based models of neurite outgrowth and 
inhibition. 
A schematic depicting the two main applications for the Orla coated 3D model of neuritogenesis. 
Neurospheres (blue) sit on top of Avetex® scaffold (grey) whilst neurites (green) penetrate the 
3D material. Scaffolds coated with poly-D-lysine and laminin promote neurite generation (A), 
this model can be used to screen compounds for neurotoxicity effects, which would result in 
impaired neurite outgrowth. Scaffolds coated with inhibitory molecules such as Nogo and OMGP, 
inhibit neurite outgrowth (B), and can be used to screen the ability of compounds to promote 
neuroregeneration, despite the presence of an inhibitory stimulus. This could be used to identify 
compounds of interest that may provide a suitable basis for therapeutic design, aimed at 
restoring connectivity in the injured spinal cord. 
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7.7 Conclusions 
 
In conclusion, this thesis has described the development of two novel, pluripotent human-
derived models of neuritogenesis in 2D culture and the more physiologically relevant, 3D 
culture system. These models have combined synthetic retinoid technology with 3D cell 
culture systems and an efficient sampling method of quantification, to produce a robust 
and reliable model of neuritogenesis that can be used to study the process of neurite 
generation and inhibition.  
 
This model, in addition to an iPSC-derived model of neuritogenesis also developed within 
this thesis, was used to study the process of neurite inhibition in the context of the glial 
scar that forms following spinal cord injury along with Alzheimer’s disease. In addition to 
this the role of NgR, Rho A and ROCK-mediated signalling in each inhibitory setting was 
evaluated and Rho A/ROCK activation deemed a common process, responsible for 
mediating neurite inhibition in many inhibitory situations.  
 
The data outlined in this thesis has provided a solid foundation for the investigation of 
neurite regeneration in vitro using a novel, physiologically relevant 3D model of 
neuritogenesis, based upon Alvetex® scaffold technology. In addition to this, the data 
contained within this thesis also demonstrates potential applications of such a model to 
study the process of neurite growth and inhibition in health and disease. 
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7.8 Future Directions 
 
 Both models of neurite outgrowth described within this thesis have many 
potential future applications. For example, these models could be adopted to 
screen agents for potential neurotoxic properties or to identify regeneration 
promoting compounds. To further the identification of regeneration promoting 
compounds, the small molecules detailed within this thesis could be added to the 
model in combination. For example combination Ch’ase and Y-27632 treatment, 
to determine any beneficial additive effects that may help promote neurite 
regeneration in degenerative states. 
 
 In this thesis, an Alzheimer’s disease specific model of neurite outgrowth was 
developed. This has applications in many areas of neurodegeneration research, as 
this provides proof of concept, that models of neurite outgrowth can be 
developed from iPSC lines. In the future, this methodology could also be used to 
develop models of other neurodegernative diseases such as Parksinon’s disease 
and Huntington’s disease. 
 
 Future work could focus on characterising the iPSC-derived model of 
neuritogenesis to the same level as the TERA2.cl.SP12-based model of 
neuritogenesis. Cytoskeletal markers were tracked over time in the EC-cell based 
model, this allowed for a comparison with in vivo neuritogenesis, to ensure 
neurite development was similar in vitro. This could be conducted for the 
ReproNeuro-based model and gene profiling could also enhance this 
characterisation. 
 
 Rho A and ROCK activation has been implicated in neurite inhibition induced by 
many molecules (CSPGs, Aβ, Nogo, OMGP). Data described herein has used an 
inhibitory strategy to determine the role of Rho A and ROCK in neurite inhibition. 
To further provide evidence to this effect, techniques to analyse gene and protein 
expression such as Western Blotting and PCR could be employed to determine 
the availability and expression of pathway constituents such as, Rac, Cdc42 and 
ROCK and active Rho A. 
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Appendix I: Standard Operating Procedure for Induction of 
Neurite Outgrowth from Human Embryonal Carcinoma 
Cells  
 
Introduction 
 
Neuritogenesis is an important developmental process that occurs during the formation 
of the mature neuron1. This process is impaired in many nervous system disorders that 
range from trauma, such as spinal cord injury (SCI)2–6 to neurodegenerative diseases 
including Alzheimer’s disease7,8. In this unit, we describe the generation of a robust and 
reproducible human pluripotent stem cell-derived model of neurite outgrowth in a 3D 
culture system, which provides a more physiologically relevant geometry to study the 
development and inhibition of neurites9. This model of neurite outgrowth uses a 
commercially available polystyrene scaffold, Alvetex® scaffold that is available in formats 
compatible with high-throughput screening. This is beneficial as a potential application of 
this model could be to screen the ability of drug candidates to overcome inhibitory stimuli 
or to assess their neurotoxicity. 
 
NOTE: All procedures in this unit require standard tissue culture facilities. All cell work 
should be conducted under sterile conditions in a Class II Biological biosafety cabinet. 
 
NOTE: All cell cultures were incubated at 37 °C in a 5 % CO2 humidified environment.  
 
 
DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS IN SUSPENSION 
CULTURE 
 
For the development of this neurite outgrowth model, the embryonal carcinoma (EC) cell 
line TERA2.cl.SP12 was used, which, is a sub-clone of the original TERA-2 line isolated 
based on its expression of the stem cell marker, SSEA-3 and exhibits enhanced 
differentiation when exposed to retinoic acid15. TERA2.cl.SP12 cells have formed the basis 
of many neuronal differentiation studies, and the neuronal subtypes that are formed 
following differentiation have been well characterised9,16–18. 
 
Materials 
 
Dulbecco’s Modified Eagle’s Medium (DMEM; ThermoFisher Scientific, cat no. 21969-035) 
Heat-treated Foetal Bovine Serum (HT-FBS; ThermoFisher Scientific, cat no. 10270-106) 
200 mM L-glutamine (ThermoFisher Scientific, cat no. 11500-626) 
10,000 U/mL Penicillin and Streptomycin (ThermoFisher Scientific, cat no. 11548-876) 
0.25 % trypsin/2 mM EDTA solution (ThermoFisher Scientific, cat no. 11570-626) 
0.1 mM EC23 Stock Solution (ReproCELL Europe, cat no. SRP002) 
Dulbecco’s Phosphate Buffered Saline (DPBS; Lonza, cat no. BE17-512F) 
0.4 % Trypan Blue Solution (Sigma Aldrich, cat no. T8154) 
 
75 cm2 Culture Flasks (BD Flacon, cat no. 353136) 
90 mm Sterile Biological Petri Dishes (ThermoFisher Scientific, cat no. FB51504) 
Acid Washed Glass Beads (ThermoFisher Scientific, cat no. G8772) 
50 mL Conical Tube (Sarstedt, cat no. 62.547.254) 
 
Vacuum Aspirator 
Haemocytometer 
Bench Top Centrifuge 
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Generation of Neurospheres 
 
1. Prepare growth medium by supplementing 500 mL DMEM with 5 mL L-glutamine (final 
concentration 2 mM), 50 mL HT-FBS and 1 mL Penicillin and Streptomycin (final 
concentration 20 active units).  
 
2. TERA2.cl.SP12 cells should be maintained in 75 cm2 culture flasks in 20 mL growth 
medium at high confluency as shown in Figure 1, and their medium should be replaced 
every 2-3 days or as needed.  
 
Cells should be maintained at high confluence to ensure their pluripotent phenotype, as they 
can spontaneously differentiate at low confluence. 
 
 
 
3. Monolayers of TERA2.cl.SP12 should be passaged every 3-4 days once 100 % 
confluence has been reached. This is achieved by aspirating the growth medium before 
adding 6 mL of fresh growth medium with 3-5 acid washed glass beads per flask. Cells can 
then be mechanically dislodged by the beads, this produces a cellular suspension that can 
then be split in a 1:3 ratio between new culture flasks and topped up to a total volume of 
20 mL growth medium per flask.  
 
4. To seed cells for neurosphere formation, a single cell suspension should be prepared by 
aspirating growth medium from cultures, and washing cells in 3 mL DPBS. Cells can then 
be dissociated by trypsinisation, achieved by incubation with 3 mL 0.25 % trypsin/2 mM 
EDTA at 37 °C in a 5 % CO2 humidified environment until cells detach from the flask. 
Trypsin should then be neutralised by addition of 7 mL growth medium, and pipetted 
gently to break up any cellular clumps. 
 
5.  To determine the number of viable cells present in the cellular suspension, a trypan 
blue exclusion assay should be performed. A sample of the cell suspension (10 μL) should 
be diluted 1:1 with trypan blue solution and cells counted using a haemocytometer. From 
this, the total number of cells in the cellular suspension can be determined. 
 
Usually 15-25 x 106 cells per 75 cm2 culture flask are obtained. 
 
6. Cells should then be centrifuged at 1,000 rpm for 3 minutes at room temperature and 
resuspended in growth medium prior to seeding. Cells should be seeded in suspension 
culture at a density of 1.5 x 106 cells per untreated 90 mm biological Petri dish to promote 
their aggregation and maintained with 20 mL growth medium.  
 
7. Following 24 hours incubation, 20 μL of 0.01 mM EC23 stock solution (final 
concentration of 0.01 μM) should be added directly to the suspension culture to promote 
neuronal differentiation.  
A B 
Fig 1. Phase contrast images of TERA2.cl.SP12 cells cultured as 2D monolayers at low 
(A) and high (B) confluence. Cells should be maintained at high confluence to reduce 
spontaneous differentiation. Scale bars: 100 μm  
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Growth medium should not be replaced after 24 hours, as this can result in disaggregation of 
the cells. 
 
8. Cells should be maintained in suspension culture for a 21-day differentiation period 
with replacement of differentiation medium every 3-4 days. Differentiation medium 
should be replaced by transferring the contents of each Petri dish into a 50 mL conical 
tube and allowing the spheroids to settle at the bottom of the tube. The medium can then 
be aspirated, leaving a pellet of spheroids remaining, and 20 mL fresh differentiation 
medium can then be added to the spheroids. Cellular aggregates should then be seeded 
into a fresh 90 mm Petri dish for incubation.  
 
Each time the medium is replaced, the Petri dish should also be replaced, as spheroids may 
begin to adhere to the plastic following a long incubation period.  
 
INDUCTION OF NEURITE OUTGROWTH IN 2D/3D CULTURE  
 
Following the initial differentiation phase of culture, mature neurospheres can be seeded 
onto a 3D polystyrene scaffold or a 2D tissue culture surface to promote the induction of 
neurite outgrowth over a 10-day culture period, figure 2 shows an overview of this two-
step process.  
 
Materials 
 
Dulbecco’s Modified Eagle’s Medium (DMEM; ThermoFisher Scientific, cat no. 21969-035) 
Heat-treated Foetal Bovine Serum (HT-FBS; ThermoFisher Scientific, cat no. 10270-106) 
200 mM L-glutamine (ThermoFisher Scientific, cat no. 11500-626) 
10,000 UmL-1 Penicillin and Streptomycin (ThermoFisher Scientific, cat no. 11548-876) 
Dulbecco’s Phosphate Buffered Saline (DPBS; Lonza, cat no. BE17-512F) 
Engelberth-Holm-Swarm murine sarcoma basement membrane (Sigma-Aldrich, cat no. 
L2020) 
1 mgmL-1 Poly-D-lysine Stock Solution (Sigma-Aldrich, cat no. P6407) 
1 mM cytosine β-D arabinofuranoside (Sigma-Aldrich, cat no. C1768) 
10 mM 5’fluoro 2’deoxyuridine (Sigma-Aldrich, cat no. F0503) 
10 mM Uridine (Sigma-Aldrich, cat no. U3003) 
4 % Paraformaldehyde (PFA; Sigma-Aldrich, cat no. P6148) 
 
12-well format Alvetex® Scaffold Inserts (ReproCELL Europe, cat no. AVP005-12) 
12-well tissue culture plates (Greiner Bio-One, cat no. 665 180) 
48-well tissue culture plates (Greiner Bio-One, cat no. 677 180) 
6-well tissue culture plates (Greiner Bio-One, 657 160) 
100 µm cell strainer (BD Falcon, cat no. 352360) 
50 mL Conical Tube (Sarstedt, cat no. 62.547.254) 
90 mm Sterile Biological Petri Dishes (ThermoFisher Scientific, cat no. FB51504) 
 
K1050X Plasma Asher 
Vacuum Aspirator 
Haemocytometer 
Bench Top Centrifuge 
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Preparation of Growth Surfaces for Neurite Outgrowth 
 
1. Alvetex® Scaffold inserts should be prepared by plasma treatment using the K1050X 
Plasma Asher at a power of 40 W for 5 minutes. Scaffolds should then be washed twice in 
DPBS.  
 
Plasma treatment renders the scaffolds hydrophilic promoting the perfusion of medium 
throughout the scaffold. Alternatively, scaffolds may be washed in 70 % ethanol to render 
them hydrophilic.  
 
2. A coating solution of 10 µgmL-1 poly-D-lysine and laminin should be prepared by adding 
500 µL of 1 mgmL-1 poly-D-lysine and 500 µL of 1 mgmL-1 laminin from Engelberth-Holm-
Swarm murine sarcoma basement membrane to 49 mL DPBS. (Final concentration of 10 
µgmL-1 laminin and poly-D-lysine).  
 
3. For 2D neurite outgrowth assays, 150 µL of coating solution should be added to each 
well of a 48-well tissue culture plate. For 3D neurite outgrowth assays, each 12-well 
format Alvetex® Scaffold insert should be placed into a well of a 6-well tissue culture plate 
and 300 µL coating solution should be added to each scaffold.  
 
4. Surfaces should be coated overnight, at room temperature prior to the seeding of fully 
differentiated neurospheres.  
 
Seeding of Mature Neurospheres for Neurite Outgrowth 
 
Following 21 days differentiation in suspension with 0.01 µM EC23, mature neurospheres 
are ready for use within a neurite outgrowth assay. 
 
1. Pass suspension culture through a 100 µm cell strainer to remove any single cells and 
retinoid containing medium. Backwash neurospheres into a clean 90 mm Petri dish with 
fresh growth medium that has not been supplemented with EC23.  
 
3. To prepare growth medium with mitotic inhibitors, add 500 µL of each mitotic inhibitor 
stock solution to a 500 mL bottle of culture medium.  
 
Final concentrations of mitotic inhibitors in culture medium: 1 µM cytosine β-D 
arabinofuranoside, 10 µM 5’fluoro 2’deoxyuridine, 10 µM Uridine 
 
2. Wash poly-D-lysine and laminin coated scaffolds in DPBS twice, and place in a 12-well 
tissue culture plate with 4 mL mitotic inhibitor containing medium.  
 
3. Using a p200 pipette seed 1-2 neurospheres per well for 2D neurite outgrowth assays 
in a volume of 10 µL or for 3D models, 5-10 neurospheres per scaffold in a volume of 50 
µL.  
 
4. Neurospheres should then be cultured for a further 10 days, during which time neurites 
begin to develop from the neurospheres and either radiate from the central neurosphere 
in 2D culture or enter the 3D growth matrix.  
 
Culture medium should not be replaced during the 10-day neurite outgrowth phase of 
culture, as this may disrupt the developing neurites.  
 
5. Following the 10 day culture period, cultures should be fixed for 1 hour in 4 % PFA at 
room temperature. Samples can then be analysed by immunofluorescence as detailed 
below.  
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IMMUNOFLUORESCENCE ANALYSIS AND NEURITE QUANTIFICATION 
 
Neurite outgrowth cultures should be analysed by staining for the pan-neuronal marker, 
TUJ-1, which allows visualisation of the neurites. Neurites can then be quantified using 
image analysis software such as Image J.  
 
Materials 
 
Phosphate Buffered Saline (PBS; Sigma-Aldrich, cat no. P4417) 
Tween 20 (Sigma-Aldrich; cat no. P1379)  
Normal Goat Serum (NGS; Sigma-Aldrich, cat no. G9023)  
Triton X-100 (Sigma-Aldrich, cat no. X100) 
Microscope Slides (ThermoFisher Scientific, cat no. J1800AMNZ) 
Hydrophobic Blocker Pen (Vector Laboratories, cat no. H4000) 
VectaShield Fluorescence Mounting Medium (Vector Laboratories, cat no. H1000) 
Anti-β-III-tubulin (Anti-TUJ-1, Cambridge Bioscience, cat no. 802001) 
Alexafluor anti-rabbit 488 (ThermoFisher Scientific, cat no. A11070) 
Hoechst 33342 (ThermoFisher Scientific, cat no. H-5370) 
22 x 50 mm Coverslips (ThermoFisher Scientific, cat no. 12373128) 
 
Immunofluorescence Staining of Scaffolds 
 
1. Models fixed in 4 % PFA should be permeabilised by incubating with permeabilisation 
buffer for 20 minutes at room temperature.  
 
2. Models can then be blocked with blocking buffer for 30 minutes at room temperature. 
 
3. To prepare scaffolds for primary antibody incubation, scaffolds should be placed on a 
clean microscope slide and drawn around with a hydrophobic barrier pen.  
 
4. The primary antibody targeted against the pan-neuronal marker TUJ-1 should be 
diluted in a 1:600 ratio with blocking buffer and 150 µL of diluted antibody solution 
should be added to each scaffold or 2D well. Scaffolds should then be incubated for 2 
hours at room temperature or overnight at 4 °C in a humidified chamber, whereas 2D 
cultures should be incubated for one hour at room temperature.  
 
5. Models should then be washed three times for 10 minutes each in blocking buffer.  
 
Washes can be carried out in a 12-well tissue culture plate.  
 
6. Secondary antibody (Alexafluor anti-rabbit 488) should be diluted in blocking buffer at 
a ratio of 1:600 along with the nuclear dye Hoechst which should be diluted a 
concentration of 1:1,000. Scaffolds should then be placed on clean microscope slides and 
drawn around with a hydrophobic barrier pen. Diluted secondary antibody solution 
should then be added to each scaffold at a volume of 150 µL and incubated for 1 hour at 
room temperature in a humidified chamber. 2D models should also be incubated with 150 
µL secondary antibody solution for 1 hour at room temperature. 
 
7. Models should then be washed three times for 10 minutes in blocking buffer. 
 
8. Scaffolds should be mounted onto clean microscope slides with a drop of Vectasheild 
fluorescence mounting medium and topped with a coverslip. 2D samples should be stored 
in PBS prior to microscopic examination. Samples are now ready for microscopic analysis. 
 
Microscopy & Image Analysis 
 
1. Either a 5x magnification lens or a 3 x 3 tile scan using a confocal microscope can be 
used to capture neurite outgrowth from neurospheres cultured in 2D. Scaffolds should be 
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imaged from above (top view) and below (bottom view) using a confocal microscope to 
reduce the out of focus light from cells present on the other side of the scaffold. The 488 
and 405 nm lasers should be used to detect neurite outgrowth and nuclear staining.  
 
The main body of the neurosphere should be visible from the top view of the scaffold, 
whereas neurites that have penetrated the scaffold should be visible from the bottom view of 
the scaffold.  
 
2. 2D images or images taken from the bottom of the scaffolds, should be opened in Image 
J software for analysis. The free-hand draw tool can be used in Image J to trace individual 
neurites that have penetrated the scaffold, and can be measured and traced by using 
keyboard shortcuts such as ctrl + m and ctrl + d. For 2D studies, a gird overlay should be 
used in conjunction with a random number generator to identify only 3 squares per image 
for quantification. 
 
REAGENTS & SOLUTIONS 
 
EC23 Stock Solution 
 
The molecular weight of EC23 is 332.44 and initially a stock solution of 10 mM should be 
produced by dissolving 1 mg of EC23 powder in 300.8 µL of sterile, cell culture grade 
DMSO (SigmalAldrich, cat no. D5879). This initial 10 mM stock solution can then be 
further diluted in DMSO in a ratio of 1:1000. This produces a 0.01 mM stock solution that 
can be aliquoted and stored at -80  °C until required.  
 
Poly-D-lysine Stock Solution 
 
Reconstitute 5 mg of poly-D-lysine powder in 5 mL sterile DPBS to give a stock solution of 
1 mgmL-1. 
 
Mitotic Inhibitor Stock Solutions 
 
Mitotic inhibitor stock solutions were made up at 10 mM (5’fluoro 2’deoxyuridine and 
uridine) or 1 mM (cytosine β-D arabinofuranoside) and diluted 1:1000 in culture medium 
to give a final concentration of 10 µM 5’fluoro 2’deoxyuridine and uridine) or 1 µM 
(cytosine β-D arabinofuranoside). 
 
5’Fluoro 2’deoxyuridine 
MW = 246.19 
To achieve a 10 mM stock solution, dissolve 0.12 g of powdered substance in 50 mL sterile 
DPBS. 
 
Uridine 
MW = 244.2 
To achieve a 10 mM stock solution, dissolve 0.12 g of powdered substance in 50 mL sterile 
DPBS. 
 
Cytosine β-D arabinofuranoside 
MW = 243.22 
To achieve a 1 mM stock solution, dissolve 0.012 g in 50 mL sterile DPBS.  
 
Immunofluorescence Permeabalisation Buffer 
 
500 mL PBS 
500 µL Triton X-100 
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Immunofluorescence Blocking Buffer 
 
495 mL PBS 
5 mL NGS 
50 µL Tween-20 
 
Blocking buffer can be stored at 4 °C for 1-2 weeks. Discard if there is any evidence of 
precipitate. 
 
 
Background Information 
 
Impairment of neurite outgrowth is common to many neurological disorders and has a 
detrimental effect on neuronal connectivity4,5,7,8,19,20. The development of accurate in vitro 
models of neurite outgrowth is an extremely active area of research, as neurite inhibition 
is a poorly understood process. In vitro models of neuritogenesis have many applications 
that range from screening of potential drug targets, neurotoxicity screening and 
investigations into the molecular mechanisms that underpin neurite inhibition in the 
context of many neurological disorders21. For this reason, the development of a 
physiologically relevant, robust and reliable model of human neuritogenesis is an 
important advancement in the field.  
 
Spinal cord injury (SCI) results in the formation of an inhibitory environment known as 
the glial scar2,3,22. Growth of neurites within the glial scar is inhibited due to a combination 
of inhibitory factors including: mechanical inhibition in the form of an astrocytic 
meshwork and inhibitory molecules found on myelin debris or secreted by reactive 
astrocytes such as, chondroitin sulphate proteoglycans (CSPGs)3. The in ability of neurites 
to develop within the area of injury, results in a loss of neuronal innervation that leads to 
functional deficits associated with injury22. Therefore, the molecular basis of CSPG-
mediated neurite inhibition has been the focus of many studies and although it is thought 
that CSPGs act through activation of Rho A signalling, the detailed molecular mechanism 
of their action still remains unclear6,10,12,23,24. The development of robust and reproducible 
neurite outgrowth models, have a potential application in the study of CSPG-mediated 
inhibition and the screening of potential small molecule candidate to overcome such 
inhibition.  
 
Many current neurite outgrowth models rely on the 2D culture of neuronal monolayers25–
27, however, not only is 2D culture far removed from the in vivo microenvironment28, 
quantification and tracing of neurites when cultured as monolayers can be time 
consuming and inaccurate. Spheroid cultures offer an alternative, as neurites radiate from 
a central perikaryon with minimal branching, allowing for a more simple method of 
quantification9,29. In this SOP we describe a human model of neurite outgrowth that 
combines spheroid and 3D scaffold technology to provide a more physiologically relevant 
geometry to study the development of neurites, which can be used as a screening tool to 
assess the effect of compounds on neurite outgrowth.  
 
Critical Parameters 
 
Retinoid Stocks 
 
EC23 is critical for the successful induction of neural differentiation in this culture system. 
Therefore, the accurate generation of 0.01 mM stock solutions is an essential step in the 
preparation of EC cell derived neurite outgrowth models using this methodology. Stock 
solutions were typically aliquoted in volumes of 100 µL and stored at -80 °C. Repeat 
freeze/thaw cycles should be avoided.  
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Cell Stocks 
 
TERA2.cl.SP12 embryonal carcinoma cells should be maintained as 2D monolayers prior 
to the seeding of cells in suspension to promote the formation of spheroids for 
differentiation purposes. These cells should be maintained at high confluency to maintain 
their pluripotent phenotype, as if cell density drops, cells may spontaneously differentiate 
toward an epithelial-like phenotype. Cells should be used at 100 % confluence and due to 
the nature of their metabolism, require frequent media changes. 
 
Troubleshooting 
 
Table 1 lists a selection of problems that may arise during the generation of neurite 
outgrowth models along with common causes and solutions. 
 
Problem Possible Cause Solution 
TERA2.cl.SP12 cells are not 
adherent in 2D 
maintenance cultures  
Incorrect heat treatment of 
FBS 
FBS should be incubated in a 
56 °C water bath for 25 
minutes 
Few / small spheroids in 
suspension culture 
Too frequent medium 
changes 
 
Changing of culture 
medium too soon after 
seeding 
Medium should be changed 4 
days after initial cell seeding 
in suspension and then every 
3-4 days throughout the 
remaining culture period. 
Excessive cellular migration 
from neurospheres 
Inefficient inhibition of 
mitosis 
Check mitotic inhibitors 
have been diluted to the 
appropriate concentration 
Neurospheres missing from 
top of scaffolds 
Excessive washes during 
processing 
Scaffolds should be gently 
washed during 
immunofluorescence 
preparation and rough 
handling may result in the 
dislodgement of 
neurospheres from the 
scaffold 
Table 1: Troubleshooting Guide for Induction of Neurite Outgrowth from Human 
Pluripotent Stem Cell-Derived Neurospheres in a Novel Three-Dimensional Assay 
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